study ID,first author,vaccine,dose_number,dose,days_since_first_dose,outcome_detail,outcome_category,country,population_detail,population_category,VE,LCL,UCL,variant_sequenced,variant_context,max duration follow-up,dose interval,notes,
1,Amit,Pfizer,1+,1+,28,infection ,infection,Israel ,HCW,HCW,75,72,84,,original & alpha,,,,
1,Amit,Pfizer,1+,1+,28,symptomatic disease,symptomatic,Israel ,HCW,HCW,85,71,92,,original & alpha,,,,
2,"Immunisation and Countermeasures Division, National Infection Service, PHE",Pfizer,1,1,>28,symptomatic disease,symptomatic,UK,> 80 years,> 80 years,57,48,63,,alpha,,,,
2,"Immunisation and Countermeasures Division, National Infection Service, PHE",Pfizer,2,final,7,symptomatic disease,symptomatic,UK,> 80 years,> 80 years,88,84,90,,alpha,,,,
3,Dagan,Pfizer,1,1,14-21,infection ,infection,Israel ,general pop,general pop,46,40,51,,original & alpha,,,,
3,Dagan,Pfizer,2,final,>7,infection ,infection,Israel ,general pop,general pop,92,88,95,,original & alpha,,,,
3,Dagan,Pfizer,1,1,14-21,symptomatic disease,symptomatic,Israel ,general pop,general pop,57,50,63,,original & alpha,,,,
3,Dagan,Pfizer,2,final,>7,symptomatic disease,symptomatic,Israel ,general pop,general pop,94,87,98,,original & alpha,,,,
3,Dagan,Pfizer,1,1,14-21,hospitalization,severe,Israel ,general pop,general pop,74,56,86,,original & alpha,,,,
3,Dagan,Pfizer,2,final,>7,hospitalization,severe,Israel ,general pop,general pop,87,55,100,,original & alpha,,,,
3,Dagan,Pfizer,1,1,14-21,severe disease,severe,Israel ,general pop,general pop,62,39,80,,original & alpha,,,,
3,Dagan,Pfizer,2,final,>7,severe disease,severe,Israel ,general pop,general pop,92,75,100,,original & alpha,,,,
4,Hyams,Pfizer,1,1,>14,hospitalization,severe,UK, > 80 years, > 80 years,79,47,93,,alpha,,,,
4,Hyams,AZD1222 (AstraZeneca),1,1,>14,hospitalization,severe,UK, > 80 years, > 80 years,80,36,95,,alpha,,,,
5,Mousten-Helms,Pfizer,1,1,>14,infection ,infection,Denmark,LTCF residents,LTCF residents,21,-11,44,,original & alpha,,,,
5,Mousten-Helms,Pfizer,2,final,>7,infection ,infection,Denmark,LTCF residents,LTCF residents,64,14,84,,original & alpha,,,,
5,Mousten-Helms,Pfizer,1,1,>14,infection ,infection,Denmark,LTCF staff,LTCF staff,17,4,28,,original & alpha,,,,
5,Mousten-Helms,Pfizer,2,final,>7,infection ,infection,Denmark,LTCF staff,LTCF staff,90,82,95,,original & alpha,,,,
6,Tande,Pfizer,1+,1+,10,asymptomatic infection,asymptomatic,USA,pre-surgical hospital patients,pre-surgical hospital patients,79,63,88,,original,,,,
6,Tande,Pfizer,2,final,>0,asymptomatic infection,asymptomatic,USA,pre-surgical hospital patients,pre-surgical hospital patients,80,56,91,,original,,,,
6,Tande,Pfizer,1,1,>10,asymptomatic infection,asymptomatic,USA,pre-surgical hospital patients,pre-surgical hospital patients,79,62,89,,original,,,,
6,Tande,Pfizer,2,final,>0,asymptomatic infection,asymptomatic,USA,pre-surgical hospital patients,pre-surgical hospital patients,80,56,91,,original,,,,
7,Britton,Pfizer,1+,1+,21,infection ,infection,USA,LTCF residents,LTCF residents,63,33,79,,original,,,,
7,Britton,Pfizer,1+,1+,21,infection ,infection,USA,LTCF residents,LTCF residents,60,30,77,,original,,,,
8,Yelin,Pfizer,1+,1+,35,infection ,infection,Israel ,general pop,general pop,91,89,93,,alpha,,,,
8,Yelin,Pfizer,1+,1+,35,symptomatic disease,symptomatic,Israel ,general pop,general pop,99,95,99,,alpha,,,,
9,Public Health England,Pfizer,1,1,>28,symptomatic disease,symptomatic,UK,> 70 years,> 70 years,58,49,65,,alpha,,,,
9,Public Health England,AZD1222 (AstraZeneca),1,1,>35,symptomatic disease,symptomatic,UK,> 70 years,> 70 years,58,38,72,,alpha,,,,
9,Public Health England,Pfizer,1,1,>14,hospitalization,severe,UK,> 70 years,> 70 years,42,32,51,,alpha,,,,
9,Public Health England,Pfizer,1,1,>14,death,death,UK,> 70 years,> 70 years,54,41,64,,alpha,,,,
9,Public Health England,AZD1222 (AstraZeneca),1,1,14-21,hospitalization,severe,UK,> 70 years,> 70 years,35,4,56,,alpha,,,,
10,Shrotri,Pfizer,1,1,35-48,infection ,infection,UK,LTCF residents,LTCF residents,65,29,83,,original & alpha,,,,
10,Shrotri,AZD1222 (AstraZeneca),1,1,35-48,infection ,infection,UK,LTCF residents,LTCF residents,68,34,85,,original & alpha,,,,
11,Thompson,Pfizer,1,1,>14,infection ,infection,USA,HCW,HCW,80,59,90,,original,,,,
11,Thompson,Pfizer,2,final,>14,infection ,infection,USA,HCW,HCW,90,68,97,,original,,,,
12,Bouton,Pfizer,1+,1+,14,infection ,infection,USA,HCW,HCW,82,68,90,,original,,,,
13,Regev-Yochay,Pfizer,2,final,>11,asymptomatic infection,asymptomatic,Israel ,HCW,HCW,65,45,79,,alpha,,,,
13,Regev-Yochay,Pfizer,2,final,>11,asymptomatic infection (presumed infectious ct<30),asymptomatic,Israel ,HCW,HCW,70,43,84,,alpha,,,,
13,Regev-Yochay,Pfizer,2,final,>11,symptomatic disease,symptomatic,Israel ,HCW,HCW,90,84,94,,alpha,,,,
13,Regev-Yochay,Pfizer,2,final,>11,symptomatic disease  (presumed infectious ct<30),symptomatic,Israel ,HCW,HCW,88,80,94,,alpha,,,,
14,Andrejko,Pfizer,1,1,≥15,infection ,infection,USA,general pop,general pop,66.9,28.7,84.6,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Pfizer,2,final,≥15,infection ,infection,USA,general pop,general pop,87.4,77.2,93.1,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Pfizer,2,final,≥15,asymptomatic infection,asymptomatic,USA,general pop,general pop,68.3,27.9,85.7,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Pfizer,2,final,≥15,symptomatic disease,symptomatic,USA,general pop,general pop,91.3,79.3,96.3,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Pfizer,2,final,≥15,hospitalization,severe,USA,general pop,general pop,100,,,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Pfizer,2,final,≥15,infection ,infection,USA,general pop,general pop,87,68.6,94.6,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Moderna,2,final,≥15,infection ,infection,USA,general pop,general pop,86.2,68.4,93.9,,B.1.427/ B.1.429 & alpha,,,,
15,Glampson,Pfizer,1,1,22-28,infection ,infection,UK,≥ 16 years,general pop,78,73,82,,alpha,,,,
15,Glampson,AZD1222 (AstraZeneca),1,1,22-28,infection ,infection,UK,≥ 16 years,general pop,74,65,81,,alpha,,,,
16,Bjork,Pfizer,1,1,>14,infection ,infection,Sweden,general pop,general pop,42,14,63,,original & alpha,,,,
16,Bjork,Pfizer,2,final,>7,infection ,infection,Sweden,general pop,general pop,86,72,94,,original & alpha,,,,
17,Mason,Pfizer,1,1,21-27,infection ,infection,UK,80-83 years,80-83 years,55,40,66,,alpha,,,,
17,Mason,Pfizer,2,final,35-41,infection ,infection,UK,80-83 years,80-83 years,70,55,80,,alpha,,,,
17,Mason,Pfizer,1,1,21-27,hospitalization,severe,UK,80-83 years,80-83 years,50,19,69,,alpha,,,,
17,Mason,Pfizer,2,final,35-41,hospitalization,severe,UK,80-83 years,80-83 years,75,52,87,,alpha,,,,
17,Mason,Pfizer,1,1,35-41,ED or UC visits,symptomatic,UK,80-83 years,80-83 years,58,31,74,,alpha,,,,
17,Mason,Pfizer,2,final,35-41,ED or UC visits,symptomatic,UK,80-83 years,80-83 years,79,60,90,,alpha,,,,
18,Hall,Pfizer,1,1,>21,infection ,infection,UK,HCW,HCW,72,58,86,,alpha,,,,
18,Hall,Pfizer,2,final,>7,infection ,infection,UK,HCW,HCW,86,76,97,,alpha,,,,
19,Vasileiou,Pfizer,1,1,28-34,hospitalization,severe,UK,general pop,general pop,91,85,94,,original & alpha,,,,
19,Vasileiou,AZD1222 (AstraZeneca),1,1,28-34,hospitalization,severe,UK,general pop,general pop,88,75,94,,original & alpha,,,,
20,Pritchard,Pfizer,1,1,>21,infection ,infection,UK,≥ 16 years,general pop,66,60,71,,original & alpha,,,,
20,Pritchard,Pfizer,2,final,>0,infection ,infection,UK,≥ 16 years,general pop,80,74,85,,original & alpha,,,,
20,Pritchard,Pfizer,1,1,>21,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,78,72,83,,original & alpha,,,,
20,Pritchard,Pfizer,2,final,>0,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,95,91,98,,original & alpha,,,,
20,Pritchard,AZD1222 (AstraZeneca),1,1,>21,infection ,infection,UK,≥ 16 years,general pop,61,54,68,,original & alpha,,,,
20,Pritchard,AZD1222 (AstraZeneca),2,final,>0,infection ,infection,UK,≥ 16 years,general pop,79,65,88,,original & alpha,,,,
20,Pritchard,AZD1222 (AstraZeneca),1,1,>21,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,71,62,78,,original & alpha,,,,
20,Pritchard,AZD1222 (AstraZeneca),2,final,>0,symptomatic disease,symptomatic,UK,general pop,general pop,92,78,97,,original & alpha,,,,
21,Goldberg,Pfizer,1+,1+,28,infection ,infection,Israel ,≥ 16 years,general pop,65.9,65.4,66.4,,alpha,,,,
21,Goldberg,Pfizer,2,final,14+,infection ,infection,Israel ,≥ 16 years,general pop,94.5,94.3,94.7,,alpha,~8 weeks,,,
21,Goldberg,Pfizer,1+,1+,28,hospitalization,severe,Israel ,≥ 16 years,general pop,74.9,73.5,76.3,,alpha,,,,
21,Goldberg,Pfizer,2,final,14+,hospitalization,severe,Israel ,≥ 16 years,general pop,95.8,95.2,96.2,,alpha,~8 weeks,,,
21,Goldberg,Pfizer,1+,1+,28,severe disease,severe,Israel ,≥ 16 years,general pop,72.1,69.9,74.1,,alpha,,,,
21,Goldberg,Pfizer,2,final,14+,severe disease,severe,Israel ,≥ 16 years,general pop,96.3,95.7,96.9,,alpha,~8 weeks,,,
21,Goldberg,Pfizer,1+,1+,28,death,death,Israel ,≥ 16 years,general pop,69.1,65.5,72.3,,alpha,,,,
21,Goldberg,Pfizer,2,final,14+,death,death,Israel ,≥ 16 years,general pop,96,94.9,96.9,,alpha,~8 weeks,,,
22,Tenforde,Pfizer,1+,1+,28,hospitalization,severe,USA,hospital patients ≥ 65 years,≥ 65 years,64,28,82,,original & alpha,,,,
22,Tenforde,Pfizer,2,final,>14,hospitalization,severe,USA,hospital patients ≥ 65 years,≥ 65 years,94,49,99,,original & alpha,,,,
23,Gras-Valenti,Pfizer,1,1,>12,infection ,infection,Spain,HCW,HCW,53,1,77,,original & alpha,,,,
24,Fabiani,Pfizer,1,1,14-21,infection ,infection,Italy,HCW,HCW,84,40,96,,unknown,,,,
24,Fabiani,Pfizer,2,final,>7,infection ,infection,Italy,HCW,HCW,95,62,99,,unknown,,,,
24,Fabiani,Pfizer,1,1,14-21,symptomatic disease,symptomatic,Italy,HCW,HCW,83,15,97,,unknown,,,,
24,Fabiani,Pfizer,2,final,>7,symptomatic disease,symptomatic,Italy,HCW,HCW,94,51,99,,unknown,,,,
25,Corchado-Garcia ,Janssen,1,final,>15,infection ,infection,USA,general pop,general pop,74.2,64.9,81.6,,original & alpha,,,,
26,Haas,Pfizer,2,final,>7,infection ,infection,Israel ,general pop,general pop,95.3,94.9,95.7,,alpha,,,,
26,Haas,Pfizer,2,final,>7,asymptomatic infection,asymptomatic,Israel ,general pop,general pop,91.5,90.7,92.2,,alpha,,,,
26,Haas,Pfizer,2,final,>7,symptomatic disease,symptomatic,Israel ,general pop,general pop,97,96.7,97.2,,alpha,,,,
26,Haas,Pfizer,2,final,>7,hospitalization,severe,Israel ,general pop,general pop,97.2,96.8,97.5,,alpha,,,,
26,Haas,Pfizer,2,final,>7,severe/critical hospitalization,severe,Israel ,general pop,general pop,97.5,97.1,97.8,,alpha,,,,
26,Haas,Pfizer,2,final,>7,death,death,Israel ,general pop,general pop,96.7,96,97.3,,alpha,,,,
27,Abu-Raddad,Pfizer,1,1,15-21,infection ,infection,Qatar,general pop,general pop,65.5,58.2,71.5,alpha,alpha,,,,
27,Abu-Raddad,Pfizer,2,final,>14,infection ,infection,Qatar,general pop,general pop,90,86,92,alpha,alpha,,,,
27,Abu-Raddad,Pfizer,1,1,15-21,severe/fatal infection,severe,Qatar,general pop,general pop,72,32,90,alpha,alpha,,,,
27,Abu-Raddad,Pfizer,2,final,>14,severe/fatal infection,severe,Qatar,general pop,general pop,100,82,100,alpha,alpha,,,,
27,Abu-Raddad,Pfizer,1,1,15-21,infection ,infection,Qatar,general pop,general pop,46.5,38.7,53.3,beta,beta,,,,
27,Abu-Raddad,Pfizer,2,final,>14,infection ,infection,Qatar,general pop,general pop,75,71,79,beta,beta,,,,
27,Abu-Raddad,Pfizer,1,1,15-21,severe/fatal infection,severe,Qatar,general pop,general pop,56.5,0,82.8,beta,beta,,,,
27,Abu-Raddad,Pfizer,2,final,>14,severe/fatal infection,severe,Qatar,general pop,general pop,100,74,100,beta,beta,,,,
27,Abu-Raddad,Pfizer,2,final,>14,infection ,infection,Qatar,general pop,general pop,87,82,91,alpha,alpha,,,,
27,Abu-Raddad,Pfizer,2,final,>14,infection ,infection,Qatar,general pop,general pop,72,66,77,beta,beta,,,,
28,Angel,Pfizer,1+,1+,14,symptomatic disease,symptomatic,Israel ,HCW,HCW,89,83,94,,alpha,,,,
28,Angel,Pfizer,2,final,>7,symptomatic disease,symptomatic,Israel ,HCW,HCW,97,94,99,,alpha,,,,
28,Angel,Pfizer,1+,1+,14,asymptomatic infection,asymptomatic,Israel ,HCW,HCW,36,-51,69,,alpha,,,,
28,Angel,Pfizer,2,final,>7,asymptomatic infection,asymptomatic,Israel ,HCW,HCW,86,69,97,,alpha,,,,
29,Lopez-Bernal,Pfizer,2,final,≥7,symptomatic disease,symptomatic,UK,> 80 years,> 80 years,79,68,86,,alpha,,,,
29,Lopez-Bernal,Pfizer,1+,1+,31,symptomatic disease,symptomatic,UK,> 70 years,> 70 years,61,51,69,,alpha,,,,
29,Lopez-Bernal,AZD1222 (AstraZeneca),1+,1+,28-34 (includes some with dose 2),symptomatic disease,symptomatic,UK,> 70 years,> 70 years,60,41,73,,alpha,,,,
30,Pilishvili ,Pfizer,1+,1+,21,symptomatic disease,symptomatic,USA,HCW,HCW,82,74,87,,unknown,,,,
30,Pilishvili ,Pfizer,2,final,>7,symptomatic disease,symptomatic,USA,HCW,HCW,94,87,97,,unknown,,,,
31,Ismail,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,UK,70-79 years,70-79 years,84,74,89,,alpha,,,,
31,Ismail,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,UK,≥ 80 years,≥ 80 years,73,60,81,,alpha,,,,
31,Ismail,Pfizer,1,1,28+,hospitalization,severe,UK,70-79 years,70-79 years,81,73,87,,alpha,,,,
31,Ismail,Pfizer,1,1,28+,hospitalization,severe,UK,≥ 80 years,≥ 80 years,81,76,85,,alpha,,,,
31,Ismail,Pfizer,2,final,>14,hospitalization,severe,UK,≥ 80 years,≥ 80 years,93,89,95,,alpha,,,,
32,Ranzani,CoronaVac (Sinovac),1,1,>14,symptomatic disease,symptomatic,Brazil,≥ 70 years,≥ 70 years,12.5,3.7,20.6,,gamma,,,,
32,Ranzani,CoronaVac (Sinovac),2,final,>14,symptomatic disease,symptomatic,Brazil,≥ 70 years,≥ 70 years,46.8,38.7,53.8,,gamma,,,,
32,Ranzani,CoronaVac (Sinovac),1,1,>14,hospitalization,severe,Brazil,≥ 70 years,≥ 70 years,16.9,5.7,26.8,,gamma,,,,
32,Ranzani,CoronaVac (Sinovac),2,final,>14,hospitalization,severe,Brazil,≥ 70 years,≥ 70 years,55.5,46.5,62.9,,gamma,,,,
32,Ranzani,CoronaVac (Sinovac),1,1,>14,death,death,Brazil,≥ 70 years,≥ 70 years,31.2,17.6,42.5,,gamma,,,,
32,Ranzani,CoronaVac (Sinovac),2,final,>14,death,death,Brazil,≥ 70 years,≥ 70 years,61.2,48.9,70.5,,gamma,,,,
33,PHE,Pfizer,1,1,28+,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,54,50,58,,alpha,,,,
33,PHE,Pfizer,2,final,>14,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,90,82,95,,alpha,,,,
33,PHE,AZD1222 (AstraZeneca),1,1,28+,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,53,49,57,,alpha,,,,
33,PHE,AZD1222 (AstraZeneca),2,final,>14,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,89,78,94,,alpha,,,,
34,Chung,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,59,55,62,,"alpha, beta & gamma",,,,
34,Chung,Pfizer,2,final,7+,symptomatic disease,symptomatic,Canada,general pop,general pop,91,88,93,,"alpha, beta & gamma",15 weeks,,,
34,Chung,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,69,59,77,,"alpha, beta & gamma",,,,
34,Chung,Pfizer,2,final,0+,hospitalization or death,severe,Canada,general pop,general pop,96,82,99,,"alpha, beta & gamma",15 weeks,,,
34,Chung,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,72,63,80,,"alpha, beta & gamma",,,,
34,Chung,Moderna,2,final,7+,symptomatic disease,symptomatic,Canada,general pop,general pop,94,86,97,,"alpha, beta & gamma",15 weeks,,,
34,Chung,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,73,42,87,,"alpha, beta & gamma",,,,
34,Chung,Moderna,2,final,0+,hospitalization or death,severe,Canada,general pop,general pop,96,74,100,,"alpha, beta & gamma",15 weeks,,,
34,Chung,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,61,56,66,alpha,alpha,,,,
34,Chung,Pfizer,2,final,7+,symptomatic disease,symptomatic,Canada,general pop,general pop,90,85,94,alpha,alpha,15 weeks,,,
34,Chung,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,59,39,73,alpha,alpha,,,,
34,Chung,Pfizer,2,final,0+,hospitalization or death,severe,Canada,general pop,general pop,94,59,99,alpha,alpha,15 weeks,,,
34,Chung,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,43,22,59,beta & gamma,beta & gamma,,,,
34,Chung,Pfizer,2,final,7+,symptomatic disease,symptomatic,Canada,general pop,general pop,88,61,96,beta & gamma,beta & gamma,15 weeks,,,
34,Chung,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,56,-9,82,   ,beta & gamma,,15 weeks,,
34,Chung,Pfizer,2,final,7+,hospitalization or death,severe,Canada,general pop,general pop,100,,,   ,beta & gamma,beta & gamma,15 weeks,,
35,Martinez-Bas,Pfizer,1,1,14+,infection ,infection,Spain,close contacts,close contacts,21,3,36,,alpha,,,,
35,Martinez-Bas,Pfizer,2,final,14+,infection ,infection,Spain,close contacts,close contacts,65,56,73,,alpha,12 weeks,,,
35,Martinez-Bas,Pfizer,1,1,14+,symptomatic disease,symptomatic,Spain,close contacts,close contacts,30,10,45,,alpha,,,,
35,Martinez-Bas,Pfizer,2,final,14+,symptomatic disease,symptomatic,Spain,close contacts,close contacts,82,73,88,,alpha,12 weeks,,,
35,Martinez-Bas,Pfizer,1,1,14+,hospitalization,severe,Spain,close contacts,close contacts,65,25,83,,alpha,,,,
35,Martinez-Bas,Pfizer,2,final,14+,hospitalization,severe,Spain,close contacts,close contacts,94,60,99,,alpha,12 weeks,,,
35,Martinez-Bas,AZD1222 (AstraZeneca),1,1,14+,infection ,infection,Spain,close contacts,close contacts,44,31,54,,alpha,,,,
35,Martinez-Bas,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Spain,close contacts,close contacts,50,37,61,,alpha,,,,
35,Martinez-Bas,AZD1222 (AstraZeneca),1,1,14+,hospitalization,severe,Spain,close contacts,close contacts,92,46,99,,alpha,,,,
36,Khan,Pfizer,1+,1+,21,infection ,infection,USA,hospital patients,general pop,-1,-50,32,,unknown,,,,
36,Khan,Pfizer,2,final,7+,infection ,infection,USA,hospital patients,general pop,69,44,83,,unknown,14 weeks,,,
36,Khan,Pfizer,1+,1+,21,hospitalization or death,severe,USA,hospital patients,general pop,9,-114,61,,unknown,,,,
36,Khan,Pfizer,2,final,7+,hospitalization or death,severe,USA,hospital patients,general pop,49,-36,81,,unknown,14 weeks,,,
37,Salo,Pfizer,1,1,4 weeks,infection ,infection,Finland,HCW,HCW,44.4,30.4,55.6,,alpha,,,,
37,Salo,Pfizer,1+,1+,84,infection ,infection,Finland,HCW,HCW,63,56.3,68.7,,alpha,,,,
38,Thompson,Pfizer,1+,1+,28,infection ,infection,USA,HCW,HCW,80,60,90,,original,,,,
38,Thompson,Pfizer,2,final,>14,infection ,infection,USA,HCW,HCW,93,78,98,,original,13 weeks,,,
38,Thompson,Moderna,1+,1+,28,infection ,infection,USA,HCW,HCW,83,40,95,,original,,,,
38,Thompson,Moderna,2,final,>14,infection ,infection,USA,HCW,HCW,82,20,96,,original,,,,
39,Emborg,Pfizer,1,1,>14,infection ,infection,Denmark,priority groups,priority groups,7,-1,15,,original & alpha,,,,
39,Emborg,Pfizer,2,final,>7,infection ,infection,Denmark,priority groups,priority groups,82,79,84,,original & alpha,10 weeks,,,
39,Emborg,Pfizer,1,1,>14,hospitalization,severe,Denmark,priority groups,priority groups,35,18,49,,original & alpha,,,,
39,Emborg,Pfizer,2,final,>7,hospitalization,severe,Denmark,priority groups,priority groups,93,89,96,,original & alpha,10 weeks,,,
39,Emborg,Pfizer,1,1,>14,death,death,Denmark,priority groups,priority groups,7,-15,25,,original & alpha,,,,
39,Emborg,Pfizer,2,final,>7,death,death,Denmark,priority groups,priority groups,94,90,96,,original & alpha,10 weeks,,,
40,Skowornski,Pfizer,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,67,57,75,alpha,alpha,,,,
40,Skowornski,Pfizer,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,61,45,72,gamma,gamma,,,,
40,Skowornski,Pfizer,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,72,58,81,non-VOC,non-VOC,,,,
40,Skowornski,Pfizer,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,64,57,71,,alpha & gamma,,,,
40,Skowornski,Moderna,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,71,56,81,,alpha & gamma,,,,
41,Flacco,Pfizer,1,1,14+,infection ,infection,Italy,general pop,general pop,55,40,66,,original & alpha,,,,
41,Flacco,Pfizer,2,final,14+,infection ,infection,Italy,general pop,general pop,98,97,99,,original & alpha,~14 weeks,,,
41,Flacco,Pfizer,2,final,14+,hospitalization,severe,Italy,general pop,general pop,99,96,100,,original & alpha,~14 weeks,,,
41,Flacco,Pfizer,2,final,14+,death,death,Italy,general pop,general pop,98,87,100,,original & alpha,~14 weeks,,,
41,Flacco,Moderna,1,1,14+,infection ,infection,Italy,general pop,general pop,93,74,98,,original & alpha,,,,
41,Flacco,AZD1222 (AstraZeneca),1,1,21+,infection ,infection,Italy,general pop,general pop,95,92,97,,original & alpha,,,,
42,Sheikh,Pfizer,1,1,28+,infection ,infection,Scotland,general pop,general pop,38,29,45,alpha,alpha,,,,
42,Sheikh,Pfizer,2,final,14+,infection ,infection,Scotland,general pop,general pop,92,90,93,alpha,alpha,~20 weeks,,,
42,Sheikh,AZD1222 (AstraZeneca),1,1,28+,infection ,infection,Scotland,general pop,general pop,37,32,42,alpha,alpha,,,,
42,Sheikh,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,Scotland,general pop,general pop,73,66,78,alpha,alpha,~20 weeks,,,
42,Sheikh,Pfizer,1,1,28+,infection ,infection,Scotland,general pop,general pop,30,17,41,delta,delta,,,,
42,Sheikh,Pfizer,2,final,14+,infection ,infection,Scotland,general pop,general pop,79,75,82,delta,delta,~20 weeks,,,
42,Sheikh,AZD1222 (AstraZeneca),1,1,28+,infection ,infection,Scotland,general pop,general pop,18,9,25,delta,delta,,,,
42,Sheikh,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,Scotland,general pop,general pop,60,53,66,delta,delta,~20 weeks,,,
43,Stowe,Pfizer,1,1,21+,hospitalization,severe,UK,hospital patients,general pop,83,62,93,alpha,alpha,,,,
43,Stowe,Pfizer,2,final,14+,hospitalization,severe,UK,hospital patients,general pop,95,78,99,alpha,alpha,~20 weeks,,,
43,Stowe,AZD1222 (AstraZeneca),1,1,21+,hospitalization,severe,UK,hospital patients,general pop,76,61,85,alpha,alpha,,,,
43,Stowe,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,UK,hospital patients,general pop,86,53,96,alpha,alpha,~20 weeks,,,
43,Stowe,Pfizer,1,1,21+,hospitalization,severe,UK,hospital patients,general pop,94,46,99,delta,delta,,,,
43,Stowe,Pfizer,2,final,14+,hospitalization,severe,UK,hospital patients,general pop,96,86,99,delta,delta,~20 weeks,,,
43,Stowe,AZD1222 (AstraZeneca),1,1,21+,hospitalization,severe,UK,hospital patients,general pop,71,51,83,delta,delta,,,,
43,Stowe,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,UK,hospital patients,general pop,92,75,97,delta,delta,~20 weeks,,,
44,Azamgarhi,Pfizer,1,1,>14,infection ,infection,UK,HCW,HCW,70,6,91,,original & alpha,,,,
45,Young-Xu,Pfizer,1,1,7+,infection ,infection,USA,general pop,general pop,58,54,62,,original & alpha,,,,
45,Young-Xu,Pfizer,2,final,7+,infection ,infection,USA,general pop,general pop,94,92,95,,original & alpha,~8 weeks,,,
45,Young-Xu,Pfizer,1,1,7+,hospitalization,severe,USA,general pop,general pop,40,27,50,,original & alpha,,,,
45,Young-Xu,Pfizer,2,final,7+,hospitalization,severe,USA,general pop,general pop,89,81,93,,original & alpha,~8 weeks,,,
45,Young-Xu,Pfizer,1,1,7+,death,death,USA,general pop,general pop,55,21,74,,original & alpha,,,,
45,Young-Xu,Pfizer,2,final,7+,death,death,USA,general pop,general pop,98.5,86.6,99.8,,original & alpha,~8 weeks,,,
45,Young-Xu,Pfizer,1,1,7+,asymptomatic infection,asymptomatic,USA,general pop,general pop,58,41.7,69.7,,original & alpha,,,,
45,Young-Xu,Pfizer,2,final,7+,asymptomatic infection,asymptomatic,USA,general pop,general pop,69.7,47.7,82.5,,original & alpha,~8 weeks,,,
45,Young-Xu,Pfizer,1,1,7+,hospitalization,severe,USA,general pop,general pop,53,25.7,70.3,,original & alpha,,,,
45,Young-Xu,Pfizer,2,final,7+,hospitalization,severe,USA,general pop,general pop,88.4,74.9,94.7,,original & alpha,~8 weeks,,,
45,Young-Xu,Pfizer,1,1,7+,death,death,USA,general pop,general pop,55.6,26.6,73.2,,original & alpha,,,,
45,Young-Xu,Pfizer,2,final,7+,death,death,USA,general pop,general pop,97,91.7,98.9,,original & alpha,~8 weeks,,,
46,Pawlowski,Pfizer,1,1,>14,infection ,infection,USA,general pop,general pop,61,50.8,69.2,,original & alpha,,,,
46,Pawlowski,Pfizer,2,final,>14,infection ,infection,USA,general pop,general pop,88,84.2,91,,original & alpha,~17 weeks,,,
46,Pawlowski,Pfizer,2,final,>14,hospitalization,severe,USA,general pop,general pop,88.3,72.6,95.9,,original & alpha,~17 weeks,,,
46,Pawlowski,Pfizer,2,final,>14,ICU admission,severe,USA,general pop,general pop,100,18.7,100,,original & alpha,~17 weeks,,,
46,Pawlowski,Moderna,1,1,>14,infection ,infection,USA,general pop,general pop,66.6,51.9,77.3,,original & alpha,,,,
46,Pawlowski,Moderna,2,final,>14,infection ,infection,USA,general pop,general pop,92.3,82.4,97.3,,original & alpha,~17 weeks,,,
46,Pawlowski,Moderna,2,final,>14,hospitalization,severe,USA,general pop,general pop,90.6,76.5,97.1,,original & alpha,~17 weeks,,,
46,Pawlowski,Moderna,2,final,>14,ICU admission,severe,USA,general pop,general pop,100,17.9,100,,original & alpha,~17 weeks,,,
47,Saciuk,Pfizer,2,final,7+,infection ,infection,Israel ,general pop,general pop,93,92.6,93.4,,original & alpha,14 weeks,,,
47,Saciuk,Pfizer,2,final,7+,hospitalization,severe,Israel ,general pop,general pop,93.4,91.9,94.7,,original & alpha,14 weeks,,,
47,Saciuk,Pfizer,2,final,7+,death,death,Israel ,general pop,general pop,91.1,86.5,94.1,,original & alpha,14 weeks,,,
48,Baum,Pfizer,1,1,21+,infection ,infection,Finland,≥ 70 years,≥ 70 years,45,36,53,,original & alpha,,,,
48,Baum,Pfizer,2,final,7+,infection ,infection,Finland,≥ 70 years,≥ 70 years,75,65,82,,original & alpha,16 weeks,,,
48,Baum,Pfizer,1,1,21+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,63,49,74,,original & alpha,,,,
48,Baum,Pfizer,2,final,7+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,93,70,98,,original & alpha,16 weeks,,,
48,Baum,Pfizer,1,1,21+,infection ,infection,Finland,chronically ill,chronically ill,40,26,51,,original & alpha,,,,
48,Baum,Pfizer,2,final,7+,infection ,infection,Finland,chronically ill,chronically ill,77,65,85,,original & alpha,16 weeks,,,
48,Baum,Pfizer,1,1,21+,hospitalization,severe,Finland,chronically ill,chronically ill,82,56,93,,original & alpha,,,,
48,Baum,Pfizer,2,final,7+,hospitalization,severe,Finland,chronically ill,chronically ill,90,29,99,,original & alpha,16 weeks,,,
48,Baum,AZD1222 (AstraZeneca),1,1,21+,infection ,infection,Finland,chronically ill,chronically ill,42,32,50,,original & alpha,,,,
48,Baum,AZD1222 (AstraZeneca),1,1,21+,hospitalization,severe,Finland,chronically ill,chronically ill,62,42,75,,original & alpha,,,,
49,Nasreen,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,63,56,68,non-VOC,non-VOC,,,,
49,Nasreen,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,92,87,95,non-VOC,non-VOC,18 weeks,,,
49,Nasreen,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,77,67,84,non-VOC,non-VOC,,,,
49,Nasreen,Pfizer,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,97,88,99,non-VOC,non-VOC,18 weeks,,,
49,Nasreen,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,63,47,74,non-VOC,non-VOC,,,,
49,Nasreen,Moderna,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,98,83,100,non-VOC,non-VOC,18 weeks,,,
49,Nasreen,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,66,43,80,non-VOC,non-VOC,,,,
49,Nasreen,Moderna,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,100,,,non-VOC,non-VOC,18 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,67,44,81,non-VOC,non-VOC,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,100,,,non-VOC,non-VOC,~3 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,92,45,99,non-VOC,non-VOC,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,100,,,non-VOC,non-VOC,~3 weeks,,,
49,Nasreen,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,67,65,68,alpha,alpha,,,,
49,Nasreen,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,88,86,90,alpha,alpha,~28 weeks,,,
49,Nasreen,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,82,81,84,alpha,alpha,,,,
49,Nasreen,Pfizer,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,96,94,97,alpha,alpha,~28 weeks,,,
49,Nasreen,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,82,80,84,alpha,alpha,,,,
49,Nasreen,Moderna,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,92,87,95,alpha,alpha,~25 weeks,,,
49,Nasreen,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,80,76,84,alpha,alpha,,,,
49,Nasreen,Moderna,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,95,92,97,alpha,alpha,~25 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,63,59,66,alpha,alpha,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,87,47,97,alpha,alpha,~3 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,87,83,90,alpha,alpha,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,92,41,99,alpha,alpha,~3 weeks,,,
49,Nasreen,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,50,15,70,beta,beta,,,,
49,Nasreen,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,86,0,98,beta,beta,~28 weeks,,,
49,Nasreen,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,64,31,82,beta,beta,,,,
49,Nasreen,Pfizer,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,92,39,99,beta,beta,~28 weeks,,,
49,Nasreen,Moderna,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,100,,,beta,beta,~25 weeks,,,
49,Nasreen,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,59,-77,90,beta,beta,,,,
49,Nasreen,Moderna,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,100,,,beta,beta,~25 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,84,-13,98,beta,beta,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,100,,,beta,beta,~3 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,61,-64,91,beta,beta,,,,
49,Nasreen,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,63,54,70,gamma,gamma,,,,
49,Nasreen,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,90,76,96,gamma,gamma,~28 weeks,,,
49,Nasreen,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,80,70,87,gamma,gamma,,,,
49,Nasreen,Pfizer,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,94,59,99,gamma,gamma,~28 weeks,,,
49,Nasreen,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,89,76,95,gamma,gamma,,,,
49,Nasreen,Moderna,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,100,,,gamma,gamma,~25 weeks,,,
49,Nasreen,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,88,63,96,gamma,gamma,,,,
49,Nasreen,Moderna,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,100,,,gamma,gamma,~25 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,41,12,60,gamma,gamma,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,100,,,gamma,gamma,~3 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,76,40,90,gamma,gamma,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,100,,,gamma,gamma,~3 weeks,,,
49,Nasreen,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,57,53,61,delta,delta,,,,
49,Nasreen,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,92,89,94,delta,delta,~28 weeks,,,
49,Nasreen,Pfizer,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,81,76,85,delta,delta,,,,
49,Nasreen,Pfizer,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,98,96,99,delta,delta,~28 weeks,,,
49,Nasreen,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,70,64,76,delta,delta,,,,
49,Nasreen,Moderna,2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,94,90,97,delta,delta,~25 weeks,,,
49,Nasreen,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,90,82,94,delta,delta,,,,
49,Nasreen,Moderna,2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,98,93,100,delta,delta,~25 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,68,57,76,delta,delta,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,88,68,96,delta,delta,~ 3 weeks,,,
49,Nasreen,AZD1222 (AstraZeneca),1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,91,82,96,delta,delta,,,,
49,Nasreen,AZD1222 (AstraZeneca),2,final,14+,hospitalization or death,severe,Canada,general pop,general pop,90,67,97,delta,delta,~3 weeks,,,
50,Jara,CoronaVac (Sinovac),1,1,14+,infection ,infection,Chile,general pop,general pop,15.5,14.2,16.8,,alpha & gamma,,,,
50,Jara,CoronaVac (Sinovac),2,final,14+,infection ,infection,Chile,general pop,general pop,65.9,65.2,66.6,,alpha & gamma,8 weeks,,,
50,Jara,CoronaVac (Sinovac),1,1,14+,hospitalization,severe,Chile,general pop,general pop,37.4,34.9,39.9,,alpha & gamma,,,,
50,Jara,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Chile,general pop,general pop,87.5,86.7,88.2,,alpha & gamma,8 weeks,,,
50,Jara,CoronaVac (Sinovac),1,1,14+,ICU admission,severe,Chile,general pop,general pop,44.7,40.8,48.3,,alpha & gamma,,,,
50,Jara,CoronaVac (Sinovac),2,final,14+,ICU admission,severe,Chile,general pop,general pop,90.3,89.1,91.4,,alpha & gamma,8 weeks,,,
50,Jara,CoronaVac (Sinovac),1,1,14+,death,death,Chile,general pop,general pop,45.7,40.9,50.2,,alpha & gamma,,,,
50,Jara,CoronaVac (Sinovac),2,final,14+,death,death,Chile,general pop,general pop,86.3,84.5,87.9,,alpha & gamma,8 weeks,,,
51,Tenforde,Pfizer,1+,1+,28,hospitalization,severe,USA,hospital patients,general pop,75.4,60.4,84.7,,original & alpha,,,,
51,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,hospital patients,general pop,86.6,79,91.4,,original & alpha,~2 weeks,,,
51,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,hospital patients,general pop,84.7,74.1,91,,original & alpha,~2 weeks,,,
51,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,hospital patients,general pop,88.9,78.7,94,,original & alpha,~2 weeks,,,
51,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,hospital patients,general pop,92.1,82.3,96.5,alpha,alpha,~2 weeks,,,
52,Chemaitelly,Moderna,1,1,14+,infection ,infection,Qatar,general pop,general pop,88.2,83.8,91.4,alpha,alpha,,,,
52,Chemaitelly,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,100,,,alpha,alpha,13 weeks,,,
52,Chemaitelly,Moderna,1,1,14+,infection ,infection,Qatar,general pop,general pop,68.2,64.3,71.7,beta,beta,,,,
52,Chemaitelly,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,96,90.9,98.2,beta,beta,13 weeks,,,
52,Chemaitelly,Moderna,1,1,14+,severe/fatal infection,severe,Qatar,general pop,general pop,83.7,74.1,89.7,,alpha & beta,,,,
52,Chemaitelly,Moderna,2,final,14+,severe/fatal infection,severe,Qatar,general pop,general pop,89.5,18.8,98.7,,alpha & beta,13 weeks,,,
52,Chemaitelly,Moderna,1,1,14+,symptomatic disease,symptomatic,Qatar,general pop,general pop,66,60.6,70.7,,alpha & beta,,,,
52,Chemaitelly,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,general pop,general pop,98.6,92,100,,alpha & beta,13 weeks,,,
52,Chemaitelly,Moderna,1,1,14+,asymptomatic infection,asymptomatic,Qatar,general pop,general pop,47.3,37.6,55.5,,alpha & beta,,,,
52,Chemaitelly,Moderna,2,final,14+,asymptomatic infection,asymptomatic,Qatar,general pop,general pop,92.5,84.8,96.9,,alpha & beta,13 weeks,,,
52,Chemaitelly,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,100,82.5,100,alpha,alpha,13 weeks,,,
52,Chemaitelly,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,87.8,73.4,95.5,beta,beta,13 weeks,,,
53,Goldshtein,Pfizer,1+,1+,21,infection ,infection,Israel ,pregnant women,pregnant persons,54,33,69,,original & alpha,,,,
53,Goldshtein,Pfizer,1+,1+,28,infection ,infection,Israel ,pregnant women,pregnant persons,78,57,89,,original & alpha,,,,
54,Bertollini,Pfizer,2,final,14+,infection ,infection,Qatar,general pop,general pop,78,72,83,,"original, alpha & beta",~4 weeks,,,
55,John,Pfizer,1+,1+,28,infection ,infection,USA,patients with cirrhosis,patients with cirrhosis,64.8,10.9,86.1,,original & alpha,,,,
55,John,Pfizer,2,final,7+,infection ,infection,USA,patients with cirrhosis,patients with cirrhosis,78.6,25.5,93.8,,original & alpha,~10 weeks,,,
55,John,Pfizer,1+,1+,28,hospitalization,severe,USA,patients with cirrhosis,patients with cirrhosis,100,99.3,100,,original & alpha,,,,
55,John,Pfizer,2,final,7+,hospitalization,severe,USA,patients with cirrhosis,patients with cirrhosis,100,99,100,,original & alpha,~10 weeks,,,
55,John,Pfizer,1+,1+,28,death,death,USA,patients with cirrhosis,patients with cirrhosis,100,99.3,100,,original & alpha,,,,
55,John,Pfizer,2,final,7+,death,death,USA,patients with cirrhosis,patients with cirrhosis,100,99,100,,original & alpha,~10 weeks,,,
56,Whitaker,Pfizer,1,1,28-90,symptomatic disease,symptomatic,UK,16-64 years,16-64 years,64.1,50.1,74.1,,original & alpha,,,,
56,Whitaker,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,16-64 years,16-64 years,48.6,-61.5,83.7,,original & alpha,~20 weeks,,,
56,Whitaker,Pfizer,1,1,28-90,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,57.7,49.7,64.3,,original & alpha,,,,
56,Whitaker,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,84.7,77.7,89.5,,original & alpha,~20 weeks,,,
56,Whitaker,Pfizer,1,1,28-90,symptomatic disease,symptomatic,UK,immunosuprressed,"immunocompromised, ≥ 16 years",24.3,-5.9,46,,alpha,,,,
56,Whitaker,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,immunosuprressed,"immunocompromised, ≥ 16 years",59.6,-35.5,86.3,,alpha,~8 weeks,,,
56,Whitaker,AZD1222 (AstraZeneca),1,1,28-90,symptomatic disease,symptomatic,UK,16-64 years,16-64 years,65.3,56.2,72.5,,alpha,,,,
56,Whitaker,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,16-64 years,16-64 years,67.9,-1.1,89.8,,alpha,~8 weeks,,,
56,Whitaker,AZD1222 (AstraZeneca),1,1,28-90,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,59.8,49.2,68.2,,alpha,,,,
56,Whitaker,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,≥ 65 years,≥ 65 years,81.7,59.6,91.7,,alpha,~8 weeks,,,
56,Whitaker,AZD1222 (AstraZeneca),1,1,28-90,symptomatic disease,symptomatic,UK,immunosuprressed,"immunocompromised, ≥ 16 years",22.5,-15.2,47.9,,alpha,,,,
56,Whitaker,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,immunosuprressed,"immunocompromised, ≥ 16 years",60,-63.6,90.2,,alpha,~8 weeks,,,
57,Prunas,Pfizer,1+,1+,17,infection ,infection,Israel ,HHC of cases,HHC of cases,62.7,61.5,63.8,,original & alpha,,,,
57,Prunas,Pfizer,2,final,10-90,infection ,infection,Israel ,HHC of cases,HHC of cases,89.4,88.7,90,,original & alpha,~11 weeks,,,
57,Prunas,Pfizer,2,final,90+,infection ,infection,Israel ,HHC of cases,HHC of cases,58.3,45.8,67.9,,original & alpha,~26.5 weeks,,,
57,Prunas,Pfizer,1+,1+,17,infection ,infection,Israel ,HHC of cases,HHC of cases,72.1,66.7,75.6,,delta,,,,
57,Prunas,Pfizer,2,final,10-90,infection ,infection,Israel ,HHC of cases,HHC of cases,72,65.9,77,,delta,~11 weeks,,,
57,Prunas,Pfizer,2,final,90+,infection ,infection,Israel ,HHC of cases,HHC of cases,40.2,37.6,42.6,,delta,~26.5 weeks,,,
58,Butt,Pfizer,2,final,14+,infection ,infection,Qatar,pregnant women,pregnant persons,87.7,43.5,97.3,,alpha & beta,~17 weeks,,,
58,Butt,Moderna,2,final,14+,infection ,infection,Qatar,pregnant women,pregnant persons,100,0,100,,alpha & beta,~17 weeks,,,
59,Balicer,Pfizer,1,1,14-20,infection ,infection,Israel ,pregnant women,pregnant persons,67,40,84,,original & alpha,,,,
59,Balicer,Pfizer,2,final,7-56,infection ,infection,Israel ,pregnant women,pregnant persons,96,89,100,,original & alpha,~18 weeks,,,
59,Balicer,Pfizer,1,1,21-27,infection ,infection,Israel ,pregnant women,pregnant persons,71,33,94,,original & alpha,,,,
59,Balicer,Pfizer,1,1,14-20,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,66,32,86,,original & alpha,,,,
59,Balicer,Pfizer,2,final,7-56,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,97,91,100,,original & alpha,~18 weeks,,,
59,Balicer,Pfizer,1,1,21-27,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,76,30,100,,original & alpha,,,,
59,Balicer,Pfizer,2,final,7-56,hospitalization,severe,Israel ,pregnant women,pregnant persons,89,43,100,,original & alpha,~18 weeks,,,
60,Layan,Pfizer,2,final,7+,infection ,infection,Israel ,HHC of cases,HHC of cases,79,56,92,,original & alpha,~12 weeks,,,
61,Butt,Pfizer,1,1,0+,infection ,infection,USA,general pop,general pop,85,84.2,85.8,,original & alpha,,,,
61,Butt,Pfizer,2,final,7+,infection ,infection,USA,general pop,general pop,97.1,96.6,97.5,,original & alpha,~6.5 weeks,,,
61,Butt,Pfizer,1,1,0+,infection ,infection,USA,general pop,general pop,84,82.7,85.1,,original & alpha,,,,
61,Butt,Pfizer,2,final,7+,infection ,infection,USA,general pop,general pop,96.2,95.5,96.9,,original & alpha,~6.5 weeks,,,
61,Butt,Moderna,1,1,0+,infection ,infection,USA,general pop,general pop,85.7,84.6,86.8,,original & alpha,,,,
61,Butt,Moderna,2,final,7+,infection ,infection,USA,general pop,general pop,98.2,97.5,98.6,,original & alpha,~6.5 weeks,,,
62,Lopez Bernal,Pfizer,1,1,21+,symptomatic disease,symptomatic,UK,general pop,general pop,47.5,41.6,52.8,alpha,alpha,,,,
62,Lopez Bernal,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,general pop,general pop,93.7,91.6,95.3,alpha,alpha,~17 weeks,,,
62,Lopez Bernal,AZD1222 (AstraZeneca),1,1,21+,symptomatic disease,symptomatic,UK,general pop,general pop,48.7,45.2,51.9,alpha,alpha,,,,
62,Lopez Bernal,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,general pop,general pop,74.5,68.4,79.4,alpha,alpha,~17 weeks,,,
62,Lopez Bernal,Pfizer,1,1,21+,symptomatic disease,symptomatic,UK,general pop,general pop,35.6,22.7,46.4,delta,delta,,,,
62,Lopez Bernal,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,general pop,general pop,88,85.3,90.1,delta,delta,~17 weeks,,,
62,Lopez Bernal,AZD1222 (AstraZeneca),1,1,21+,symptomatic disease,symptomatic,UK,general pop,general pop,30,24.3,35.3,delta,delta,,,,
62,Lopez Bernal,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,general pop,general pop,67,61.3,71.8,delta,delta,~17 weeks,,,
63,Kim,Pfizer,1+,1+,28,symptomatic disease,symptomatic,USA,general pop,general pop,75,55,87,,non-VOC & alpha,,,,
63,Kim,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,general pop,general pop,91,83,95,,non-VOC & alpha,~18.5 weeks,,,
64,Hitchings,AZD1222 (AstraZeneca),1,1,28+,symptomatic disease,symptomatic,Brazil,> 60 years,> 60 years,33.4,26.4,39.7,,gamma,,,,
64,Hitchings,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Brazil,> 60 years,> 60 years,77.9,69.2,84.2,,gamma,~9.5 weeks,,,
64,Hitchings,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,Brazil,> 60 years,> 60 years,55.1,46.6,62.2,,gamma,,,,
64,Hitchings,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,Brazil,> 60 years,> 60 years,87.6,78.2,92.9,,gamma,~9.5 weeks,,,
64,Hitchings,AZD1222 (AstraZeneca),1,1,28+,death,death,Brazil,> 60 years,> 60 years,61.8,48.9,71.4,,gamma,,,,
64,Hitchings,AZD1222 (AstraZeneca),2,final,14+,death,death,Brazil,> 60 years,> 60 years,93.6,81.9,97.7,,gamma,~9.5 weeks,,,
65,Carazo,Pfizer,1,1,14+,infection ,infection,Canada,HCW,HCW,70.3,68.1,72.4,,non-VOC & alpha,,,,
65,Carazo,Pfizer,2,final,7+,infection ,infection,Canada,HCW,HCW,85.5,80.4,89.3,,non-VOC & alpha,~20 weeks,,,
65,Carazo,Pfizer,1,1,14+,symptomatic disease,symptomatic,Canada,HCW,HCW,72.8,70.5,74.9,,non-VOC & alpha,,,,
65,Carazo,Pfizer,2,final,7+,symptomatic disease,symptomatic,Canada,HCW,HCW,92.2,87.8,95.1,,non-VOC & alpha,~20 weeks,,,
65,Carazo,Moderna,1,1,14+,infection ,infection,Canada,HCW,HCW,68.7,59.5,75.9,,non-VOC & alpha,,,,
65,Carazo,Moderna,2,final,7+,infection ,infection,Canada,HCW,HCW,84.1,34.9,96.1,,non-VOC & alpha,~20 weeks,,,
65,Carazo,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,HCW,HCW,80.9,74.3,85.8,,non-VOC & alpha,,,,
65,Carazo,Pfizer,1,1,14+,hospitalization,severe,Canada,HCW,HCW,97.2,92.3,99,,non-VOC & alpha,,,,
65,Carazo,Pfizer,1,1,14+,infection ,infection,Canada,HCW,HCW,60,53.6,65.5,alpha,alpha,,,,
65,Carazo,Pfizer,2,final,7+,infection ,infection,Canada,HCW,HCW,92.6,87.1,95.8,alpha,alpha,~20 weeks,,,
65,Carazo,Pfizer,1,1,14+,infection ,infection,Canada,HCW,HCW,77,72.6,80.7,non-VOC,non-VOC,,,,
65,Carazo,Pfizer,2,final,7+,infection ,infection,Canada,HCW,HCW,86.5,56.8,95.8,non-VOC,non-VOC,~20 weeks,,,
66,Kissling,Pfizer,1,1,14+,symptomatic disease,symptomatic,"UK, FR, NL, PT, ES, SE",≥ 65 years,≥ 65 years,61,39,75,,alpha,,,,
66,Kissling,Pfizer,2,final,14+,symptomatic disease,symptomatic,"UK, FR, NL, PT, ES, SE",≥ 65 years,≥ 65 years,87,74,93,,alpha,~16 weeks,,,
66,Kissling,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,"UK, FR, NL, PT, ES, SE",≥ 65 years,≥ 65 years,68,39,83,,alpha,,,,
67,Amirthalingam,Pfizer,1,1,28+,infection ,infection,UK,> 80 years,> 80 years,42,31,52,,alpha,,,,
67,Amirthalingam,Pfizer,2,final,14+,infection ,infection,UK,> 80 years,> 80 years,77,56,88,,alpha,~16 weeks,19-29 days,,
67,Amirthalingam,Pfizer,2,1,14+,infection ,infection,UK,> 80 years,> 80 years,90,83,94,,alpha,,65-84 days,,
67,Amirthalingam,Pfizer,1,final,28+,infection ,infection,UK,65-79 years,65-79 years,53,48,58,,alpha,~16 weeks,,,
67,Amirthalingam,Pfizer,2,final,14+,infection ,infection,UK,65-79 years,65-79 years,77,66,85,,alpha,~16 weeks,19-29 days,,
67,Amirthalingam,Pfizer,2,final,14+,infection ,infection,UK,65-79 years,65-79 years,89,86,92,,alpha,~16 weeks,65-84 days,,
67,Amirthalingam,Pfizer,1,1,28+,infection ,infection,UK,50-64 years,50-64 years,51,47,55,,alpha,,,,
67,Amirthalingam,Pfizer,2,final,14+,infection ,infection,UK,50-64 years,50-64 years,88,67,96,,alpha,~16 weeks,19-29 days,,
67,Amirthalingam,Pfizer,2,final,14+,infection ,infection,UK,50-64 years,50-64 years,92,91,94,,alpha,~16 weeks,65-84 days,,
67,Amirthalingam,AZD1222 (AstraZeneca),1,1,28+,infection ,infection,UK,> 80 years,> 80 years,42,29,53,,alpha,,,,
67,Amirthalingam,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,> 80 years,> 80 years,96,68,99,,alpha,~16 weeks,45-64 days,,
67,Amirthalingam,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,> 80 years,> 80 years,82,68,89,,alpha,~16 weeks,65-84 days,,
67,Amirthalingam,AZD1222 (AstraZeneca),1,1,28+,infection ,infection,UK,65-79 years,65-79 years,52,46,56,,alpha,,,,
67,Amirthalingam,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,65-79 years,65-79 years,73,25,90,,alpha,~16 weeks,30-44 days,,
67,Amirthalingam,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,65-79 years,65-79 years,74,69,79,,alpha,~16 weeks,65-84 days,,
67,Amirthalingam,AZD1222 (AstraZeneca),1,1,28+,infection ,infection,UK,50-64 years,50-64 years,42,39,46,,alpha,,,,
67,Amirthalingam,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,50-64 years,50-64 years,55,34,69,,alpha,~16 weeks,30-44 days,,
67,Amirthalingam,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,50-64 years,50-64 years,77,74,79,,alpha,~16 weeks,65-84 days,,
68,Gram,AZD1222 (AstraZeneca) & any mRNA - heterologous,1,1,14-20,infection ,infection,Denmark,general pop,general pop,39,23,52,,alpha,,,,
68,Gram,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,infection ,infection,Denmark,general pop,general pop,88,83,92,,alpha,~20 weeks,,,
68,Gram,AZD1222 (AstraZeneca) & any mRNA - heterologous,1,1,105+,infection ,infection,Denmark,general pop,general pop,-47,-208,30,,alpha,,,,
68,Gram,AZD1222 (AstraZeneca) & any mRNA - heterologous,1,1,14+,hospitalization,severe,Denmark,general pop,general pop,93,80,98,,alpha,,,,
69,Alali,Pfizer,1,1,14+,infection ,infection,Kuwait,HCW,HCW,91.4,65.1,97.9,,alpha,,,,
69,Alali,Pfizer,2,final,7+,infection ,infection,Kuwait,HCW,HCW,94.5,89.4,97.2,,alpha,~18 weeks,,,
69,Alali,AZD1222 (AstraZeneca),1,1,28+,infection ,infection,Kuwait,HCW,HCW,75.4,67.2,81.6,,alpha,,,,
70,Lefèvre,Pfizer,1+,1+,28,infection ,infection,France,LTCF residents,LTCF residents,55,13,76,beta,beta,,,,
70,Lefèvre,Pfizer,2,final,7+,infection ,infection,France,LTCF residents,LTCF residents,49,14,69,beta,beta,~16 weeks,,,
70,Lefèvre,Pfizer,1+,1+,28,hospitalization or death,severe,France,LTCF residents,LTCF residents,86,32,97,beta,beta,,,,
70,Lefèvre,Pfizer,2,final,7+,hospitalization or death,severe,France,LTCF residents,LTCF residents,86,67,94,beta,beta,~16 weeks,,,
71,de Gier,AZD1222 (AstraZeneca),1,1,14+,infection ,infection,Netherlands,HHC of cases,HHC of cases,2,-11,14,,alpha,,,,
71,de Gier,AZD1222 (AstraZeneca),2,final,7+,infection ,infection,Netherlands,HHC of cases,HHC of cases,87,77,93,,alpha,~15 weeks,,,
71,de Gier,Pfizer,1,1,14+,infection ,infection,Netherlands,HHC of cases,HHC of cases,-18,-43,2,,alpha,,,,
71,de Gier,Pfizer,2,final,7+,infection ,infection,Netherlands,HHC of cases,HHC of cases,65,60,70,,alpha,~15 weeks,,,
71,de Gier,Moderna,1,1,14+,infection ,infection,Netherlands,HHC of cases,HHC of cases,33,-27,64,,alpha,,,,
71,de Gier,Moderna,2,final,7+,infection ,infection,Netherlands,HHC of cases,HHC of cases,91,79,97,,alpha,~15 weeks,,,
71,de Gier,Janssen,1,final,14+,infection ,infection,Netherlands,HHC of cases,HHC of cases,12,-71,54,,alpha,~15 weeks,,,
72,Puranik,Pfizer,1,1,1-7,infection ,infection,USA,general pop,general pop,16,-20,42,,alpha & delta,,,,
72,Puranik,Pfizer,2,final,14+,infection ,infection,USA,general pop,general pop,76,69,81,,alpha & delta,~26 weeks,,,
72,Puranik,Pfizer,1,1,1-7,hospitalization,severe,USA,general pop,general pop,75,-30,97.4,,alpha & delta,,,,
72,Puranik,Pfizer,2,final,14+,hospitalization,severe,USA,general pop,general pop,85,73,93,,alpha & delta,~26 weeks,,,
72,Puranik,Pfizer,1,1,1-7,ICU admission,severe,USA,general pop,general pop,100,-430,100,,alpha & delta,,,,
72,Puranik,Pfizer,2,final,14+,ICU admission,severe,USA,general pop,general pop,87,46,98.6,,alpha & delta,~26 weeks,,,
72,Puranik,Moderna,1,1,1-7,infection ,infection,USA,general pop,general pop,-10,-50,24,,alpha & delta,,,,
72,Puranik,Moderna,2,final,14+,infection ,infection,USA,general pop,general pop,86,81,90.6,,alpha & delta,~26 weeks,,,
72,Puranik,Moderna,1,1,1-7,hospitalization,severe,USA,general pop,general pop,25,-150,79,,alpha & delta,,,,
72,Puranik,Moderna,2,final,14+,hospitalization,severe,USA,general pop,general pop,91.6,81,97,,alpha & delta,~26 weeks,,,
72,Puranik,Moderna,1,1,1-7,ICU admission,severe,USA,general pop,general pop,100,-430,100,,alpha & delta,,,,
72,Puranik,Moderna,2,final,14+,ICU admission,severe,USA,general pop,general pop,93.3,57,99.8,,alpha & delta,~26 weeks,,,
73,Chemaitelly,Pfizer,2,final,14+,infection ,infection,Qatar,transplant patients,transplant patients,46.6,0,73.7,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Pfizer,2,final,42+,infection ,infection,Qatar,transplant patients,transplant patients,66,21.3,85.3,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Pfizer,2,final,56+,infection ,infection,Qatar,transplant patients,transplant patients,73.9,33,89.9,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Pfizer,2,final,14+,severe infection,severe,Qatar,transplant patients,transplant patients,72.3,0,90.9,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Pfizer,2,final,42+,severe infection,severe,Qatar,transplant patients,transplant patients,85,35.7,96.5,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Pfizer,2,final,56+,severe infection,severe,Qatar,transplant patients,transplant patients,83.8,31.3,96.2,,alpha & beta,~17 weeks,,,
74,Tang,Pfizer,1,1,14+,infection ,infection,Qatar,general pop,general pop,42.8,18.2,60.1,delta,delta,,,,
74,Tang,Pfizer,2,final,14+,infection ,infection,Qatar,general pop,general pop,50.6,45.4,55.3,delta,delta,~25 weeks,,,
74,Tang,Moderna,1,1,14+,infection ,infection,Qatar,general pop,general pop,73.2,57.3,83.2,delta,delta,,,,
74,Tang,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,72,66.1,76.9,delta,delta,~25 weeks,,,
74,Tang,Pfizer,1,1,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,84.5,-25.2,98.1,delta,delta,,,,
74,Tang,Pfizer,2,final,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,94.1,85.9,97.6,delta,delta,~25 weeks,,,
74,Tang,Moderna,1,1,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,87.5,23.4,95.8,delta,delta,,,,
74,Tang,Moderna,2,final,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,96.1,71.4,99.5,delta,delta,~25 weeks,,,
74,Tang,Pfizer,1,1,14+,symptomatic disease,symptomatic,Qatar,general pop,general pop,56.2,30.6,72.4,delta,delta,,,,
74,Tang,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,general pop,general pop,44.4,37,50.9,delta,delta,~25 weeks,,,
74,Tang,Moderna,1,1,14+,symptomatic disease,symptomatic,Qatar,general pop,general pop,82.5,65.2,91.2,delta,delta,,,,
74,Tang,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,general pop,general pop,73.9,65.9,79.9,delta,delta,~25 weeks,,,
74,Tang,Pfizer,1,1,14+,asymptomatic infection,asymptomatic,Qatar,general pop,general pop,46.7,-56.2,81.8,delta,delta,,,,
74,Tang,Pfizer,2,final,14+,asymptomatic infection,asymptomatic,Qatar,general pop,general pop,46,32.3,56.9,delta,delta,~25 weeks,,,
74,Tang,Moderna,1,1,14+,asymptomatic infection,asymptomatic,Qatar,general pop,general pop,61.8,-9.6,86.7,delta,delta,,,,
74,Tang,Moderna,2,final,14+,asymptomatic infection,asymptomatic,Qatar,general pop,general pop,53.6,33.4,67.6,delta,delta,~25 weeks,,,
74,Tang,Pfizer,1,1,14+,infection ,infection,Qatar,general pop,general pop,18.9,-1.8,35.4,beta,beta,,,,
74,Tang,Pfizer,2,final,14+,infection ,infection,Qatar,general pop,general pop,74.3,70.3,77.7,beta,beta,~25 weeks,,,
74,Tang,Moderna,1,1,14+,infection ,infection,Qatar,general pop,general pop,66.3,55.8,74.2,beta,beta,,,,
74,Tang,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,80.8,69,88.2,beta,beta,~25 weeks,,,
74,Tang,Pfizer,1,1,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,74.8,-7.6,94.1,beta,beta,,,,
74,Tang,Pfizer,2,final,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,92.7,81.5,97.1,beta,beta,~25 weeks,,,
74,Tang,Moderna,1,1,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,72.5,7.7,91.8,beta,beta,,,,
74,Tang,Moderna,2,final,14+,"severe, critical, fatal disease",severe,Qatar,general pop,general pop,100,,,beta,beta,~25 weeks,,,
75,Nanduri,Pfizer,2,final,14+,infection ,infection,USA,SNF residents,SNF residents,74.2,69,78.7,,non-VOC & alpha,~16 weeks,,,
75,Nanduri,Moderna,2,final,14+,infection ,infection,USA,SNF residents,SNF residents,74.7,66.2,81.1,,non-VOC & alpha,~16 weeks,,,
75,Nanduri,Pfizer,2,final,14+,infection ,infection,USA,SNF residents,SNF residents,66.5,58.3,73.1,,alpha,~22 weeks,,,
75,Nanduri,Moderna,2,final,14+,infection ,infection,USA,SNF residents,SNF residents,70.4,60.1,78,,alpha,~22 weeks,,,
75,Nanduri,Pfizer,2,final,14+,infection ,infection,USA,SNF residents,SNF residents,52.4,48,56.4,,delta,~25 weeks,,,
75,Nanduri,Moderna,2,final,14+,infection ,infection,USA,SNF residents,SNF residents,50.6,45,55.7,,delta,~25 weeks,,,
76,Chin,Pfizer,1,1,14+,infection ,infection,USA,incarcerated persons,incarcerated persons,74,64,82,,non-VOC,,,,
76,Chin,Pfizer,2,final,14+,infection ,infection,USA,incarcerated persons,incarcerated persons,97,88,99,,non-VOC,~5 weeks,,,
76,Chin,Pfizer,1,1,14+,infection ,infection,USA,"incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",74,62,82,,non-VOC,,,,
76,Chin,Pfizer,2,final,14+,infection ,infection,USA,"incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",92,74,98,,non-VOC,~5 weeks,,,
76,Chin,Moderna,1,1,14+,infection ,infection,USA,incarcerated persons,incarcerated persons,71,58,80,,non-VOC,,,,
76,Chin,Moderna,2,final,14+,infection ,infection,USA,incarcerated persons,incarcerated persons,96,67,99,,non-VOC,~5 weeks,,,
77,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,general pop,general pop,81,77,84,,alpha & delta,~30 weeks,,,
77,Tenforde,Pfizer,2,final,14-120,hospitalization,severe,USA,general pop,general pop,85,82,88,,alpha & delta,,,,
77,Tenforde,Pfizer,2,final,120+,hospitalization,severe,USA,general pop,general pop,64,51,73,,alpha & delta,~30 weeks,,,
77,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,general pop,general pop,89,86,92,,alpha & delta,~30 weeks,,,
77,Tenforde,Moderna,2,final,14-120,hospitalization,severe,USA,general pop,general pop,91,87,93,,alpha & delta,,,,
77,Tenforde,Moderna,2,final,120+,hospitalization,severe,USA,general pop,general pop,85,77,91,,alpha & delta,~30 weeks,,,
77,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,immuncompetent,immuncompetent,90,87,91,,alpha & delta,~30 weeks,,,
77,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,immucompromised,"immunocompromised, ≥ 16 years",51,31,65,,alpha & delta,~30 weeks,,,
77,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,general pop,general pop,90,84,94,alpha,alpha,~30 weeks,,,
77,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,general pop,general pop,86,79,90,delta,delta,~30 weeks,,,
78,Pouwels,Pfizer,1,1,21+,infection ,infection,UK,general pop,general pop,59,52,95,,alpha,,,,
78,Pouwels,Pfizer,1,1,21+,"infection, ct<30",infection,UK,general pop,general pop,70,65,74,,alpha,,,,
78,Pouwels,Pfizer,2,final,14+,infection ,infection,UK,general pop,general pop,78,68,84,,alpha,~28 weeks,,,
78,Pouwels,Pfizer,2,final,14+,"infection, ct<30",infection,UK,general pop,general pop,94,94,96,,alpha,~28 weeks,,,
78,Pouwels,AZD1222 (AstraZeneca),1,1,21+,infection ,infection,UK,general pop,general pop,63,55,69,,alpha,,,,
78,Pouwels,AZD1222 (AstraZeneca),1,1,21+,"infection, ct<30",infection,UK,general pop,general pop,74,69,79,,alpha,,,,
78,Pouwels,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,general pop,general pop,79,56,90,,alpha,~28 weeks,,,
78,Pouwels,AZD1222 (AstraZeneca),2,final,14+,"infection, ct<30",infection,UK,general pop,general pop,86,71,93,,alpha,~28 weeks,,,
78,Pouwels,Pfizer,1,1,21+,infection ,infection,UK,general pop,general pop,57,50,63,,delta,,,,
78,Pouwels,Pfizer,1,1,21+,"infection, ct<30",infection,UK,general pop,general pop,62,56,68,,delta,,,,
78,Pouwels,Pfizer,2,final,14+,infection ,infection,UK,general pop,general pop,80,77,83,,delta,~28 weeks,,,
78,Pouwels,Pfizer,2,final,14+,"infection, ct<30",infection,UK,general pop,general pop,84,82,86,,delta,~28 weeks,,,
78,Pouwels,AZD1222 (AstraZeneca),1,1,21+,infection ,infection,UK,general pop,general pop,46,35,55,,delta,,,,
78,Pouwels,AZD1222 (AstraZeneca),1,1,21+,"infection, ct<30",infection,UK,general pop,general pop,50,41,59,,delta,,,,
78,Pouwels,AZD1222 (AstraZeneca),2,final,14+,infection ,infection,UK,general pop,general pop,67,62,71,,delta,~28 weeks,,,
78,Pouwels,AZD1222 (AstraZeneca),2,final,14+,"infection, ct<30",infection,UK,general pop,general pop,70,65,73,,delta,~28 weeks,,,
79,Prasad,Pfizer,2,final,14+,post-operative infection,infection,USA,surgery patients,surgery patients,91,56,99,,non-VOC,~8 weeks,,,
80,Tartof,Pfizer,1,1,14+,infection,infection,USA,≥ 12 years,general pop,58,54,61,,epsilon & alpha & delta,,,,
80,Tartof,Pfizer,2,final,7+,infection ,infection,USA,≥ 12 years,general pop,73,72,74,,epsilon & alpha & delta,~29 weeks,,,
80,Tartof,Pfizer,2,final,7-36,infection,infection,USA,≥ 12 years,general pop,88,86,89,,epsilon & alpha & delta,~3 weeks,,,
80,Tartof,Pfizer,2,final,157+,infection,infection,USA,≥ 12 years,general pop,47,43,51,,epsilon & alpha & delta,~29 weeks,,,
80,Tartof,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 12 years,general pop,54,43,63,,epsilon & alpha & delta,,,,
80,Tartof,Pfizer,2,final,7+,hospitalization,severe,USA,≥ 12 years,general pop,90,89,92,,epsilon & alpha & delta,~29 weeks,,,
80,Tartof,Pfizer,2,final,7-36,hospitalization,severe,USA,≥ 12 years,general pop,87,82,91,,epsilon & alpha & delta,~3 weeks,,,
80,Tartof,Pfizer,2,final,157+,hospitalization,severe,USA,≥ 12 years,general pop,88,82,92,,epsilon & alpha & delta,~29 weeks,,,
80,Tartof,Pfizer,1,1,14+,infection ,infection,USA,≥ 12 years,general pop,74,55,85,delta,delta,,,,
80,Tartof,Pfizer,2,final,7+,infection ,infection,USA,≥ 12 years,general pop,75,71,78,delta,delta,~29 weeks,,,
80,Tartof,Pfizer,2,final,7-36,infection,infection,USA,≥ 12 years,general pop,93,85,97,delta,delta,~3 weeks,,,
80,Tartof,Pfizer,2,final,127+,infection,infection,USA,≥ 12 years,general pop,53,39,65,delta,delta,~29 weeks,,,
80,Tartof,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 12 years,general pop,79,-49,97,delta,delta,,,,
80,Tartof,Pfizer,2,final,7+,hospitalization,severe,USA,≥ 12 years,general pop,93,84,96,delta,delta,~29 weeks,,,
80,Tartof,Pfizer,1,1,14+,infection ,infection,USA,≥ 12 years,general pop,74,64,81,non-delta,non-delta,,,,
80,Tartof,Pfizer,2,final,7+,infection ,infection,USA,≥ 12 years,general pop,91,88,92,non-delta,non-delta,~29 weeks,,,
80,Tartof,Pfizer,2,final,7-36,infection,infection,USA,≥ 12 years,general pop,97,95,99,non-delta,non-delta,~3 weeks,,,
80,Tartof,Pfizer,2,final,127+,infection,infection,USA,≥ 12 years,general pop,67,45,80,non-delta,non-delta,~29 weeks,,,
80,Tartof,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 12 years,general pop,75,21,92,non-delta,non-delta,,,,
80,Tartof,Pfizer,2,final,7+,hospitalization,severe,USA,≥ 12 years,general pop,95,90,98,non-delta,non-delta,~29 weeks,,,
81,Golberg,Pfizer,2,final,168-203,infection,infection,Israel ,16-39 years,16-39 years,55,50,60,,delta,28 weeks,,,
81,Golberg,Pfizer,2,final,55-98,infection,infection,Israel ,16-39 years,16-39 years,80,75,84,,delta,13 weeks,,,
81,Golberg,Pfizer,2,final,168-203,infection,infection,Israel ,40-59 years,40-59 years,57,53,61,,delta,28 weeks,,,
81,Golberg,Pfizer,2,final,55-98,infection,infection,Israel ,40-59 years,40-59 years,83,75,88,,delta,13 weeks,,,
81,Golberg,Pfizer,2,final,168-203,infection,infection,Israel ,≥ 60 years,≥ 60 years,57,52,62,,delta,28 weeks,,,
81,Golberg,Pfizer,2,final,55-98,infection,infection,Israel ,≥ 60 years,≥ 60 years,82,70,89,,delta,13 weeks,,,
81,Golberg,Pfizer,2,final,168-203,severe disease,severe,Israel ,40-59 years,40-59 years,98,94,99,,delta,28 weeks,,,
81,Golberg,Pfizer,2,final,168-203,severe disease,severe,Israel ,≥ 60 years,≥ 60 years,93,86,97,,delta,13 weeks,,,
81,Golberg,Pfizer,2,final,109-159,severe disease,severe,Israel ,40-59 years,40-59 years,92,87,95,,delta,22 weeks,,,
81,Golberg,Pfizer,2,final,109-159,severe disease,severe,Israel ,≥ 60 years,≥ 60 years,85,81,88,,delta,22 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,infection,infection,Qatar,≥ 12 years,general pop,36.8,33.2,40.2,,"alpha, beta & delta",,,,
82,Chemaitelly ,Pfizer,2,final,28-63,infection ,infection,Qatar,≥ 12 years,general pop,73.2,71.3,75,,"alpha, beta & delta",7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,175+,infection ,infection,Qatar,≥ 12 years,general pop,22.3,-1.7,40.7,,"alpha, beta & delta",~32 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,symptomatic disease,symptomatic,Qatar,≥ 12 years,general pop,47.9,43.6,51.9,,"alpha, beta & delta",,,,
82,Chemaitelly ,Pfizer,2,final,28-63,symptomatic disease,symptomatic,Qatar,≥ 12 years,general pop,72.5,69.6,75.1,,"alpha, beta & delta",7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,175+,symptomatic disease,symptomatic,Qatar,≥ 12 years,general pop,27.8,-1.4,48.7,,"alpha, beta & delta",~32 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,asymptomatic infection,asymptomatic,Qatar,≥ 12 years,general pop,22.2,12.1,31.2,,"alpha, beta & delta",,,,
82,Chemaitelly ,Pfizer,2,final,28-63,asymptomatic infection,asymptomatic,Qatar,≥ 12 years,general pop,66.9,61.9,71.3,,"alpha, beta & delta",7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,175+,asymptomatic infection,asymptomatic,Qatar,≥ 12 years,general pop,-33.3,-181.8,36.9,,"alpha, beta & delta",~29 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,"severe, critical, fatal disease",severe,Qatar,≥ 12 years,general pop,66.1,56.8,73.5,,"alpha, beta & delta",,,,
82,Chemaitelly ,Pfizer,2,final,28-63,"severe, critical, fatal disease",severe,Qatar,≥ 12 years,general pop,96.8,93.9,98.3,,"alpha, beta & delta",7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,175+,"severe, critical, fatal disease",severe,Qatar,≥ 12 years,general pop,55.6,-44.3,86.3,,"alpha, beta & delta",~32 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,infection,infection,Qatar,≥ 12 years,general pop,47.9,15.5,67.9,alpha,alpha,,,,
82,Chemaitelly ,Pfizer,2,final,28-63,infection,infection,Qatar,≥ 12 years,general pop,88.6,79.2,93.7,alpha,alpha,7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,147+,infection,infection,Qatar,≥ 12 years,general pop,80,-71.2,97.7,alpha,alpha,~29 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,infection,infection,Qatar,≥ 12 years,general pop,25.8,-2,46.1,beta,beta,,,,
82,Chemaitelly ,Pfizer,2,final,28-63,infection,infection,Qatar,≥ 12 years,general pop,63.9,52.6,72.5,beta,beta,7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,147+,infection ,infection,Qatar,≥ 12 years,general pop,40,-151.1,85.7,beta,beta,~29 weeks,,,
82,Chemaitelly ,Pfizer,1,1,14+,infection,infection,Qatar,≥ 12 years,general pop,63.4,42.6,76.6,delta,delta,,,,
82,Chemaitelly ,Pfizer,2,final,28-63,infection,infection,Qatar,≥ 12 years,general pop,73.3,63.6,80.4,delta,delta,7 weeks,,,
82,Chemaitelly ,Pfizer,2,final,147+,infection,infection,Qatar,≥ 12 years,general pop,17.9,-12.9,40.3,delta,delta,~29 weeks,,,
83,Nunes,Pfizer,1,1,28,hospitalization,severe,Portugal,65-79 years,65-79 years,78,61,87,,alpha & delta,,,,
83,Nunes,Pfizer,2,final,14+,hospitalization,severe,Portugal,65-79 years,65-79 years,94,88,97,,alpha & delta,~14.5 weeks,,,
83,Nunes,Pfizer,1,1,28,death,death,Portugal,65-79 years,65-79 years,77,56,88,,alpha & delta,,,,
83,Nunes,Pfizer,2,final,14+,death,death,Portugal,65-79 years,65-79 years,96,92,98,,alpha & delta,~14.5 weeks,,,
83,Nunes,Pfizer,1,1,28,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,55,36,69,,alpha & delta,,,,
83,Nunes,Pfizer,2,final,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,82,72,89,,alpha & delta,~22.5 weeks,,,
83,Nunes,Pfizer,1,1,28,death,death,Portugal,≥ 80 years,≥ 80 years,56,35,70,,alpha & delta,,,,
83,Nunes,Pfizer,2,final,14+,death,death,Portugal,≥ 80 years,≥ 80 years,81,74,87,,alpha & delta,~22.5 weeks,,,
84,Katz,Pfizer,2,final,14+,infection,infection,Israel ,HCW,HCW,94.5,82.5,98.2,,alpha,~18 weeks,,,
84,Katz,Pfizer,2,final,7+,symptomatic disease,symptomatic,Israel ,HCW,HCW,97,72,99.7,,alpha,~18 weeks,,,
85,Giansante,Pfizer,1,1,14+,infection,infection,Italy,HCW and staff,HCW and staff,85.5,75.9,91.3,,alpha & delta,,,,
85,Giansante,Pfizer,2,final,14+,infection,infection,Italy,HCW and staff,HCW and staff,84.8,73.2,91.4,,alpha & delta,~16 weeks,,,
85,Giansante,Pfizer,1,1,14+,symptomatic disease,symptomatic,Italy,HCW and staff,HCW and staff,81.7,62.7,91,,alpha & delta,,,,
85,Giansante,Pfizer,2,final,14+,symptomatic disease,symptomatic,Italy,HCW and staff,HCW and staff,87.1,69.3,94.6,,alpha & delta,~16 weeks,,,
85,Giansante,Pfizer,1,1,14+,infection,infection,Italy,HCW,HCW,87.8,76.5,93.7,,alpha & delta,,,,
85,Giansante,Pfizer,2,final,14+,infection,infection,Italy,HCW,HCW,84.4,69.7,92,,alpha & delta,~16 weeks,,,
85,Giansante,Pfizer,1,1,14+,symptomatic disease,symptomatic,Italy,HCW,HCW,83.1,60,92.9,,alpha & delta,,,,
85,Giansante,Pfizer,2,final,14+,symptomatic disease,symptomatic,Italy,HCW,HCW,86.5,62.9,95.1,,alpha & delta,~16 weeks,,,
86,Bruxvoort,Moderna,2,final,14+,infection,infection,USA,adults,general pop,87.4,85.6,89.1,,alpha & delta,~20 weeks,,,
86,Bruxvoort,Moderna,2,final,14+,asymptomatic infection,asymptomatic,USA,adults,general pop,72.7,57.6,82.4,,alpha & delta,~20 weeks,,,
86,Bruxvoort,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,adults,general pop,88.3,86.5,89.9,,alpha & delta,~20 weeks,,,
86,Bruxvoort,Moderna,2,final,14+,hospitalization,severe,USA,adults,general pop,95.8,92.5,97.6,,alpha & delta,~20 weeks,,,
86,Bruxvoort,Moderna,2,final,14+,death,death,USA,adults,general pop,97.9,84.5,99.7,,alpha & delta,~20 weeks,,,
87,Barlow,Pfizer,2,final,14+,infection,infection,USA,≥ 15 years,general pop,74,65,82,,delta,~4 weeks,,,
87,Barlow,Janssen,1,final,14+,infection,infection,USA,≥ 15 years,general pop,51,-2,76,,delta,~4 weeks,,,
88,Tande,Pfizer,1,1,20+,asymptomatic infection (January-March),asymptomatic,USA,surgery patients,surgery patients,44,-6,71,,non-VOC,,,,
88,Tande,Pfizer,2,final,14+,asymptomatic infection (January-March),asymptomatic,USA,surgery patients,surgery patients,91,72,98,,non-VOC,~10 weeks,,,
88,Tande,Pfizer,1,1,20+,asymptomatic infection (April-May),asymptomatic,USA,surgery patients,surgery patients,46,53,83,,alpha,,,,
88,Tande,Pfizer,2,final,14+,asymptomatic infection (April-May),asymptomatic,USA,surgery patients,surgery patients,71,53,83,,alpha,~19 weeks,,,
88,Tande,Pfizer,1,1,20+,asymptomatic infection (June-August),asymptomatic,USA,surgery patients,surgery patients,63,44,76,,delta,,,,
88,Tande,Pfizer,2,final,14+,asymptomatic infection (June-August),asymptomatic,USA,surgery patients,surgery patients,63,44,76,,delta,~32 weeks,,,
89,Iliaki,Pfizer,1,1,14+,infection,infection,USA,HCW,HCW,80.2,57.5,90.8,,alpha,,,,
89,Iliaki,Pfizer,2,final,14+,infection,infection,USA,HCW,HCW,95.2,80,98.8,,alpha,~10 weeks,,,
90,Thompson,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,33,18,46,,non-VOC & alpha,,,,
90,Thompson,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,87,85,90,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Pfizer,1,1,14+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,58,46,68,,non-VOC & alpha,,,,
90,Thompson,Pfizer,2,final,14+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,89,85,91,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Moderna,1,1,14+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,68,59,75,,non-VOC & alpha,,,,
90,Thompson,Moderna,2,final,14+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,91,89,93,,non-VOC & alpha,20 weeks,,,
90,Thompson,Moderna,1,1,14+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,73,64,79,,non-VOC & alpha,,,,
90,Thompson,Moderna,2,final,14+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,92,89,94,,non-VOC & alpha,20 weeks,,,
90,Thompson,Janssen,1,final,14+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,68,50,79,,non-VOC & alpha,14 weeks,,,
90,Thompson,Janssen,1,final,14+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,73,59,82,,non-VOC & alpha,14 weeks,,,
90,Thompson,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic respiratory condition,≥ 50 years with ≥ 1 chronic respiratory condition,56,47,64,,non-VOC & alpha,,,,
90,Thompson,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic respiratory condition,≥ 50 years with ≥ 1 chronic respiratory condition,90,88,92,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic non-respiratory condition,≥ 50 years with ≥ 1 chronic non-respiratory condition,54,45,61,,non-VOC & alpha,,,,
90,Thompson,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic non-respiratory condition,≥ 50 years with ≥ 1 chronic non-respiratory condition,88,86,90,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Pfizer,2,final,14-27,hospitalization,severe,USA,≥ 50 years,≥ 50 years,88,84,92,,non-VOC & alpha,~2 weeks,,,
90,Thompson,Pfizer,2,final,112+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,86,74,93,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Pfizer,2,final,14-27,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,92,88,95,,non-VOC & alpha,~2 weeks,,,
90,Thompson,Pfizer,2,final,112+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,86,74,93,,non-VOC & alpha,~22 weeks,,,
91,Dagan,Pfizer,1,1,21-27,infection,infection,Israel ,pregnant women,pregnant persons,71,33,94,,alpha,,,,
91,Dagan,Pfizer,2,final,7-56,infection ,infection,Israel ,pregnant women,pregnant persons,96,89,100,,alpha,~11 weeks,,,
91,Dagan,Pfizer,1,1,21-27,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,76,30,100,,alpha,,,,
91,Dagan,Pfizer,2,final,7-56,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,97,91,100,,alpha,~11 weeks,,,
91,Dagan,Pfizer,2,final,7-56,hospitalization,severe,Israel ,pregnant women,pregnant persons,89,43,100,,alpha,~11 weeks,,,
92,Grannis,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,80,73,85,,delta,4 weeks,,,
92,Grannis,Pfizer,2,final,14+,ED or UC visits,symptomatic,USA,≥ 18 years,general pop,77,74,80,,delta,4 weeks,,,
92,Grannis,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,95,92,97,,delta,4 weeks,,,
92,Grannis,Moderna,2,final,14+,ED or UC visits,symptomatic,USA,≥ 18 years,general pop,92,89,93,,delta,4 weeks,,,
92,Grannis,Janssen,1,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,60,31,77,,delta,4 weeks,,,
92,Grannis,Janssen,1,final,14+,ED or UC visits,symptomatic,USA,≥ 18 years,general pop,65,56,72,,delta,4 weeks,,,
93,Polinski,Janssen,1,final,14+,infection,infection,USA,≥ 18 years,general pop,76,75,77,,alpha,~14 weeks,,,
93,Polinski,Janssen,1,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,81,78,82,,alpha,~14 weeks,,,
93,Polinski,Janssen,1,final,14+,infection,infection,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,64,59,68,,alpha,~14 weeks,,,
93,Polinski,Janssen,1,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,67,57,74,,alpha,~14 weeks,,,
93,Polinski,Janssen,1,final,14+,infection (June-July),infection,USA,≥ 18 years,general pop,74,71,77,,delta,~14 weeks,,,
93,Polinski,Janssen,1,final,14+,hospitalization (June-July),severe,USA,≥ 18 years,general pop,81,75,86,,delta,~14 weeks,,,
94,Bajema,Pfizer,2,final,<104 days,hospitalization,severe,USA,hospitalized veterans,hospitalized veterans,86.1,76.5,91.8,,"alpha, delta, non-VOC",~13 weeks,,,
94,Bajema,Pfizer,2,final,>104 days,hospitalization,severe,USA,hospitalized veterans,hospitalized veterans,87.2,78.2,92.5,,"alpha, delta, non-VOC",~28.5 weeks,,,
94,Bajema,Pfizer,2,final,14+,hospitalization,severe,USA,hospitalized veterans,hospitalized veterans,83.4,74,89.4,,"alpha, delta, non-VOC",~28.5 weeks,,,
94,Bajema,Moderna,2,final,14+,hospitalization,severe,USA,hospitalized veterans,hospitalized veterans,91.6,83.5,95.7,,"alpha, delta, non-VOC",~26.5 weeks,,,
94,Bajema,Pfizer,2,final,14+,hospitalization (February-June),severe,USA,hospitalized veterans,hospitalized veterans,84.1,74.1,90.2,,alpha,~23 weeks,,,
94,Bajema,Pfizer,2,final,14+,hospitalization (July-August),severe,USA,hospitalized veterans,hospitalized veterans,89.3,80.1,94.3,,delta,~28.5 weeks,,,
95,Andrews,Pfizer,1,1,28+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,45.9,44.2,47.6,alpha,alpha,,,,
95,Andrews,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,94.9,93.6,95.9,alpha,alpha,~33.5 weeks,,,
95,Andrews,Pfizer,2,final,70+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,94.8,88.4,97.7,alpha,alpha,~8 weeks,,,
95,Andrews,Pfizer,1,1,28+,hospitalization,severe,UK,≥ 16 years,general pop,85.2,81.6,88.1,alpha,alpha,,,,
95,Andrews,Pfizer,2,final,14-63,hospitalization,severe,UK,≥ 16 years,general pop,97.7,90.8,99.4,alpha,alpha,~33.5 weeks,,,
95,Andrews,Pfizer,1,1,28+,death,death,UK,≥ 16 years,general pop,73.1,65,79.3,alpha,alpha,,,,
95,Andrews,Pfizer,2,final,14+,death,death,UK,≥ 16 years,general pop,96.6,94.4,96.5,alpha,alpha,~33.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),1,1,28+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,45.1,43.3,46.7,alpha,alpha,,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,82.1,79.4,84.5,alpha,alpha,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14-63,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,82.4,79.6,84.7,alpha,alpha,~8 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,70+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,76.2,49.8,88.7,alpha,alpha,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,UK,≥ 16 years,general pop,82.5,78.7,85.7,alpha,alpha,,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14-63,hospitalization,severe,UK,≥ 16 years,general pop,95.1,86.7,98.2,alpha,alpha,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,70+,hospitalization,severe,UK,≥ 16 years,general pop,100,,,alpha,alpha,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),1,1,28+,death,death,UK,≥ 16 years,general pop,79.1,68.8,86,alpha,alpha,,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14+,death,death,UK,≥ 16 years,general pop,100,,,alpha,alpha,~20.5 weeks,,,
95,Andrews,Moderna,1,1,28+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,58.1,11.7,80.1,alpha,alpha,,,,
95,Andrews,Pfizer,1,1,28+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,51.2,50.7,51.7,delta,delta,,,,
95,Andrews,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,83.3,83.1,83.5,delta,delta,~33.5 weeks,,,
95,Andrews,Pfizer,2,final,14-69,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,89.8,89.6,90,delta,delta,~8 weeks,,,
95,Andrews,Pfizer,2,final,140+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,69.7,68.7,70.5,delta,delta,~33.5 weeks,,,
95,Andrews,Pfizer,1,1,28+,hospitalization,severe,UK,≥ 16 years,general pop,91.1,89.7,92.3,delta,delta,,,,
95,Andrews,Pfizer,2,final,14+,hospitalization,severe,UK,≥ 16 years,general pop,96.6,96.2,96.9,delta,delta,~33.5 weeks,,,
95,Andrews,Pfizer,2,final,14-69,hospitalization,severe,UK,≥ 16 years,general pop,98.4,97.9,98.8,delta,delta,~8 weeks,,,
95,Andrews,Pfizer,2,final,140+,hospitalization,severe,UK,≥ 16 years,general pop,92.7,90.3,94.6,delta,delta,~33.5 weeks,,,
95,Andrews,Pfizer,1,1,28+,death,death,UK,≥ 16 years,general pop,88.6,78.8,93.9,delta,delta,,,,
95,Andrews,Pfizer,2,final,14+,death,death,UK,≥ 16 years,general pop,95.6,94.4,96.6,delta,delta,~33.5 weeks,,,
95,Andrews,Pfizer,2,final,14-69,death,death,UK,≥ 16 years,general pop,98.2,95.9,99.2,delta,delta,~8 weeks,,,
95,Andrews,Pfizer,2,final,140+,death,death,UK,≥ 16 years,general pop,90.4,85.1,93.8,delta,delta,~33.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),1,1,28+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,45.1,43.4,46.7,delta,delta,,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,64.2,63.9,64.5,delta,delta,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14-69,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,66.7,66.3,67,delta,delta,~8 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,140+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,47.3,45,49.6,delta,delta,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,UK,≥ 16 years,general pop,80.7,78,83,delta,delta,,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,UK,≥ 16 years,general pop,92.5,92,93,delta,delta,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14-69,hospitalization,severe,UK,≥ 16 years,general pop,95.2,94.6,95.6,delta,delta,~8 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,140+,hospitalization,severe,UK,≥ 16 years,general pop,77,70.3,82.3,delta,delta,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),1,1,28+,death,death,UK,≥ 16 years,general pop,86.9,77.5,92.4,delta,delta,,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14+,death,death,UK,≥ 16 years,general pop,93.2,91.7,94.5,delta,delta,~20.5 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,14-69,death,death,UK,≥ 16 years,general pop,94.1,91.8,95.8,delta,delta,~8 weeks,,,
95,Andrews,AZD1222 (AstraZeneca),2,final,140+,death,death,UK,≥ 16 years,general pop,78.7,52.7,90.4,delta,delta,~20.5 weeks,,,
95,Andrews,Moderna,1,1,28+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,64.9,64,65.7,delta,delta,,,,
95,Andrews,Moderna,2,final,14+,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,94.8,94.4,95.2,delta,delta,~7 weeks,,,
95,Andrews,Moderna,2,final,14-63,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,93.8,93.4,94.1,delta,delta,~7 weeks,,,
95,Andrews,Moderna,2,final,70-104,symptomatic disease,symptomatic,UK,≥ 16 years,general pop,85.6,83.8,87.2,delta,delta,~7 weeks,,,
95,Andrews,Moderna,1,1,28+,hospitalization,severe,UK,≥ 16 years,general pop,93.7,89.9,96,delta,delta,,,,
95,Andrews,Moderna,2,final,14-69,hospitalization,severe,UK,≥ 16 years,general pop,100,,,delta,delta,~7 weeks,,,
96,Glatman-Freedman,Pfizer,1,1,14-20,infection,infection,Israel ,≥ 16 years,general pop,54.3,50.6,57.8,,alpha,,,,
96,Glatman-Freedman,Pfizer,2,final,22-28,infection,infection,Israel ,≥ 16 years,general pop,97.3,96.7,97.8,,alpha,2 weeks,,,
96,Glatman-Freedman,Pfizer,1,1,14-20,symptomatic disease,symptomatic,Israel ,≥ 16 years,general pop,58.3,54.7,61.6,,alpha,,,,
96,Glatman-Freedman,Pfizer,2,final,22-28,symptomatic disease,symptomatic,Israel ,≥ 16 years,general pop,97.9,97.4,98.3,,alpha,2 weeks,,,
96,Glatman-Freedman,Pfizer,1,1,14-20,hospitalization,severe,Israel ,≥ 16 years,general pop,74.5,69.1,79,,alpha,,,,
96,Glatman-Freedman,Pfizer,2,final,22-28,hospitalization,severe,Israel ,≥ 16 years,general pop,99,98.4,99.3,,alpha,2 weeks,,,
96,Glatman-Freedman,Pfizer,1,1,14-20,severe/critical disease,severe,Israel ,≥ 16 years,general pop,77.3,71.2,82.1,,alpha,,,,
96,Glatman-Freedman,Pfizer,2,final,22-28,severe/critical disease,severe,Israel ,≥ 16 years,general pop,99.2,98.6,99.5,,alpha,2 weeks,,,
96,Glatman-Freedman,Pfizer,1,1,14-20,death,death,Israel ,≥ 16 years,general pop,71.7,64.1,77.7,,alpha,,,,
96,Glatman-Freedman,Pfizer,2,final,22-28,death,death,Israel ,≥ 16 years,general pop,98.6,97,99.3,,alpha,2 weeks,,,
97,Self,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,88,85,91,,alpha & delta,~20 weeks,,,
97,Self,Pfizer,2,final,14-120,hospitalization,severe,USA,≥ 18 years,general pop,91,88,93,,alpha & delta,~20 weeks,,,
97,Self,Pfizer,2,final,>120,hospitalization,severe,USA,≥ 18 years,general pop,77,67,84,,alpha & delta,~20 weeks,,,
97,Self,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,93,91,95,,alpha & delta,~20 weeks,,,
97,Self,Moderna,2,final,14-120,hospitalization,severe,USA,≥ 18 years,general pop,93,90,95,,alpha & delta,~20 weeks,,,
97,Self,Moderna,2,final,>120,hospitalization,severe,USA,≥ 18 years,general pop,92,87,96,,alpha & delta,~20 weeks,,,
97,Self,Janssen,1,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,71,56,81,,alpha & delta,~20 weeks,,,
97,Self,Janssen,1,final,>28,hospitalization,severe,USA,≥ 18 years,general pop,68,49,80,,alpha & delta,~20 weeks,,,
98,Skowronski,Pfizer,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,70,68,72,,"alpha, gamma & delta",,,,
98,Skowronski,Pfizer,1,1,14-20,infection,infection,Canada,50-69 years,50-69 years,55,48,61,,"alpha, gamma & delta",,,,
98,Skowronski,Pfizer,1,1,98+,infection,infection,Canada,50-69 years,50-69 years,65,57,71,,"alpha, gamma & delta",,,,
98,Skowronski,Pfizer,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,81,75,85,,"alpha, gamma & delta",,,,
98,Skowronski,Moderna,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,75,71,78,,"alpha, gamma & delta",,,,
98,Skowronski,Moderna,1,1,14-20,infection,infection,Canada,50-69 years,50-69 years,67,57,75,,"alpha, gamma & delta",,,,
98,Skowronski,Moderna,1,1,98+,infection,infection,Canada,50-69 years,50-69 years,54,38,66,,"alpha, gamma & delta",,,,
98,Skowronski,Moderna,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,85,76,91,,"alpha, gamma & delta",,,,
98,Skowronski,Pfizer,1,1,14-20,hospitalization,severe,Canada,50-69 years,50-69 years,74,60,83,,"alpha, gamma & delta",,,,
98,Skowronski,Pfizer,1,1,98+,hospitalization,severe,Canada,50-69 years,50-69 years,65,47,77,,"alpha, gamma & delta",,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,infection,infection,Canada,50-69 years,50-69 years,60,54,65,,"alpha, gamma & delta",,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,14-20,infection,infection,Canada,50-69 years,50-69 years,25,10,37,,"alpha, gamma & delta",,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,98+,infection,infection,Canada,50-69 years,50-69 years,62,36,77,,"alpha, gamma & delta",,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,93,85,97,,"alpha, gamma & delta",,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,14-20,hospitalization,severe,Canada,50-69 years,50-69 years,67,30,84,,"alpha, gamma & delta",,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,84+,hospitalization,severe,Canada,50-69 years,50-69 years,74,-4,94,,"alpha, gamma & delta",,,,
98,Skowronski,Pfizer,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,77,73,80,alpha,alpha,,,,
98,Skowronski,Pfizer,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,85,72,92,alpha,alpha,,,,
98,Skowronski,Moderna,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,84,77,89,alpha,alpha,,,,
98,Skowronski,Moderna,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,78,44,91,alpha,alpha,,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,infection ,infection,Canada,50-69 years,50-69 years,69,61,75,alpha,alpha,,,,
98,Skowronski,Pfizer,1,1,21+,infection ,infection,Canada,50-69 years,50-69 years,77,72,81,gamma,gamma,,,,
98,Skowronski,Pfizer,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,89,79,94,gamma,gamma,,,,
98,Skowronski,Moderna,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,85,76,90,gamma,gamma,,,,
98,Skowronski,Moderna,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,96,71,99,gamma,gamma,,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,infection,infection,Canada,50-69 years,50-69 years,67,58,74,gamma,gamma,,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,93,78,98,gamma,gamma,,,,
98,Skowronski,Pfizer,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,58,52,63,delta,delta,,,,
98,Skowronski,Pfizer,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,73,60,82,delta,delta,,,,
98,Skowronski,Moderna,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,70,64,76,delta,delta,,,,
98,Skowronski,Moderna,1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,86,72,93,delta,delta,,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,infection,infection,Canada,50-69 years,50-69 years,41,15,59,delta,delta,,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,hospitalization,severe,Canada,50-69 years,50-69 years,61,-8,86,delta,delta,,,,
98,Skowronski,Pfizer,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,88,75,95,non-VOC,non-VOC,,,,
98,Skowronski,Moderna,1,1,21+,infection,infection,Canada,50-69 years,50-69 years,78,31,93,non-VOC,non-VOC,,,,
98,Skowronski,AZD1222 (AstraZeneca),1,1,21+,infection,infection,Canada,50-69 years,50-69 years,93,70,98,non-VOC,non-VOC,,,,
99,Pilishvili,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,HCW,HCW,88.9,84.7,92,,alpha,~14 weeks,,,
99,Pilishvili,Pfizer,2,final,15-28,symptomatic disease,symptomatic,USA,HCW,HCW,96.3,92.5,98.2,,alpha,~14 weeks,,,
99,Pilishvili,Pfizer,2,final,85-98,symptomatic disease,symptomatic,USA,HCW,HCW,80.7,61,90.4,,alpha,~14 weeks,,,
99,Pilishvili,Pfizer,1,1,21,symptomatic disease,symptomatic,USA,immunocompromised HCW,immunocompromised HCW,39.1,-45,74.4,,alpha,,,,
99,Pilishvili,Pfizer,1,1,21,symptomatic disease,symptomatic,USA,pregnant HCW,pregnant HCW,77.1,32.2,92.2,,alpha,,,,
99,Pilishvili,Pfizer,1,1,21,symptomatic disease,symptomatic,USA,HCW,HCW,77.6,70.9,82.7,,alpha,,,,
99,Pilishvili,Pfizer,2,final,7+,symptomatic disease,symptomatic,USA,HCW,HCW,88.8,84.6,91.8,,alpha,~14 weeks,,,
99,Pilishvili,Moderna,1,1,21,symptomatic disease,symptomatic,USA,HCW,HCW,88.9,78.7,94.2,,alpha,,,,
99,Pilishvili,Moderna,2,final,7+,symptomatic disease,symptomatic,USA,HCW,HCW,96.3,91.3,98.4,,alpha,~14 weeks,,,
100,Meyer,Pfizer,2,final,7+,infection,infection,Germany,LTCF residents and staff,LTCF residents and staff,56,15,77,,alpha,~11 weeks,,,
101,Glatman-Freedman,Pfizer,2,final,8-28,infection,infection,Israel ,12-15 years,12-15 years,91.5,88.2,93.9,,delta,2 weeks,,,
102,Eyre,Pfizer,1,1,27,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,15,12,18,alpha,alpha,,,,
102,Eyre,Pfizer,2,final,14+,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,85,79,89,alpha,alpha,~20.5 weeks,,,
102,Eyre,AZD1222 (AstraZeneca),1,1,0+ up to 13 days post dose 2,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,6,2,9,alpha,alpha,,,,
102,Eyre,AZD1222 (AstraZeneca),2,final,14+,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,60,41,73,alpha,alpha,~8 weeks,,,
102,Eyre,Pfizer,1,1,14,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,33,31,35,delta,delta,,,,
102,Eyre,Pfizer,2,final,14+,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,81,77,84,delta,delta,~29 weeks,,,
102,Eyre,AZD1222 (AstraZeneca),1,1,0+ up to 13 days post dose 2,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,31,28,34,delta,delta,,,,
102,Eyre,AZD1222 (AstraZeneca),2,final,14+,infection,infection,UK,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,58,55,62,delta,delta,~16 weeks,,,
103,Martinez-Baz,Pfizer,1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,57,52,61,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Pfizer,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,69,66,72,,"non-VOC, alpha, & delta",~31 weeks,,,
103,Martinez-Baz,Pfizer,1,1,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,57,51,61,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Pfizer,2,final,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,70,67,73,,"non-VOC, alpha, & delta",~11 weeks,,,
103,Martinez-Baz,Pfizer,2,final,90+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,63,58,68,,"non-VOC, alpha, & delta",~18 weeks,,,
103,Martinez-Baz,Pfizer,1,1,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,66,60,71,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Pfizer,2,final,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,72,69,75,,"non-VOC, alpha, & delta",~31 weeks,,,
103,Martinez-Baz,Pfizer,1,1,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,86,69,94,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Pfizer,2,final,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,93,88,96,,"non-VOC, alpha, & delta",~31 weeks,,,
103,Martinez-Baz,Moderna,1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,66,56,73,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Moderna,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,82,78,86,,"non-VOC, alpha, & delta",~28 weeks,,,
103,Martinez-Baz,Moderna,1,1,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,65,56,73,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Moderna,2,final,90+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,67,50,78,,"non-VOC, alpha, & delta",~15 weeks,,,
103,Martinez-Baz,Moderna,1,1,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,71,61,79,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Moderna,2,final,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,85,80,89,,"non-VOC, alpha, & delta",~28 weeks,,,
103,Martinez-Baz,Moderna,1,1,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,73,-10,93,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,Moderna,2,final,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,98,82,100,,"non-VOC, alpha, & delta",~28 weeks,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,41,34,48,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,54,48,60,,"non-VOC, alpha, & delta",~16 weeks,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,40,31,47,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),2,final,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,54,47,60,,"non-VOC, alpha, & delta",~11 weeks,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,90+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,52,37,64,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,46,37,54,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,56,48,63,,"non-VOC, alpha, & delta",~16 weeks,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,78,54,89,,"non-VOC, alpha, & delta",,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,95,79,99,,"non-VOC, alpha, & delta",~16 weeks,,,
103,Martinez-Baz,Janssen,1,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,50,42,57,,"non-VOC, alpha, & delta",~23 weeks,,,
103,Martinez-Baz,Janssen,1,final,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,52,44,59,,"non-VOC, alpha, & delta",~11 weeks,,,
103,Martinez-Baz,Janssen,1,final,90+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,28,-8,53,,"non-VOC, alpha, & delta",~10 weeks,,,
103,Martinez-Baz,Janssen,1,final,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,54,45,62,,"non-VOC, alpha, & delta",~23 weeks,,,
103,Martinez-Baz,Janssen,1,final,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,74,43,88,,"non-VOC, alpha, & delta",~23 weeks,,,
103,Martinez-Baz,Pfizer,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,86,70,93,,"non-VOC, alpha, & delta",~21 weeks,,,
103,Martinez-Baz,Pfizer,2,final,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,85,69,93,,"non-VOC, alpha, & delta",~11 weeks,,,
103,Martinez-Baz,Pfizer,2,final,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,91,71,97,,"non-VOC, alpha, & delta",~21 weeks,,,
103,Martinez-Baz,Pfizer,2,final,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,95,79,99,,"non-VOC, alpha, & delta",~21 weeks,,,
103,Martinez-Baz,Pfizer,1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,54,37,67,alpha,alpha,,,,
103,Martinez-Baz,Pfizer,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,71,61,78,alpha,alpha,~31 weeks,,,
103,Martinez-Baz,Moderna,1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,60,14,81,alpha,alpha,,,,
103,Martinez-Baz,Moderna,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,86,56,95,alpha,alpha,~28 weeks,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,37,21,50,alpha,alpha,,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,38,-42,73,alpha,alpha,~16 weeks,,,
103,Martinez-Baz,Janssen,1,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,77,27,92,alpha,alpha,,,,
103,Martinez-Baz,Pfizer,1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,63,51,73,delta,delta,,,,
103,Martinez-Baz,Pfizer,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,67,59,74,delta,delta,~31 weeks,,,
103,Martinez-Baz,Moderna,1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,72,51,84,delta,delta,,,,
103,Martinez-Baz,Moderna,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,77,64,85,delta,delta,~28 weeks,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),1,1,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,53,26,70,delta,delta,,,,
103,Martinez-Baz,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,55,39,67,delta,delta,~16 weeks,,,
103,Martinez-Baz,Janssen,1,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,42,18,53,delta,delta,,,,
103,Martinez-Baz,Pfizer,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,86,45,97,delta,delta,~21 weeks,,,
104,Bruxvoort,Moderna,1,1,14+,infection,infection,USA,≥ 18 years,general pop,77,60.7,86.5,delta,delta,,,,
104,Bruxvoort,Moderna,2,final,14+,infection,infection,USA,≥ 18 years,general pop,86.7,84.3,88.7,delta,delta,~25 weeks,,,
104,Bruxvoort,Moderna,2,final,14-60,infection,infection,USA,≥ 18 years,general pop,94.1,90.5,96.3,delta,delta,~6.5 weeks,,,
104,Bruxvoort,Moderna,2,final,151-180,infection,infection,USA,≥ 18 years,general pop,80,70.2,86.6,delta,delta,~23.5 weeks,,,
104,Bruxvoort,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,97.5,92.7,99.2,delta,delta,~25 weeks,,,
104,Bruxvoort,Moderna,2,final,14-60,infection,infection,USA,≥ 18 years,general pop,98.6,97.3,99.3,non-delta,non-delta,~6.5 weeks,,,
104,Bruxvoort,Moderna,2,final,121-150,infection,infection,USA,≥ 18 years,general pop,88.7,73.2,95.2,non-delta,non-delta,~19.5 weeks,,,
104,Bruxvoort,Moderna,1,1,14+,infection,infection,USA,≥ 18 years,general pop,90.1,82.9,94.2,alpha,alpha,,,,
104,Bruxvoort,Moderna,2,final,14+,infection,infection,USA,≥ 18 years,general pop,98.4,96.9,99.1,alpha,alpha,~25 weeks,,,
104,Bruxvoort,Moderna,1,1,14+,infection,infection,USA,≥ 18 years,general pop,74.2,43.8,88.1,gamma,gamma,,,,
104,Bruxvoort,Moderna,2,final,14+,infection,infection,USA,≥ 18 years,general pop,95.5,90.9,97.8,gamma,gamma,~25 weeks,,,
105,Liu,Pfizer,2,final,14+,infection,infection,USA,≥ 18 years,general pop,59,52,65,,alpha & delta,~35 weeks,,,
105,Liu,Pfizer,2,final,14+,infection,infection,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,57,45,66,,alpha & delta,~35 weeks,,,
106,Ranzani,Janssen,1,final,28+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,50.9,35.5,63,,gamma,~10 weeks,,,
106,Ranzani,Janssen,1,final,28+,hospitalization,severe,Brazil,≥ 18 years,general pop,72.9,35.1,91.1,,gamma,~10 weeks,,,
106,Ranzani,Janssen,1,final,28+,ICU admission,severe,Brazil,≥ 18 years,general pop,92.5,54.9,99.6,,gamma,~10 weeks,,,
106,Ranzani,Janssen,1,final,28+,death,death,Brazil,≥ 18 years,general pop,90.5,31.5,99.6,,gamma,~10 weeks,,,
107,Arregoces,Pfizer,2,final,14+,hospitalization,severe,Colombia,≥ 60 years,≥ 60 years,90.3,87.1,92.7,,mu,~9 weeks,,,
107,Arregoces,Pfizer,2,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,≥ 60 years,98.5,97.8,98.9,,mu,~9 weeks,,,
107,Arregoces,Pfizer,2,final,14+,death without prior hospitalization,death,Colombia,≥ 60 years,≥ 60 years,89.2,85.6,91.9,,mu,~9 weeks,,,
107,Arregoces,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Colombia,≥ 60 years,≥ 60 years,67.2,63.7,70.4,,mu,~11 weeks,,,
107,Arregoces,CoronaVac (Sinovac),2,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,≥ 60 years,77.1,75.5,78.6,,mu,~11 weeks,,,
107,Arregoces,CoronaVac (Sinovac),2,final,14+,death without prior hospitalization,death,Colombia,≥ 60 years,≥ 60 years,69.8,66.7,72.6,,mu,~11 weeks,,,
107,Arregoces,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,Colombia,≥ 60 years,≥ 60 years,75.4,48.2,88.3,,mu,~7 weeks,,,
107,Arregoces,AZD1222 (AstraZeneca),2,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,≥ 60 years,96.3,88.4,98.8,,mu,~7 weeks,,,
107,Arregoces,AZD1222 (AstraZeneca),2,final,14+,death without prior hospitalization,death,Colombia,≥ 60 years,≥ 60 years,88.7,64.8,96.4,,mu,~7 weeks,,,
107,Arregoces,Janssen,1,final,14+,hospitalization,severe,Colombia,≥ 60 years,≥ 60 years,80,19.9,95,,mu,~4 weeks,,,
107,Arregoces,Janssen,1,final,14+,death without prior hospitalization,death,Colombia,≥ 60 years,≥ 60 years,75,0,93.8,,mu,~4 weeks,,,
108,Olson,Pfizer,2,final,14+,hospitalization,severe,USA,12-15 years,12-15 years,91,74,97,,delta,~12 weeks,,,
108,Olson,Pfizer,2,final,14+,hospitalization,severe,USA,16-18 years,16-18 years,94,78,99,,delta,~12 weeks,,,
109,Irizarry,Pfizer,2,final,14+,hospitalization,severe,Puerto Rico,45-74 years,45-74 years,92,90.8,93,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,hospitalization,severe,Puerto Rico,75-84 years,75-84 years,93.3,91.3,95,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,hospitalization,severe,Puerto Rico,≥ 85 years,≥ 85 years,97.1,95.8,98,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,death,death,Puerto Rico,45-74 years,45-74 years,86,81,89,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,death,death,Puerto Rico,75-84 years,75-84 years,87,80,92,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,death,death,Puerto Rico,≥ 85 years,≥ 85 years,95.2,91.5,97,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,hospitalization,severe,Puerto Rico,45-74 years,45-74 years,82,78,85,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,hospitalization,severe,Puerto Rico,75-84 years,75-84 years,91.5,89,94,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,hospitalization,severe,Puerto Rico,≥ 85 years,≥ 85 years,97.2,96,98,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,death,death,Puerto Rico,45-74 years,45-74 years,69,52,79,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,death,death,Puerto Rico,75-84 years,75-84 years,87,79,92,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,death,death,Puerto Rico,≥ 85 years,≥ 85 years,96.2,93.9,98,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Janssen,1,final,14+,hospitalization,severe,Puerto Rico,45-74 years,45-74 years,96.1,95,97,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Janssen,1,final,14+,hospitalization,severe,Puerto Rico,75-84 years,75-84 years,98,96.7,99,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Janssen,1,final,14+,hospitalization,severe,Puerto Rico,≥ 85 years,≥ 85 years,99.2,98.6,99.5,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Janssen,1,final,14+,death,death,Puerto Rico,45-74 years,45-74 years,93.8,90,96,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Janssen,1,final,14+,death,death,Puerto Rico,75-84 years,75-84 years,96.6,91.7,98,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Janssen,1,final,14+,death,death,Puerto Rico,≥ 85 years,≥ 85 years,99.3,98.6,99.6,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,infection,infection,Puerto Rico,≥ 12 years,general pop,87,85,89,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,144+,infection,infection,Puerto Rico,≥ 12 years,general pop,57,53,60,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,hospitalization,severe,Puerto Rico,≥ 12 years,general pop,92,85,95,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,144+,hospitalization,severe,Puerto Rico,≥ 12 years,general pop,80,73,85,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,14+,death,death,Puerto Rico,≥ 12 years,general pop,97,86,100,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Pfizer,2,final,144+,death,death,Puerto Rico,≥ 12 years,general pop,86,75,92,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,14+,infection,infection,Puerto Rico,≥ 12 years,general pop,90,88,91,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Moderna,2,final,144+,infection,infection,Puerto Rico,≥ 12 years,general pop,73,70,76,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Moderna,2,final,14+,hospitalization,severe,Puerto Rico,≥ 12 years,general pop,95,89,97,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Moderna,2,final,144+,hospitalization,severe,Puerto Rico,≥ 12 years,general pop,90,84,94,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Moderna,2,final,14+,death,death,Puerto Rico,≥ 12 years,general pop,99,89,100,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Moderna,2,final,144+,death,death,Puerto Rico,≥ 12 years,general pop,93,81,97,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Janssen,1,final,14+,infection,infection,Puerto Rico,≥ 12 years,general pop,62,54,68,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
109,Irizarry,Janssen,1,final,144+,infection,infection,Puerto Rico,≥ 12 years,general pop,36,30,42,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
109,Irizarry,Janssen,1,final,14+,hospitalization,severe,Puerto Rico,≥ 12 years,general pop,81,60,91,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
109,Irizarry,Janssen,1,final,144+,hospitalization,severe,Puerto Rico,≥ 12 years,general pop,67,53,76,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
109,Irizarry,Janssen,1,final,14+,death,death,Puerto Rico,≥ 12 years,general pop,78,16,94,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
109,Irizarry,Janssen,1,final,144+,death,death,Puerto Rico,≥ 12 years,general pop,72,49,95,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
109,Irizarry,Pfizer,2,final,day 137,infection,infection,Puerto Rico,≥ 12 years,general pop,56,53,59,,"non-VOC, alpha, beta, & delta",~20 weeks,,,
109,Irizarry,Moderna,2,final,day 139,infection,infection,Puerto Rico,≥ 12 years,general pop,71,68,74,,"non-VOC, alpha, beta, & delta",~18 weeks,,,
109,Irizarry,Janssen,1,final,day 158,infection,infection,Puerto Rico,≥ 12 years,general pop,27,17,37,,"non-VOC, alpha, beta, & delta",~22 weeks,,,
110,Chin,Moderna,2,final,14+,infection,infection,USA,incarcerated men,incarcerated men,56.6,42,67.5,,delta,~27 weeks,,,
110,Chin,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,incarcerated men,incarcerated men,84.2,56.4,94.3,,delta,~27 weeks,,,
110,Chin,Moderna,2,final,14+,infection,infection,USA,incarcerated men,incarcerated men,80.5,52.8,92,,delta,~27 weeks,,,
110,Chin,Moderna,2,final,14+,infection,infection,USA,incarcerated men,incarcerated men,49.5,31.5,62.7,,delta,~27 weeks,,,
111,Ranzani,AZD1222 (AstraZeneca),1,1,>21,infection,infection,Brazil,≥ 18 years,general pop,31,12.7,45.5,,gamma & delta,,,,
111,Ranzani,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Brazil,≥ 18 years,general pop,59,33.1,74.8,,gamma & delta,~31 weeks,,,
111,Ranzani,AZD1222 (AstraZeneca),1,1,>21,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,31.6,12,46.8,,gamma & delta,,,,
111,Ranzani,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,65.1,40.9,79.4,,gamma & delta,~31 weeks,,,
111,Ranzani,AZD1222 (AstraZeneca),1,1,>21,asymptomatic infection,asymptomatic,Brazil,≥ 18 years,general pop,26.6,-53.8,65,,gamma & delta,,,,
112,Nordstrom,Pfizer,2,final,15-30,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,92,92,93,,delta,~30 weeks,,,
112,Nordstrom,Pfizer,2,final,210+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,23,-2,41,,delta,~30 weeks,,,
112,Nordstrom,Moderna,2,final,15-30,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,96,94,97,,delta,~30 weeks,,,
112,Nordstrom,Moderna,2,final,210+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,59,18,79,,delta,~30 weeks,,,
112,Nordstrom,AZD1222 (AstraZeneca),2,final,15-30,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,68,52,79,,delta,~30 weeks,,,
112,Nordstrom,AZD1222 (AstraZeneca),2,final,210+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,-19,-97,28,,delta,~30 weeks,,,
112,Nordstrom,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,15-30,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,89,79,94,,delta,~30 weeks,,,
112,Nordstrom,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,210+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,66,41,80,,delta,~30 weeks,,,
113,Lin,Pfizer,2,final,1.25 months,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,94.5,94.1,94.9,,alpha & delta,~27 weeks,,,
113,Lin,Pfizer,2,final,7.25 months,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,67.8,65.9,69.7,,alpha & delta,~27 weeks,,,
113,Lin,Pfizer,2,final,1.25 months,hospitalization,severe,USA,≥ 18 years,general pop,96.4,95.1,97.4,,alpha & delta,~27 weeks,,,
113,Lin,Pfizer,2,final,7.25 months,hospitalization,severe,USA,≥ 18 years,general pop,92.4,89.7,94.4,,alpha & delta,~27 weeks,,,
113,Lin,Pfizer,2,final,1.25 months,death,death,USA,≥ 18 years,general pop,98,95.5,99.1,,alpha & delta,~27 weeks,,,
113,Lin,Pfizer,2,final,7.25 months,death,death,USA,≥ 18 years,general pop,95.5,92.2,97.4,,alpha & delta,~32 weeks,,,
113,Lin,Moderna,2,final,1 month,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,95.9,95.5,96.2,,alpha & delta,~32 weeks,,,
113,Lin,Moderna,2,final,7 months,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,77.8,75.9,79.6,,alpha & delta,~32 weeks,,,
113,Lin,Moderna,2,final,1 month,hospitalization,severe,USA,≥ 18 years,general pop,97.2,96.1,98,,alpha & delta,~32 weeks,,,
113,Lin,Moderna,2,final,7 months,hospitalization,severe,USA,≥ 18 years,general pop,94.9,92.4,96.6,,alpha & delta,~32 weeks,,,
113,Lin,Moderna,2,final,1 month,death,death,USA,≥ 18 years,general pop,98.6,97.3,99.3,,alpha & delta,~32 weeks,,,
113,Lin,Moderna,2,final,7 months,death,death,USA,≥ 18 years,general pop,96,92.8,97.8,,alpha & delta,~22 weeks,,,
113,Lin,Janssen,1,final,2 months,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,71.4,68.3,74.2,,alpha & delta,~22 weeks,,,
113,Lin,Janssen,1,final,6 months,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,64,60.3,67.4,,alpha & delta,~22 weeks,,,
113,Lin,Janssen,1,final,2 months,hospitalization,severe,USA,≥ 18 years,general pop,85.8,74.9,91.9,,alpha & delta,~22 weeks,,,
113,Lin,Janssen,1,final,6 months,hospitalization,severe,USA,≥ 18 years,general pop,81.7,68.6,89.3,,alpha & delta,~22 weeks,,,
113,Lin,Janssen,1,final,2 months,death,death,USA,≥ 18 years,general pop,82.2,46.3,94.1,,alpha & delta,~22 weeks,,,
113,Lin,Janssen,1,final,6 months,death,death,USA,≥ 18 years,general pop,71.2,40.8,86,,alpha & delta,~22 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,89,89,89,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Pfizer,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,93,92,94,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Pfizer,2,final,252-279,Infection,infection,Canada,≥ 18 years,general pop,80,75,83,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,97,97,98,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Pfizer,2,final,14-27,Hospitalization,severe,Canada,≥ 18 years,general pop,98,96,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Pfizer,2,final,252-279,Hospitalization,severe,Canada,≥ 18 years,general pop,96,86,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Moderna,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,90,89,90,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Moderna,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,95,94,96,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Moderna,2,final,252-279,Infection,infection,Canada,≥ 18 years,general pop,55,40,66,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Moderna,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,97,97,98,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Moderna,2,final,14-27,Hospitalization,severe,Canada,≥ 18 years,general pop,99,95,100,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Moderna,2,final,252-279,Hospitalization,severe,Canada,≥ 18 years,general pop,95,65,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,74,72,76,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,77,57,87,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,168-195,Infection,infection,Canada,≥ 18 years,general pop,67,48,80,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,95,94,97,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,28-55,Hospitalization,severe,Canada,≥ 18 years,general pop,97,71,97,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,168-195,Hospitalization,severe,Canada,≥ 18 years,general pop,91,35,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,90,89,90,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,95,91,97,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,168-195,Infection,infection,Canada,≥ 18 years,general pop,96,73,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,98,97,98,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14-27,Hospitalization,severe,Canada,≥ 18 years,general pop,96,75,100,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,140-167,Hospitalization,severe,Canada,≥ 18 years,general pop,96,92,98,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,89,88,89,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,94,89,97,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,140-167,Infection,infection,Canada,≥ 18 years,general pop,82,78,85,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,99,99,100,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-27,Hospitalization,severe,Canada,≥ 18 years,general pop,93,48,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,140-167,hospitalization,severe,Canada,≥ 18 years,general pop,98,91,99,,"non-VOC, alpha, gamma & delta",~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,89,89,89,delta,delta,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,93,93,94,delta,delta,~38 weeks,,,
114,Skowronski,Pfizer,2,final,252-279,Infection,infection,Canada,≥ 18 years,general pop,79,75,83,delta,delta,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,hospitalization,severe,Canada,≥ 18 years,general pop,98,97,98,delta,delta,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14-27,hospitalization,severe,Canada,≥ 18 years,general pop,98,95,99,delta,delta,~38 weeks,,,
114,Skowronski,Pfizer,2,final,196-223,hospitalization,severe,Canada,≥ 18 years,general pop,94,87,97,delta,delta,~38 weeks,,,
114,Skowronski,Moderna,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,90,89,90,delta,delta,~38 weeks,,,
114,Skowronski,Moderna,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,95,94,96,delta,delta,~38 weeks,,,
114,Skowronski,Moderna,2,final,196-223,Infection,infection,Canada,≥ 18 years,general pop,55,41,66,delta,delta,~38 weeks,,,
114,Skowronski,Moderna,2,final,14+,hospitalization,severe,Canada,≥ 18 years,general pop,97,97,98,delta,delta,~38 weeks,,,
114,Skowronski,Moderna,2,final,14-27,hospitalization,severe,Canada,≥ 18 years,general pop,98,94,100,delta,delta,~38 weeks,,,
114,Skowronski,Moderna,2,final,196-223,hospitalization,severe,Canada,≥ 18 years,general pop,95,80,99,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,73,72,75,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,70,39,86,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,168-195,Infection,infection,Canada,≥ 18 years,general pop,67,48,80,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,95,93,97,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,28-55,Hospitalization,severe,Canada,≥ 18 years,general pop,89,67,97,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,168-195,Hospitalization,severe,Canada,≥ 18 years,general pop,91,34,99,delta,delta,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,90,89,90,delta,delta,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,94,90,97,delta,delta,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,168-195,Infection,infection,Canada,≥ 18 years,general pop,96,73,99,delta,delta,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,98,97,98,delta,delta,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,28-55,Hospitalization,severe,Canada,≥ 18 years,general pop,97,93,99,delta,delta,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,140-167,Hospitalization,severe,Canada,≥ 18 years,general pop,96,92,98,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,88,88,89,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-27,Infection,infection,Canada,≥ 18 years,general pop,94,88,97,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,140-167,Infection,infection,Canada,≥ 18 years,general pop,82,77,85,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,99,99,100,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-27,Hospitalization,severe,Canada,≥ 18 years,general pop,91,33,99,delta,delta,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,140-167,Hospitalization,severe,Canada,≥ 18 years,general pop,98,91,99,delta,delta,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,96,92,98,alpha,alpha,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,96,83,99,alpha,alpha,~38 weeks,,,
114,Skowronski,Moderna,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,95,84,98,alpha,alpha,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,75,33,91,alpha,alpha,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,96,73,99,alpha,alpha,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,92,88,95,gamma,gamma,~38 weeks,,,
114,Skowronski,Pfizer,2,final,14+,Hospitalization,severe,Canada,≥ 18 years,general pop,95,82,98,gamma,gamma,~38 weeks,,,
114,Skowronski,Moderna,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,95,85,98,gamma,gamma,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,91,63,98,gamma,gamma,~38 weeks,,,
114,Skowronski,Any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,94,76,99,gamma,gamma,~38 weeks,,,
114,Skowronski,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,Infection,infection,Canada,≥ 18 years,general pop,96,69,99,gamma,gamma,~38 weeks,,,
115,Nordstrom,Pfizer,2,final,14+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,78,78,79,,delta,~11 weeks,,,
115,Nordstrom,Moderna,2,final,14+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,87,84,88,,delta,~11 weeks,,,
115,Nordstrom,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,50,41,58,,delta,~11 weeks,,,
115,Nordstrom,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,67,59,73,,delta,~11 weeks,,,
115,Nordstrom,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,symptomatic disease,symptomatic,Sweden,≥ 18 years,general pop,79,62,88,,delta,~11 weeks,,,
116,Reis,Pfizer,1,1,14-20,infection,infection,Israel ,12-18 years,12-18 years,59,52,65,,delta,,,,
116,Reis,Pfizer,2,final,7-21,infection,infection,Israel ,12-18 years,12-18 years,90,88,92,,delta,~12 weeks,,,
116,Reis,Pfizer,1,1,21-27,infection,infection,Israel ,12-18 years,12-18 years,66,59,72,,delta,,,,
116,Reis,Pfizer,1,1,14-20,symptomatic disease,symptomatic,Israel ,12-18 years,12-18 years,57,39,71,,delta,,,,
116,Reis,Pfizer,2,final,7-21,symptomatic disease,symptomatic,Israel ,12-18 years,12-18 years,93,88,97,,delta,~12 weeks,,,
116,Reis,Pfizer,1,1,21-27,symptomatic disease,symptomatic,Israel ,12-18 years,12-18 years,82,73,91,,delta,,,,
117,Sheikh,Pfizer,1,1,14+,death,death,Scotland,40-59 years,40-59 years,100,,,,alpha & delta,,,,
117,Sheikh,Pfizer,2,final,14+,death,death,Scotland,40-59 years,40-59 years,95,79,99,,alpha & delta,~25 weeks,,,
117,Sheikh,Pfizer,1,1,14+,death,death,Scotland,≥ 60 years,60+ years,75,26,91,,alpha & delta,,,,
117,Sheikh,Pfizer,2,final,14+,death,death,Scotland,≥ 60 years,60+ years,87,77,93,,alpha & delta,~25 weeks,,,
117,Sheikh,AZD1222 (AstraZeneca),1,1,14+,death,death,Scotland,40-59 years,40-59 years,96,85,99,,alpha & delta,,,,
117,Sheikh,AZD1222 (AstraZeneca),2,final,14+,death,death,Scotland,40-59 years,40-59 years,88,76,93,,alpha & delta,~25 weeks,,,
117,Sheikh,AZD1222 (AstraZeneca),1,1,14+,death,death,Scotland,≥ 60 years,60+ years,97,86,99,,alpha & delta,,,,
117,Sheikh,AZD1222 (AstraZeneca),2,final,14+,death,death,Scotland,≥ 60 years,60+ years,90,84,94,,alpha & delta,~25 weeks,,,
117,Sheikh,Pfizer,1,1,14+,death,death,Scotland,≥ 18 years,general pop,92,66,98,delta,delta,,,,
117,Sheikh,Pfizer,2,final,14+,death,death,Scotland,≥ 18 years,general pop,90,83,94,delta,delta,~25 weeks,,,
117,Sheikh,AZD1222 (AstraZeneca),1,1,14+,death,death,Scotland,≥ 18 years,general pop,96,89,99,delta,delta,,,,
117,Sheikh,AZD1222 (AstraZeneca),2,final,14+,death,death,Scotland,≥ 18 years,general pop,91,86,94,delta,delta,~25 weeks,,,
118,Embi,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,71,65,76,,"non-VOC, alpha, & delta",~33 weeks,,,
118,Embi,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,88,86,89,,"non-VOC, alpha, & delta",~33 weeks,,,
118,Embi,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,81,76,85,,"non-VOC, alpha, & delta",~33 weeks,,,
118,Embi,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,93,92,94,,"non-VOC, alpha, & delta",~33 weeks,,,
118,Embi,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,76,69,81,,non-VOC & alpha,~33 weeks,,,
118,Embi,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,91,90,93,,non-VOC & alpha,~33 weeks,,,
118,Embi,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,79,74,83,,delta,~33 weeks,,,
118,Embi,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,90,89,91,,delta,~33 weeks,,,
119,Poukka,Pfizer,1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,40,33,46,,"non-VOC, alpha, & delta",,,,
119,Poukka,Pfizer,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,83,80,85,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,Pfizer,2,final,181+,Infection,infection,Finland,HCW,HCW aged 16-69 years,55,45,64,,"non-VOC, alpha, & delta",~29.5 weeks,,,
119,Poukka,Pfizer,1,1,42+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,82,68,90,,"non-VOC, alpha, & delta",,,,
119,Poukka,Pfizer,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,99,97,100,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,Pfizer,2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,98,89,100,,"non-VOC, alpha, & delta",~38 weeks,,,
119,Poukka,Moderna,1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,61,45,72,,"non-VOC, alpha, & delta",,,,
119,Poukka,Moderna,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,84,68,92,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,Moderna,2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,69,-124,96,,"non-VOC, alpha, & delta",~24 weeks,,,
119,Poukka,Moderna,1,1,42+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,89,22,98,,"non-VOC, alpha, & delta",,,,
119,Poukka,Moderna,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,Moderna,2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~34 weeks,,,
119,Poukka,Any mRNA - heterologous,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,Any mRNA - heterologous,2,final,181+,Infection,infection,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~29.5 weeks,,,
119,Poukka,Any mRNA - heterologous,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,Any mRNA - heterologous,2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~38 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,22,-3,42,,"non-VOC, alpha, & delta",,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,89,73,95,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,63,-166,95,,"non-VOC, alpha, & delta",~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),1,1,42+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,88,10,98,,"non-VOC, alpha, & delta",,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~25 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,80,72,86,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,62,30,79,,"non-VOC, alpha, & delta",~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,"non-VOC, alpha, & delta",~25 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,38,23,50,,non-VOC & alpha,,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,77,71,82,,non-VOC & alpha,~11 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,55,34,69,,non-VOC & alpha,~24 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,1,1,42+,hospitalization,severe,Finland,HCW,HCW aged 16-69 years,90,27,99,,non-VOC & alpha,,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,14-90,hospitalization,severe,Finland,HCW,HCW aged 16-69 years,95,64,99,,non-VOC & alpha,~11 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,91-180,hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,15,-15,37,,non-VOC & alpha,,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),1,1,42+,hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,-inf,100,,non-VOC & alpha,,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,14-90,hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,non-VOC & alpha,~11 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,45,37,51,,delta,,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,85,81,88,,delta,~11 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,181+,Infection,infection,Finland,HCW,HCW aged 16-69 years,56,46,65,,delta,~29.5 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,1,1,42+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,83,68,91,,delta,,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,97,100,,delta,~11 weeks,,,
119,Poukka,Any mRNA - homologous or heterologous,2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,98,88,100,,delta,~38 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),1,1,42+,Infection,infection,Finland,HCW,HCW aged 16-69 years,49,-16,77,,delta,,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,88,71,95,,delta,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,62,-177,95,,delta,~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),1,1,42+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,42,-330,92,,delta,,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,delta,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca),2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,delta,~25 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-90,Infection,infection,Finland,HCW,HCW aged 16-69 years,80,72,86,,delta,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,91-180,Infection,infection,Finland,HCW,HCW aged 16-69 years,63,33,80,,delta,~24 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14-90,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,delta,~11 weeks,,,
119,Poukka,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,181+,Hospitalization,severe,Finland,HCW,HCW aged 16-69 years,100,,,,delta,~25 weeks,,,
120,Al Hosani,BBIBP-CorV (Beijing CNBG),1,1,14+,Hospitalization,severe,United Arab Emirates,≥ 15 years,≥ 15 years,-20,-28.6,11.8,,non-VOC & alpha,,,,
120,Al Hosani,BBIBP-CorV (Beijing CNBG),2,final,14+,Hospitalization,severe,United Arab Emirates,≥ 15 years,≥ 15 years,79.8,78,81.4,,non-VOC & alpha,~34 weeks,,,
120,Al Hosani,BBIBP-CorV (Beijing CNBG),1,1,14+,ICU admission,severe,United Arab Emirates,≥ 15 years,≥ 15 years,3.7,-12.8,18.1,,non-VOC & alpha,,,,
120,Al Hosani,BBIBP-CorV (Beijing CNBG),2,final,14+,ICU admission,severe,United Arab Emirates,≥ 15 years,≥ 15 years,92.2,89.7,94.1,,non-VOC & alpha,~34 weeks,,,
120,Al Hosani,BBIBP-CorV (Beijing CNBG),1,1,14+,death,death,United Arab Emirates,≥ 15 years,≥ 15 years,27.9,-61,72.6,,non-VOC & alpha,,,,
120,Al Hosani,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,United Arab Emirates,≥ 15 years,≥ 15 years,97.1,83,99.9,,non-VOC & alpha,~34 weeks,,,
121,Ng,Pfizer,2,final,15+,Infection,infection,Singapore,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,61.6,37.5,80.4,delta,delta,~16.5 weeks,,,
121,Ng,Pfizer,2,final,15+,symptomatic disease,symptomatic,Singapore,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,67.9,41.3,87.8,delta,delta,~16.5 weeks,,,
121,Ng,Pfizer,2,final,15+,severe disease,severe,Singapore,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,100,,,delta,delta,~16.5 weeks,,,
122,Paixao,CoronaVac (Sinovac),1,1,14+,symptomatic disease,symptomatic,Brazil,pregnant women,pregnant persons,5,-18.2,23.7,,gamma & delta,,,,
122,Paixao,CoronaVac (Sinovac),2,final,14+,symptomatic disease,symptomatic,Brazil,pregnant women,pregnant persons,41,27,52.2,,gamma & delta,~25 weeks,,,
122,Paixao,CoronaVac (Sinovac),1,1,14+,severe disease,severe,Brazil,pregnant women,pregnant persons,67.7,20,87,,gamma & delta,,,,
122,Paixao,CoronaVac (Sinovac),2,final,14+,severe disease,severe,Brazil,pregnant women,pregnant persons,85.4,59.4,94.8,,gamma & delta,~25 weeks,,,
123,Desai,BBV152 (Bharat),1,1,21+,symptomatic disease,symptomatic,India,HCW,HCW,-1,-51,33,,delta,,,,
123,Desai,BBV152 (Bharat),2,final,14+,symptomatic disease,symptomatic,India,HCW,HCW,50,33,62,,delta,~4 weeks,,,
123,Desai,BBV152 (Bharat),2,final,28+,symptomatic disease,symptomatic,India,HCW,HCW,46,22,62,,delta,~4 weeks,,,
123,Desai,BBV152 (Bharat),2,final,42+,symptomatic disease,symptomatic,India,HCW,HCW,57,21,76,,delta,~4 weeks,,,
123,Desai,BBV152 (Bharat),2,final,14+,symptomatic disease,symptomatic,India,HCW,HCW,47,29,61,,delta,~4 weeks,,,
124,Thiruvengadam,AZD1222 (AstraZeneca),1,1,21+,infection,infection,India,≥ 18 years,general pop,46.2,31.6,57.7,,delta,,,,
124,Thiruvengadam,AZD1222 (AstraZeneca),2,final,14+,infection,infection,India,≥ 18 years,general pop,63.1,51.5,72.1,,delta,~10 weeks,,,
125,Hall,Pfizer,1,1,21-27,Infection,infection,UK,HCW,HCW,59,42,71,,"non-VOC, alpha, & delta",,,,
125,Hall,Pfizer,2,final,14-73,Infection,infection,UK,HCW,HCW,89,78,94,,"non-VOC, alpha, & delta",~8 weeks,<6 weeks,,
125,Hall,Pfizer,2,final,194-265,Infection,infection,UK,HCW,HCW,53,28,69,,"non-VOC, alpha, & delta",36 weeks,<6 weeks,,
125,Hall,Pfizer,1,1,56-280,Infection,infection,UK,HCW,HCW,63,46,75,,"non-VOC, alpha, & delta",,,,
125,Hall,Pfizer,2,final,14-73,Infection,infection,UK,HCW,HCW,85,72,92,,"non-VOC, alpha, & delta",~8 weeks,6+ weeks,,
125,Hall,Pfizer,2,final,194-239,Infection,infection,UK,HCW,HCW,51,22,69,,"non-VOC, alpha, & delta",~32 weeks,6+ weeks,,
125,Hall,AZD1222 (AstraZeneca),1,1,21-27,Infection,infection,UK,HCW,HCW,63,-80,92,,"non-VOC, alpha, & delta",,,,
125,Hall,AZD1222 (AstraZeneca),2,final,14-73,Infection,infection,UK,HCW,HCW,58,23,77,,"non-VOC, alpha, & delta",~8 weeks,,,
125,Hall,AZD1222 (AstraZeneca),1,1,56-249,Infection,infection,UK,HCW,HCW,9,-87,55,,"non-VOC, alpha, & delta",,,,
125,Hall,AZD1222 (AstraZeneca),2,final,134-220,Infection,infection,UK,HCW,HCW,72,39,87,,"non-VOC, alpha, & delta",~29 weeks,,,
126,Vokó,Pfizer,1,1+,0+,Infection,infection,Hungary,≥ 16 years,general pop,41,39.5,42.4,,alpha,,,,
126,Vokó,Pfizer,2,final,14+,Infection,infection,Hungary,≥ 16 years,general pop,84,83.3,84.7,,alpha,~19 weeks,,,
126,Vokó,Pfizer,1,1+,0+,death,death,Hungary,≥ 16 years,general pop,64.3,61.8,66.6,,alpha,,,,
126,Vokó,Pfizer,2,final,14+,death,death,Hungary,≥ 16 years,general pop,90.3,88.9,91.5,,alpha,~19 weeks,,,
126,Vokó,BBIBP-CorV (Beijing CNBG),1,1+,0+,Infection,infection,Hungary,≥ 16 years,general pop,34,31.8,36.1,,alpha,,,,
126,Vokó,BBIBP-CorV (Beijing CNBG),2,final,14+,Infection,infection,Hungary,≥ 16 years,general pop,72.8,71.2,74.4,,alpha,~10.5 weeks,,,
126,Vokó,BBIBP-CorV (Beijing CNBG),1,1+,0+,death,death,Hungary,≥ 16 years,general pop,39.4,34.1,44.3,,alpha,,,,
126,Vokó,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,Hungary,≥ 16 years,general pop,86,83.7,87.9,,alpha,~10.5 weeks,,,
126,Vokó,Sputnik V (Gamaleya),1,1+,0+,Infection,infection,Hungary,≥ 16 years,general pop,48.7,47.1,50.2,,alpha,,,,
126,Vokó,Sputnik V (Gamaleya),2,final,14+,Infection,infection,Hungary,≥ 16 years,general pop,88.1,86.5,89.4,,alpha,~11 weeks,,,
126,Vokó,Sputnik V (Gamaleya),1,1+,0+,death,death,Hungary,≥ 16 years,general pop,78,74.3,81.2,,alpha,,,,
126,Vokó,Sputnik V (Gamaleya),2,final,14+,death,death,Hungary,≥ 16 years,general pop,97.8,95.5,98.9,,alpha,~11 weeks,,,
126,Vokó,AZD1222 (AstraZeneca),1,1+,0+,Infection,infection,Hungary,≥ 16 years,general pop,49.2,47.7,50.6,,alpha,,,,
126,Vokó,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Hungary,≥ 16 years,general pop,73.3,71.1,76,,alpha,~11.5 weeks,,,
126,Vokó,AZD1222 (AstraZeneca),1,1+,0+,death,death,Hungary,≥ 16 years,general pop,71.3,67.9,74.4,,alpha,,,,
126,Vokó,AZD1222 (AstraZeneca),2,final,14+,death,death,Hungary,≥ 16 years,general pop,85.8,73.5,92.4,,alpha,~11.5 weeks,,,
126,Vokó,Moderna,1,1+,0+,Infection,infection,Hungary,≥ 16 years,general pop,60.8,58.6,63,,alpha,,,,
126,Vokó,Moderna,2,final,14+,Infection,infection,Hungary,≥ 16 years,general pop,88.2,85.8,90.3,,alpha,~15 weeks,,,
126,Vokó,Moderna,1,1+,0+,death,death,Hungary,≥ 16 years,general pop,68.7,62.5,73.8,,alpha,,,,
126,Vokó,Moderna,2,final,14+,death,death,Hungary,≥ 16 years,general pop,93.8,90.3,96.1,,alpha,~15 weeks,,,
127,Wu,Pfizer,1,1,14+,Infection,infection,USA,cancer patients,immunocompromised adults,45,8,66,,non-VOC & alpha,,,,
127,Wu,Pfizer,2,final,14+,Infection,infection,USA,cancer patients,immunocompromised adults,58,39,73,,non-VOC & alpha,15 weeks,,,
128,Muhsen,Pfizer,2,final,14+,Infection,infection,Israel ,HCW,HCW,89,83,93,,alpha,~11 weeks,,,
129,Yassi,Pfizer,2,final,7+,Infection,infection,Canada,HCW,HCW,74.1,62.5,82.1,,"non-VOC, alpha, & delta",~40.5 weeks,,,
129,Yassi,Pfizer,2,final,7+,Infection,infection,Canada,HCW,HCW,82.8,74,88.6,,"non-VOC, alpha, & delta",~40.5 weeks,,,
130,UKHSA,Pfizer,2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,65.8,64.4,67.2,omicron,omicron,~32 weeks,,,
130,UKHSA,Pfizer,2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,9.4,7.8,11.1,omicron,omicron,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,49.8,40.7,57.5,omicron,omicron,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,-1,-2.4,0.3,omicron,omicron,~32 weeks,,,
130,UKHSA,Moderna,2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,76,72,79,omicron,omicron,~32 weeks,,,
130,UKHSA,Moderna,2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,13,3,22,omicron,omicron,~32 weeks,,,
130,UKHSA,Pfizer,2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,90.9,89.6,92,delta,delta,~32 weeks,,,
130,UKHSA,Pfizer,2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,62.7,61.6,63.7,delta,delta,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,82.8,74.5,88.4,delta,delta,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,43.5,42.4,44.5,delta,delta,~32 weeks,,,
130,UKHSA,Moderna,2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,94.5,90.5,96.9,delta,delta,~32 weeks,,,
130,UKHSA,Moderna,2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,80.4,67.3,88.2,delta,delta,~32 weeks,,,
130,UKHSA,Pfizer,2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,73.6,40.7,88.3,omicron,omicron,~32 weeks,,,
130,UKHSA,Pfizer,2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,34.9,17.7,48.4,omicron,omicron,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,20-24 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,55.8,34.1,70.3,omicron,omicron,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,32.7,19.7,43.6,omicron,omicron,~32 weeks,,,
130,UKHSA,Pfizer,2,final,2-4 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,94.1,81.6,98.1,delta,delta,~32 weeks,,,
130,UKHSA,Pfizer,2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,95.3,93.9,96.5,delta,delta,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,20-24 weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,92.9,91.3,94.2,delta,delta,~32 weeks,,,
130,UKHSA,AZD1222 (AstraZeneca),2,final,25+ weeks,symptomatic disease,symptomatic,UK,≥ 18 years,general pop,90.6,89.3,91.8,delta,delta,~32 weeks,,,
131,Bajema,Pfizer,2,final,14-119,Hospitalization,severe,USA,≥ 18 years,general pop,86,77.6,91.3,,"non-VOC, alpha, & delta",~36 weeks,,,
131,Bajema,Pfizer,2,final,120+,Hospitalization,severe,USA,≥ 18 years,general pop,75.1,64.6,82.4,,"non-VOC, alpha, & delta",~36 weeks,,,
131,Bajema,Moderna,2,final,14-119,Hospitalization,severe,USA,≥ 18 years,general pop,89.6,80.1,94.5,,"non-VOC, alpha, & delta",~36 weeks,,,
131,Bajema,Moderna,2,final,120+,Hospitalization,severe,USA,≥ 18 years,general pop,86.1,77.7,91.3,,"non-VOC, alpha, & delta",~36 weeks,,,
132,Powell,Pfizer,1,1,14-20,symptomatic disease,symptomatic,UK,12-15 years,12-15 years,49.6,43.9,54.8,omicron,omicron,,,,
132,Powell,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,12-15 years,12-15 years,73,66.4,78.3,omicron,omicron,~33 weeks,,,
132,Powell,Pfizer,1,1,84+,symptomatic disease,symptomatic,UK,12-15 years,12-15 years,17.2,12,22.1,omicron,omicron,,,,
132,Powell,Pfizer,1,1,14-20,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,51.4,42.7,58.8,omicron,omicron,,,,
132,Powell,Pfizer,2,final,14-34,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,71.3,69.3,73.1,omicron,omicron,~33 weeks,,,
132,Powell,Pfizer,1,1,105+,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,12.5,6.9,17.8,omicron,omicron,,,,
132,Powell,Pfizer,2,final,70+,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,22.6,14.5,29.9,omicron,omicron,~33 weeks,,,
132,Powell,Pfizer,1,1,14-20,symptomatic disease,symptomatic,UK,12-15 years,12-15 years,74.5,73.2,75.6,delta,delta,,,,
132,Powell,Pfizer,2,final,14+,symptomatic disease,symptomatic,UK,12-15 years,12-15 years,87.2,73.7,93.8,delta,delta,~33 weeks,,,
132,Powell,Pfizer,1,1,84+,symptomatic disease,symptomatic,UK,12-15 years,12-15 years,53.1,41.6,62.4,delta,delta,,,,
132,Powell,Pfizer,1,1,14-20,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,75.9,74.3,77.3,delta,delta,,,,
132,Powell,Pfizer,2,final,14-34,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,93.1,91.6,94.4,delta,delta,~33 weeks,,,
132,Powell,Pfizer,1,1,105+,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,30.9,25.4,36,delta,delta,,,,
132,Powell,Pfizer,2,final,70+,symptomatic disease,symptomatic,UK,16-17 years,16-17 years,83.7,72,90.5,delta,delta,~33 weeks,,,
132,Powell,Pfizer,1,1,28+,hospitalization,severe,UK,12-15 years,12-15 years,83.4,54,94,delta,delta,,,,
132,Powell,Pfizer,1,1,28+,hospitalization,severe,UK,16-17 years,16-17 years,76.3,61.1,85.6,delta,delta,,,,
133,Berec,Pfizer,2,final,0-2 months,Infection,infection,Czech Republic,≥ 18 years,general pop,87,86,87,,alpha & delta,~35 weeks,,,
133,Berec,Pfizer,2,final,7-8 months,Infection,infection,Czech Republic,≥ 18 years,general pop,53,52,54,,alpha & delta,~35 weeks,,,
133,Berec,Pfizer,2,final,0-2 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,90,89,91,,alpha & delta,~35 weeks,,,
133,Berec,Pfizer,2,final,7-8 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,75,73,76,,alpha & delta,~35 weeks,,,
133,Berec,Pfizer,2,final,0-2 months,death,death,Czech Republic,≥ 18 years,general pop,92,90,93,,alpha & delta,~35 weeks,,,
133,Berec,Pfizer,2,final,7-8 months,death,death,Czech Republic,≥ 18 years,general pop,83,81,86,,alpha & delta,~35 weeks,,,
133,Berec,Moderna,2,final,0-2 months,Infection,infection,Czech Republic,≥ 18 years,general pop,90,89,91,,alpha & delta,~35 weeks,,,
133,Berec,Moderna,2,final,7-8 months,Infection,infection,Czech Republic,≥ 18 years,general pop,65,63,67,,alpha & delta,~35 weeks,,,
133,Berec,Moderna,2,final,0-2 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,94,92,96,,alpha & delta,~35 weeks,,,
133,Berec,Moderna,2,final,7-8 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,81,78,84,,alpha & delta,~35 weeks,,,
133,Berec,Moderna,2,final,0-2 months,death,death,Czech Republic,≥ 18 years,general pop,96,91,98,,alpha & delta,~35 weeks,,,
133,Berec,Moderna,2,final,7-8 months,death,death,Czech Republic,≥ 18 years,general pop,88,82,92,,alpha & delta,~35 weeks,,,
133,Berec,AZD1222 (AstraZeneca),2,final,0-2 months,Infection,infection,Czech Republic,≥ 18 years,general pop,83,80,85,,alpha & delta,~35 weeks,,,
133,Berec,AZD1222 (AstraZeneca),2,final,5-6 months,Infection,infection,Czech Republic,≥ 18 years,general pop,55,54,56,,alpha & delta,~35 weeks,,,
133,Berec,AZD1222 (AstraZeneca),2,final,0-2 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,87,81,91,,alpha & delta,~35 weeks,,,
133,Berec,AZD1222 (AstraZeneca),2,final,5-6 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,70,68,72,,alpha & delta,~35 weeks,,,
133,Berec,AZD1222 (AstraZeneca),2,final,0-2 months,death,death,Czech Republic,≥ 18 years,general pop,93,77,98,,alpha & delta,~35 weeks,,,
133,Berec,AZD1222 (AstraZeneca),2,final,5-6 months,death,death,Czech Republic,≥ 18 years,general pop,82,78,85,,alpha & delta,~35 weeks,,,
133,Berec,Janssen,2,final,0-2 months,Infection,infection,Czech Republic,≥ 18 years,general pop,68,66,70,,alpha & delta,~35 weeks,,,
133,Berec,Janssen,2,final,5-6 months,Infection,infection,Czech Republic,≥ 18 years,general pop,67,65,69,,alpha & delta,~35 weeks,,,
133,Berec,Janssen,2,final,2 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,68,60,75,,alpha & delta,~35 weeks,,,
133,Berec,Janssen,2,final,5-6 months,Hospitalization,severe,Czech Republic,≥ 18 years,general pop,67,62,72,,alpha & delta,~35 weeks,,,
133,Berec,Janssen,2,final,2 months,death,death,Czech Republic,≥ 18 years,general pop,68,42,82,,alpha & delta,~35 weeks,,,
133,Berec,Janssen,2,final,5-6 months,death,death,Czech Republic,≥ 18 years,general pop,68,53,78,,alpha & delta,~35 weeks,,,
134,Machado,Pfizer,2,final,14-41,symptomatic disease,symptomatic,Portugal,65-79 years,65-79 years,79,76,83,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,98+,symptomatic disease,symptomatic,Portugal,65-79 years,65-79 years,39,29,48,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,14-41,symptomatic disease,symptomatic,Portugal,≥ 80 years,≥ 80 years,72,61,79,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,124+,symptomatic disease,symptomatic,Portugal,≥ 80 years,≥ 80 years,34,29,48,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,14-41,Hospitalization,severe,Portugal,65-79 years,65-79 years,95,90,97,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,70+,Hospitalization,severe,Portugal,65-79 years,65-79 years,93,86,96,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,14-41,Hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,83,68,91,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,124+,Hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,63,37,78,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,14-41,death,death,Portugal,65-79 years,65-79 years,95,88,98,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,70+,death,death,Portugal,65-79 years,65-79 years,93,87,96,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,14-41,death,death,Portugal,≥ 80 years,≥ 80 years,87,71,93,,alpha & delta,~29 weeks,,,
134,Machado,Pfizer,2,final,124+,death,death,Portugal,≥ 80 years,≥ 80 years,75,64,82,,alpha & delta,~29 weeks,,,
134,Machado,AZD1222 (AstraZeneca),2,final,14-41,symptomatic disease,symptomatic,Portugal,65-79 years,65-79 years,95,90,97,,alpha & delta,~29 weeks,,,
134,Machado,AZD1222 (AstraZeneca),2,final,70+,symptomatic disease,symptomatic,Portugal,65-79 years,65-79 years,93,86,96,,alpha & delta,~29 weeks,,,
134,Machado,AZD1222 (AstraZeneca),2,final,14+,Hospitalization,severe,Portugal,65-79 years,65-79 years,89,52,94,,alpha & delta,~29 weeks,,,
134,Machado,AZD1222 (AstraZeneca),2,final,14+,death,death,Portugal,65-79 years,65-79 years,95,90,97,,alpha & delta,~29 weeks,,,
135,Florea,Moderna,2,final,14+,Infection,infection,USA,≥ 18 years,general pop,82.8,82.2,83.3,,"non-VOC, alpha, & delta",~35 weeks,,,
135,Florea,Moderna,2,final,14-60,Infection,infection,USA,≥ 18 years,general pop,88,86.8,89.1,,"non-VOC, alpha, & delta",~6.5 weeks,,,
135,Florea,Moderna,2,final,180-240,Infection,infection,USA,≥ 18 years,general pop,75.5,70.4,79.7,,"non-VOC, alpha, & delta",~35 weeks,,,
135,Florea,Moderna,2,final,14+,Hospitalization,severe,USA,≥ 18 years,general pop,96.1,95.5,96.6,,"non-VOC, alpha, & delta",~35 weeks,,,
135,Florea,Moderna,2,final,14-60,Hospitalization,severe,USA,≥ 18 years,general pop,95.9,93.5,97.4,,"non-VOC, alpha, & delta",~6.5 weeks,,,
135,Florea,Moderna,2,final,180-240,Hospitalization,severe,USA,≥ 18 years,general pop,94.5,90.9,96.7,,"non-VOC, alpha, & delta",~35 weeks,,,
135,Florea,Moderna,2,final,14+,death,death,USA,≥ 18 years,general pop,97.2,94.8,98.4,,"non-VOC, alpha, & delta",~35 weeks,,,
135,Florea,Moderna,2,final,14+,Infection,infection,USA,≥ 18 years,general pop,86.5,84.8,88,,delta,~15 weeks,,,
136,Young-Xu,Pfizer,2,final,14-43,Infection,infection,USA,males 65+,males 65+,94.5,90.7,96.7,,non-VOC & alpha,4 weeks,,,
136,Young-Xu,Pfizer,2,final,74-103,Infection,infection,USA,males 65+,males 65+,87.9,85.9,89.5,,non-VOC & alpha,12 weeks,,,
136,Young-Xu,Pfizer,2,final,14-43,Infection,infection,USA,males 65+,males 65+,92.1,87.2,95.1,,alpha & delta,4 weeks,,,
136,Young-Xu,Pfizer,2,final,134-163,Infection,infection,USA,males 65+,males 65+,67.3,63.2,70.9,,alpha & delta,20 weeks,,,
136,Young-Xu,Pfizer,2,final,14-43,Infection,infection,USA,males 65+,males 65+,62,45.6,73.5,,delta,4 weeks,,,
136,Young-Xu,Pfizer,2,final,224-253,Infection,infection,USA,males 65+,males 65+,24.8,18.8,30.4,,delta,32 weeks,,,
137,Castillo-Arregoces,Pfizer,2,final,14+,hospitalization,severe,Colombia,≥ 60 years,60+ years,83,78.4,86.6,,mu,32 weeks,,,
137,Castillo-Arregoces,Pfizer,2,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,60+ years,94.8,93.3,96,,mu,32 weeks,,,
137,Castillo-Arregoces,Pfizer,2,final,14+,death,death,Colombia,≥ 60 years,60+ years,88.3,84.1,91.4,,mu,32 weeks,,,
137,Castillo-Arregoces,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,Colombia,≥ 60 years,60+ years,90.8,85.5,94.2,,mu,32 weeks,,,
137,Castillo-Arregoces,AZD1222 (AstraZeneca),2,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,60+ years,97.5,95.8,98.5,,mu,32 weeks,,,
137,Castillo-Arregoces,AZD1222 (AstraZeneca),2,final,14+,death,death,Colombia,≥ 60 years,60+ years,93.9,89.3,96.6,,mu,32 weeks,,,
137,Castillo-Arregoces,Janssen,1,final,14+,hospitalization,severe,Colombia,≥ 60 years,60+ years,60.9,36.8,75.8,,mu,32 weeks,,,
137,Castillo-Arregoces,Janssen,1,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,60+ years,85.8,77.1,91.2,,mu,32 weeks,,,
137,Castillo-Arregoces,Janssen,1,final,14+,death,death,Colombia,≥ 60 years,60+ years,95.5,82,98.9,,mu,32 weeks,,,
137,Castillo-Arregoces,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Colombia,≥ 60 years,≥ 60 years,47.3,41.9,52.3,,mu,32 weeks,,,
137,Castillo-Arregoces,CoronaVac (Sinovac),2,final,14+,post-hospitalization death,death,Colombia,≥ 60 years,60+ years,72.1,70.1,73.9,,mu,32 weeks,,,
137,Castillo-Arregoces,CoronaVac (Sinovac),2,final,14+,death,death,Colombia,≥ 60 years,60+ years,64.9,61.2,68.9,,mu,32 weeks,,,
138,McLean,Pfizer,2,final,14+,infection,infection,USA,≥ 12 years,general pop,50,21,69,,"non-VOC, alpha, & delta",~52 weeks,,,
138,McLean,Moderna,2,final,14+,Infection,infection,USA,≥ 12 years,general pop,65,37,81,,"non-VOC, alpha, & delta",~52 weeks,,,
138,McLean,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥ 12 years,general pop,54,26,71,,"non-VOC, alpha, & delta",~52 weeks,,,
138,McLean,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥ 12 years,general pop,65,38,81,,"non-VOC, alpha, & delta",~52 weeks,,,
138,McLean,Pfizer,2,final,14+,Infection,infection,USA,≥ 12 years,general pop,51,22,70,,"non-VOC, alpha, & delta",~52 weeks,,,
138,McLean,Moderna,2,final,14+,Infection,infection,USA,≥ 12 years,general pop,66,38,82,,"non-VOC, alpha, & delta",~52 weeks,,,
138,McLean,Pfizer,2,final,14+,Infection,infection,USA,≥ 12 years,general pop,52,20,71,delta,delta,~52 weeks,,,
138,McLean,Moderna,2,final,14+,Infection,infection,USA,≥ 12 years,general pop,59,24,78,delta,delta,~52 weeks,,,
139,Abu-Raddad,Moderna,1,1,14+,Infection,infection,Qatar,≥ 18 years,general pop,60.3,57,63.3,,beta & delta,,,,
139,Abu-Raddad,Moderna,2,final,30+,Infection,infection,Qatar,≥ 18 years,general pop,85.3,83.5,86.9,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,2,final,240+,Infection,infection,Qatar,≥ 18 years,general pop,-29.5,-84,8.8,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,1,1,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,78.3,75.2,81.1,,beta & delta,,,,
139,Abu-Raddad,Moderna,2,final,30+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,94.4,92.8,95.6,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,2,final,240+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,20,-29,59.3,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,1,1,14+,asymptomatic infection,asymptomatic,Qatar,≥ 18 years,general pop,54.6,47.7,60.6,,beta & delta,,,,
139,Abu-Raddad,Moderna,2,final,30+,asymptomatic infection,asymptomatic,Qatar,≥ 18 years,general pop,79.9,75.5,83.4,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,2,final,240+,asymptomatic infection,asymptomatic,Qatar,≥ 18 years,general pop,-28.4,-129.3,28.1,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,1,1,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,82.1,73.1,88.1,,beta & delta,,,,
139,Abu-Raddad,Moderna,2,final,30+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,97.2,92.4,99,,beta & delta,~35 weeks,,,
139,Abu-Raddad,Moderna,2,final,180+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,61,-225.5,95.3,,beta & delta,~35 weeks,,,
140,Bekker,Janssen,1,final,28+,hospitalization,severe,South Africa,HCW,HCW,67,62,71,,"beta, delta, & kappa",12 weeks,,,
140,Bekker,Janssen,1,final,28+,ICU admission,severe,South Africa,HCW,HCW,75,69,82,,"beta, delta, & kappa",12 weeks,,,
140,Bekker,Janssen,1,final,28+,death,death,South Africa,HCW,HCW,83,75,89,,"beta, delta, & kappa",12 weeks,,,
140,Bekker,Janssen,1,final,28+,hospitalization,severe,South Africa,HCW,HCW,62,42,76,beta,beta,12 weeks,,,
140,Bekker,Janssen,1,final,28+,ICU admission,severe,South Africa,HCW,HCW,49,8,77,beta,beta,12 weeks,,,
140,Bekker,Janssen,1,final,28+,death,death,South Africa,HCW,HCW,86,57,100,beta,beta,12 weeks,,,
140,Bekker,Janssen,1,final,28+,hospitalization,severe,South Africa,HCW,HCW,67,62,71,delta,delta,12 weeks,,,
140,Bekker,Janssen,1,final,28+,ICU admission,severe,South Africa,HCW,HCW,78,71,88,delta,delta,12 weeks,,,
140,Bekker,Janssen,1,final,28+,death,death,South Africa,HCW,HCW,82,74,89,delta,delta,12 weeks,,,
141,Tartof,Pfizer,2,final,7-36,Infection,infection,USA,≥ 18 years,general pop,85,83,86,,"non-VOC, alpha, & delta",~48 weeks,,,
141,Tartof,Pfizer,2,final,217+,Infection,infection,USA,≥ 18 years,general pop,49,46,51,,"non-VOC, alpha, & delta",~48 weeks,,,
141,Tartof,Pfizer,2,final,7-36,hospitalization,severe,USA,≥ 18 years,general pop,90,86,92,,"non-VOC, alpha, & delta",~48 weeks,,,
141,Tartof,Pfizer,2,final,217+,hospitalization,severe,USA,≥ 18 years,general pop,88,85,90,,"non-VOC, alpha, & delta",~48 weeks,,,
142,Lewis,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,96,93,98,,alpha & delta,~30 weeks,,,
142,Lewis,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,93,89,95,,alpha & delta,~30 weeks,,,
142,Lewis,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,87,82,91,,alpha & delta,~30 weeks,,,
142,Lewis,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,83,72,88,,alpha & delta,~30 weeks,,,
143,Ioannou,Pfizer,1,1,14+,infection (March 31 2021),infection,USA,≥ 18 years,general pop,31,26,35,,non-VOC & alpha,,,,
143,Ioannou,Pfizer,2,final,7+,infection (March 31 2021),infection,USA,≥ 18 years,general pop,65,63,68,,non-VOC & alpha,~28 weeks,,,
143,Ioannou,Pfizer,2,final,7+,infection (June 30 2021),infection,USA,≥ 18 years,general pop,69,67,70,,non-VOC & alpha,~28 weeks,,,
143,Ioannou,Pfizer,1,1,14+,death (March 31 2021),death,USA,≥ 18 years,general pop,55,42,64,,non-VOC & alpha,,,,
143,Ioannou,Pfizer,2,final,7+,death (March 31 2021),death,USA,≥ 18 years,general pop,89,84,92,,non-VOC & alpha,~28 weeks,,,
143,Ioannou,Pfizer,2,final,7+,death (June 30 2021),death,USA,≥ 18 years,general pop,86,82,89,,non-VOC & alpha,~28 weeks,,,
144,Hansen,Pfizer,2,final,15-44,Infection,infection,Denmark,≥ 12 years,general pop,55.2,23.5,73.7,omicron,omicron,21 weeks,,,
144,Hansen,Pfizer,2,final,105-164,Infection,infection,Denmark,≥ 12 years,general pop,-76.5,-95.3,-59.5,omicron,omicron,22 weeks,,,
144,Hansen,Moderna,2,final,15-44,Infection,infection,Denmark,≥ 12 years,general pop,36.7,-69.9,76.4,omicron,omicron,23 weeks,,,
144,Hansen,Moderna,2,final,105-164,Infection,infection,Denmark,≥ 12 years,general pop,-39.3,-61.6,-20,omicron,omicron,24 weeks,,,
144,Hansen,Pfizer,2,final,15-44,Infection,infection,Denmark,≥ 12 years,general pop,86.7,84.6,88.6,delta,delta,25 weeks,,,
144,Hansen,Pfizer,2,final,105-164,Infection,infection,Denmark,≥ 12 years,general pop,53.8,52.9,54.6,delta,delta,26 weeks,,,
144,Hansen,Moderna,2,final,15-44,Infection,infection,Denmark,≥ 12 years,general pop,88.2,83.1,91.8,delta,delta,27 weeks,,,
144,Hansen,Moderna,2,final,105-164,Infection,infection,Denmark,≥ 12 years,general pop,65,63.6,66.3,delta,delta,28 weeks,,,
145,Kissling,Pfizer,2,final,14-29,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,87,83,89,,delta,~30 weeks,,,
145,Kissling,Pfizer,2,final,90+,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,65,56,71,,delta,~30 weeks,,,
145,Kissling,Pfizer,2,final,30-59,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",≥ 60 years,≥ 60 years,65,37,80,,delta,~30 weeks,,,
145,Kissling,Pfizer,2,final,90+,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",≥ 60 years,≥ 60 years,64,44,77,,delta,~30 weeks,,,
145,Kissling,Moderna,2,final,14-29,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,98,93,100,,delta,~30 weeks,,,
145,Kissling,Moderna,2,final,60-89,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,90,76,96,,delta,~30 weeks,,,
145,Kissling,AZD1222 (AstraZeneca),2,final,14-29,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,72,52,83,,delta,~30 weeks,,,
145,Kissling,AZD1222 (AstraZeneca),2,final,60-89,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,65,48,76,,delta,~30 weeks,,,
145,Kissling,Janssen,1,final,30-59,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,50,36,62,,delta,~30 weeks,,,
145,Kissling,Janssen,1,final,60-89,symptomatic disease,symptomatic,"Croatia, France, Ireland, Netherlands, Portugal, Romania, Spain, and UK",30-59 years,30-59 years,52,33,66,,delta,~30 weeks,,,
146,Katikireddi,AZD1222 (AstraZeneca),2,final,14-27,severe disease,severe,Scotland,≥ 18 years,general pop,83.7,79.7,87,,delta,~20 weeks,,,
146,Katikireddi,AZD1222 (AstraZeneca),2,final,140-153,severe disease,severe,Scotland,≥ 18 years,general pop,53.6,48.4,58.3,,delta,~20 weeks,,,
147,Amir,Pfizer,2,final,14-60,Infection,infection,Israel ,12-14 years,12-14 years,92,91.1,92.8,,delta,~6.5 weeks,,,
147,Amir,Pfizer,2,final,14-60,Infection,infection,Israel ,16-18 years,16-18 years,89.8,80,93.8,,delta,~6.5 weeks,,,
148,Ostropolets,Pfizer,2,final,14+,Infection,infection,USA,≥ 18 years,general pop,94,91,95,,"non-VOC, alpha, & delta",52 weeks,,,
148,Ostropolets,Pfizer,2,final,14+,Hospitalization,severe,USA,≥ 18 years,general pop,95,92,97,,"non-VOC, alpha, & delta",52 weeks,,,
148,Ostropolets,Moderna,2,final,14+,infection,infection,USA,≥ 18 years,general pop,97,94,98,,"non-VOC, alpha, & delta",52 weeks,,,
148,Ostropolets,Moderna,2,final,14+,Hospitalization,severe,USA,≥ 18 years,general pop,96,92,99,,"non-VOC, alpha, & delta",52 weeks,,,
148,Ostropolets,Janssen,1,final,14+,Infection,infection,USA,≥ 18 years,general pop,81,50,94,,"non-VOC, alpha, & delta",52 weeks,,,
148,Ostropolets,Janssen,1,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,92,58,100,,"non-VOC, alpha, & delta",52 weeks,,,
149,Alali,Pfizer,1,1,14+,symptomatic disease,symptomatic,Kuwait,HCW,HCW,91.4,65.1,97.9,,alpha,,,,
149,Alali,AZD1222 (AstraZeneca),1,1,28+,symptomatic disease,symptomatic,Kuwait,HCW,HCW,75.4,67.2,81.6,,alpha,,,,
149,Alali,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Kuwait,HCW,HCW,94.5,89.4,97.2,,alpha,~20 weeks,,,
150,Mendola,Pfizer,2,final,8-98,infection,infection,Italy,HCW,HCW,89,78,95,,alpha,~12 weeks,,,
151,Collie,Pfizer,2,final,14+,Hospitalization,severe,South Africa,≥ 18 years,general pop,70,62,76,,omicron,~24 weeks,,,
151,Collie,Pfizer,2,final,14+,Hospitalization,severe,South Africa,≥ 18 years,general pop,93,90,94,,delta,~19 weeks,,,
152,Lutrick,Pfizer,2,final,14+,infection,infection,USA,12-17 years,12-17 years,92,79,97,,delta,~17 weeks,,,
153,Chung,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥ 12 years,general pop,66,56,73,,"non-VOC, alpha, & delta",~34 weeks,,,
153,Chung,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥ 12 years,general pop,81,73,86,,"non-VOC, alpha, & delta",~34 weeks,,,
154,Buchan,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,36,24,45,omicron,omicron,~34 weeks,,,
154,Buchan,Pfizer,2,final,240+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,2,-17,17,omicron,omicron,~34 weeks,,,
154,Buchan,Pfizer,2,final,7-59,Infection,infection,Canada,≥ 18 years,general pop,5,-25,30,omicron,omicron,~34 weeks,,,
154,Buchan,Pfizer,2,final,240+,Infection,infection,Canada,≥ 18 years,general pop,-18,-62,18,omicron,omicron,~34 weeks,,,
154,Buchan,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,89,86,92,,delta,~34 weeks,,,
154,Buchan,Pfizer,2,final,240+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,80,74,84,,delta,~34 weeks,,,
154,Buchan,Pfizer,2,final,7-59,Infection,infection,Canada,≥ 18 years,general pop,82,81,83,,delta,~34 weeks,,,
154,Buchan,Pfizer,2,final,240+,Infection,infection,Canada,≥ 18 years,general pop,70,65,72,,delta,~34 weeks,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),1,1,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,18.8,10.7,26.1,,"non-VOC, gamma, & delta",,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),2,final,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,39.4,36.1,42.6,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),2,final,14-90,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,40.5,36.4,44.3,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),2,final,90+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,38,33.1,42.5,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),1,1,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,35.3,7.9,54.5,,"non-VOC, gamma, & delta",,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),2,final,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,81.3,75.3,85.8,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),2,final,14-90,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,86.6,79.8,90.3,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,CoronaVac (Sinovac),2,final,90+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,74.4,63.3,82.2,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),1,1,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,34.2,30.1,38.1,,"non-VOC, gamma, & delta",,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),2,final,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,56,51.4,60.2,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),2,final,14-90,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,55.5,50.5,60.1,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),2,final,90+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,56.8,46.6,65.1,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),1,1,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,56.9,45.2,66.1,,"non-VOC, gamma, & delta",,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),2,final,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,89.9,83.5,93.8,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),2,final,14-90,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,86.6,77.6,92,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,AZD1222 (AstraZeneca),2,final,90+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,95.1,84.8,98.4,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Pfizer,1,1,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,45,39.7,49.9,,"non-VOC, gamma, & delta",,,,
155,Cerqueira-Silva ,Pfizer,2,final,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,64.8,54.9,72.4,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Pfizer,2,final,14-90,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,64.2,54.2,72,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,Pfizer,2,final,90+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,100,,,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Pfizer,1,1,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,61.8,40.8,75.3,,"non-VOC, gamma, & delta",,,,
155,Cerqueira-Silva ,Pfizer,2,final,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,89.7,54.3,97.7,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Pfizer,2,final,14-90,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,88.8,50,97.5,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,Pfizer,2,final,90+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,100,,,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Janssen,1,final,14+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,44,31.5,54.2,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Janssen,1,final,14-90,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,46.1,32.7,56.7,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,Janssen,1,final,90+,symptomatic reinfection,symptomatic,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,30.6,-12.4,57.1,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Janssen,1,final,14+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,57.7,-2.6,82.5,,"non-VOC, gamma, & delta",~37 weeks,,,
155,Cerqueira-Silva ,Janssen,1,final,14-90,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,60.2,-10.8,85.7,,"non-VOC, gamma, & delta",~11 weeks,,,
155,Cerqueira-Silva ,Janssen,1,final,90+,hospitalization or death,severe,Brazil,≥ 18 years with prior SARS-CoV-2 infection,general pop with prior SARS-CoV-2 infection,41,-240.9,89.9,,"non-VOC, gamma, & delta",~37 weeks,,,
156,Petráš,Pfizer,1,1,14+,infection,infection,Czech Republic,HCW,HCW,47.7,19.2,66.2,,alpha & delta,,,,
156,Petráš,Pfizer,2,final,14+,Infection,infection,Czech Republic,HCW,HCW,88.3,83.2,91.8,,alpha & delta,~30 weeks,,,
156,Petráš,Pfizer,1,1,14+,symptomatic disease,symptomatic,Czech Republic,HCW,HCW,76.4,46,89.7,,alpha & delta,,,,
156,Petráš,Pfizer,2,final,14+,symptomatic disease,symptomatic,Czech Republic,HCW,HCW,91.7,85.7,95.2,,alpha & delta,~30 weeks,,,
156,Petráš,Pfizer,2,final,14+,infection (February 2021),infection,Czech Republic,HCW,HCW,96.2,91.6,98.7,,alpha & delta,4 weeks,,,
156,Petráš,Pfizer,2,final,14+,infection (June-August 2021),infection,Czech Republic,HCW,HCW,65,<0,96.6,,alpha & delta,~30 weeks,,,
157,Prunas,Pfizer,2,final,14-89,Infection,infection,Israel ,12-16 years,12-16 years,85,84,86,,delta,~25 weeks,,,
157,Prunas,Pfizer,2,final,150-180,Infection,infection,Israel ,12-16 years,12-16 years,53,46,60,,delta,~25 weeks,,,
157,Prunas,Pfizer,2,final,14-89,symptomatic disease,symptomatic,Israel ,12-16 years,12-16 years,90,89,91,,delta,~25 weeks,,,
157,Prunas,Pfizer,2,final,150-180,symptomatic disease,symptomatic,Israel ,12-16 years,12-16 years,66,59,72,,delta,~25 weeks,,,
157,Prunas,Pfizer,2,final,14-89,Infection,infection,Israel ,12-16 years,12-16 years,84,82,85,,delta,~25 weeks,,,
157,Prunas,Pfizer,2,final,150-180,Infection,infection,Israel ,12-16 years,12-16 years,50,43,57,,delta,~25 weeks,,,
158,Zambrano,Pfizer,2,final,14+,MIS-C,MIS-C,USA,12-18 years,12-18 years,86,70,93,,delta,~23 weeks,,,
158,Zambrano,Pfizer,2,final,28+,MIS-C,MIS-C,USA,12-18 years,12-18 years,91,78,97,,delta,~23 weeks,,,
158,Zambrano,Pfizer,2,final,28+,MIS-C,MIS-C,USA,12-18 years,12-18 years,90,75,96,,delta,~23 weeks,,,
159,Tseng,Moderna,1,1,14+,Infection,infection,USA,≥ 18 years,general pop,20.4,9.5,30,omicron,omicron,,,,
159,Tseng,Moderna,2,final,14+,Infection,infection,USA,≥ 18 years,general pop,13.9,10.5,17.1,omicron,omicron,~47.5 weeks,,,
159,Tseng,Moderna,2,final,14-90,Infection,infection,USA,≥ 18 years,general pop,44,35.1,51.6,omicron,omicron,~11 weeks,,,
159,Tseng,Moderna,2,final,270+,Infection,infection,USA,≥ 18 years,general pop,5.9,0.4,11,omicron,omicron,~47.5 weeks,,,
159,Tseng,Moderna,2,final,14+,Hospitalization,severe,USA,≥ 18 years,general pop,84.5,23,96.9,omicron,omicron,~47.5 weeks,,,
159,Tseng,Moderna,1,1,14+,Infection,infection,USA,≥ 18 years,general pop,56.7,40.7,68.4,delta,delta,,,,
159,Tseng,Moderna,2,final,14+,Infection,infection,USA,≥ 18 years,general pop,63.6,59.9,66.9,delta,delta,~47.5 weeks,,,
159,Tseng,Moderna,2,final,14-90,Infection,infection,USA,≥ 18 years,general pop,80.2,68.2,87.7,delta,delta,~11 weeks,,,
159,Tseng,Moderna,2,final,270+,Infection,infection,USA,≥ 18 years,general pop,61.3,55,66.7,delta,delta,~47.5 weeks,,,
159,Tseng,Moderna,1,1,14+,Hospitalization,severe,USA,≥ 18 years,general pop,71.2,-68.7,97.4,delta,delta,,,,
159,Tseng,Moderna,2,final,14+,Hospitalization,severe,USA,≥ 18 years,general pop,99,93.3,99.9,delta,delta,~47.5 weeks,,,
160,Chiew,Pfizer,2,final,8+,Infection,infection,Singapore,12-17 years,12-17 years,25,21,29,,omicron,~44 weeks,,,
160,Chiew,Pfizer,2,final,8-59,Infection,infection,Singapore,12-17 years,12-17 years,38,32,43,,omicron,,,,
160,Chiew,Pfizer,2,final,240+,Infection,infection,Singapore,12-17 years,12-17 years,40,34,46,,omicron,~44 weeks,,,
160,Chiew,Pfizer,2,final,8+,Hospitalization,severe,Singapore,12-17 years,12-17 years,75,56,86,,omicron,~44 weeks,,,
160,Chiew,Pfizer,2,final,8-59,Hospitalization,severe,Singapore,12-17 years,12-17 years,74,26,91,,omicron,,,,
160,Chiew,Pfizer,2,final,240+,Hospitalization,severe,Singapore,12-17 years,12-17 years,77,54,89,,omicron,~44 weeks,,,
160,Chiew,Pfizer,2,final,8+,Infection,infection,Singapore,12-17 years,12-17 years,66,63,69,,delta,~24 weeks,,,
160,Chiew,Pfizer,2,final,8-59,Infection,infection,Singapore,12-17 years,12-17 years,71,67,74,,delta,,,,
160,Chiew,Pfizer,2,final,240+,Infection,infection,Singapore,12-17 years,12-17 years,57,27,75,,delta,~24 weeks,,,
160,Chiew,Pfizer,2,final,8+,Hospitalization,severe,Singapore,12-17 years,12-17 years,83,74,89,,delta,~24 weeks,,,
160,Chiew,Pfizer,2,final,8-59,Hospitalization,severe,Singapore,12-17 years,12-17 years,76,62,85,,delta,,,,
160,Chiew,Pfizer,2,final,240+,Hospitalization,severe,Singapore,12-17 years,12-17 years,89,64,94,,delta,~24 weeks,,,
161,Olson,Pfizer,1,1,14+,Hospitalization,severe,USA,12-18 years,12-18 years,97,86,100,,delta,,,,
161,Olson,Pfizer,2,final,14+,Hospitalization,severe,USA,12-18 years,12-18 years,94,90,96,,delta,~18 weeks,,,
161,Olson,Pfizer,2,final,14+,ICU admission,severe,USA,12-18 years,12-18 years,98,93,99,,delta,~18 weeks,,,
161,Olson,Pfizer,2,final,14+,life support,severe,USA,12-18 years,12-18 years,98,92,100,,delta,~18 weeks,,,
161,Olson,Pfizer,1,1,14+,hospitalization,severe,USA,12-18 years,12-18 years,98,88,100,,delta,,,,
161,Olson,Pfizer,2,final,14+,hospitalization,severe,USA,12-18 years,12-18 years,95,91,97,,delta,~18 weeks,,,
161,Olson,Pfizer,2,final,14+,ICU admission,severe,USA,12-18 years,12-18 years,98,94,100,,delta,~18 weeks,,,
161,Olson,Pfizer,2,final,14+,life support,severe,USA,12-18 years,12-18 years,99,93,100,,delta,~18 weeks,,,
162,Gazit,Pfizer,2,final,7+,infection,infection,Israel ,adult contacts of SARS-CoV-2 index cases,contacts of index cases,80.3,73.5,85.4,,alpha,~7.5 weeks,,,
163,Suah,Pfizer,2,final,9-26 weeks,infection (vaccinated April to June),infection,Malaysia,≥ 15 years,general pop,79.3,76.1,82.1,,delta,~26 weeks,,,
163,Suah,Pfizer,2,final,2-13 weeks,infection (vaccinated July to August),infection,Malaysia,≥ 15 years,general pop,90.8,89.4,92.1,,delta,~26 weeks,,,
163,Suah,CoronaVac (Sinovac),2,final,9-26 weeks,infection (vaccinated April to June),infection,Malaysia,≥ 15 years,general pop,30.4,18.8,40.3,,delta,~26 weeks,,,
163,Suah,CoronaVac (Sinovac),2,final,2-13 weeks,infection (vaccinated July to August),infection,Malaysia,≥ 15 years,general pop,74.5,70.6,78,,delta,~26 weeks,,,
164,Young-Xu,Pfizer,2,final,14+,infection,infection,USA,veterans 18+ years,veterans 18+ years,12,10,15,omicron,omicron,~48 weeks,,,
164,Young-Xu,Pfizer,2,final,14+,hospitalization,severe,USA,veterans 18+ years,veterans 18+ years,63,58,67,omicron,omicron,~48 weeks,,,
164,Young-Xu,Pfizer,2,final,14+,death,death,USA,veterans 18+ years,veterans 18+ years,77,67,83,omicron,omicron,~48 weeks,,,
164,Young-Xu,Pfizer,2,final,14+,infection,infection,USA,veterans 18+ years,veterans 18+ years,54,50,57,delta,delta,~48 weeks,,,
164,Young-Xu,Pfizer,2,final,14+,hospitalization,severe,USA,veterans 18+ years,veterans 18+ years,75,69,80,delta,delta,~48 weeks,,,
164,Young-Xu,Pfizer,2,final,14+,death,death,USA,veterans 18+ years,veterans 18+ years,92,83,96,delta,delta,~48 weeks,,,
165,Tartof,Pfizer,2,final,7+,ED visits,symptomatic,USA,hospital admissions,general pop,47,40,54,omicron,omicron,~47 weeks,,,
165,Tartof,Pfizer,2,final,45,ED visits,symptomatic,USA,hospital admissions,general pop,64,51,73,omicron,omicron,~47 weeks,,,
165,Tartof,Pfizer,2,final,≥9 months,ED visits,symptomatic,USA,hospital admissions,general pop,31,16,43,omicron,omicron,~47 weeks,,,
165,Tartof,Pfizer,2,final,7+,hospitalization,severe,USA,hospital admissions,general pop,62,53,69,omicron,omicron,~47 weeks,,,
165,Tartof,Pfizer,2,final,45,hospitalization,severe,USA,hospital admissions,general pop,68,48,80,omicron,omicron,~47 weeks,,,
165,Tartof,Pfizer,2,final,≥9 months,Hospitalization,severe,USA,hospital admissions,general pop,41,21,55,omicron,omicron,~47 weeks,,,
165,Tartof,Pfizer,2,final,7+,ED visits,symptomatic,USA,hospital admissions,general pop,61,55,66,delta,delta,~47 weeks,,,
165,Tartof,Pfizer,2,final,45,ED visits,symptomatic,USA,hospital admissions,general pop,78,69,85,delta,delta,~47 weeks,,,
165,Tartof,Pfizer,2,final,≥9 months,ED visits,symptomatic,USA,hospital admissions,general pop,57,45,66,delta,delta,~47 weeks,,,
165,Tartof,Pfizer,2,final,7+,hospitalization,severe,USA,hospital admissions,general pop,76,69,82,delta,delta,~47 weeks,,,
166,Tartof,Pfizer,2,final,45,hospitalization,severe,USA,hospital admissions,general pop,78,55,89,delta,delta,~47 weeks,,,
167,Tartof,Pfizer,2,final,≥9 months,hospitalization,severe,USA,hospital admissions,general pop,73,58,83,delta,delta,~47 weeks,,,
166,Amodio,Pfizer,2,final,2 months,Infection,infection,Italy,≥ 18 years,general pop,81.3,80.3,82.3,,alpha & delta,~37 weeks,,,
166,Amodio,Pfizer,2,final,8 months,infection,infection,Italy,≥ 18 years,general pop,57.8,55.4,60.2,,alpha & delta,~37 weeks,,,
166,Amodio,Pfizer,2,final,2 months,severe disease,severe,Italy,≥ 18 years,general pop,96.1,94.5,97.7,,alpha & delta,~37 weeks,,,
166,Amodio,Pfizer,2,final,8 months,severe disease,severe,Italy,≥ 18 years,general pop,90.3,86.2,94.4,,alpha & delta,~37 weeks,,,
166,Amodio,Pfizer,2,final,2 months,death or intubation,severe,Italy,≥ 18 years,general pop,93.4,91.2,95.6,,alpha & delta,~37 weeks,,,
166,Amodio,Pfizer,2,final,8 months,death or intubation,severe,Italy,≥ 18 years,general pop,83.7,75.1,92.3,,alpha & delta,~37 weeks,,,
167,Thompson,Pfizer,2,final,14-179,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,52,46,58,,omicron,~32 weeks,,,
167,Thompson,Pfizer,2,final,180+,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,38,32,43,,omicron,~32 weeks,,,
167,Thompson,Pfizer,2,final,14-179,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,81,65,90,,omicron,~32 weeks,,,
167,Thompson,Pfizer,2,final,180+,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,57,39,70,,omicron,~32 weeks,,,
167,Thompson,Pfizer,2,final,14-179,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,86,85,87,,delta,~32 weeks,,,
167,Thompson,Pfizer,2,final,180+,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,76,75,77,,delta,~32 weeks,,,
167,Thompson,Pfizer,2,final,14-179,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,90,89,90,,delta,~32 weeks,,,
167,Thompson,Pfizer,2,final,180+,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,81,80,82,,delta,~32 weeks,,,
168,Bedston,Pfizer,1,1,3-6 weeks,infection,infection,UK,HCW,HCW,52,45,58,,alpha,,,,
168,Bedston,Pfizer,2,final,2-5 weeks,infection,infection,UK,HCW,HCW,86,74,91,,alpha,~37 weeks,,,
168,Bedston,Pfizer,1,1,7+ weeks,infection,infection,UK,HCW,HCW,39,24,50,,alpha,,,,
168,Bedston,Pfizer,2,final,26+ weeks,infection,infection,UK,HCW,HCW,45,39,51,,alpha,~37 weeks,,,
169,Botton,Pfizer,1,1,14+,hospitalization,severe,France,≥ 75 years,≥ 75 years,34,28,40,,non-VOC & alpha,,,,
169,Botton,Pfizer,2,final,7+,hospitalization,severe,France,≥ 75 years,≥ 75 years,86,83,89,,non-VOC & alpha,~7 weeks,,,
170,Spensley,Pfizer,2,final,14+,infection,infection,UK,end stage kidney disease patients,end stage kidney disease patients,17,-62,57,omicron,omicron,~52.5 weeks,,,
170,Spensley,AZD1222 (AstraZeneca),2,final,14+,infection,infection,UK,end stage kidney disease patients,end stage kidney disease patients,-4,-97,43,omicron,omicron,~52.5 weeks,,,
171,Willet,Pfizer,2,final,14+,infection,infection,Scotland,≥ 18 years,general pop,26,13.9,36.4,omicron,omicron,~11 weeks,,,
171,Willet,Moderna,2,final,14+,infection,infection,Scotland,≥ 18 years,general pop,23.7,4.4,39.4,omicron,omicron,~11 weeks,,,
171,Willet,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Scotland,≥ 18 years,general pop,11.4,-18.8,34.6,omicron,omicron,~11 weeks,,,
171,Willet,Pfizer,2,final,14+,infection,infection,Scotland,≥ 18 years,general pop,83.5,78.6,87.3,delta,delta,~11 weeks,,,
171,Willet,Moderna,2,final,14+,infection,infection,Scotland,≥ 18 years,general pop,87.8,79.8,92.7,delta,delta,~11 weeks,,,
171,Willet,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Scotland,≥ 18 years,general pop,78.9,66.6,86.7,delta,delta,~11 weeks,,,
172,Belayachi,BBIBP-CorV (Beijing CNBG),2,final,1-273,severe hospitalization,severe,Morocco,hospital patients,general pop,73,71,76,,"non-VOC, alpha, & delta",~39 weeks,,,
172,Belayachi,BBIBP-CorV (Beijing CNBG),2,final,1-30,severe hospitalization,severe,Morocco,hospital patients,general pop,88,84,91,,"non-VOC, alpha, & delta",~39 weeks,,,
172,Belayachi,BBIBP-CorV (Beijing CNBG),2,final,150+,severe hospitalization,severe,Morocco,hospital patients,general pop,64,59,69,,"non-VOC, alpha, & delta",~39 weeks,,,
173,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,hospital patients 18+ years,general pop,69,57,78,,delta,~47 weeks,,,
173,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,hospital patients 18+ years,general pop,82,77,86,,delta,~47 weeks,,,
174,Lytras,Pfizer,2,final,14+,intubation,severe,Greece,15-59 years,15-59 years,98.1,97.5,98.6,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,6 months,intubation,severe,Greece,15-59 years,15-59 years,95.5,94.3,96.5,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,14+,intubation,severe,Greece,60-79 years,60-79 years,96.7,95.9,97.4,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,6 months,intubation,severe,Greece,60-79 years,60-79 years,92,91,92.9,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,14+,intubation,severe,Greece,≥ 80 years,≥ 80 years,94.2,92,95.7,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,6 months,intubation,severe,Greece,≥ 80 years,≥ 80 years,85.9,83.5,88,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,14+,death,death,Greece,15-59 years,15-59 years,96.5,94.8,97.6,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,6 months,death,death,Greece,15-59 years,15-59 years,93.8,91,95.7,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,14+,death,death,Greece,60-79 years,60-79 years,94.1,92.7,95.2,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,6 months,death,death,Greece,60-79 years,60-79 years,89.4,87.9,90.8,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,14+,death,death,Greece,≥ 80 years,≥ 80 years,91,88.4,93,,delta,~48 weeks,,,
174,Lytras,Pfizer,2,final,6 months,death,death,Greece,≥ 80 years,≥ 80 years,84,82.2,85.6,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,14+,intubation,severe,Greece,15-59 years,15-59 years,99.4,98.2,99.8,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,6 months,intubation,severe,Greece,15-59 years,15-59 years,97.3,93.1,98.9,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,14+,intubation,severe,Greece,60-79 years,60-79 years,98.9,97.3,99.5,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,6 months,intubation,severe,Greece,60-79 years,60-79 years,95.1,93,96.5,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,14+,intubation,severe,Greece,≥ 80 years,≥ 80 years,97.9,90.2,99.5,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,6 months,intubation,severe,Greece,≥ 80 years,≥ 80 years,90.6,67,97.3,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,14+,death,death,Greece,15-59 years,15-59 years,99.3,94.7,99.9,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,6 months,death,death,Greece,15-59 years,15-59 years,98.3,88.3,99.8,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,14+,death,death,Greece,60-79 years,60-79 years,98.4,95.5,99.5,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,6 months,death,death,Greece,60-79 years,60-79 years,96.2,93.6,97.7,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,14+,death,death,Greece,≥ 80 years,≥ 80 years,96.7,87.9,99.1,,delta,~48 weeks,,,
174,Lytras,Moderna,2,final,6 months,death,death,Greece,≥ 80 years,≥ 80 years,92,80,96.8,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,14+,intubation,severe,Greece,15-59 years,15-59 years,97.8,95.3,99,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,6 months,intubation,severe,Greece,15-59 years,15-59 years,92.4,84,96.4,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,14+,intubation,severe,Greece,60-79 years,60-79 years,97.2,95.3,98.3,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,6 months,intubation,severe,Greece,60-79 years,60-79 years,90.3,87.4,92.5,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,14+,intubation,severe,Greece,≥ 80 years,≥ 80 years,97.8,91.7,99.4,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,6 months,intubation,severe,Greece,≥ 80 years,≥ 80 years,92.4,72.7,97.9,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,14+,death,death,Greece,15-59 years,15-59 years,97.5,89.7,99.4,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,6 months,death,death,Greece,15-59 years,15-59 years,94.5,77.2,98.7,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,14+,death,death,Greece,60-79 years,60-79 years,95.4,91.2,97.6,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,6 months,death,death,Greece,60-79 years,60-79 years,89.8,85.2,93,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,14+,death,death,Greece,≥ 80 years,≥ 80 years,92.6,84.2,96.5,,delta,~48 weeks,,,
174,Lytras,AZD1222 (AstraZeneca),2,final,6 months,death,death,Greece,≥ 80 years,≥ 80 years,83.4,69.6,90.9,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,14+,intubation,severe,Greece,15-59 years,15-59 years,85,73.9,91.4,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,6 months,intubation,severe,Greece,15-59 years,15-59 years,91.7,84.4,95.6,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,14+,intubation,severe,Greece,60-79 years,60-79 years,79.6,65.2,88,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,6 months,intubation,severe,Greece,60-79 years,60-79 years,88.7,78.7,94,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,14+,intubation,severe,Greece,≥ 80 years,≥ 80 years,85,62.3,94,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,6 months,intubation,severe,Greece,≥ 80 years,≥ 80 years,91.7,75.5,97.2,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,14+,death,death,Greece,15-59 years,15-59 years,81.7,57.5,92.1,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,6 months,death,death,Greece,15-59 years,15-59 years,90.7,77.2,96.2,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,14+,death,death,Greece,60-79 years,60-79 years,69.1,43.2,83.2,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,6 months,death,death,Greece,60-79 years,60-79 years,84.3,67.9,92.3,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,14+,death,death,Greece,≥ 80 years,≥ 80 years,61.9,43.2,74.4,,delta,~48 weeks,,,
174,Lytras,Janssen,1,final,6 months,death,death,Greece,≥ 80 years,≥ 80 years,80.6,59.7,90.7,,delta,~48 weeks,,,
175,Roberts,Pfizer,2,final,<3 months,infection,infection,USA,≥ 18 years,general pop,83,81,84,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,≥3 months,infection,infection,USA,≥ 18 years,general pop,60,58,62,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,<3 months,infection (Jan-March),infection,USA,≥ 18 years,general pop,80,74,85,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,≥3 months,infection (Jan-March),infection,USA,≥ 18 years,general pop,80.5,74,86,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,<3 months,infection (Oct-Dec),infection,USA,≥ 18 years,general pop,75,64,81,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,≥3 months,infection (Oct-Dec),infection,USA,≥ 18 years,general pop,60,55,62,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,<3 months,severe disease,severe,USA,≥ 18 years,general pop,88,80,91,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,≥3 months,severe disease,severe,USA,≥ 18 years,general pop,75,70,80,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,<3 months,severe disease (Jan-March),severe,USA,≥ 18 years,general pop,90,49,99,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,≥3 months,severe disease (Jan-March),severe,USA,≥ 18 years,general pop,90,50,99,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,<3 months,severe disease (Oct-Dec),severe,USA,≥ 18 years,general pop,69,22,88,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Pfizer,2,final,≥3 months,severe disease (Oct-Dec),severe,USA,≥ 18 years,general pop,78,70,82,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,<3 months,infection,infection,USA,≥ 18 years,general pop,88,85,90,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,≥3 months,infection,infection,USA,≥ 18 years,general pop,65,62,68,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,<3 months,infection (Jan-March),infection,USA,≥ 18 years,general pop,89,73,95,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,≥3 months,infection (Jan-March),infection,USA,≥ 18 years,general pop,89,74,93,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,<3 months,infection (Oct-Dec),infection,USA,≥ 18 years,general pop,82,69,91,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,≥3 months,infection (Oct-Dec),infection,USA,≥ 18 years,general pop,68,64,69,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,<3 months,severe disease,severe,USA,≥ 18 years,general pop,85,75,90,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,≥3 months,severe disease,severe,USA,≥ 18 years,general pop,72,65,78,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,<3 months,severe disease (Jan-March),severe,USA,≥ 18 years,general pop,70,0,95,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,≥3 months,severe disease (Jan-March),severe,USA,≥ 18 years,general pop,70,0,93,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,<3 months,severe disease (Oct-Dec),severe,USA,≥ 18 years,general pop,91,5,99,,"non-VOC, alpha, & delta",~48 weeks,,,
175,Roberts,Moderna,2,final,≥3 months,severe disease (Oct-Dec),severe,USA,≥ 18 years,general pop,80,72,88,,"non-VOC, alpha, & delta",~48 weeks,,,
176,Sritipsukho,AZD1222 (AstraZeneca),1,1,21+,Infection,infection,Thailand,≥ 18 years,general pop,49,36,58,,delta,,,,
176,Sritipsukho,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Thailand,≥ 18 years,general pop,83,70,90,,delta,~13 weeks,,,
176,Sritipsukho,CoronaVac (Sinovac),1,1,21+,Infection,infection,Thailand,≥ 18 years,general pop,-15,-45,15,,delta,,,,
176,Sritipsukho,CoronaVac (Sinovac),2,final,14+,Infection,infection,Thailand,≥ 18 years,general pop,60,49,69,,delta,~13 weeks,,,
176,Sritipsukho,CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous,2,final,14+,Infection,infection,Thailand,≥ 18 years,general pop,74,43,88,,delta,~13 weeks,,,
177,Suryatma,CoronaVac (Sinovac),1,1,14+,infection,infection,Indonesia,≥ 18 years,general pop,10.5,-12,28.6,,non-VOC & alpha,,,,
177,Suryatma,CoronaVac (Sinovac),2,final,14+,infection,infection,Indonesia,≥ 18 years,general pop,66.7,58.1,73.5,,non-VOC & alpha,~24 weeks,,,
177,Suryatma,CoronaVac (Sinovac),1,1,14+,hospitalization,severe,Indonesia,≥ 18 years,general pop,34.1,16.4,48.1,,non-VOC & alpha,,,,
177,Suryatma,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Indonesia,≥ 18 years,general pop,71.1,62.9,77.6,,non-VOC & alpha,~24 weeks,,,
177,Suryatma,CoronaVac (Sinovac),1,1,14+,death,death,Indonesia,≥ 18 years,general pop,58.6,28.3,76.1,,non-VOC & alpha,,,,
177,Suryatma,CoronaVac (Sinovac),2,final,14+,death,death,Indonesia,≥ 18 years,general pop,87.4,65.1,95.4,,non-VOC & alpha,~24 weeks,,,
178,Lauring,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,65,51,75,omicron,omicron,~3 weeks,,,
178,Lauring,Pfizer,2,final,150+,hospitalization,severe,USA,≥ 18 years,general pop,85,83,87,delta,delta,~27 weeks,,,
178,Lauring,Pfizer,2,final,>150,hospitalization,severe,USA,≥ 18 years,general pop,90,85,93,delta,delta,~27 weeks,,,
178,Lauring,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,82,80,84,delta,delta,~27 weeks,,,
178,Lauring,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,88,86,90,delta,delta,~27 weeks,,,
178,Lauring,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,82,77,86,alpha,alpha,~44 weeks,,,
178,Lauring,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,90,85,93,alpha,alpha,~44 weeks,,,
178,Lauring,Pfizer,1,1,14+,hospitalization,severe,USA,≥ 18 years,general pop,77,71,81,,"alpha, delta, & omicron",,,,
179,Chemaitelly,Pfizer,2,final,1-3 months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,46.6,33.4,57.2,omicron BA.1,omicron BA.1,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,7+ months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-17.8,-28.2,-8.2,omicron BA.1,omicron BA.1,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,1-3 months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,71,24,89,omicron BA.1,omicron BA.1,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,7+ months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-10.2,-23.1,1.3,omicron BA.1,omicron BA.1,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,1-3 months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,51.7,43.2,58.9,omicron BA.2,omicron BA.2,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,7+ months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-12.1,-19.1,5.5,omicron BA.2,omicron BA.2,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,1-3 months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,35.9,-5.9,61.2,omicron BA.2,omicron BA.2,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,7+ months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-20.4,-30.2,1.2,omicron BA.2,omicron BA.2,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,1-3 months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,51.7,43.2,58.9,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,7+ months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-9,-14.5,-3.7,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,1-3 months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,43.2,15,62.1,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,7+ months,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-13.7,-21.3,-6.6,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,1-6 months,"severe, critical or fatal disease",severe,Qatar,≥ 18 years,general pop,70.4,45,85,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Pfizer,2,final,≥7 months,"severe, critical or fatal disease",severe,Qatar,≥ 18 years,general pop,77.5,67.8,84.3,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,1-6 months,"severe, critical or fatal disease",severe,Qatar,≥ 18 years,general pop,87.1,40.2,97.2,omicron,omicron,~58 weeks,,,
179,Chemaitelly,Moderna,2,final,≥7 months,"severe, critical or fatal disease",severe,Qatar,≥ 18 years,general pop,68.4,46.1,81.5,omicron,omicron,~58 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-30,infection,infection,Brazil,≥ 18 years,general pop,55,54.3,55.7,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,infection,infection,Brazil,≥ 18 years,general pop,34.7,33.1,36.3,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-30,severe disease,severe,Brazil,≥ 18 years,general pop,82.1,81.4,82.8,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,severe disease,severe,Brazil,≥ 18 years,general pop,72.6,71,74.2,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-30,hospitalization,severe,Brazil,≥ 18 years,general pop,82.1,81.4,82.8,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,hospitalization,severe,Brazil,≥ 18 years,general pop,72.4,70.7,73.9,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-30,death,death,Brazil,≥ 18 years,general pop,82.7,81.7,83.6,,gamma & delta,~30 weeks,,,
180,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,death,death,Brazil,≥ 18 years,general pop,74.8,72.2,77.2,,gamma & delta,~30 weeks,,,
181,Butt,Pfizer,1,1,14+,infection,infection,USA,haemodialysis patients,haemodialysis patients,60.6,25.5,79.2,,delta,,,,
181,Butt,Pfizer,2,final,14+,infection,infection,USA,haemodialysis patients,haemodialysis patients,68.9,61.9,74.7,,delta,~31 weeks,,,
181,Butt,Moderna,1,1,14+,infection,infection,USA,haemodialysis patients,haemodialysis patients,37.2,27.1,69,,delta,,,,
181,Butt,Moderna,2,final,14+,infection,infection,USA,haemodialysis patients,haemodialysis patients,66.7,58.9,73,,delta,~31 weeks,,,
182,ECDC,Pfizer,1,1,14+,hospitalization,severe,"Belgium, Croatia, Czechia, France, Greece, Malta, Portugal and Spain",hospital patients,general pop,76,61,86,,alpha,,,,
182,ECDC,Pfizer,2,final,14+,hospitalization,severe,"Belgium, Croatia, Czechia, France, Greece, Malta, Portugal and Spain",hospital patients,general pop,94,88,97,,alpha,~28 weeks,,,
183,Hayek,Pfizer,2,final,7+,infection,infection,Israel ,households with children,households with children,94.4,93.2,95.4,,alpha,~12 weeks,,,
184,Goldin,Pfizer,1,1,10+,infection,infection,Israel ,LTCF residents,LTCF residents,61.8,58.2,65.1,,non-VOC & alpha,,,,
184,Goldin,Pfizer,2,final,7+,infection,infection,Israel ,LTCF residents,LTCF residents,81.2,78.6,83.5,,non-VOC & alpha,~16.5 weeks,,,
184,Goldin,Pfizer,1,1,10+,death,death,Israel ,LTCF residents,LTCF residents,72.3,66.9,76.8,,non-VOC & alpha,,,,
184,Goldin,Pfizer,2,final,7+,death,death,Israel ,LTCF residents,LTCF residents,85.3,80.4,88.9,,non-VOC & alpha,~16.5 weeks,,,
185,Ferdinands,Pfizer,2,final,<2 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,69,62,75,,omicron,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,≥5 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,37,34,40,,omicron,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,71,51,83,,omicron,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,≥5 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,54,48,59,,omicron,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,<2 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,92,91,94,,delta,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,≥5 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,77,76,78,,delta,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,94,92,96,,delta,~25 weeks,,,
185,Ferdinands,Pfizer,2,final,≥5 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,82,82,83,,delta,~25 weeks,,,
186,Jara,CoronaVac (Sinovac),2,final,14+,infection,infection,Chile,6-16 years,6-16 years,74.8,74.1,75.5,,delta,~28 weeks,,,
186,Jara,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Chile,6-16 years,6-16 years,91.3,88.1,93.6,,delta,~28 weeks,,,
186,Jara,CoronaVac (Sinovac),2,final,14+,ICU admission,severe,Chile,6-16 years,6-16 years,93.8,85.7,97.3,,delta,~28 weeks,,,
186,Jara,Pfizer,2,final,14+,infection,infection,Chile,12-16 years,12-16 years,84.4,83.7,85,,delta,~30 weeks,,,
186,Jara,Pfizer,2,final,14+,hospitalization,severe,Chile,12-16 years,12-16 years,93.5,90.4,95.6,,delta,~30 weeks,,,
186,Jara,Pfizer,2,final,14+,ICU admission,severe,Chile,12-16 years,12-16 years,98,89.9,99.6,,delta,~30 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,52.0,33.0,65.0,,delta & omicron,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was in first 20 weeks,infants <6 months when timing of maternal vaccination was in first 20 weeks,38.0,3.0,60.0,,delta & omicron,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,69.0,50.0,80.0,,delta & omicron,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,38.0,8.0,58.0,,omicron,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was in first 20 weeks,infants <6 months when timing of maternal vaccination was in first 20 weeks,25.0,-26.0,56.0,,omicron,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,57.0,25.0,75.0,,omicron,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,80.0,60.0,90.0,,delta,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was in first 20 weeks,infants <6 months when timing of maternal vaccination was in first 20 weeks,68.0,19.0,87.0,,delta,~33 weeks,,,
187,Halasa,Pfizer,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,88.0,68.0,96.0,,delta,~33 weeks,,,
188,Gazit,Pfizer,2,final,14+,infection,infection,Israel ,≥ 18 years,general pop,82,80,85,,alpha & delta,~40 weeks,,,
188,Gazit,Pfizer,2,final,14+,symptomatic disease,symptomatic,Israel ,≥ 18 years,general pop,76,71,80,,alpha & delta,~40 weeks,,,
189,Filon,Pfizer,2,final,14+,infection (March),infection,Italy,HCW,HCW,95,92,98,,non-VOC & alpha,~16 weeks,,,
189,Filon,Pfizer,2,final,14+,infection (April),infection,Italy,HCW,HCW,95,92,98,,non-VOC & alpha,~16 weeks,,,
189,Filon,Pfizer,2,final,14+,infection (May),infection,Italy,HCW,HCW,80,70,84,,non-VOC & alpha,~16 weeks,,,
190,Wu,BBIBP-CorV (Beijing CNBG),1+,1+,14+,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,24.7,-98.8,71.4,,delta,,,,
190,Wu,BBIBP-CorV (Beijing CNBG),2,final,14+,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,50.5,3.8,74.6,,delta,~24 weeks,,,
190,Wu,BBIBP-CorV (Beijing CNBG),2,final,≤3 months,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,39.3,-20.4,69.4,,delta,~24 weeks,,,
190,Wu,BBIBP-CorV (Beijing CNBG),2,final,4-6 months,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,82,-25.7,97.4,,delta,~24 weeks,,,
190,Wu,BBIBP-CorV (Beijing CNBG),1+,1+,14+,pneumonia,severe,China,close contacts,Contacts of index cases,16.3,-164.3,73.2,,delta,,,,
190,Wu,BBIBP-CorV (Beijing CNBG),2,final,14+,pneumonia,severe,China,close contacts,Contacts of index cases,54.7,-3.4,80.2,,delta,~24 weeks,,,
190,Wu,BBIBP-CorV (Beijing CNBG),2,final,≤3 months,pneumonia,severe,China,close contacts,Contacts of index cases,39.6,-35.4,73.1,,delta,~24 weeks,,,
190,Wu,BBIBP-CorV (Beijing CNBG),1+,1+,14+,severe disease,severe,China,close contacts,Contacts of index cases,7.5,-655.6,88.7,,delta,,,,
190,Wu,CoronaVac (Sinovac),1+,1+,14+,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,29.9,-44.3,66,,delta,,,,
190,Wu,CoronaVac (Sinovac),2,final,14+,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,39.1,-0.9,63.3,,delta,~24 weeks,,,
190,Wu,CoronaVac (Sinovac),2,final,≤3 months,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,45.5,-5.9,71.9,,delta,~24 weeks,,,
190,Wu,CoronaVac (Sinovac),2,final,4-6 months,symptomatic disease,symptomatic,China,close contacts,Contacts of index cases,29.8,-41.1,65.1,,delta,~24 weeks,,,
190,Wu,CoronaVac (Sinovac),1,1,14+,pneumonia,severe,China,close contacts,Contacts of index cases,52.6,-25.2,82.1,,delta,,,,
190,Wu,CoronaVac (Sinovac),2,final,14+,pneumonia,severe,China,close contacts,Contacts of index cases,64.9,22.8,84,,delta,~24 weeks,,,
190,Wu,CoronaVac (Sinovac),2,final,≤3 months,pneumonia,severe,China,close contacts,Contacts of index cases,73.8,17.9,91.6,,delta,~24 weeks,,,
190,Wu,CoronaVac (Sinovac),2,final,4-6 months,pneumonia,severe,China,close contacts,Contacts of index cases,47.4,-44.3,80.8,,delta,~24 weeks,,,
190,Wu,CoronaVac (Sinovac),1,1,14+,severe disease,severe,China,close contacts,Contacts of index cases,59.7,-209.9,94.7,,delta,,,,
191,Mallow,Pfizer,2,final,14+,ED visits,symptomatic,USA,ED patients (aged 18+),general pop,73.9,66.3,79.8,,"non-VOC, alpha, & delta",~31 weeks,,,
191,Mallow,Moderna,2,final,14+,ED visits,symptomatic,USA,ED patients (aged 18+),general pop,78,68.1,84.9,,"non-VOC, alpha, & delta",~31 weeks,,,
192,Shen,Pfizer,2,final,14+,Infection,infection,USA,immunocompromised,immunocompromised adults,41,9,62,,"non-VOC, alpha, & delta",~36 weeks,,,
192,Shen,Moderna,2,final,14+,Infection,infection,USA,immunocompromised,immunocompromised adults,48,18,67,,"non-VOC, alpha, & delta",~36 weeks,,,
192,Shen,Janssen,1,final,14+,Infection,infection,USA,immunocompromised,immunocompromised adults,66,-30,91,,"non-VOC, alpha, & delta",~36 weeks,,,
193,Cura-Bilbao,Pfizer,1,1,12+,Infection,infection,Spain,≥ 18 years,general pop,20.8,11.6,29,,non-VOC & alpha,,,,
193,Cura-Bilbao,Pfizer,2,final,7+,Infection,infection,Spain,≥ 18 years,general pop,70,65.3,74.1,,non-VOC & alpha,~16 weeks,,,
193,Cura-Bilbao,Moderna,1,1,14+,Infection,infection,Spain,≥ 18 years,general pop,52.8,30.7,67.8,,non-VOC & alpha,,,,
193,Cura-Bilbao,Moderna,2,final,14+,Infection,infection,Spain,≥ 18 years,general pop,70.3,52.2,81.5,,non-VOC & alpha,~16 weeks,,,
193,Cura-Bilbao,AZD1222 (AstraZeneca),1,1,21+,Infection,infection,Spain,≥ 18 years,general pop,40.3,31.8,47.7,,non-VOC & alpha,,,,
194,Šmíd,Pfizer,1,1,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,31,28,34,,omicron,,,,
194,Šmíd,Pfizer,2,final,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,49,48,50,,omicron,~54 weeks,,,
194,Šmíd,Pfizer,1,1,75+,Infection,infection,Czech Republic,≥ 18 years,general pop,53,46,59,,omicron,,,,
194,Šmíd,Pfizer,2,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,11,10,12,,omicron,~54 weeks,,,
194,Šmíd,Pfizer,1,1,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,41,-3,66,,omicron,,,,
194,Šmíd,Pfizer,2,final,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,46,28,60,,omicron,~54 weeks,,,
194,Šmíd,Pfizer,1,1,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,4,-287,76,,omicron,,,,
194,Šmíd,Pfizer,2,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,34,24,42,,omicron,~54 weeks,,,
194,Šmíd,Moderna,1,1,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,49,42,55,,omicron,,,,
194,Šmíd,Moderna,2,final,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,48,44,52,,omicron,~54 weeks,,,
194,Šmíd,Moderna,1,1,75+,Infection,infection,Czech Republic,≥ 18 years,general pop,60,36,75,,omicron,,,,
194,Šmíd,Moderna,2,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,20,17,22,,omicron,~54 weeks,,,
194,Šmíd,Moderna,1,1,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,56,-78,89,,omicron,,,,
194,Šmíd,Moderna,2,final,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,51,-20,80,,omicron,~54 weeks,,,
194,Šmíd,Moderna,1,1,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,-160,-1743,64,,omicron,,,,
194,Šmíd,Moderna,2,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,31,9,49,,omicron,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,75-135,Infection,infection,Czech Republic,≥ 18 years,general pop,51,23,69,,omicron,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,5,1,9,,omicron,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,75-135,hospitalization,severe,Czech Republic,≥ 18 years,general pop,-139,-861,41,,omicron,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,13,-8,30,,omicron,~54 weeks,,,
194,Šmíd,Janssen,1,final,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,47,45,49,,omicron,~54 weeks,,,
194,Šmíd,Janssen,1,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,35,33,38,,omicron,~54 weeks,,,
194,Šmíd,Janssen,1,final,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,28,-22,57,,omicron,~54 weeks,,,
194,Šmíd,Janssen,1,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,38,8,58,,omicron,~54 weeks,,,
194,Šmíd,Pfizer,1,1,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,67,65,69,,delta,,,,
194,Šmíd,Pfizer,2,final,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,82,81,83,,delta,~54 weeks,,,
194,Šmíd,Pfizer,1,1,75+,Infection,infection,Czech Republic,≥ 18 years,general pop,61,51,69,,delta,,,,
194,Šmíd,Pfizer,2,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,54,53,55,,delta,~54 weeks,,,
194,Šmíd,Pfizer,1,1,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,53,40,63,,delta,,,,
194,Šmíd,Pfizer,2,final,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,80,72,85,,delta,~54 weeks,,,
194,Šmíd,Pfizer,1,1,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,61,-20,87,,delta,,,,
194,Šmíd,Pfizer,2,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,82,77,86,,delta,~54 weeks,,,
194,Šmíd,Moderna,1,1,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,68,61,74,,delta,,,,
194,Šmíd,Moderna,2,final,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,71,65,76,,delta,~54 weeks,,,
194,Šmíd,Moderna,1,1,75+,Infection,infection,Czech Republic,≥ 18 years,general pop,67,34,84,,delta,,,,
194,Šmíd,Moderna,2,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,68,66,69,,delta,~54 weeks,,,
194,Šmíd,Moderna,1,1,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,49,13,71,,delta,,,,
194,Šmíd,Moderna,2,final,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,100,,,,delta,~54 weeks,,,
194,Šmíd,Moderna,1,1,75+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,100,,,,delta,,,,
194,Šmíd,Moderna,2,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,82,78,85,,delta,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,75-135,Infection,infection,Czech Republic,≥ 18 years,general pop,65,57,72,,delta,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,45,43,48,,delta,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,75-135,hospitalization,severe,Czech Republic,≥ 18 years,general pop,80,62,89,,delta,~54 weeks,,,
194,Šmíd,AZD1222 (AstraZeneca),2,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,68,64,71,,delta,~54 weeks,,,
194,Šmíd,Janssen,1,final,14-74,Infection,infection,Czech Republic,≥ 18 years,general pop,60,57,63,,delta,~54 weeks,,,
194,Šmíd,Janssen,1,final,135+,Infection,infection,Czech Republic,≥ 18 years,general pop,54,50,57,,delta,~54 weeks,,,
194,Šmíd,Janssen,1,final,14-74,hospitalization,severe,Czech Republic,≥ 18 years,general pop,54,39,65,,delta,~54 weeks,,,
194,Šmíd,Janssen,1,final,135+,hospitalization,severe,Czech Republic,≥ 18 years,general pop,61,51,69,,delta,~54 weeks,,,
195,Klein,Pfizer,2,final,14-67,ED or UC encounters,symptomatic,USA,5-11 years,5-11 years,51,30,65,,omicron,~33 weeks,,,
195,Klein,Pfizer,2,final,14-149,ED or UC encounters,symptomatic,USA,12-15 years,12-15 years,45,30,57,,omicron,~33 weeks,,,
195,Klein,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,12-15 years,12-15 years,-2,-25,17,,omicron,~33 weeks,,,
195,Klein,Pfizer,2,final,14-149,ED or UC encounters,symptomatic,USA,16-17 years,16-17 years,34,8,53,,omicron,~33 weeks,,,
195,Klein,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,16-17 years,16-17 years,-3,-30,18,,omicron,~33 weeks,,,
195,Klein,Pfizer,2,final,14-149,ED or UC encounters,symptomatic,USA,12-15 years,12-15 years,92,89,94,,delta,~33 weeks,,,
195,Klein,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,12-15 years,12-15 years,79,68,86,,delta,~33 weeks,,,
195,Klein,Pfizer,2,final,14-149,ED or UC encounters,symptomatic,USA,16-17 years,16-17 years,85,81,89,,delta,~33 weeks,,,
195,Klein,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,16-17 years,16-17 years,77,67,84,,delta,~33 weeks,,,
195,Klein,Pfizer,2,final,14-67,hospitalization,severe,USA,5-11 years,5-11 years,74,-35,95,,omicron or delta,~33 weeks,,,
195,Klein,Pfizer,2,final,14-149,hospitalization,severe,USA,12-15 years,12-15 years,92,79,97,,omicron or delta,~33 weeks,,,
195,Klein,Pfizer,2,final,150+,hospitalization,severe,USA,12-15 years,12-15 years,73,43,88,,omicron or delta,~33 weeks,,,
195,Klein,Pfizer,2,final,14-149,hospitalization,severe,USA,16-17 years,16-17 years,94,87,97,,omicron or delta,~33 weeks,,,
195,Klein,Pfizer,2,final,150+,hospitalization,severe,USA,16-17 years,16-17 years,88,72,95,,omicron or delta,~33 weeks,,,
196,Wright,Pfizer,2,final,14+,severe disease,severe,USA,≥ 18 years,general pop,87.9,86.7,89,,alpha & delta,~40 weeks,,,
196,Wright,Moderna,2,final,14+,severe disease,severe,USA,≥ 18 years,general pop,92.9,92,93.7,,alpha & delta,~40 weeks,,,
196,Wright,Janssen,1,final,14+,severe disease,severe,USA,≥ 18 years,general pop,73,68.8,76.6,,alpha & delta,~40 weeks,,,
197,Perry,Pfizer,1,1,14-20,infection,infection,UK,≥ 50 years,≥ 50 years,19,9,28,,alpha & delta,,,,
197,Perry,Pfizer,1,1,>27,infection,infection,UK,≥ 50 years,≥ 50 years,16,8,24,,alpha & delta,,,,
197,Perry,Pfizer,2,final,>6,infection,infection,UK,≥ 50 years,≥ 50 years,50,44,55,,alpha & delta,~26.5 weeks,,,
197,Perry,Pfizer,1,1,14-20,hospitalization,severe,UK,≥ 50 years,≥ 50 years,69,43,83,,alpha & delta,,,,
197,Perry,Pfizer,1,1,>27,hospitalization,severe,UK,≥ 50 years,≥ 50 years,75,56,85,,alpha & delta,,,,
197,Perry,Pfizer,2,final,>6,hospitalization,severe,UK,≥ 50 years,≥ 50 years,88,81,93,,alpha & delta,~26.5 weeks,,,
197,Perry,AZD1222 (AstraZeneca),1,1,14-20,infection,infection,UK,≥ 50 years,≥ 50 years,7,-5,19,,alpha & delta,,,,
197,Perry,AZD1222 (AstraZeneca),1,1,>27,infection,infection,UK,≥ 50 years,≥ 50 years,17,9,25,,alpha & delta,,,,
197,Perry,AZD1222 (AstraZeneca),2,final,>6,infection,infection,UK,≥ 50 years,≥ 50 years,25,15,33,,alpha & delta,~18 weeks,,,
197,Perry,AZD1222 (AstraZeneca),1,1,14-20,hospitalization,severe,UK,≥ 50 years,≥ 50 years,48,26,64,,alpha & delta,,,,
197,Perry,AZD1222 (AstraZeneca),1,1,>27,hospitalization,severe,UK,≥ 50 years,≥ 50 years,72,62,80,,alpha & delta,,,,
197,Perry,AZD1222 (AstraZeneca),2,final,>6,hospitalization,severe,UK,≥ 50 years,≥ 50 years,81,71,88,,alpha & delta,~18 weeks,,,
198,Oliver,Pfizer,1,1,14+,infection,infection,Canada,hemodialysis patients,hemodialysis patients,41,24,54,,alpha,,,,
198,Oliver,Pfizer,2,final,7+,infection,infection,Canada,hemodialysis patients,hemodialysis patients,69,58,78,,alpha,~22 weeks,,,
198,Oliver,Pfizer,1,1,14+,severe disease,severe,Canada,hemodialysis patients,hemodialysis patients,46,23,63,,alpha,,,,
198,Oliver,Pfizer,2,final,7+,severe disease,severe,Canada,hemodialysis patients,hemodialysis patients,83,70,90,,alpha,~22 weeks,,,
198,Oliver,Pfizer,1,1,14+,hospitalization,severe,Canada,hemodialysis patients,hemodialysis patients,40,13,58,,alpha,,,,
198,Oliver,Pfizer,2,final,7+,hospitalization,severe,Canada,hemodialysis patients,hemodialysis patients,82,69,90,,alpha,~22 weeks,,,
198,Oliver,Pfizer,1,1,14+,death,death,Canada,hemodialysis patients,hemodialysis patients,71,40,86,,alpha,,,,
198,Oliver,Pfizer,2,final,7+,death,death,Canada,hemodialysis patients,hemodialysis patients,85,59,95,,alpha,~22 weeks,,,
199,Oliveira,Pfizer,1,1,14+,infection,infection,USA,12-18 years,12-18 years,74,18,92,,delta,,,,
199,Oliveira,Pfizer,2,final,1-4 weeks,infection,infection,USA,12-18 years,12-18 years,91,33,99,,delta,~11 weeks,,,
199,Oliveira,Pfizer,2,final,13-17 weeks,infection,infection,USA,12-18 years,12-18 years,83,34,95,,delta,~11 weeks,,,
199,Oliveira,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,12-18 years,12-18 years,93,81,97,,delta,~11 weeks,,,
199,Oliveira,Pfizer,2,final,14+,asymptomatic infection,asymptomatic,USA,12-18 years,12-18 years,85,57,95,,delta,~11 weeks,,,
200,Ashmawy,BBIBP-CorV (Beijing CNBG),2,final,14+,symptomatic disease,symptomatic,Egypt,HCW,HCW,67,43,80,,delta,~29 weeks,,,
200,Ashmawy,BBIBP-CorV (Beijing CNBG),2,final,14+,infection,infection,Egypt,HCW,HCW,46,24,62,,delta,~29 weeks,,,
200,Ashmawy,BBIBP-CorV (Beijing CNBG),2,final,14+,hospitalization,severe,Egypt,HCW,HCW,65,-8,88,,delta,~29 weeks,,,
201,Fowlkes,Pfizer,2,final,14-82,infection,infection,USA,5-11 years,5-11 years,31,9,48,omicron,omicron,~29 weeks,,,
201,Fowlkes,Pfizer,2,final,14+,infection,infection,USA,12-15 years,12-15 years,59,24,78,omicron,omicron,~29 weeks,,,
201,Fowlkes,Pfizer,2,final,14-149,infection,infection,USA,12-15 years,12-15 years,59,22,79,omicron,omicron,,,,
201,Fowlkes,Pfizer,2,final,150+,infection,infection,USA,12-15 years,12-15 years,62,-28,29,omicron,omicron,~29 weeks,,,
201,Fowlkes,Pfizer,2,final,14+,infection,infection,USA,12-15 years,12-15 years,81,51,93,delta,delta,~29 weeks,,,
201,Fowlkes,Pfizer,2,final,14-149,infection,infection,USA,12-15 years,12-15 years,87,49,97,delta,delta,,,,
201,Fowlkes,Pfizer,2,final,150+,infection,infection,USA,12-15 years,12-15 years,60,-35,88,delta,delta,~29 weeks,,,
202,Shrotri,Pfizer,1,1,28+,infection,infection,UK,LTCF residents,LTCF residents,31.7,-14.2,59.1,,alpha & delta,,,,
202,Shrotri,Pfizer,2,final,14-83,Infection,infection,UK,LTCF residents,LTCF residents,25.5,-57.5,64.7,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,2,final,84+,Infection,infection,UK,LTCF residents,LTCF residents,26.3,-21.7,55.4,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,1,1,28+,hospitalization,severe,UK,LTCF residents,LTCF residents,40.8,-16,69.7,,alpha & delta,,,,
202,Shrotri,Pfizer,2,final,14-83,hospitalization,severe,UK,LTCF residents,LTCF residents,88.8,16.8,98.5,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,2,final,84+,hospitalization,severe,UK,LTCF residents,LTCF residents,65.1,33.6,81.6,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,1,1,28+,death,death,UK,LTCF residents,LTCF residents,58.6,25.3,77,,alpha & delta,,,,
202,Shrotri,Pfizer,2,final,14-83,death,death,UK,LTCF residents,LTCF residents,100,,,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,2,final,84+,death,death,UK,LTCF residents,LTCF residents,66.1,26,84.4,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),1,1,28+,Infection,infection,UK,LTCF residents,LTCF residents,41.3,8.8,62.2,,alpha & delta,,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,14-83,Infection,infection,UK,LTCF residents,LTCF residents,62.1,12.1,83.6,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,84+,Infection,infection,UK,LTCF residents,LTCF residents,13.6,-33.2,43.9,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,UK,LTCF residents,LTCF residents,44.9,7.9,67.1,,alpha & delta,,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,14-83,hospitalization,severe,UK,LTCF residents,LTCF residents,82.7,46.4,94.4,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,84+,hospitalization,severe,UK,LTCF residents,LTCF residents,48.7,12.5,70,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),1,1,28+,death,death,UK,LTCF residents,LTCF residents,52.7,16.4,73.2,,alpha & delta,,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,14-83,death,death,UK,LTCF residents,LTCF residents,91.7,65.1,98,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,84+,death,death,UK,LTCF residents,LTCF residents,61.1,26.2,79.5,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,1,1,28+,Infection,infection,UK,LTCF staff,LTCF staff,27,4.4,44.3,,alpha & delta,,,,
202,Shrotri,Pfizer,2,final,14-83,infection,infection,UK,LTCF staff,LTCF staff,60.7,44.2,72.4,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,2,final,84+,Infection,infection,UK,LTCF staff,LTCF staff,45.1,31.3,56.2,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,1,1,28+,hospitalization,severe,UK,LTCF staff,LTCF staff,100,,,,alpha & delta,,,,
202,Shrotri,Pfizer,2,final,14-83,hospitalization,severe,UK,LTCF staff,LTCF staff,100,,,,alpha & delta,45 weeks,,,
202,Shrotri,Pfizer,2,final,84+,hospitalization,severe,UK,LTCF staff,LTCF staff,92.1,69.3,97.9,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),1,1,28+,Infection,infection,UK,LTCF staff,LTCF staff,19.6,-10.7,41.6,,alpha & delta,,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,14-83,Infection,infection,UK,LTCF staff,LTCF staff,29,-10.3,54.3,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,84+,Infection,infection,UK,LTCF staff,LTCF staff,36.9,20.6,49.9,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),1,1,28+,hospitalization,severe,UK,LTCF staff,LTCF staff,19.6,-121.6,70.8,,alpha & delta,,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,14-83,hospitalization,severe,UK,LTCF staff,LTCF staff,100,,,,alpha & delta,45 weeks,,,
202,Shrotri,AZD1222 (AstraZeneca),2,final,84+,hospitalization,severe,UK,LTCF staff,LTCF staff,89.6,64.4,96.9,,alpha & delta,45 weeks,,,
203,Baum,Pfizer,1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,61,49,71,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Pfizer,1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,64,49,75,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Pfizer,2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,93,89,95,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Pfizer,2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,69,63,74,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,Pfizer,1,1,21-83,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,84,63,93,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Pfizer,1,1,84+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,69,15,89,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Pfizer,2,final,14-90,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,98,92,99,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Pfizer,2,final,181+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,79,65,87,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,Moderna,1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,70,43,84,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Moderna,1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,63,26,82,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Moderna,2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,93,82,97,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,Moderna,2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,73,59,83,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,Moderna,1,1,21-83,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,70,-29,93,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Moderna,1,1,84+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,100,,,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,Moderna,2,final,14-90,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,100,,,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,Moderna,2,final,181+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,93,46,99,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,AZD1222 (AstraZeneca),1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,68,-3,90,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,AZD1222 (AstraZeneca),1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,37,-95,80,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,AZD1222 (AstraZeneca),2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,81,49,93,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,AZD1222 (AstraZeneca),2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,48,17,68,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,AZD1222 (AstraZeneca),1,1,21-83,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,68,-151,96,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,AZD1222 (AstraZeneca),1,1,84+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,100,,,,"non-VOC, alpha, delta, & omicron",,,,
203,Baum,AZD1222 (AstraZeneca),2,final,14-90,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,78,2,95,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,AZD1222 (AstraZeneca),2,final,181+,ICU admission,severe,Finland,≥ 70 years,≥ 70 years,64,-14,89,,"non-VOC, alpha, delta, & omicron",~56 weeks,,,
203,Baum,Pfizer,1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,53,-16,81,,delta,,,,
203,Baum,Pfizer,1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,68,45,81,,delta,,,,
203,Baum,Pfizer,2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,90,78,96,,delta,~48.5 weeks,,,
203,Baum,Pfizer,2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,79,71,84,,delta,~48.5 weeks,,,
203,Baum,Moderna,1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,60,-189,94,,delta,,,,
203,Baum,Moderna,1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,91,35,99,,delta,,,,
203,Baum,Moderna,2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,92,42,99,,delta,~48.5 weeks,,,
203,Baum,Moderna,2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,87,70,94,,delta,~48.5 weeks,,,
203,Baum,AZD1222 (AstraZeneca),1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,62,-171,95,,delta,,,,
203,Baum,AZD1222 (AstraZeneca),2,final,91-180,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,79,67,87,,delta,~48.5 weeks,,,
203,Baum,AZD1222 (AstraZeneca),2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,23,-76,67,,delta,~48.5 weeks,,,
203,Baum,Pfizer,1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,22,-38,56,,omicron,,,,
203,Baum,Pfizer,1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,61,34,77,,omicron,,,,
203,Baum,Pfizer,2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,91,83,95,,omicron,~56 weeks,,,
203,Baum,Pfizer,2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,58,48,66,,omicron,~56 weeks,,,
203,Baum,Moderna,1,1,21-83,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,81,-33,97,,omicron,,,,
203,Baum,Moderna,1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,23,-63,64,,omicron,,,,
203,Baum,Moderna,2,final,14-90,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,79,43,92,,omicron,~56 weeks,,,
203,Baum,Moderna,2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,60,34,75,,omicron,~56 weeks,,,
203,Baum,AZD1222 (AstraZeneca),1,1,84+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,100,,,,omicron,,,,
203,Baum,AZD1222 (AstraZeneca),2,final,91-180,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,37,-154,85,,omicron,,,,
203,Baum,AZD1222 (AstraZeneca),2,final,181+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,51,12,73,,omicron,~56 weeks,,,
204,Jara,CoronaVac (Sinovac),2,final,14+,infection,infection,Chile,3-5 years,3-5 years,37.9,36.1,39.6,omicron,omicron,~12 weeks,,,
204,Jara,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Chile,3-5 years,3-5 years,65.2,50.4,75.6,omicron,omicron,~12 weeks,,,
204,Jara,CoronaVac (Sinovac),2,final,14+,ICU admission,severe,Chile,3-5 years,3-5 years,68.8,18,88.1,omicron,omicron,~12 weeks,,,
205,Rearte,AZD1222 (AstraZeneca),1,1,21+,infection,infection,Argentina,≥ 18 years,general pop,39.9,39,41,,"alpha, gamma, & delta",,,,
205,Rearte,AZD1222 (AstraZeneca),2,final,21+,infection,infection,Argentina,≥ 18 years,general pop,68.5,67,69,,"alpha, gamma, & delta",~26 weeks,,,
205,Rearte,AZD1222 (AstraZeneca),1,1,21+,death,death,Argentina,≥ 18 years,general pop,83.1,82.3,83.9,,"alpha, gamma, & delta",,,,
205,Rearte,AZD1222 (AstraZeneca),2,final,21+,death,death,Argentina,≥ 18 years,general pop,93.7,93.2,94.3,,"alpha, gamma, & delta",~26 weeks,,,
205,Rearte,BBIBP-CorV (Beijing CNBG),1,1,21+,infection,infection,Argentina,≥ 18 years,general pop,22.6,20,25,,"alpha, gamma, & delta",,,,
205,Rearte,BBIBP-CorV (Beijing CNBG),2,final,21+,infection,infection,Argentina,≥ 18 years,general pop,43.6,42,45,,"alpha, gamma, & delta",~26 weeks,,,
205,Rearte,BBIBP-CorV (Beijing CNBG),1,1,21+,death,death,Argentina,≥ 18 years,general pop,70.4,68.1,72.8,,"alpha, gamma, & delta",,,,
205,Rearte,BBIBP-CorV (Beijing CNBG),2,final,21+,death,death,Argentina,≥ 18 years,general pop,85,84,86,,"alpha, gamma, & delta",~26 weeks,,,
205,Rearte,Sputnik V (Gamaleya),1,1,21+,infection,infection,Argentina,≥ 18 years,general pop,39.5,39,40,,"alpha, gamma, & delta",,,,
205,Rearte,Sputnik V (Gamaleya),2,final,21+,infection,infection,Argentina,≥ 18 years,general pop,64,63,65,,"alpha, gamma, & delta",~26 weeks,,,
205,Rearte,Sputnik V (Gamaleya),1,1,21+,death,death,Argentina,≥ 18 years,general pop,81.1,80.5,81.7,,"alpha, gamma, & delta",,,,
205,Rearte,Sputnik V (Gamaleya),2,final,21+,death,death,Argentina,≥ 18 years,general pop,93.1,92.6,93.5,,"alpha, gamma, & delta",~26 weeks,,,
206,Can,CoronaVac (Sinovac),2,final,14+,infection,infection,Turkey,HCW,HCW,39,20,54,,alpha,13 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,51.7,43.5,58.7,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,96.2,37.7,99.8,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,44.3,30.4,55.4,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100,-51.5,100,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-4.9,-16.4,5.4,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,96.8,71.1,99.6,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-2.7,-16.8,9.7,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,88.8,-1.7,98.8,omicron BA.1,omicron BA.1,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,55.1,50.9,58.9,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,97.8,82.6,99.7,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,47.9,40.8,54.1,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100,55.4,100,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-1.1,-7.1,4.6,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,76.8,58,87.1,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-7.3,-15.6,0.3,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,84.8,47.9,95.6,omicron BA.2,omicron BA.2,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,55.5,51.8,59,omicron,omicron,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,94.3,81.3,98.3,omicron,omicron,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,52,45.8,57.4,omicron,omicron,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,100,,,omicron,omicron,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,-0.2,-5.5,4.9,omicron,omicron,44 weeks,,,
207,Altarawneh,Pfizer,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,73.5,60.5,82.2,omicron,omicron,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,symptomatic disease,symptomatic,Qatar,≥ 18 years,general pop,2.2,-4.6,8.5,omicron,omicron,44 weeks,,,
207,Altarawneh,Moderna,2,final,14+,hospitalization or death,severe,Qatar,≥ 18 years,general pop,66.3,38.3,81.6,omicron,omicron,44 weeks,,,
208,Kaura,Pfizer,1,1,14-84,Infection,infection,UK,≥ 16 years,general pop,31,14,45,,alpha,,,,
208,Kaura,Pfizer,1,1,14-84,hospitalization,severe,UK,≥ 16 years,general pop,75,45,91,,alpha,,,,
208,Kaura,Pfizer,1,1,14-84,death,death,UK,≥ 16 years,general pop,86,42,98,,alpha,,,,
208,Kaura,AZD1222 (AstraZeneca),1,1,14-84,Infection,infection,UK,≥ 16 years,general pop,15,-5,31,,alpha,,,,
208,Kaura,AZD1222 (AstraZeneca),1,1,14-84,hospitalization,severe,UK,≥ 16 years,general pop,75,45,91,,alpha,,,,
208,Kaura,AZD1222 (AstraZeneca),1,1,14-84,death,death,UK,≥ 16 years,general pop,86,42,98,,alpha,,,,
209,Horne,Pfizer,2,final,21-42,infection,infection,UK,18-39 years,18-39 years,76,75,77,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,infection,infection,UK,18-39 years,18-39 years,-53,-118,-7,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,21-42,hospitalization,severe,UK,18-39 years,18-39 years,96,94,98,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,133-154,hospitalization,severe,UK,18-39 years,18-39 years,82,71,90,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,21-42,infection,infection,UK,40-64 years,40-64 years,73,69,77,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,infection,infection,UK,40-64 years,40-64 years,-3,-15,7,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,infection,infection,UK,40-64 years,40-64 years,21,18,24,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,infection,infection,UK,40-64 years,40-64 years,-99,-105,-94,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,hospitalization,severe,UK,40-64 years,40-64 years,95,93,96,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,hospitalization,severe,UK,40-64 years,40-64 years,86,83,88,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,105-126,death,death,UK,40-64 years,40-64 years,55,-5,81,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,death,death,UK,40-64 years,40-64 years,41,-7,68,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,21-42,infection,infection,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,34,30,39,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,infection,infection,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,4,-1,8,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,49-70,hospitalization,severe,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,95,94,97,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,hospitalization,severe,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,91,88,93,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,77-98,death,death,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,96,91,98,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,death,death,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,92,86,96,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,infection,infection,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,34,30,39,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,infection,infection,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,-45,-50,-40,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,hospitalization,severe,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,92,88,95,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,hospitalization,severe,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,75,71,78,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,77-98,death,death,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,92,88,95,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,death,death,UK,clinically vulnerable 16-64 years,clinically vulnerable 16-64 years,87,81,92,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,21-42,infection,infection,UK,≥ 65 years,≥ 65 years,81,74,86,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,infection,infection,UK,≥ 65 years,≥ 65 years,15,8,22,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,21-42,hospitalization,severe,UK,≥ 65 years,≥ 65 years,91,86,95,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,hospitalization,severe,UK,≥ 65 years,≥ 65 years,80,76,82,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,21-42,death,death,UK,≥ 65 years,≥ 65 years,98,93,99,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,Pfizer,2,final,161-182,death,death,UK,≥ 65 years,≥ 65 years,88,84,91,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,infection,infection,UK,≥ 65 years,≥ 65 years,53,41,62,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,infection,infection,UK,≥ 65 years,≥ 65 years,-21,-30,-13,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,hospitalization,severe,UK,≥ 65 years,≥ 65 years,88,85,90,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,hospitalization,severe,UK,≥ 65 years,≥ 65 years,75,71,79,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,21-42,death,death,UK,≥ 65 years,≥ 65 years,90,84,94,,"alpha, delta, & omicron",~30 weeks,,,
209,Horne,AZD1222 (AstraZeneca),2,final,161-182,death,death,UK,≥ 65 years,≥ 65 years,83,77,88,,"alpha, delta, & omicron",~30 weeks,,,
210,Stowe,Pfizer,1,1,28+,hospitalization with ARI,severe,UK,18-64 years,18-64 years,31.7,-3.1,54.8,,omicron,,,,
210,Stowe,Pfizer,2,final,14-174,hospitalization with ARI,severe,UK,18-64 years,18-64 years,73.8,62.5,81.7,,omicron,~43 weeks,,,
210,Stowe,Pfizer,2,final,175+,hospitalization with ARI,severe,UK,18-64 years,18-64 years,65.1,51.3,74.9,,omicron,~43 weeks,,,
210,Stowe,Pfizer,1,1,0-27,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,54.8,-25.3,83.7,,omicron,,,,
210,Stowe,Pfizer,2,final,14-174,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,87.6,79.4,92.5,,omicron,~43 weeks,,,
210,Stowe,Pfizer,1,1,28+,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,59.5,35.5,74.6,,omicron,,,,
210,Stowe,Pfizer,2,final,175+,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,65.4,56.6,72.5,,omicron,~43 weeks,,,
210,Stowe,AZD1222 (AstraZeneca),1,1,28+,hospitalization with ARI,severe,UK,18-64 years,18-64 years,48.5,25.7,64.3,,omicron,,,,
210,Stowe,AZD1222 (AstraZeneca),2,final,14-174,hospitalization with ARI,severe,UK,18-64 years,18-64 years,59,31.9,75.3,,omicron,~43 weeks,,,
210,Stowe,AZD1222 (AstraZeneca),2,final,175+,hospitalization with ARI,severe,UK,18-64 years,18-64 years,53,41.7,62,,omicron,~43 weeks,,,
210,Stowe,AZD1222 (AstraZeneca),1,1,28+,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,48.1,23.5,64.8,,omicron,,,,
210,Stowe,AZD1222 (AstraZeneca),2,final,14-174,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,71.2,50,83.4,,omicron,~43 weeks,,,
210,Stowe,AZD1222 (AstraZeneca),2,final,175+,hospitalization with ARI,severe,UK,≥ 65 years,≥ 65 years,53.1,43.4,61.2,,omicron,~43 weeks,,,
211,Tenforde,Pfizer,2,final,14+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,79,66,87,,omicron,~45 weeks,,,
211,Tenforde,Pfizer,2,final,14+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,88,86,90,,delta,~45 weeks,,,
211,Tenforde,Pfizer,2,final,14-150,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,92,90,94,,alpha,~45 weeks,,,
211,Tenforde,Pfizer,2,final,>150,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,84,80,87,,alpha,~45 weeks,,,
212,Veneti,Pfizer,1,1,21-48,infection,infection,Norway,12-15 years,12-15 years,16.2,-2.4,31.3,,omicron,,,,
212,Veneti,Pfizer,1,1,77+,infection,infection,Norway,12-15 years,12-15 years,-12.8,-21.7,-4.6,,omicron,,,,
212,Veneti,Pfizer,1,1,21-48,infection,infection,Norway,12-15 years,12-15 years,68.9,64.3,72.9,,delta,,,,
212,Veneti,Pfizer,1,1,77+,infection,infection,Norway,12-15 years,12-15 years,70.1,6.2,90.5,,delta,,,,
212,Veneti,Pfizer,1,1,21-48,infection,infection,Norway,16-17 years,16-17 years,-33.7,-88.3,5.1,,omicron,,,,
212,Veneti,Pfizer,2,final,7-34,infection,infection,Norway,16-17 years,16-17 years,53.1,42.6,61.7,,omicron,~12 weeks,,,
212,Veneti,Pfizer,1,1,77+,infection,infection,Norway,16-17 years,16-17 years,-5.3,-32.9,16.6,,omicron,,,,
212,Veneti,Pfizer,2,final,63+,infection,infection,Norway,16-17 years,16-17 years,23.3,2.7,39.5,,omicron,~12 weeks,,,
212,Veneti,Pfizer,1,1,21-48,infection,infection,Norway,16-17 years,16-17 years,63.3,56.5,69,,delta,,,,
212,Veneti,Pfizer,2,final,7-34,infection,infection,Norway,16-17 years,16-17 years,89.9,82.8,94.1,,delta,~12 weeks,,,
212,Veneti,Pfizer,1,1,77+,infection,infection,Norway,16-17 years,16-17 years,46.5,27.8,60.3,,delta,,,,
212,Veneti,Pfizer,2,final,63+,infection,infection,Norway,16-17 years,16-17 years,80.3,60,90.3,,delta,~12 weeks,,,
213,Wang,Pfizer,2,final,14-179,infection,infection,USA,patients,general pop,26,22,30,,omicron,~23.5 weeks,,,
213,Wang,Pfizer,2,final,180+,infection,infection,USA,patients,general pop,7,4,10,,omicron,54 weeks,,,
213,Wang,Pfizer,2,final,14-179,infection,infection,USA,patients,general pop,70,68,72,,delta,~23.5 weeks,,,
213,Wang,Pfizer,2,final,180+,infection,infection,USA,patients,general pop,53,52,55,,delta,54 weeks,,,
214,Natarajan,Janssen,1,final,14+,ED or UC visits,symptomatic,USA,ED/UC encounters or hospitalization among adults with COVID-19 like illness,ED/UC encounters or hospitalization among adults with COVID-19 like illness,24,18,29,,omicron,40 weeks,,,
214,Natarajan,Janssen,1,final,14+,hospitalization,severe,USA,ED/UC encounters or hospitalization among adults with COVID-19 like illness,ED/UC encounters or hospitalization among adults with COVID-19 like illness,31,21,40,,omicron,40 weeks,,,
215,Hansen,Pfizer,2,final,14-30,infection,infection,Denmark,≥ 12 years,general pop,37,35.6,38.3,,omicron,~2 weeks,,,
215,Hansen,Pfizer,2,final,121+,infection,infection,Denmark,≥ 12 years,general pop,9.8,9.2,10.4,,omicron,~30 weeks,,,
215,Hansen,Pfizer,2,final,14-30,hospitalization,severe,Denmark,≥ 12 years,general pop,50.5,33.9,63,,omicron,~2 weeks,,,
215,Hansen,Pfizer,2,final,121+,hospitalization,severe,Denmark,≥ 12 years,general pop,51.6,47.2,55.6,,omicron,~30 weeks,,,
215,Hansen,Moderna,2,final,14-30,infection,infection,Denmark,≥ 12 years,general pop,37.9,34.4,41.2,,omicron,~2 weeks,,,
215,Hansen,Moderna,2,final,121+,infection,infection,Denmark,≥ 12 years,general pop,13.2,12.3,14.2,,omicron,~30 weeks,,,
216,Price,Pfizer,2,final,14+,hospitalization,severe,USA,12-18 years,12-18 years,40,9,60,,omicron,~42 weeks,,,
216,Price,Pfizer,2,final,14-160,hospitalization,severe,USA,12-18 years,12-18 years,43,-1,68,,omicron,~20 weeks,,,
216,Price,Pfizer,2,final,161-314,hospitalization,severe,USA,12-18 years,12-18 years,38,-3,62,,omicron,~42 weeks,,,
216,Price,Pfizer,2,final,14+,hospitalization,severe,USA,5-11 years,5-11 years,68,42,82,,omicron,~11 weeks,,,
216,Price,Pfizer,2,final,14+,hospitalization,severe,USA,12-18 years,12-18 years,92,89,95,,delta,~42 weeks,,,
216,Price,Pfizer,2,final,14-160,hospitalization,severe,USA,12-18 years,12-18 years,93,89,95,,delta,~20 weeks,,,
216,Price,Pfizer,2,final,161-314,hospitalization,severe,USA,12-18 years,12-18 years,92,80,97,,delta,~42 weeks,,,
217,Marra,CoronaVac (Sinovac),2,final,14+,Infection,infection,Brazil,HCW,HCW,51.3,34.6,63.7,,gamma,~23 weeks,,,
217,Marra,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Brazil,HCW,HCW,88.1,82.8,91.7,,gamma,~15 weeks,,,
218,Starrfelt,Pfizer,1,1,21+,Infection,infection,Norway,≥ 18 years,general pop,15.5,12.9,18,,delta,,,,
218,Starrfelt,Pfizer,2,final,2-9 weeks,Infection,infection,Norway,≥ 18 years,general pop,77.7,76.8,78.5,,delta,~7 weeks,,,
218,Starrfelt,Pfizer,2,final,>33 weeks,Infection,infection,Norway,≥ 18 years,general pop,8.2,3.4,12.8,,delta,~43 weeks,,,
218,Starrfelt,Pfizer,1,1,21+,hospitalization,severe,Norway,≥ 18 years,general pop,75.3,66.4,81.9,,delta,,,,
218,Starrfelt,Pfizer,2,final,2-9 weeks,hospitalization,severe,Norway,≥ 18 years,general pop,97.5,95.6,98.6,,delta,~7 weeks,,,
218,Starrfelt,Pfizer,2,final,>33 weeks,hospitalization,severe,Norway,≥ 18 years,general pop,63.9,54.3,71.5,,delta,~43 weeks,,,
218,Starrfelt,Moderna,1,1,21+,Infection,infection,Norway,≥ 18 years,general pop,38.1,34.7,41.3,,delta,,,,
218,Starrfelt,Moderna,2,final,2-9 weeks,Infection,infection,Norway,≥ 18 years,general pop,86.6,85.6,87.6,,delta,~7 weeks,,,
218,Starrfelt,Moderna,2,final,>33 weeks,Infection,infection,Norway,≥ 18 years,general pop,28.6,9.6,43.6,,delta,~43 weeks,,,
218,Starrfelt,Moderna,1,1,21+,hospitalization,severe,Norway,≥ 18 years,general pop,77.1,58.9,87.3,,delta,,,,
218,Starrfelt,Moderna,2,final,18-25 weeks,hospitalization,severe,Norway,≥ 18 years,general pop,95.3,91.5,97.4,,delta,~23 weeks,,,
218,Starrfelt,Moderna,2,final,26-33 weeks,hospitalization,severe,Norway,≥ 18 years,general pop,91.1,84.9,94.8,,delta,~31 weeks,,,
218,Starrfelt,Pfizer,2,final,2-9 weeks,Infection,infection,Norway,≥ 18 years,general pop,84.1,83.2,85,,delta,~7 weeks,,,
218,Starrfelt,Pfizer,2,final,18-25 weeks,Infection,infection,Norway,≥ 18 years,general pop,40.7,23.9,53.8,,delta,~23 weeks,,,
219,Pardo-Seco,Pfizer,1,1,14-20,Infection,infection,Spain,≥ 18 years,general pop,67.7,64.6,70.6,,non-VOC & alpha,,,,
219,Pardo-Seco,Pfizer,2,final,14+,Infection,infection,Spain,≥ 18 years,general pop,90.8,88.6,92.7,,non-VOC & alpha,~7.5 weeks,,,
220,Nordstrom,Pfizer,2,final,14+,Infection,infection,Sweden,≥ 18 years,general pop,68,63,72,,"non-VOC, alpha, & delta",~38 weeks,,,
220,Nordstrom,AZD1222 (AstraZeneca),2,final,14+,Infection,infection,Sweden,≥ 18 years,general pop,25,-37,59,,"non-VOC, alpha, & delta",~38 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,14-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,28.1,26.5,29.6,,omicron,~10 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,180+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,6.3,5.3,7.3,,omicron,~59 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,14-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,56.1,40.6,67.5,,omicron,~10 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,180+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,57.6,54.4,60.6,,omicron,~59 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,14-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,51.3,49.9,52.7,,delta,~10 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,180+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,34,49.9,52.7,,delta,~59 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,14-59,hospitalization or death,severe,Brazil,≥ 18 years,general pop,86.5,83.4,88.9,,delta,~10 weeks,,,
221,Ranzani,CoronaVac (Sinovac),2,final,180+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,60.9,57.3,64.2,,delta,~59 weeks,,,
222,Florentino,Pfizer,2,final,14-27,symptomatic disease,symptomatic,Brazil,12-17 years,12-17 years,64.7,63,66.3,,omicron,2 weeks,,,
222,Florentino,Pfizer,2,final,98+,symptomatic disease,symptomatic,Brazil,12-17 years,12-17 years,5.9,2.2,9.4,,omicron,~21 weeks,,,
222,Florentino,Pfizer,2,final,14-27,severe disease,severe,Brazil,12-17 years,12-17 years,75.6,58.1,85.8,,omicron,2 weeks,,,
222,Florentino,Pfizer,2,final,98+,severe disease,severe,Brazil,12-17 years,12-17 years,82.7,68.8,90.4,,omicron,~21 weeks,,,
222,Florentino,Pfizer,2,final,14-27,symptomatic disease,symptomatic,Brazil,12-17 years,12-17 years,80.7,77.8,83.3,,delta,2 weeks,,,
222,Florentino,Pfizer,2,final,56-69,symptomatic disease,symptomatic,Brazil,12-17 years,12-17 years,26.6,4.1,43.9,,delta,~8 weeks,,,
222,Florentino,Pfizer,2,final,14-27,symptomatic disease,symptomatic,Scotland,12-17 years,12-17 years,82.6,80.6,84.5,,omicron,2 weeks,,,
222,Florentino,Pfizer,2,final,98+,symptomatic disease,symptomatic,Scotland,12-17 years,12-17 years,50.6,42.7,57.4,,omicron,~15.5 weeks,,,
222,Florentino,Pfizer,2,final,14-27,symptomatic disease,symptomatic,Scotland,12-17 years,12-17 years,92.8,85.7,96.4,,delta,2 weeks,,,
222,Florentino,Pfizer,2,final,56-69,symptomatic disease,symptomatic,Scotland,12-17 years,12-17 years,86.5,72.2,93.4,,delta,~8 weeks,,,
223,Yoon,Pfizer,2,final,14+,infection,infection,USA,HCW,HCW,46,25,61,omicron,omicron,~21 weeks,,,
223,Yoon,Pfizer,2,final,14+,infection,infection,USA,HCW,HCW,65,49,76,delta,delta,~21 weeks,,,
224,Kwon,Pfizer,2,final,14+,hospitalization,severe,USA,transplant recipients,transplant recipients,29,-19,58,,alpha & delta,~37 weeks,,,
224,Kwon,Pfizer,2,final,14+,hospitalization,severe,USA,immunocompromised,immunocompromised adults,72,64,79,,alpha & delta,~37 weeks,,,
224,Kwon,Pfizer,2,final,14+,hospitalization,severe,USA,immunocompetent adults,general pop,88,87,90,,alpha & delta,~37 weeks,,,
224,Kwon,Pfizer,2,final,14+,supplemental oxygen/oxygen support,severe,USA,transplant recipients,transplant recipients,31,-27,63,,alpha & delta,~37 weeks,,,
224,Kwon,Pfizer,2,final,14+,supplemental oxygen/oxygen support,severe,USA,immunocompromised,immunocompromised adults,73,64,80,,alpha & delta,~37 weeks,,,
224,Kwon,Pfizer,2,final,14+,supplemental oxygen/oxygen support,severe,USA,immunocompetent adults,general pop,90,89,92,,alpha & delta,~37 weeks,,,
225,Paraguay Ministry of Health and Social Welfare,BBV152 (Bharat),2,final,14+,hospitalization with SARI,severe,Paraguay,patients ≥16 years with severe acute respiratory infection,general pop,27.7,-10.2,52.6,,gamma & delta,~38 weeks,,,
225,Paraguay Ministry of Health and Social Welfare,AZD1222 (AstraZeneca),2,final,14+,hospitalization with SARI,severe,Paraguay,patients ≥16 years with severe acute respiratory infection,general pop,85.8,70.6,93.1,,gamma & delta,~38 weeks,,,
225,Paraguay Ministry of Health and Social Welfare,Hayat-Vax (Julphar),2,final,14+,hospitalization with SARI,severe,Paraguay,patients ≥16 years with severe acute respiratory infection,general pop,56.4,15.5,77.6,,gamma & delta,~38 weeks,,,
225,Paraguay Ministry of Health and Social Welfare,Sputnik V (Gamaleya),2,final,14+,hospitalization with SARI,severe,Paraguay,patients ≥16 years with severe acute respiratory infection,general pop,77,30.8,92.3,,gamma & delta,~38 weeks,,,
225,Paraguay Ministry of Health and Social Welfare,Pfizer,2,final,14+,hospitalization with SARI,severe,Paraguay,patients ≥16 years with severe acute respiratory infection,general pop,95.4,65.7,99.4,,gamma & delta,~38 weeks,,,
226,Buchan,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,12-17 years,12-17 years,51,38,61,omicron,omicron,~41 weeks,,,
226,Buchan,Pfizer,2,final,180+,symptomatic disease,symptomatic,Canada,12-17 years,12-17 years,29,17,38,omicron,omicron,~41 weeks,,,
226,Buchan,Pfizer,2,final,7-59,hospitalization or death,severe,Canada,12-17 years,12-17 years,76,-10,95,omicron,omicron,~41 weeks,,,
226,Buchan,Pfizer,2,final,180+,hospitalization or death,severe,Canada,12-17 years,12-17 years,88,77,94,omicron,omicron,~32 weeks,,,
226,Buchan,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,12-17 years,12-17 years,97,94,99,delta,delta,~32 weeks,,,
226,Buchan,Pfizer,2,final,180+,symptomatic disease,symptomatic,Canada,12-17 years,12-17 years,90,79,95,delta,delta,~32 weeks,,,
227,Kim,Pfizer,2,final,14-149,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,45,14,66,omicron,omicron,~58 weeks,,,
227,Kim,Pfizer,2,final,150+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,11,-21,35,omicron,omicron,~58 weeks,,,
227,Kim,Pfizer,2,final,14-149,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,89,78,94,delta,delta,~48 weeks,,,
227,Kim,Pfizer,2,final,150+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,58,44,68,delta,delta,~48 weeks,,,
228,Kildegard,Pfizer,1,1,0-20,infection,infection,Denmark,12-17 years,12-17 years,62,59,65,,delta,,,,
228,Kildegard,Pfizer,2,final,0-59,infection,infection,Denmark,12-17 years,12-17 years,93,93,94,,delta,~13 weeks,,,
229,Institute of Public Health,Pfizer,1,1,14+,hospitalization,severe,Chile,≥ 18 years,general pop,53.5,-27.3,83,,gamma & delta,,,,
229,Institute of Public Health,Pfizer,2,final,14+,hospitalization,severe,Chile,≥ 18 years,general pop,85.3,73.5,91.8,,gamma & delta,~53 weeks,,,
229,Institute of Public Health,CoronaVac (Sinovac),1,1,14+,hospitalization,severe,Chile,≥ 18 years,general pop,36.6,6,57.2,,gamma & delta,,,,
229,Institute of Public Health,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Chile,≥ 18 years,general pop,59.5,49,67.9,,gamma & delta,~53 weeks,,,
230,Plumb,Pfizer,1,1,14+,hospitalization,severe,USA,hospitalized adults,general pop,33,15,47.2,,omicron,,,,
230,Plumb,Pfizer,2,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,37.3,25.8,46.9,,omicron,~55 weeks,,,
230,Plumb,Moderna,2,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,35.9,21.7,47.4,,omicron,~55 weeks,,,
230,Plumb,Pfizer,1,1,14+,hospitalization,severe,USA,hospitalized adults,general pop,58.8,41.3,71.1,,delta,,,,
230,Plumb,Pfizer,2,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,50,39,59,,delta,~55 weeks,,,
230,Plumb,Moderna,2,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,44,29.9,55.2,,delta,~55 weeks,,,
231,Dale,Pfizer,2,final,14+,infection,infection,USA,≥ 18 years,general pop,51,-27,81,delta,delta,~25 weeks,,,
231,Dale,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,67,-7,90,delta,delta,~25 weeks,,,
231,Dale,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,61,-59,90,delta,delta,~25 weeks,,,
231,Dale,Pfizer,2,final,14+,death,death,USA,≥ 18 years,general pop,80,-10,96,delta,delta,~25 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,51.9,50,53.8,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,140+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,26.2,22.8,29.4,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,59.6,36.6,74.2,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,140+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,53.6,30.2,69.1,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,25.5,1,29.7,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,140+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,17,14.4,19.6,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,41,-8.1,67.8,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,140+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,55.4,44.6,64.1,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Janssen,1,final,14+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,16.2,12.4,19.8,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Janssen,1,final,14+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,39.5,8.3,69,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,23.4,18.2,28.3,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,140+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,12.3,9.4,15.1,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,34.1,-28.9,66.3,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,140+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,34.4,18.3,47.3,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,54.1,52.1,55.9,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,140+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,30.6,27.3,33.7,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,53.6,-6.4,79.8,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Pfizer,2,final,140+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,55.1,-1.9,80.2,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,27.2,22.9,31.3,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,140+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,15.9,13.2,18.5,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,67.5,-7.9,90.2,,omicron,~59 weeks,,,
232,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,140+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,63.2,39,77.8,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Janssen,1,final,14+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,16.9,13.2,20.5,,omicron,~59 weeks,,,
232,Cerqueira-Silva,Janssen,1,final,14+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,45.4,-19.6,75.1,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-69,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,27.3,22.3,31.9,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,140+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,14.3,11.4,17,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-69,hospitalization or death,severe,Brazil,≥ 18 years,general pop,21.4,-148.4,75.1,,omicron,~59 weeks,,,
232,Cerqueira-Silva,CoronaVac (Sinovac),2,final,140+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,66.4,37.6,81.9,,omicron,~59 weeks,,,
233,Nasreen,Pfizer,2,final,7-55,hospitalization or death,severe,Canada,≥ 18 years,general pop,98,95,99,,"non-VOC, alpha, beta, gamma, & delta",~32 weeks,,,
233,Nasreen,Pfizer,2,final,112+,hospitalization or death,severe,Canada,≥ 18 years,general pop,98,95,99,,"non-VOC, alpha, beta, gamma, & delta",~32 weeks,,,
233,Nasreen,AZD1222 (AstraZeneca),2,final,7-55,hospitalization or death,severe,Canada,≥ 18 years,general pop,96,88,96,,"non-VOC, alpha, beta, gamma, & delta",~7 weeks,,,
233,Nasreen,AZD1222 (AstraZeneca),2,final,56+,hospitalization or death,severe,Canada,≥ 18 years,general pop,97,91,99,,"non-VOC, alpha, beta, gamma, & delta",~7 weeks,,,
233,Nasreen,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,hospitalization or death,severe,Canada,≥ 18 years,general pop,99,98,100,,"non-VOC, alpha, beta, gamma, & delta",~7 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,14-60,infection,infection,Mexico,childcare workers,childcare workers,48,32,61,,"non-VOC, alpha, gamma, & delta",~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,120+,infection,infection,Mexico,childcare workers,childcare workers,-3,-26,16,,"non-VOC, alpha, gamma, & delta",~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,14-60,hospitalization,severe,Mexico,childcare workers,childcare workers,92,23,99,,"non-VOC, alpha, gamma, & delta",~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,120+,hospitalization,severe,Mexico,childcare workers,childcare workers,24,-263,84,,"non-VOC, alpha, gamma, & delta",~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,61-120,death,death,Mexico,childcare workers,childcare workers,95,53,100,,"non-VOC, alpha, gamma, & delta",~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,120+,death,death,Mexico,childcare workers,childcare workers,93,22,99,,"non-VOC, alpha, gamma, & delta",~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,14+,infection,infection,Mexico,childcare workers,childcare workers,53,23,71,,alpha & gamma,~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,14+,infection,infection,Mexico,childcare workers,childcare workers,18,8,28,,delta,~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,14+,hospitalization,severe,Mexico,childcare workers,childcare workers,74,38,89,,delta,~33 weeks,,,
234,Richardson,Ad5-nCOV (CanSino),1,final,14+,death,death,Mexico,childcare workers,childcare workers,94,67,99,,delta,~33 weeks,,,
235,Vokó,Pfizer,2,final,14-120,infection,infection,Hungary,18-64 years,18-64 years,70.3,69.2,71.3,,delta,~47 weeks,,,
235,Vokó,Pfizer,2,final,240+,infection,infection,Hungary,18-64 years,18-64 years,0.6,-2.3,3.4,,delta,~47 weeks,,,
235,Vokó,Pfizer,2,final,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,82.6,80.1,84.7,,delta,~47 weeks,,,
235,Vokó,Pfizer,2,final,240+,hospitalization,severe,Hungary,18-64 years,18-64 years,69.6,64.9,73.6,,delta,~47 weeks,,,
235,Vokó,Pfizer,2,final,14-120,death,death,Hungary,18-64 years,18-64 years,87.4,81.5,91.5,,delta,~47 weeks,,,
235,Vokó,Pfizer,2,final,240+,death,death,Hungary,18-64 years,18-64 years,73.6,61.1,82.1,,delta,~47 weeks,,,
235,Vokó,Moderna,2,final,14-120,infection,infection,Hungary,18-64 years,18-64 years,76.9,73.3,80,,delta,~47 weeks,,,
235,Vokó,Moderna,2,final,240+,infection,infection,Hungary,18-64 years,18-64 years,22.6,6.1,36.2,,delta,~47 weeks,,,
235,Vokó,Moderna,2,final,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,84.9,75.4,90.8,,delta,~47 weeks,,,
235,Vokó,Moderna,2,final,240+,hospitalization,severe,Hungary,18-64 years,18-64 years,42.5,-4,68.2,,delta,~47 weeks,,,
235,Vokó,Moderna,2,final,14-120,death,death,Hungary,18-64 years,18-64 years,77.7,30.7,92.8,,delta,~47 weeks,,,
235,Vokó,Moderna,2,final,240+,death,death,Hungary,18-64 years,18-64 years,100,,,,delta,~47 weeks,,,
235,Vokó,AZD1222 (AstraZeneca),2,final,14-120,infection,infection,Hungary,18-64 years,18-64 years,39.2,36.4,41.9,,delta,~47 weeks,,,
235,Vokó,AZD1222 (AstraZeneca),2,final,240+,infection,infection,Hungary,18-64 years,18-64 years,-14,-20.5,-7.9,,delta,~47 weeks,,,
235,Vokó,AZD1222 (AstraZeneca),2,final,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,76.2,70.6,80.7,,delta,~47 weeks,,,
235,Vokó,AZD1222 (AstraZeneca),2,final,240+,hospitalization,severe,Hungary,18-64 years,18-64 years,48.8,38.2,57.6,,delta,~47 weeks,,,
235,Vokó,AZD1222 (AstraZeneca),2,final,14-120,death,death,Hungary,18-64 years,18-64 years,90.1,73.5,96.3,,delta,~47 weeks,,,
235,Vokó,AZD1222 (AstraZeneca),2,final,240+,death,death,Hungary,18-64 years,18-64 years,57.1,35.2,71.6,,delta,~47 weeks,,,
235,Vokó,Sputnik V (Gamaleya),2,final,14-120,infection,infection,Hungary,18-64 years,18-64 years,38.3,31.8,44.3,,delta,~47 weeks,,,
235,Vokó,Sputnik V (Gamaleya),2,final,240+,infection,infection,Hungary,18-64 years,18-64 years,-4.6,-12.5,2.9,,delta,~47 weeks,,,
235,Vokó,Sputnik V (Gamaleya),2,final,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,90.4,78.5,95.7,,delta,~47 weeks,,,
235,Vokó,Sputnik V (Gamaleya),2,final,240+,hospitalization,severe,Hungary,18-64 years,18-64 years,78.7,69.1,85.4,,delta,~47 weeks,,,
235,Vokó,Sputnik V (Gamaleya),2,final,121-180,death,death,Hungary,18-64 years,18-64 years,89.3,79.9,94.3,,delta,~47 weeks,,,
235,Vokó,Sputnik V (Gamaleya),2,final,240+,death,death,Hungary,18-64 years,18-64 years,79.1,59.8,89.2,,delta,~47 weeks,,,
235,Vokó,Janssen,1,final,14-120,infection,infection,Hungary,18-64 years,18-64 years,39.3,36.1,42.4,,delta,~47 weeks,,,
235,Vokó,Janssen,1,final,181-240,infection,infection,Hungary,18-64 years,18-64 years,35.9,32.5,39.2,,delta,~47 weeks,,,
235,Vokó,Janssen,1,final,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,43.2,32.9,52,,delta,~47 weeks,,,
235,Vokó,Janssen,1,final,181-240,hospitalization,severe,Hungary,18-64 years,18-64 years,59.4,50.1,67,,delta,~47 weeks,,,
235,Vokó,Janssen,1,final,14-120,death,death,Hungary,18-64 years,18-64 years,59.8,35.2,75.1,,delta,~47 weeks,,,
235,Vokó,Janssen,1,final,181-240,death,death,Hungary,18-64 years,18-64 years,76.1,56.7,86.8,,delta,~47 weeks,,,
235,Vokó,BBIBP-CorV (Beijing CNBG),2,final,14-120,infection,infection,Hungary,18-64 years,18-64 years,10.9,6.7,15,,delta,~47 weeks,,,
235,Vokó,BBIBP-CorV (Beijing CNBG),2,final,240+,infection,infection,Hungary,18-64 years,18-64 years,-19.9,-31.9,-9,,delta,~47 weeks,,,
235,Vokó,BBIBP-CorV (Beijing CNBG),2,final,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,53.8,43.9,61.9,,delta,~47 weeks,,,
235,Vokó,BBIBP-CorV (Beijing CNBG),2,final,240+,hospitalization,severe,Hungary,18-64 years,18-64 years,40.9,24.4,53.8,,delta,~47 weeks,,,
235,Vokó,BBIBP-CorV (Beijing CNBG),2,final,14-120,death,death,Hungary,18-64 years,18-64 years,67.4,39.2,82.5,,delta,~47 weeks,,,
235,Vokó,BBIBP-CorV (Beijing CNBG),2,final,240+,death,death,Hungary,18-64 years,18-64 years,50.7,21.4,69.1,,delta,~47 weeks,,,
236,Gram,Pfizer,2,final,14-30,infection,infection,Denmark,12-59 years,12-59 years,39.8,38.4,41.2,,omicron,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,infection,infection,Denmark,12-59 years,12-59 years,13.2,12.5,13.9,,omicron,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,62.4,46.3,73.6,,omicron,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,hospitalization,severe,Denmark,12-59 years,12-59 years,65.9,62,69.4,,omicron,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,infection,infection,Denmark,12-59 years,12-59 years,92.2,91.8,92.6,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,infection,infection,Denmark,12-59 years,12-59 years,64.9,64,65.8,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,99.1,98,99.6,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,hospitalization,severe,Denmark,12-59 years,12-59 years,91.6,89.5,93.2,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,39.9,26.4,50.9,,omicron,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,4.7,0.2,8.9,,omicron,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,82.2,75.3,87.1,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,49.8,46.5,52.8,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,31-60,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,97.7,95.2,98.9,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,86.2,84.2,87.9,,delta,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,91,88.5,92.9,,alpha,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,71.5,54.7,82.1,,alpha,~56 weeks,,,
236,Gram,Pfizer,2,final,14-30,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,96.4,92.6,98.3,,alpha,~56 weeks,,,
236,Gram,Pfizer,2,final,120+,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,90.5,67,97.2,,alpha,~56 weeks,,,
237,Lind,Pfizer,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,28.5,20,36.2,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,150+,infection,infection,USA,≥ 18 years,general pop,15.3,10.4,20,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,36.1,7.1,56.1,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,150+,infection,infection,USA,≥ 18 years,general pop,34,18.5,46.5,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,30.7,20.6,39.6,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,150+,infection,infection,USA,≥ 18 years,general pop,20,14,25.6,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,14.3,-43.1,48.7,omicron,omicron,~40 weeks,,,
237,Lind,Pfizer,2,final,150+,infection,infection,USA,≥ 18 years,general pop,18.8,-9,39.5,omicron,omicron,~40 weeks,,,
238,Sanchez Ruiz,Pfizer,2,final,14+,infection,infection,France,LTCF residents,LTCF residents,11.2,0,61.1,delta,delta,,,,
238,Sanchez Ruiz,Pfizer,2,final,14+,symptomatic disease,symptomatic,France,LTCF residents,LTCF residents,88.4,59.9,96.7,delta,delta,,,,
238,Sanchez Ruiz,Pfizer,2,final,14+,severe disease,severe,France,LTCF residents,LTCF residents,93.5,67.2,98.7,delta,delta,,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,82,78,85,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,86,80,90,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,83,80,86,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,severe disease,severe,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,92,88,95,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,88,82,93,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,93,83,97,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,89,83,93,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,severe disease,severe,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,97,83,99,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with psoriasis,individuals with psoriasis,82,79,85,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with psoriasis,individuals with psoriasis,87,82,91,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with psoriasis,individuals with psoriasis,84,81,86,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,severe disease,severe,Canada,individuals with psoriasis,individuals with psoriasis,92,86,95,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,82,79,85,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,87,82,91,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,infection,infection,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,79,74,82,,alpha & delta,~44 weeks,,,
239,Widdifield,Pfizer,2,final,7+,severe disease,severe,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,94,88,97,,alpha & delta,~44 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,14-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,49.2,48.5,49.9,,omicron,~7 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,150+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,9.6,8.1,11,,omicron,~33 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,14-59,severe disease,severe,Brazil,≥ 18 years,general pop,82.9,80.6,85,,omicron,~7 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,150+,severe disease,severe,Brazil,≥ 18 years,general pop,82.6,80.7,84.3,,omicron,~33 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-59,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,26.7,25.2,28.2,,omicron,~7 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,150+,symptomatic disease,symptomatic,Brazil,≥ 18 years,general pop,0.9,0,1.9,,omicron,~36 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-59,severe disease,severe,Brazil,≥ 18 years,general pop,77.1,72.9,80.6,,omicron,~7 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,150+,severe disease,severe,Brazil,≥ 18 years,general pop,67.8,66.7,69,,omicron,~36 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,14-59,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,57.7,54.5,60.6,,omicron,~7 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,150+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,17.8,15.1,20.5,,omicron,~38.5 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,14-59,severe disease,severe,Scotland,≥ 18 years,general pop,90.4,30.4,98.7,,omicron,~7 weeks,,,
240,Cerqueira-Silva,Pfizer,2,final,150+,severe disease,severe,Scotland,≥ 18 years,general pop,72.9,57.9,82.5,,omicron,~38.5 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,14-59,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,40.7,26.6,52.1,,omicron,~7 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,150+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,9.6,6.3,12.9,,omicron,~35.5 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,60-149,severe disease,severe,Scotland,≥ 18 years,general pop,78.8,31.8,93.4,,omicron,~19 weeks,,,
240,Cerqueira-Silva,AZD1222 (AstraZeneca),2,final,150+,severe disease,severe,Scotland,≥ 18 years,general pop,52.8,33.3,66.7,,omicron,~35.5 weeks,,,
241,Gonzalez,Pfizer,2,final,14+,hospitalization,severe,Argentina,12-17 years,12-17 years,81,59.9,90.1,,delta & omicron,~17 weeks,,,
241,Gonzalez,BBIBP-CorV (Beijing CNBG),2,final,14+,hospitalization,severe,Argentina,3-11 years,3-11 years,83.4,70.9,90.2,,delta & omicron,~9 weeks,,,
241,Gonzalez,Pfizer,2,final,14+,hospitalization,severe,Argentina,12-17 years,12-17 years,78.2,42,90.3,,omicron,~25 weeks,,,
241,Gonzalez,BBIBP-CorV (Beijing CNBG),2,final,14+,hospitalization,severe,Argentina,3-11 years,3-11 years,58.6,4.1,79.7,,omicron,16 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,infection,infection,USA,military personnel,military personnel,87.6,86.2,88.9,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,asymptomatic infection,asymptomatic,USA,military personnel,military personnel,80.3,76.5,83.5,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,military personnel,military personnel,89.9,88.4,91.2,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,hospitalization,severe,USA,military personnel,military personnel,88,75.4,94.1,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,infection,infection,USA,military personnel,military personnel,93.5,91.9,94.7,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,asymptomatic infection,asymptomatic,USA,military personnel,military personnel,94.7,91.9,96.6,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,military personnel,military personnel,93.1,91.2,94.6,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,hospitalization,severe,USA,military personnel,military personnel,89.6,57.5,97.4,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,infection,infection,USA,military personnel,military personnel,81.8,74.2,87.1,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,asymptomatic infection,asymptomatic,USA,military personnel,military personnel,81.4,62.6,90.8,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,symptomatic disease,symptomatic,USA,military personnel,military personnel,82.4,73.9,88.2,,"pre-delta (non-VOC, alpha)",~19 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,infection,infection,USA,military personnel,military personnel,69.3,68.2,70.3,,delta,~35 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,asymptomatic infection,asymptomatic,USA,military personnel,military personnel,66,64,67.8,,delta,~35 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,military personnel,military personnel,71,69.7,72.1,,delta,~35 weeks,,,
242,Eick-Cost,Pfizer,2,final,14+,hospitalization,severe,USA,military personnel,military personnel,88.4,82.1,92.5,,delta,~35 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,infection,infection,USA,military personnel,military personnel,79.4,78.3,80.4,,delta,~35 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,asymptomatic infection,asymptomatic,USA,military personnel,military personnel,77,75.1,78.8,,delta,~35 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,military personnel,military personnel,80.6,79.4,81.8,,delta,~35 weeks,,,
242,Eick-Cost,Moderna,2,final,14+,hospitalization,severe,USA,military personnel,military personnel,88.1,75.7,94.2,,delta,~35 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,infection,infection,USA,military personnel,military personnel,38.3,34.5,41.9,,delta,~35 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,asymptomatic infection,asymptomatic,USA,military personnel,military personnel,19.6,12.2,26.4,,delta,~35 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,symptomatic disease,symptomatic,USA,military personnel,military personnel,48.9,45,52.7,,delta,~35 weeks,,,
242,Eick-Cost,Janssen,1,final,14+,hospitalization,severe,USA,military personnel,military personnel,57.7,2.6,81.6,,delta,~35 weeks,,,
243,Castillo,Pfizer,2,final,0-30,symptomatic disease,symptomatic,France,≥ 18 years,general pop,43,41,45,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,11,10,13,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,hospitalization,severe,France,≥ 18 years,general pop,59,49,70,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,hospitalization,severe,France,≥ 18 years,general pop,56,51,62,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,ICU admission,severe,France,≥ 18 years,general pop,70,40,97,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,ICU admission,severe,France,≥ 18 years,general pop,72,63,81,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,death,death,France,≥ 18 years,general pop,60,24,92,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,death,death,France,≥ 18 years,general pop,54,41,69,omicron,omicron,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,symptomatic disease,symptomatic,France,≥ 18 years,general pop,78,77,80,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,63,62,64,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,hospitalization,severe,France,≥ 18 years,general pop,91,87,95,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,hospitalization,severe,France,≥ 18 years,general pop,90,89,91,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,ICU admission,severe,France,≥ 18 years,general pop,93,86,99,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,ICU admission,severe,France,≥ 18 years,general pop,95,93,97,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,0-30,death,death,France,≥ 18 years,general pop,90,79,100,delta,delta,~48 weeks,,,
243,Castillo,Pfizer,2,final,180+,death,death,France,≥ 18 years,general pop,87,83,91,delta,delta,~48 weeks,,,
244,Sharma,Pfizer,2,final,14+,infection,infection,USA,veterans,veterans,25.3,21.8,28.7,,omicron,~42 weeks,,,
244,Sharma,Pfizer,2,final,14+,hospitalization,severe,USA,veterans,veterans,52.9,47.8,57.6,,omicron,~42 weeks,,,
244,Sharma,Pfizer,2,final,14+,death,death,USA,veterans,veterans,50.7,37.9,61.6,,omicron,~42 weeks,,,
244,Sharma,Moderna,2,final,14+,infection,infection,USA,veterans,veterans,39.5,35.8,43,,omicron,~42 weeks,,,
244,Sharma,Moderna,2,final,14+,hospitalization,severe,USA,veterans,veterans,66.7,61.4,71.6,,omicron,~42 weeks,,,
244,Sharma,Moderna,2,final,14+,death,death,USA,veterans,veterans,65.6,52.8,76.3,,omicron,~42 weeks,,,
246,Florentino,CoronaVac (Sinovac),2,final,14+,symptomatic disease,symptomatic,Brazil,6-11 years,6-11 years,39.8,33.7,45.4,,omicron,~12 weeks,,,
246,Florentino,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Brazil,6-11 years,6-11 years,59.2,11.3,84.5,,omicron,~12 weeks,,,
247,Kirsebom,AZD1222 (AstraZeneca),2,final,175+,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,8,6,9.9,omicron,omicron,~44.5 weeks,,,
247,Kirsebom,AZD1222 (AstraZeneca),2,final,175+,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,19.5,11.7,26.6,omicron,omicron,~44.5 weeks,,,
247,Kirsebom,AZD1222 (AstraZeneca),2,final,175+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,61,49.8,69.7,omicron,omicron,~44.5 weeks,,,
247,Kirsebom,AZD1222 (AstraZeneca),2,final,175+,hospitalization,severe,UK,≥ 65 years,≥ 65 years,73.4,70.4,76.2,delta,delta,~44.5 weeks,,,
248,Carazo,Pfizer,2,final,7+,infection,infection,Canada,≥ 12 years,general pop,42,41,44,,omicron,~51 weeks,,,
248,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥ 12 years,general pop,76,74,78,,omicron,~51 weeks,,,
248,Carazo,Pfizer,2,final,7+,infection,infection,Canada,≥ 12 years,general pop,23.2,21.2,27.4,,omicron,~51 weeks,,,
248,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥ 12 years,general pop,68.4,63.6,73.5,,omicron,~51 weeks,,,
249,Ma,BBIBP-CorV (Beijing CNBG),2,final,14+,symptomatic disease,symptomatic,China,close contacts,close contacts,75.5,63,93.6,,delta,~8 weeks,,,
249,Ma,BBIBP-CorV (Beijing CNBG),2,final,14+,pneumonia,severe,China,close contacts,close contacts,56.5,-95.9,90.4,,delta,~8 weeks,,,
249,Ma,CoronaVac (Sinovac),2,final,14+,symptomatic disease,symptomatic,China,close contacts,close contacts,73,22.3,96,,delta,~8 weeks,,,
249,Ma,CoronaVac (Sinovac),2,final,14+,pneumonia,severe,China,close contacts,close contacts,84.6,18.8,97.1,,delta,~8 weeks,,,
249,Ma,Ad5-nCOV (CanSino),1,final,14+,symptomatic disease,symptomatic,China,close contacts,close contacts,61.5,9.5,83.6,,delta,~8 weeks,,,
249,Ma,Ad5-nCOV (CanSino),1,final,14+,pneumonia,severe,China,close contacts,close contacts,67.9,1.7,89.9,,delta,~8 weeks,,,
249,Ma,Ad5-nCOV (CanSino),1,final,14+,severe disease,severe,China,close contacts,close contacts,100,,,,delta,~8 weeks,,,
250,Rennert,Pfizer,2,final,14+,infection,infection,USA,students 18-64 years,students 18-64 years,2.1,-21.2,21,,omicron,~23 weeks,,,
250,Rennert,Moderna,2,final,14+,infection,infection,USA,students 18-64 years,students 18-64 years,17.3,-10.8,38.3,,omicron,~23 weeks,,,
250,Rennert,Pfizer,2,final,14+,infection,infection,USA,employees 18-65 years,employees 18-65 years,30.1,-24.5,60.8,,omicron,~23 weeks,,,
250,Rennert,Moderna,2,final,14+,infection,infection,USA,employees 18-65 years,employees 18-65 years,14.4,-64.2,55.4,,omicron,~23 weeks,,,
251,Simwanza,Janssen,1,final,14+,infection,infection,Zambia,≥ 18 years in a correctional facility,18+ years in a correctional facility,63.6,33.6,80.5,,omicron,~13 weeks,,,
251,Simwanza,Janssen,1,final,14+,symptomatic disease,symptomatic,Zambia,≥ 18 years in a correctional facility,18+ years in a correctional facility,73,41.6,87.7,,omicron,~13 weeks,,,
251,Simwanza,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Zambia,≥ 18 years in a correctional facility,18+ years in a correctional facility,89.4,59.5,97.8,,omicron,~13 weeks,,,
251,Simwanza,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Zambia,≥ 18 years in a correctional facility,18+ years in a correctional facility,85.1,19.5,98,,omicron,~13 weeks,,,
252,Zahradka,Pfizer,2,final,14+,infection,infection,Czech Republic,kidney transplant recipients,transplant recipients,45.6,12.4,67.6,,alpha,~12.5 weeks,,,
253,Martellucci,Pfizer,2,final,14+,infection,infection,Italy,≥ 18 years,general pop,24,23,25,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Pfizer,2,final,14+,hospitalization,severe,Italy,≥ 18 years,general pop,86,84,88,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Pfizer,2,final,14+,death,death,Italy,≥ 18 years,general pop,92,90,94,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Moderna,2,final,14+,infection,infection,Italy,≥ 18 years,general pop,32,31,34,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Moderna,2,final,14+,hospitalization,severe,Italy,≥ 18 years,general pop,90,86,93,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Moderna,2,final,14+,death,death,Italy,≥ 18 years,general pop,96,92,98,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Italy,≥ 18 years,general pop,4,1,6,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,Italy,≥ 18 years,general pop,93,92,95,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,AZD1222 (AstraZeneca),2,final,14+,death,death,Italy,≥ 18 years,general pop,98,96,99,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Janssen,1,final,14+,infection,infection,Italy,≥ 18 years,general pop,12,7,17,,"alpha, delta, & omicron",~53 weeks,,,
253,Martellucci,Janssen,1,final,14+,hospitalization,severe,Italy,≥ 18 years,general pop,87,73,94,,"alpha, delta, & omicron",~53 weeks,,,
254,Braeye,Pfizer,2,final,7-57,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,72,70,74,,alpha,~28.5 weeks,,,
254,Braeye,Moderna,2,final,14-64,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,82,79,84,,alpha,~28.5 weeks,,,
254,Braeye,Janssen,1,final,21-71,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,38,34,44,,alpha,~28.5 weeks,,,
254,Braeye,AZD1222 (AstraZeneca),2,final,14-64,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,56,51,59,,alpha,~28.5 weeks,,,
254,Braeye,Pfizer,2,final,7-57,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,64,63,66,,delta,~28.5 weeks,,,
254,Braeye,Pfizer,2,final,157-207,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,44,43,44,,delta,~28.5 weeks,,,
254,Braeye,Moderna,2,final,14-64,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,75,71,77,,delta,~28.5 weeks,,,
254,Braeye,Moderna,2,final,164-214,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,56,55,58,,delta,~28.5 weeks,,,
254,Braeye,Janssen,1,final,21-71,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,33,28,38,,delta,~28.5 weeks,,,
254,Braeye,Janssen,1,final,171-221,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,22,19,25,,delta,~28.5 weeks,,,
254,Braeye,AZD1222 (AstraZeneca),2,final,14-64,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,49,45,52,,delta,~28.5 weeks,,,
254,Braeye,AZD1222 (AstraZeneca),2,final,164-214,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,35,33,37,,delta,~28.5 weeks,,,
254,Braeye,Pfizer,2,final,7-57,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,87,84,88,,delta,~28.5 weeks,,,
254,Braeye,Pfizer,2,final,157-207,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,82,81,83,,delta,~28.5 weeks,,,
254,Braeye,Moderna,2,final,14-64,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,87,83,92,,delta,~28.5 weeks,,,
254,Braeye,Moderna,2,final,164-214,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,85,80,89,,delta,~28.5 weeks,,,
254,Braeye,Janssen,1,final,21-71,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,88,85,91,,delta,~28.5 weeks,,,
254,Braeye,Janssen,1,final,171-221,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,87,84,89,,delta,~28.5 weeks,,,
254,Braeye,AZD1222 (AstraZeneca),2,final,14-64,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,88,84,94,,delta,~28.5 weeks,,,
254,Braeye,AZD1222 (AstraZeneca),2,final,164-214,infection,infection,Belgium,contacts of index cases among women aged 45-64,contacts of index cases among women aged 45-64,83,81,85,,delta,~28.5 weeks,,,
255,Lan,Pfizer,2,final,14+,infection,infection,USA,HCW,HCW,82.3,75.1,87.4,,"non-VOC, alpha, & delta",~36 weeks,,,
255,Lan,Pfizer,2,final,14+,infection,infection,USA,HCW,HCW,76.5,40.9,90.6,,"non-VOC, alpha, & delta",~36 weeks,,,
256,Tenforde,Pfizer,2,final,14-179,hospitalization,severe,USA,hospitalized adults,hospitalized adults,88,86,90,,alpha & delta,~23.5 weeks,,,
256,Tenforde,Pfizer,2,final,180+,hospitalization,severe,USA,hospitalized adults,hospitalized adults,79,74,83,,alpha & delta,~47 weeks,,,
256,Tenforde,Moderna,2,final,14-179,hospitalization,severe,USA,hospitalized adults,hospitalized adults,93,91,94,,alpha & delta,~23.5 weeks,,,
256,Tenforde,Moderna,2,final,180+,hospitalization,severe,USA,hospitalized adults,hospitalized adults,87,83,90,,alpha & delta,~47 weeks,,,
256,Tenforde,Pfizer,2,final,14-179,hospitalization,severe,USA,immunocompetent adults,general pop,90,88,91,,alpha & delta,~23.5 weeks,,,
256,Tenforde,Pfizer,2,final,180+,hospitalization,severe,USA,immunocompetent adults,general pop,82,79,85,,alpha & delta,~47 weeks,,,
256,Tenforde,Pfizer,2,final,14+,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,63,55,69,,alpha & delta,~47 weeks,,,
256,Tenforde,Pfizer,2,final,14-179,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,65,57,72,,alpha & delta,~23.5 weeks,,,
256,Tenforde,Pfizer,2,final,180+,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,53,38,65,,alpha & delta,~47 weeks,,,
256,Tenforde,Pfizer,2,final,14-179,hospitalization,severe,USA,hospitalized adults,hospitalized adults,90,88,91,,delta,~23.5 weeks,,,
256,Tenforde,Pfizer,2,final,180+,hospitalization,severe,USA,hospitalized adults,hospitalized adults,83,80,86,,delta,~47 weeks,,,
257,Fano,Pfizer,2,final,40-44,infection,infection,Italy,≥ 12 years,general pop,70.9,69.3,72.4,,alpha & delta,~48 weeks,,,
257,Fano,Pfizer,2,final,200+,infection,infection,Italy,≥ 12 years,general pop,22.7,18.5,26.8,,alpha & delta,~48 weeks,,,
257,Fano,AZD1222 (AstraZeneca),2,final,40-44,infection,infection,Italy,≥ 12 years,general pop,76.3,71.9,80,,alpha & delta,~48 weeks,,,
257,Fano,AZD1222 (AstraZeneca),2,final,125+,infection,infection,Italy,≥ 12 years,general pop,3.8,0,9.2,,alpha & delta,~48 weeks,,,
257,Fano,Janssen,1,final,40-44,infection,infection,Italy,≥ 12 years,general pop,39.4,28.3,48.8,,alpha & delta,~48 weeks,,,
257,Fano,Janssen,1,final,150+,infection,infection,Italy,≥ 12 years,general pop,2.5,0,9.1,,alpha & delta,~48 weeks,,,
257,Fano,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,40-44,infection,infection,Italy,≥ 12 years,general pop,81.6,75.3,86.3,,alpha & delta,~48 weeks,,,
257,Fano,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,125+,infection,infection,Italy,≥ 12 years,general pop,3.1,0,12,,alpha & delta,~48 weeks,,,
258,Paranthaman,Pfizer,2,final,7-34,infection,infection,UK,LTCF residents,LTCF residents,62,46,73,,alpha & delta,~3 weeks,,,
258,Paranthaman,Pfizer,2,final,147+,infection,infection,UK,LTCF residents,LTCF residents,47,32,58,,alpha & delta,~37 weeks,,,
258,Paranthaman,Pfizer,2,final,7-34,death,death,UK,LTCF residents,LTCF residents,86,67,94,,alpha & delta,~3 weeks,,,
258,Paranthaman,Pfizer,2,final,147+,death,death,UK,LTCF residents,LTCF residents,69,51,80,,alpha & delta,~37 weeks,,,
258,Paranthaman,AZD1222 (AstraZeneca),2,final,7-34,infection,infection,UK,LTCF residents,LTCF residents,61,40,74,,alpha & delta,~3 weeks,,,
258,Paranthaman,AZD1222 (AstraZeneca),2,final,147+,infection,infection,UK,LTCF residents,LTCF residents,29,10,43,,alpha & delta,~24.5 weeks,,,
258,Paranthaman,AZD1222 (AstraZeneca),2,final,7-34,death,death,UK,LTCF residents,LTCF residents,83,58,94,,alpha & delta,~3 weeks,,,
258,Paranthaman,AZD1222 (AstraZeneca),2,final,147+,death,death,UK,LTCF residents,LTCF residents,56,33,70,,alpha & delta,~24.5 weeks,,,
258,Paranthaman,Pfizer,2,final,7-34,infection,infection,UK,LTCF residents,LTCF residents,79,15,95,,alpha & delta,~3 weeks,,,
258,Paranthaman,Pfizer,2,final,147+,infection,infection,UK,LTCF residents,LTCF residents,80,43,93,,alpha & delta,~37 weeks,,,
258,Paranthaman,AZD1222 (AstraZeneca),2,final,7-34,infection,infection,UK,LTCF residents,LTCF residents,37,-50,73,,alpha & delta,~3 weeks,,,
258,Paranthaman,AZD1222 (AstraZeneca),2,final,147+,infection,infection,UK,LTCF residents,LTCF residents,65,14,86,,alpha & delta,~24.5 weeks,,,
259,Tsundue,Covishield,2,final,14+,infection,infection,India,residents of congregate living facilities,general pop,98,85,99.8,,delta,13 weeks,,,
259,Tsundue,Covishield,2,final,14+,"shortness of breath/use of supplemental oxygen, hospitalization or death",severe,India,residents of congregate living facilities,general pop,99,90,99.8,,delta,13 weeks,,,
260,Amir,Pfizer,2,final,14-35,infection,infection,Israel,5-10 years,5-10 years,58.3,54.6,61.5,,omicron,~2 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison residents ≥ 18 years,prison residents,18.6,7.7,28.1,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison staff ≥ 18 years,prison staff,40.1,34,45.6,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison residents ≥ 18 years,prison residents,51.2,41.5,59.2,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison staff ≥ 18 years,prison staff,55.8,49.6,61.2,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison residents ≥ 18 years,prison residents,68.7,38.5,84.1,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison staff ≥ 18 years,prison staff,83.2,77.7,87.4,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,14.9,12.3,19.7,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,47.8,46.6,52.8,,omicron,~65 weeks,,,
261,Chin,Pfizer,2,final,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,73.1,69.8,80.1,,omicron,~65 weeks,,,
262,Carlsen,Pfizer,2,final,14+,infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester),infection during an infant's first 4 months of life,Norway,newborns,newborns,30,17,41,,omicron,~45 weeks,,,
262,Carlsen,Pfizer,2,final,14+,infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester),infection during an infant's first 4 months of life,Norway,newborns,newborns,71,56,81,,delta,~45 weeks,,,
263,Grewal,Pfizer,2,final,0+,infection,infection,Canada,LTCF residents,LTCF residents,6,-5,15,omicron,omicron,~66 weeks,,,
263,Grewal,Pfizer,2,final,0+,symptomatic disease,symptomatic,Canada,LTCF residents,LTCF residents,23,1,40,omicron,omicron,~66 weeks,,,
263,Grewal,Pfizer,2,final,0+,hospitalization or death,severe,Canada,LTCF residents,LTCF residents,52,33,65,omicron,omicron,~66 weeks,,,
264,Spicer,Pfizer,2,final,14+,infection,infection,USA,12-17 years,12-17 years,81,79.7,82.3,,delta,~36.5 weeks,,,
264,Spicer,Pfizer,2,final,14+,infection,infection,USA,12-17 years,12-17 years,78.3,66.7,86.5,,delta,~36.5 weeks,,,
265,Richterman,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,HCW,HCW,41,-17,87,,omicron,~63 weeks,,,
265,Richterman,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,HCW,HCW,5,-69,47,,omicron,~63 weeks,,,
265,Richterman,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,HCW,HCW,75,52,87,,delta,~63 weeks,,,
265,Richterman,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,HCW,HCW,73,56,84,,delta,~63 weeks,,,
266,Lin,Moderna,2,final,12 days,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,92.6,80.5,97.2,,original & alpha,~0 weeks,,,
266,Lin,Moderna,2,final,172 days,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,89.6,41.7,98.2,,original & alpha,~22.5 weeks,,,
267,Lewis,Janssen,1,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,70,63,75,,alpha & delta,~39.5 weeks,,,
267,Lewis,Janssen,1,final,14-90,hospitalization,severe,USA,hospitalized adults,general pop,73,60,82,,alpha & delta,~39.5 weeks,,,
267,Lewis,Janssen,1,final,180+,hospitalization,severe,USA,hospitalized adults,general pop,70,54,81,,alpha & delta,~39.5 weeks,,,
267,Lewis,Janssen,1,final,14+,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,55,31,72,,alpha & delta,~39.5 weeks,,,
267,Lewis,Janssen,1,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,68,43,83,,alpha,~39.5 weeks,,,
267,Lewis,Janssen,1,final,14+,hospitalization,severe,USA,hospitalized adults,general pop,72,64,78,,delta,~39.5 weeks,,,
268,European Centre for Disease Prevention and Control,Pfizer,2,final,14+,hospitalization,severe,10 EU countries,≥ 65 years,≥ 65 years,91,80,96,,non-VOC & alpha (pre-delta),~22 weeks,,,
269,European Centre for Disease Prevention and Control,Pfizer,2,final,14+,hospitalization,severe,11 EU countries,≥ 30 years,≥ 30 years,94,88,97,,non-VOC & alpha (pre-delta),~45 weeks,,,
269,European Centre for Disease Prevention and Control,Pfizer,2,final,14+,hospitalization,severe,11 EU countries,≥ 30 years,≥ 30 years,82,76,87,,delta,~45 weeks,,,
269,European Centre for Disease Prevention and Control,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,11 EU countries,≥ 30 years,≥ 30 years,79,69,86,,delta,~45 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,hospitalization,severe,UAE,≥ 18 years,general pop,97.3,95.7,98.3,,non-VOC,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,critical care admission,severe,UAE,≥ 18 years,general pop,98.8,95.3,99.7,,non-VOC,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,UAE,≥ 18 years,general pop,100,100,100,,non-VOC,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,hospitalization,severe,UAE,≥ 18 years,general pop,73.3,70.6,75.7,,alpha,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,critical care admission,severe,UAE,≥ 18 years,general pop,79.1,73.1,83.7,,alpha,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,UAE,≥ 18 years,general pop,81.9,66.9,90.1,,alpha,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,hospitalization,severe,UAE,≥ 18 years,general pop,34.6,14.2,50.2,,delta,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,critical care admission,severe,UAE,≥ 18 years,general pop,49.6,0,76.4,,delta,~39 weeks,,,
270,Al Kaabi,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,UAE,≥ 18 years,general pop,62.5,31.4,79.5,,delta,~39 weeks,,,
271,Gray,Pfizer,2,final,14-27,hospitalization,severe,South Africa,HCW,HCW,88,62,96,,omicron,~30 weeks,,,
271,Gray,Pfizer,2,final,148-207,hospitalization,severe,South Africa,HCW,HCW,67,63,71,,omicron,~30 weeks,,,
271,Gray,Pfizer,2,final,14-27,ICU admission,severe,South Africa,HCW,HCW,69,56,79,,omicron,~30 weeks,,,
271,Gray,Pfizer,2,final,148-207,ICU admission,severe,South Africa,HCW,HCW,71,65,76,,omicron,~30 weeks,,,
272,Adams,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,36,21,48,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5",~72 weeks,,,
272,Adams,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,41,25,54,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5",~72 weeks,,,
272,Adams,Janssen,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,32,9,62,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5",~72 weeks,,,
273,Magro,Pfizer,2,final,14+,infection,infection,USA,SNF personnel 18+ years,SNF employees,1,55.9,81.8,,non-VOC & alpha,~10 weeks,,,
273,Magro,Pfizer,2,final,14+,infection,infection,USA,SNF personnel 18+ years,SNF employees,32,1,54,,non-VOC & alpha,~10 weeks,,,
274,Moline,Pfizer,2,final,14+,infection,infection,USA,SNF residents,SNF residents,65,25,84,,beta,~12 weeks,,,
275,Carazo,Pfizer,2,final,14+,infection,infection,Canada,HCW,HCW,35,27,42,omicron BA.2,omicron BA.2,~70 weeks,,,
275,Carazo,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada,HCW,HCW,61,52,69,omicron BA.2,omicron BA.2,~70 weeks,,,
276,Cohen-Stavi,Pfizer,2,final,7-21,infection,infection,Israel,5-11 years,5-11 years,51,39,61,,omicron,1 week,,,
276,Cohen-Stavi,Pfizer,2,final,7-21,symptomatic disease,symptomatic,Israel,5-11 years,5-11 years,48,29,63,,omicron,1 week,,,
277,Ionescu,Pfizer,2,final,14+,infection,infection,Canada (Quebec),12-17 years,12-17 years,41.9,37.7,45.8,,omicron,~26 weeks,,,
277,Ionescu,Pfizer,2,final,14-27,infection,infection,Canada (Quebec),12-17 years,12-17 years,75.6,65.8,82.6,,omicron,2 weeks,,,
277,Ionescu,Pfizer,2,final,168-195,infection,infection,Canada (Quebec),12-17 years,12-17 years,33.9,27.4,39.9,,omicron,~26 weeks,,,
277,Ionescu,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada (Quebec),12-17 years,12-17 years,55.2,49.5,60.3,,omicron,~26 weeks,,,
277,Ionescu,Pfizer,2,final,14+,infection,infection,Canada (Quebec),12-17 years,12-17 years,82.8,81,94.4,,delta & omicron,~22 weeks,,,
277,Ionescu,Pfizer,2,final,14-27,infection,infection,Canada (Quebec),12-17 years,12-17 years,83.1,68.9,90.8,,delta & omicron,2 weeks,,,
277,Ionescu,Pfizer,2,final,140-167,infection,infection,Canada (Quebec),12-17 years,12-17 years,75.4,72.1,78.4,,delta & omicron,~22 weeks,,,
277,Ionescu,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada (Quebec),12-17 years,12-17 years,87.9,86.1,89.5,,delta & omicron,~22 weeks,,,
277,Ionescu,Pfizer,2,final,14+,infection,infection,Canada (Quebec),12-17 years,12-17 years,95.5,95,96,,delta,~18 weeks,,,
277,Ionescu,Pfizer,2,final,14-27,infection,infection,Canada (Quebec),12-17 years,12-17 years,97.7,96.2,98.6,,delta,2 weeks,,,
277,Ionescu,Pfizer,2,final,112-139,infection,infection,Canada (Quebec),12-17 years,12-17 years,92.4,90.4,94,,delta,~18 weeks,,,
277,Ionescu,Pfizer,2,final,14+,symptomatic disease,symptomatic,Canada (Quebec),12-17 years,12-17 years,97.3,96.8,97.7,,delta,~18 weeks,,,
277,Ionescu,Pfizer,2,final,14+,infection,infection,Canada (British Colombia),12-17 years,12-17 years,33.9,25.7,41.1,,omicron,~26 weeks,,,
277,Ionescu,Pfizer,2,final,14-27,infection,infection,Canada (British Colombia),12-17 years,12-17 years,63.4,21.4,83,,omicron,2 weeks,,,
277,Ionescu,Pfizer,2,final,168-195,infection,infection,Canada (British Colombia),12-17 years,12-17 years,22.2,8.4,33.9,,omicron,~26 weeks,,,
277,Ionescu,Pfizer,2,final,14+,infection,infection,Canada (British Colombia),12-17 years,12-17 years,88,85.1,90.3,,delta & omicron,~22 weeks,,,
277,Ionescu,Pfizer,2,final,28-55,infection,infection,Canada (British Colombia),12-17 years,12-17 years,94.8,83.7,98.4,,delta & omicron,2 weeks,,,
277,Ionescu,Pfizer,2,final,140-167,infection,infection,Canada (British Colombia),12-17 years,12-17 years,84.2,77.8,88.8,,delta & omicron,~22 weeks,,,
277,Ionescu,Pfizer,2,final,14+,infection,infection,Canada (British Colombia),12-17 years,12-17 years,95.7,95.1,96.2,,delta,~18 weeks,,,
277,Ionescu,Pfizer,2,final,14-27,infection,infection,Canada (British Colombia),12-17 years,12-17 years,96.8,94.4,98.2,,delta,2 weeks,,,
277,Ionescu,Pfizer,2,final,112-139,infection,infection,Canada (British Colombia),12-17 years,12-17 years,90.9,87.7,93.2,,delta,~18 weeks,,,
278,Tartof,Pfizer,2,final,<6 months,hospitalization,severe,USA,≥ 18 years,general pop,54,38,65,omicron BA.1,omicron BA.1,~70 weeks,,,
278,Tartof,Pfizer,2,final,≥6 months,hospitalization,severe,USA,≥ 18 years,general pop,32,16,45,omicron BA.1,omicron BA.1,~70 weeks,,,
278,Tartof,Pfizer,2,final,<6 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,42,31,52,omicron BA.1,omicron BA.1,~70 weeks,,,
278,Tartof,Pfizer,2,final,≥6 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,19,6,31,omicron BA.1,omicron BA.1,~70 weeks,,,
278,Tartof,Pfizer,2,final,<6 months,hospitalization,severe,USA,≥ 18 years,general pop,56,-2,81,omicron BA.2,omicron BA.2,~70 weeks,,,
278,Tartof,Pfizer,2,final,≥6 months,hospitalization,severe,USA,≥ 18 years,general pop,56,28,73,omicron BA.2,omicron BA.2,~70 weeks,,,
278,Tartof,Pfizer,2,final,<6 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,27,-11,52,omicron BA.2,omicron BA.2,~70 weeks,,,
278,Tartof,Pfizer,2,final,≥6 months,ED admissions,symptomatic,USA,≥ 18 years,general pop,12,-10,31,omicron BA.2,omicron BA.2,~70 weeks,,,
279,Paternina-Caicedo,Pfizer,2,final,14+,symptomatic disease,symptomatic,Colombia,≥ 40 years,≥ 40 years,13,5.3,20,,mu,~25 weeks,,,
279,Paternina-Caicedo,Pfizer,2,final,14+,hospitalization,severe,Colombia,≥ 40 years,≥ 40 years,45.5,29.4,58,,mu,~25 weeks,,,
279,Paternina-Caicedo,Pfizer,2,final,14+,critical care admission,severe,Colombia,≥ 40 years,≥ 40 years,82.2,60.1,92.1,,mu,~25 weeks,,,
279,Paternina-Caicedo,Pfizer,2,final,14+,death,death,Colombia,≥ 40 years,≥ 40 years,94.1,76.4,98.5,,mu,~25 weeks,,,
279,Paternina-Caicedo,CoronaVac (Sinovac),2,final,14+,symptomatic disease,symptomatic,Colombia,≥ 40 years,≥ 40 years,-45.1,-53.6,-37.1,,mu,~25 weeks,,,
279,Paternina-Caicedo,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,Colombia,≥ 40 years,≥ 40 years,-3,-18,10.2,,mu,~25 weeks,,,
279,Paternina-Caicedo,CoronaVac (Sinovac),2,final,14+,critical care admission,severe,Colombia,≥ 40 years,≥ 40 years,13.6,-13.2,34,,mu,~25 weeks,,,
279,Paternina-Caicedo,CoronaVac (Sinovac),2,final,14+,death,death,Colombia,≥ 40 years,≥ 40 years,20.6,-0.5,37.3,,mu,~25 weeks,,,
280,Tonnara,Sputnik V (Gamaleya),2,final,7-59,infection,infection,Republic of San Marino,≥ 18 years,general pop,91.8,86.3,95.1,,alpha & delta,~27 weeks,,,
280,Tonnara,Sputnik V (Gamaleya),2,final,120+,infection,infection,Republic of San Marino,≥ 18 years,general pop,57.8,42.2,69.2,,alpha & delta,~27 weeks,,,
280,Tonnara,Sputnik V (Gamaleya),2,final,7-59,hospitalization,severe,Republic of San Marino,≥ 18 years,general pop,95.2,79.1,98.9,,alpha & delta,~27 weeks,,,
280,Tonnara,Sputnik V (Gamaleya),2,final,120+,hospitalization,severe,Republic of San Marino,≥ 18 years,general pop,89.7,52.7,97.7,,alpha & delta,~27 weeks,,,
280,Tonnara,Sputnik V (Gamaleya),2,final,7+,infection,infection,Republic of San Marino,≥ 18 years,general pop,97.3,94.2,98.7,,alpha,~15 weeks,,,
280,Tonnara,Sputnik V (Gamaleya),2,final,7+,hospitalization,severe,Republic of San Marino,≥ 18 years,general pop,96.9,86.5,99.3,,alpha,~15 weeks,,,
281,Kerr,Pfizer,2,final,14+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,78.7,69.9,85,,delta & delta plus (AY.4.2),~38 weeks,,,
281,Kerr,Moderna,2,final,14+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,93.7,86.4,97.1,,delta & delta plus (AY.4.2),~38 weeks,,,
281,Kerr,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Scotland,≥ 18 years,general pop,54.5,35.7,67.8,,delta & delta plus (AY.4.2),~38 weeks,,,
282,Stephenson,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,85,81,89,,non-VOC & alpha,~18 weeks,,,
283,Guedalia,Pfizer,2,final,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant persons,-12,-36,8,,omicron BA.1,~60 weeks,,,
283,Guedalia,Pfizer,2,final,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant persons,51,-47,84,,omicron BA.1,~60 weeks,,,
283,Guedalia,Pfizer,2,final,0+,severe disease,severe,Israel,pregnant women aged 16+,pregnant persons,83,-47,98,,omicron BA.1,~60 weeks,,,
283,Guedalia,Pfizer,2,final,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant persons,61,51,69,,delta,~44 weeks,,,
283,Guedalia,Pfizer,2,final,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant persons,97,92,99,,delta,~44 weeks,,,
283,Guedalia,Pfizer,2,final,0+,severe disease,severe,Israel,pregnant women aged 16+,pregnant persons,96,86,99,,delta,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,14-140,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,47,44,50,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,39,37,41,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,14-140,hospitalization,severe,USA,≥ 18 years,general pop,68,63,73,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,150+,hospitalization,severe,USA,≥ 18 years,general pop,61,58,63,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,14-140,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,59,40,71,,omicron BA.2,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,18,10,26,,omicron BA.2,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,14-140,hospitalization,severe,USA,≥ 18 years,general pop,57,19,77,,omicron BA.2,~44 weeks,,,
284,Link-Gelles,Pfizer,2,final,150+,hospitalization,severe,USA,≥ 18 years,general pop,24,12,35,,omicron BA.2,~44 weeks,,,
285,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-180,infection,infection,Brazil,≥ 18 years,general pop,-0.7,-1.6,0.2,,omicron,~59 weeks,,,
285,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,infection,infection,Brazil,≥ 18 years,general pop,3.2,2.1,4.2,,omicron,~59 weeks,,,
285,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-180,hospitalization or death,severe,Brazil,≥ 18 years,general pop,64.5,62.6,66.3,,omicron,~59 weeks,,,
285,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,hospitalization or death,severe,Brazil,≥ 18 years,general pop,61.8,60.3,63.2,,omicron,~59 weeks,,,
285,Cerqueira-Silva,CoronaVac (Sinovac),2,final,14-180,death,death,Brazil,≥ 18 years,general pop,67.8,64,71.3,,omicron,~59 weeks,,,
285,Cerqueira-Silva,CoronaVac (Sinovac),2,final,180+,death,death,Brazil,≥ 18 years,general pop,63.1,60.9,65.1,,omicron,~59 weeks,,,
286,Hatfield,Pfizer,2,final,7-157,infection,infection,USA,nursing home residents,nursing home residents,67,40,82,,non-VOC & alpha,~44 weeks,,,
286,Hatfield,Moderna,2,final,7-157,infection,infection,USA,nursing home residents,nursing home residents,75,32,91,,non-VOC & alpha,~44 weeks,,,
286,Hatfield,Pfizer,2,final,157+,infection,infection,USA,nursing home residents,nursing home residents,33,-2,56,,delta,~44 weeks,,,
286,Hatfield,Moderna,2,final,157+,infection,infection,USA,nursing home residents,nursing home residents,77,48,91,,delta,~44 weeks,,,
287,Tan,Pfizer,2,final,7-14,infection (PCR or antigen),infection,Singapore,5-11 years,5-11 years,48.8,46.9,50.8,,omicron,~9 weeks,,,
287,Tan,Pfizer,2,final,60+,infection (PCR or antigen),infection,Singapore,5-11 years,5-11 years,25.6,19.3,31.5,,omicron,~9 weeks,,,
287,Tan,Pfizer,2,final,7-14,infection (PCR only),infection,Singapore,5-11 years,5-11 years,70.6,65.9,74.7,,omicron,~9 weeks,,,
287,Tan,Pfizer,2,final,60+,infection (PCR only),infection,Singapore,5-11 years,5-11 years,42.7,12,62.7,,omicron,~9 weeks,,,
287,Tan,Pfizer,2,final,7-14,hospitalization,severe,Singapore,5-11 years,5-11 years,87.8,72.2,94.7,,omicron,~9 weeks,,,
287,Tan,Pfizer,2,final,30-59,hospitalization,severe,Singapore,5-11 years,5-11 years,80.4,67,88.4,,omicron,~9 weeks,,,
288,Mazagatos,Pfizer,2,final,14+,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,92,78,97,,alpha & delta,~19 weeks,,,
288,Mazagatos,Pfizer,2,final,<90,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,95,82,98,,alpha & delta,~19 weeks,,,
288,Mazagatos,Pfizer,2,final,152+,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,91,50,98,,alpha & delta,~19 weeks,,,
288,Mazagatos,Pfizer,2,final,14+,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,97,86,99,,alpha & delta,~19 weeks,,,
288,Mazagatos,Pfizer,2,final,<90,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,97,87,99,,alpha & delta,~19 weeks,,,
288,Mazagatos,Pfizer,2,final,152+,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,96,47,100,,alpha & delta,~19 weeks,,,
288,Mazagatos,Pfizer,2,final,<90,hospitalization with SARI,severe,Spain,70-79 years,70-79 years,98,90,100,,alpha & delta,~23 weeks,,,
288,Mazagatos,Pfizer,2,final,152+,hospitalization with SARI,severe,Spain,70-79 years,70-79 years,91,24,99,,alpha & delta,~23 weeks,,,
288,Mazagatos,Pfizer,2,final,<90,hospitalization with SARI,severe,Spain,≥ 80 years,≥ 80 years,86,70,94,,alpha & delta,~33 weeks,,,
288,Mazagatos,Pfizer,2,final,152+,hospitalization with SARI,severe,Spain,≥ 80 years,≥ 80 years,48,-51,82,,alpha & delta,~33 weeks,,,
288,Mazagatos,Janssen,1,final,14+,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,71,-3,92,,alpha & delta,~19 weeks,,,
288,Mazagatos,Janssen,1,final,14+,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,82,-78,98,,alpha & delta,~19 weeks,,,
288,Mazagatos,AZD1222 (AstraZeneca),2,final,14+,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,89,25,98,,alpha & delta,~19 weeks,,,
289,Chemaitelly,Pfizer,2,final,14+,infection,infection,Qatar,12-17 years,12-17 years,51.3,34.9,63.6,,omicron,~68 weeks,,,
289,Chemaitelly,Pfizer,2,final,172+,infection,infection,Qatar,12-17 years,12-17 years,-1.7,-20,10,,omicron,~68 weeks,,,
289,Chemaitelly,Pfizer,2,final,14-30,infection,infection,Qatar,5-11 years,5-11 years,49.6,28.5,64.5,,omicron,~68 weeks,,,
289,Chemaitelly,Pfizer,2,final,120+,infection,infection,Qatar,5-11 years,5-11 years,-9.5,-30,35,,omicron,~68 weeks,,,
289,Chemaitelly,Pfizer,2,final,14-30,infection,infection,Qatar,12-17 years,12-17 years,95.3,92,97.2,,alpha & delta,~68 weeks,,,
289,Chemaitelly,Pfizer,2,final,152+,infection,infection,Qatar,12-17 years,12-17 years,70.6,18,92,,alpha & delta,~68 weeks,,,
290,Mayr,Pfizer,2,final,21,symptomatic disease,symptomatic,USA,veterans,veterans,76.1,71.1,80.2,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,symptomatic disease,symptomatic,USA,veterans,veterans,0.1,-10.9,10.1,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,symptomatic disease,symptomatic,USA,veterans < 65 years,veterans < 65 years,81.6,75.9,85.9,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,symptomatic disease,symptomatic,USA,veterans < 65 years,veterans < 65 years,22.5,7.2,35.2,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,symptomatic disease,symptomatic,USA,veterans ≥ 65 years,veterans ≥ 65 years,66.3,55.7,74.4,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,symptomatic disease,symptomatic,USA,veterans ≥ 65 years,veterans ≥ 65 years,-23.3,-40.5,-8.2,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,hospitalization,severe,USA,veterans,veterans,72.9,61.7,80.7,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,hospitalization,severe,USA,veterans,veterans,19.8,2.5,34.1,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,hospitalization,severe,USA,veterans < 65 years,veterans < 65 years,85.6,72.6,92.4,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,hospitalization,severe,USA,veterans < 65 years,veterans < 65 years,57,31.2,73.2,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,hospitalization,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,61,41.3,74.2,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,hospitalization,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,1.7,-22,20.8,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,ICU admission or death,severe,USA,veterans,veterans,74.7,54.2,86,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,ICU admission or death,severe,USA,veterans,veterans,39.5,17.6,55.6,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,ICU admission or death,severe,USA,veterans < 65 years,veterans < 65 years,87.6,61,96.1,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,ICU admission or death,severe,USA,veterans < 65 years,veterans < 65 years,66.4,7.7,87.8,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Pfizer,2,final,21,ICU admission or death,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,67.4,32.6,84.3,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Pfizer,2,final,7 months,ICU admission or death,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,29.3,2.3,48.9,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,symptomatic disease,symptomatic,USA,veterans,veterans,84.6,80.5,87.8,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,symptomatic disease,symptomatic,USA,veterans,veterans,46.6,40.8,51.9,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,symptomatic disease,symptomatic,USA,veterans < 65 years,veterans < 65 years,89.7,84.8,93,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,symptomatic disease,symptomatic,USA,veterans < 65 years,veterans < 65 years,57.3,48.4,64.7,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,symptomatic disease,symptomatic,USA,veterans ≥ 65 years,veterans ≥ 65 years,78.4,71.1,83.9,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,symptomatic disease,symptomatic,USA,veterans ≥ 65 years,veterans ≥ 65 years,36.2,27.7,43.6,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,hospitalization,severe,USA,veterans,veterans,76.6,63.9,84.8,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,hospitalization,severe,USA,veterans,veterans,71.3,64,77.1,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,hospitalization,severe,USA,veterans < 65 years,veterans < 65 years,92,76.1,97.3,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,hospitalization,severe,USA,veterans < 65 years,veterans < 65 years,83.1,66.8,91.4,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,hospitalization,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,66.1,45.3,79,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,hospitalization,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,64.7,55.2,72.3,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,ICU admission or death,severe,USA,veterans,veterans,80.5,64.1,89.4,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,ICU admission or death,severe,USA,veterans,veterans,77.2,68.4,83.5,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,ICU admission or death,severe,USA,veterans < 65 years,veterans < 65 years,89.2,49.5,97.7,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,ICU admission or death,severe,USA,veterans < 65 years,veterans < 65 years,84.4,59,94.1,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Moderna,2,final,21,ICU admission or death,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,75.4,51.7,87.5,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Moderna,2,final,7 months,ICU admission or death,severe,USA,veterans ≥ 65 years,veterans ≥ 65 years,73.8,62.9,81.5,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Janssen,1,final,21,symptomatic disease,symptomatic,USA,veterans,veterans,25.4,2.9,42.6,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Janssen,1,final,7 months,symptomatic disease,symptomatic,USA,veterans,veterans,25.5,-2.2,45.6,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Janssen,1,final,21,hospitalization,severe,USA,veterans,veterans,55.8,20.6,75.4,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Janssen,1,final,7 months,hospitalization,severe,USA,veterans,veterans,16.9,-90.9,63.8,,"non-VOC, alpha, & delta",~26 weeks,,,
290,Mayr,Janssen,1,final,21,ICU admission or death,severe,USA,veterans,veterans,61.1,11.9,82.8,,"non-VOC, alpha, & delta",2 weeks,,,
290,Mayr,Janssen,1,final,7 months,ICU admission or death,severe,USA,veterans,veterans,63.3,-15.5,88.3,,"non-VOC, alpha, & delta",~26 weeks,,,
291,Piche-Renaud,Pfizer,2,final,7-29,symptomatic disease,symptomatic,Canada,5-11 years,5-11 years,67,60,72,omicron,omicron,~16 weeks,,,
291,Piche-Renaud,Pfizer,2,final,90+,symptomatic disease,symptomatic,Canada,5-11 years,5-11 years,35,21,46,omicron,omicron,~16 weeks,,,
291,Piche-Renaud,Pfizer,2,final,7-29,hospitalization or death,severe,Canada,5-11 years,5-11 years,94,56,99,omicron,omicron,~16 weeks,,,
291,Piche-Renaud,Pfizer,2,final,60+,hospitalization or death,severe,Canada,5-11 years,5-11 years,74,44,88,omicron,omicron,~16 weeks,,,
292,Arashiro,Pfizer,2,final,14-89,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,55,34,69,,omicron,~54 weeks,,,
292,Arashiro,Pfizer,2,final,180+,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,52,37,63,,omicron,~54 weeks,,,
292,Arashiro,Pfizer,2,final,14-89,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,88,80,92,,delta,~54 weeks,,,
292,Arashiro,Pfizer,2,final,90-179,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,86,35,97,,delta,~54 weeks,,,
293,Tartof,Pfizer,2,final,<60,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,73,54,84,omicron,omicron,~44 weeks,,,
293,Tartof,Pfizer,2,final,180+,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,16,-7,34,omicron,omicron,~44 weeks,,,
293,Tartof,Pfizer,2,final,<60,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,72,52,84,omicron,omicron,~44 weeks,,,
293,Tartof,Pfizer,2,final,180+,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,18,-6,36,omicron,omicron,~44 weeks,,,
293,Tartof,Pfizer,2,final,<60,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,89,69,96,,delta,~44 weeks,,,
293,Tartof,Pfizer,2,final,180+,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,49,27,65,,delta,~44 weeks,,,
293,Tartof,Pfizer,2,final,<60,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,88,68,96,,delta,~44 weeks,,,
293,Tartof,Pfizer,2,final,180+,ED or UC encounters,symptomatic,USA,12-17 years,12-17 years,47,23,63,,delta,~44 weeks,,,
294,Pinto-Álvarez,Pfizer,2,final,15+,infection,infection,Colombia,≥ 16 years,general pop,73.4,68.6,77.5,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Pfizer,2,final,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,85.4,80.1,89.3,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Pfizer,2,final,15+,death,death,Colombia,≥ 16 years,general pop,93.4,89.8,95.7,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Moderna,2,final,15+,infection,infection,Colombia,≥ 16 years,general pop,28.1,0,48.9,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Moderna,2,final,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,85.2,64.6,93.8,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Moderna,2,final,15+,death,death,Colombia,≥ 16 years,general pop,96.9,76.5,99.6,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,AZD1222 (AstraZeneca),2,final,15+,infection,infection,Colombia,≥ 16 years,general pop,67.9,57.9,75.5,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,AZD1222 (AstraZeneca),2,final,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,82.5,70.9,89.5,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,AZD1222 (AstraZeneca),2,final,15+,death,death,Colombia,≥ 16 years,general pop,93.8,86.4,97.1,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,CoronaVac (Sinovac),2,final,15+,infection,infection,Colombia,≥ 16 years,general pop,74.2,68.3,79.1,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,CoronaVac (Sinovac),2,final,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,83.3,75.3,88.7,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,CoronaVac (Sinovac),2,final,15+,death,death,Colombia,≥ 16 years,general pop,92.6,87.5,95.6,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Janssen,1,final,15+,infection,infection,Colombia,≥ 16 years,general pop,73.7,65.2,80.1,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Janssen,1,final,15+,hospitalization,severe,Colombia,≥ 16 years,general pop,88.4,77.4,94,,"mu, delta, & omicron",~56 weeks,,,
294,Pinto-Álvarez,Janssen,1,final,15+,death,death,Colombia,≥ 16 years,general pop,97.1,87.9,99.3,,"mu, delta, & omicron",~56 weeks,,,
295,Zambrano,Pfizer,2,final,28+,hospitalization with MIS-C,hospitalization with MIS-C,USA,12-18 years,12-18 years,92,71,98,,omicron,~40 weeks,,,
295,Zambrano,Pfizer,2,final,28+,hospitalization with MIS-C,hospitalization with MIS-C,USA,12-18 years,12-18 years,94,83,98,,delta,~40 weeks,,,
295,Zambrano,Pfizer,2,final,28-120,hospitalization with MIS-C,hospitalization with MIS-C,USA,12-18 years,12-18 years,90,75,96,,delta & omicron,~40 weeks,,,
295,Zambrano,Pfizer,2,final,120+,hospitalization with MIS-C,hospitalization with MIS-C,USA,12-18 years,12-18 years,92,78,97,,delta & omicron,~40 weeks,,,
295,Zambrano,Pfizer,2,final,28+,hospitalization with MIS-C,hospitalization with MIS-C,USA,5-11 years,5-11 years,78,48,90,,delta & omicron,~16 weeks,,,
296,El Adam,Pfizer,2,final,14+,infection,infection,Canada (British Colombia),HCW,HCW,89,87,91,,"alpha, gamma, & delta",~34 weeks,,,
296,El Adam,Moderna,2,final,14+,infection,infection,Canada (British Colombia),HCW,HCW,93,90,95,,"alpha, gamma, & delta",~34 weeks,,,
296,El Adam,Heterologous mRNA,2,final,14+,infection,infection,Canada (British Colombia),HCW,HCW,92,86,95,,"alpha, gamma, & delta",~34 weeks,,,
296,El Adam,Any mRNA,2,final,14+,infection,infection,Canada (British Colombia),HCW,HCW,90,88,92,,"alpha, gamma, & delta",~34 weeks,,,
296,El Adam,Any mRNA,2,final,14-20,infection,infection,Canada (British Colombia),HCW,HCW,99,90,100,,"alpha, gamma, & delta",~34 weeks,,,
296,El Adam,Any mRNA,2,final,196+,infection,infection,Canada (British Colombia),HCW,HCW,82,75,87,,"alpha, gamma, & delta",~34 weeks,,,
297,Lewis,Pfizer,2,final,14+,infection,infection,USA,≥ 12 years,≥ 12 years,64,58,69,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Janssen,1,final,14+,infection,infection,USA,≥ 12 years,≥ 12 years,48,26,63,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Pfizer,2,final,14+,infection,infection,USA,LTCF residents,LTCF residents,49,26,65,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Janssen,1,final,14+,infection,infection,USA,LTCF residents,LTCF residents,57,-211,94,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Pfizer,2,final,14+,infection,infection,USA,LTCF employees,LTCF employees,52,26,68,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Janssen,1,final,14+,infection,infection,USA,LTCF employees,LTCF employees,-68,-415,45,,"non-VOC, alpha, & delta",~46 weeks,,,
298,Cheng,Pfizer,2,final,14+,infection,infection,"Hong Kong, SAR",patients with chronic kidney disease,patients with chronic kidney disease,38,34,41,,omicron,~51 weeks,,,
298,Cheng,Pfizer,2,final,14+,hospitalization,severe,"Hong Kong, SAR",patients with chronic kidney disease,patients with chronic kidney disease,64,57,69,,omicron,~51 weeks,,,
298,Cheng,Pfizer,2,final,14+,death,death,"Hong Kong, SAR",patients with chronic kidney disease,patients with chronic kidney disease,86,80,90,,omicron,~51 weeks,,,
298,Cheng,CoronaVac (Sinovac),2,final,14+,infection,infection,"Hong Kong, SAR",patients with chronic kidney disease,patients with chronic kidney disease,4,0,8,,omicron,~51 weeks,,,
298,Cheng,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,"Hong Kong, SAR",patients with chronic kidney disease,patients with chronic kidney disease,44,37,91,,omicron,~51 weeks,,,
298,Cheng,CoronaVac (Sinovac),2,final,14+,death,death,"Hong Kong, SAR",patients with chronic kidney disease,patients with chronic kidney disease,70,64,75,,omicron,~51 weeks,,,
299,Risk,Pfizer,2,final,14+,infection,infection,USA,immunocompromised adults,immunocompromised adults,13,-23,39,,omicron,~56 weeks,,,
299,Risk,Pfizer,2,final,14+,infection,infection,USA,immunocompetent adults,general pop,-6,-16,4,,omicron,~56 weeks,,,
299,Risk,Pfizer,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,67,51,78,,omicron,~56 weeks,,,
299,Risk,Moderna,2,final,14+,infection,infection,USA,immunocompromised adults,immunocompromised adults,57,29,74,,omicron,~56 weeks,,,
299,Risk,Moderna,2,final,14+,infection,infection,USA,immunocompetent adults,general pop,16,5,26,,omicron,~56 weeks,,,
299,Risk,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,79,63,88,,omicron,~56 weeks,,,
299,Risk,Pfizer,2,final,14+,hospitalization,severe,USA,immunocompromised adults,immunocompromised adults,85,62,94,,omicron,~56 weeks,,,
299,Risk,Pfizer,2,final,14+,hospitalization,severe,USA,immunocompetent adults,general pop,68,53,78,,omicron,~56 weeks,,,
299,Risk,Pfizer,2,final,14+,ICU admission,severe,USA,≥ 18 years,general pop,92,66,98,,omicron,~56 weeks,,,
300,Kim,Pfizer,2,final,14-29,infection,infection,South Korea,12-18 years,12-18 years,76.6,74.3,78.6,,delta & omicron,~6 weeks,,,
300,Kim,Pfizer,2,final,30-59,infection,infection,South Korea,12-18 years,12-18 years,49.6,45.9,53.2,,delta & omicron,~6 weeks,,,
300,Kim,Pfizer,2,final,14-29,infection,infection,South Korea,12-18 years,12-18 years,83.5,81.3,85.4,,delta & omicron,~11 weeks,,,
300,Kim,Pfizer,2,final,60-89,infection,infection,South Korea,12-18 years,12-18 years,41.8,35.3,47.6,,delta & omicron,~11 weeks,,,
300,Kim,Pfizer,2,final,14-29,infection,infection,South Korea,12-18 years,12-18 years,82.8,75.1,88.1,,delta & omicron,~22 weeks,,,
300,Kim,Pfizer,2,final,90+,infection,infection,South Korea,12-18 years,12-18 years,28.9,20.6,36.4,,delta & omicron,~22 weeks,,,
301,Yan,Pfizer,2,final,14+,severe disease,severe,"Hong Kong, SAR",18-50 years,18-50 years,73.7,54.2,84.9,,omicron BA.2,~52 weeks,,,
301,Yan,Pfizer,2,final,14+,severe disease,severe,"Hong Kong, SAR",51-64 years,51-64 years,84.5,72.2,91.4,,omicron BA.2,~52 weeks,,,
301,Yan,Pfizer,2,final,14+,severe disease,severe,"Hong Kong, SAR",≥ 65 years,≥ 65 years,81.9,74.4,87.2,,omicron BA.2,~52 weeks,,,
301,Yan,Pfizer,2,final,14+,death,death,"Hong Kong, SAR",18-50 years,18-50 years,84.2,67.3,92.4,,omicron BA.2,~52 weeks,,,
301,Yan,Pfizer,2,final,14+,death,death,"Hong Kong, SAR",51-64 years,51-64 years,86.9,80.3,91.3,,omicron BA.2,~52 weeks,,,
301,Yan,Pfizer,2,final,14+,death,death,"Hong Kong, SAR",≥ 65 years,≥ 65 years,90.6,88.5,92.4,,omicron BA.2,~52 weeks,,,
301,Yan,CoronaVac (Sinovac),2,final,14+,severe disease,severe,"Hong Kong, SAR",18-50 years,18-50 years,72.6,40.1,87.5,,omicron BA.2,~52 weeks,,,
301,Yan,CoronaVac (Sinovac),2,final,14+,severe disease,severe,"Hong Kong, SAR",51-64 years,51-64 years,67.8,48.7,79.7,,omicron BA.2,~52 weeks,,,
301,Yan,CoronaVac (Sinovac),2,final,14+,severe disease,severe,"Hong Kong, SAR",≥ 65 years,≥ 65 years,56.7,47.4,64.4,,omicron BA.2,~52 weeks,,,
301,Yan,CoronaVac (Sinovac),2,final,14+,death,death,"Hong Kong, SAR",18-50 years,18-50 years,83.7,57.9,93.7,,omicron BA.2,~52 weeks,,,
301,Yan,CoronaVac (Sinovac),2,final,14+,death,death,"Hong Kong, SAR",51-64 years,51-64 years,78.1,69.4,84.3,,omicron BA.2,~52 weeks,,,
301,Yan,CoronaVac (Sinovac),2,final,14+,death,death,"Hong Kong, SAR",≥ 65 years,≥ 65 years,72.5,69.9,74.9,,omicron BA.2,~52 weeks,,,
302,Powell,Pfizer,2,final,14-104,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,64.5,63.6,65.4,,omicron,~38 weeks,,,
302,Powell,Pfizer,2,final,280-286,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,25.7,-4.2,47,,omicron,~38 weeks,,,
302,Powell,Pfizer,2,final,14-104,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,91.8,91.2,92.3,,delta,~38 weeks,,,
302,Powell,Pfizer,2,final,175-279,symptomatic disease,symptomatic,UK,11-17 years,11-17 years,71.9,67.9,75.4,,delta,~38 weeks,,,
303,Wan,Pfizer,2,final,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,22.1,20,24.2,,omicron BA.2,~53 weeks,,,
303,Wan,Pfizer,2,final,14+,hospitalization,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,74.2,71.7,76.4,,omicron BA.2,~53 weeks,,,
303,Wan,Pfizer,2,final,14+,ICU admission,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,82.3,72.1,88.8,,omicron BA.2,~53 weeks,,,
303,Wan,CoronaVac (Sinovac),2,final,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,-0.3,-2.7,2.1,,omicron BA.2,~53 weeks,,,
303,Wan,CoronaVac (Sinovac),2,final,14+,hospitalization,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,64.2,61.8,66.4,,omicron BA.2,~53 weeks,,,
303,Wan,CoronaVac (Sinovac),2,final,14+,ICU admission,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,58.1,45,68.1,,omicron BA.2,~53 weeks,,,
304,Tsang,Pfizer,2,final,14-89,infection,infection,"Hong Kong, SAR",≥5 years,≥5 years,27.6,-6.3,50.7,,omicron BA.2,~55 weeks,,,
304,Tsang,Pfizer,2,final,90+,infection,infection,"Hong Kong, SAR",≥5 years,≥5 years,1.1,-22.4,20.1,,omicron BA.2,~55 weeks,,,
304,Tsang,Pfizer,2,final,14-89,symptomatic disease,symptomatic,"Hong Kong, SAR",≥5 years,≥5 years,31.6,-9.3,57.2,,omicron BA.2,~55 weeks,,,
304,Tsang,Pfizer,2,final,90+,symptomatic disease,symptomatic,"Hong Kong, SAR",≥5 years,≥5 years,4.7,-23.5,26.6,,omicron BA.2,~55 weeks,,,
304,Tsang,CoronaVac (Sinovac),2,final,14-89,infection,infection,"Hong Kong, SAR",≥5 years,≥5 years,22.7,-15.2,48.2,,omicron BA.2,~55 weeks,,,
304,Tsang,CoronaVac (Sinovac),2,final,90+,infection,infection,"Hong Kong, SAR",≥5 years,≥5 years,5.4,-25.6,28.8,,omicron BA.2,~55 weeks,,,
304,Tsang,CoronaVac (Sinovac),2,final,14-89,symptomatic disease,symptomatic,"Hong Kong, SAR",≥5 years,≥5 years,12.2,-40,44.9,,omicron BA.2,~55 weeks,,,
304,Tsang,CoronaVac (Sinovac),2,final,90+,symptomatic disease,symptomatic,"Hong Kong, SAR",≥5 years,≥5 years,6.4,-32.1,33.7,,omicron BA.2,~55 weeks,,,
305,Cocchio,Pfizer,2,final,14-34,infection,infection,Italy,5-11 years,5-11 years,53,51,55,,omicron,~16 weeks,,,
305,Cocchio,Pfizer,2,final,70+,infection,infection,Italy,5-11 years,5-11 years,23,20,26,,omicron,~16 weeks,,,
305,Cocchio,Pfizer,2,final,14-34,infection,infection,Italy,12-17 years,12-17 years,59,55,62,,omicron,~53 weeks,,,
305,Cocchio,Pfizer,2,final,70+,infection,infection,Italy,12-17 years,12-17 years,8,5,11,,omicron,~53 weeks,,,
305,Cocchio,Moderna,2,final,14-34,infection,infection,Italy,12-17 years,12-17 years,55,49,61,,omicron,~33 weeks,,,
305,Cocchio,Moderna,2,final,70+,infection,infection,Italy,12-17 years,12-17 years,20,15,24,,omicron,~33 weeks,,,
305,Cocchio,Pfizer,2,final,14-34,infection,infection,Italy,12-17 years,12-17 years,88,85,91,,delta,~28 weeks,,,
305,Cocchio,Pfizer,2,final,70+,infection,infection,Italy,12-17 years,12-17 years,82,74,88,,delta,~28 weeks,,,
305,Cocchio,Moderna,2,final,14-34,infection,infection,Italy,12-17 years,12-17 years,90,68,97,,delta,~7 weeks,,,
305,Cocchio,Moderna,2,final,35-69,infection,infection,Italy,12-17 years,12-17 years,96,86,99,,delta,~7 weeks,,,
306,Lim,Pfizer,2,final,14-27,infection,infection,Malaysia,≥18 years,general pop,58.9,40.7,71.9,,alpha & delta,~28 weeks,,,
306,Lim,Pfizer,2,final,98-111,infection,infection,Malaysia,≥18 years,general pop,31.3,10.8,47.2,,alpha & delta,~28 weeks,,,
306,Lim,Pfizer,2,final,14+,ICU admission,severe,Malaysia,≥18 years,general pop,92.5,72.3,98.8,,alpha & delta,~28 weeks,,,
306,Lim,Pfizer,2,final,14+,death,death,Malaysia,≥18 years,general pop,96.5,82.3,99.8,,alpha & delta,~28 weeks,,,
306,Lim,Pfizer,2,final,14+,infection,infection,Malaysia,≥18 years,general pop,87.9,86.3,89.4,,alpha & delta,~28 weeks,,,
306,Lim,Pfizer,2,final,14+,ICU admission,severe,Malaysia,≥18 years,general pop,97.5,81.2,99.6,,alpha & delta,~28 weeks,,,
306,Lim,Pfizer,2,final,14+,death,death,Malaysia,≥18 years,general pop,99.3,96.3,100,,alpha & delta,~28 weeks,,,
307,Lind,Pfizer,2,final,14-89,infection,infection,USA,≥16 years,general pop,84.4,75.5,90,,alpha,~29 weeks,,,
307,Lind,Pfizer,2,final,90-149,infection,infection,USA,≥16 years,general pop,96.5,75.1,99.5,,alpha,~29 weeks,,,
307,Lind,Pfizer,2,final,14-89,symptomatic disease,symptomatic,USA,≥16 years,general pop,86.6,75.5,92.7,,alpha,~29 weeks,,,
307,Lind,Pfizer,2,final,90-149,symptomatic disease,symptomatic,USA,≥16 years,general pop,93.8,55,99.1,,alpha,~29 weeks,,,
307,Lind,Pfizer,2,final,14-89,hospitalization,severe,USA,≥16 years,general pop,85.5,65.5,93.9,,alpha,~29 weeks,,,
307,Lind,Pfizer,2,final,90-149,hospitalization,severe,USA,≥16 years,general pop,82.2,-34.5,97.7,,alpha,~29 weeks,,,
307,Lind,Pfizer,2,final,14-89,infection,infection,USA,≥16 years,general pop,68.9,58,77.1,,delta,~29 weeks,,,
307,Lind,Pfizer,2,final,150+,infection,infection,USA,≥16 years,general pop,37.1,24,48.1,,delta,~29 weeks,,,
307,Lind,Pfizer,2,final,14-89,symptomatic disease,symptomatic,USA,≥16 years,general pop,74.8,62.9,82.9,,delta,~29 weeks,,,
307,Lind,Pfizer,2,final,150+,symptomatic disease,symptomatic,USA,≥16 years,general pop,48.4,32.8,60.4,,delta,~29 weeks,,,
307,Lind,Pfizer,2,final,14-89,hospitalization,severe,USA,≥16 years,general pop,85.4,60.2,94.6,,delta,~29 weeks,,,
307,Lind,Pfizer,2,final,150+,hospitalization,severe,USA,≥16 years,general pop,66.2,42.5,80.1,,delta,~29 weeks,,,
308,Suphanchaimat,Pfizer,2,final,15-29,infection,infection,Thailand,≥18 years,general pop,74.2,71.8,76.3,,delta,~2 weeks,,,
308,Suphanchaimat,Pfizer,2,final,90+,infection,infection,Thailand,≥18 years,general pop,57,43.6,57.2,,delta,~15 weeks,,,
308,Suphanchaimat,AZD1222 (AstraZeneca),2,final,15-29,infection,infection,Thailand,≥18 years,general pop,61.4,59.6,63.2,,delta,~2 weeks,,,
308,Suphanchaimat,AZD1222 (AstraZeneca),2,final,90+,infection,infection,Thailand,≥18 years,general pop,25.8,19.1,31.9,,delta,~31 weeks,,,
308,Suphanchaimat,CoronaVac (Sinovac),2,final,15-29,infection,infection,Thailand,≥18 years,general pop,27.9,0.3,47.9,,delta,~2 weeks,,,
308,Suphanchaimat,CoronaVac (Sinovac),2,final,90+,infection,infection,Thailand,≥18 years,general pop,49.8,47.8,51.6,,delta,~40 weeks,,,
308,Suphanchaimat,Pfizer,2,final,15-29,infection,infection,Thailand,≥18 years,general pop,79.9,74,84.5,,delta,~2 weeks,,,
308,Suphanchaimat,Pfizer,2,final,90+,infection,infection,Thailand,≥18 years,general pop,77.4,68.2,84,,delta,~19 weeks,,,
308,Suphanchaimat,CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous,2,final,15-29,infection,infection,Thailand,≥18 years,general pop,57.8,56.3,59.2,,delta,~2 weeks,,,
308,Suphanchaimat,CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous,2,final,90+,infection,infection,Thailand,≥18 years,general pop,36.6,33.6,39.4,,delta,~39 weeks,,,
308,Suphanchaimat,Pfizer,2,final,15-29,infection,infection,Thailand,≥18 years,general pop,74.7,62.8,82.8,,delta,~2 weeks,,,
308,Suphanchaimat,Pfizer,2,final,90+,infection,infection,Thailand,≥18 years,general pop,84.6,64.9,89.3,,delta,~19 weeks,,,
309,Barraza,Pfizer,2,final,14+,hospitalization with SARI,severe,Chile,≥18 years,general pop,80.3,68.9,87.5,,"gamma, delta & omicron",~77 weeks,,,
309,Barraza,AZD1222 (AstraZeneca),2,final,14+,hospitalization with SARI,severe,Chile,≥18 years,general pop,72.4,32.8,88.6,,"gamma, delta & omicron",~71 weeks,,,
309,Barraza,CoronaVac (Sinovac),2,final,14+,hospitalization with SARI,severe,Chile,≥18 years,general pop,54.5,45.2,62.3,,"gamma, delta & omicron",~72 weeks,,,
310,Penayo,Pfizer,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,91.9,72.2,97.6,,delta,~38 weeks,,,
310,Penayo,Moderna,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,76.1,-127.4,97.5,,delta,~37 weeks,,,
310,Penayo,AZD1222 (AstraZeneca),2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,83,66.3,91.5,,delta,~33 weeks,,,
310,Penayo,Sputnik V (Gamaleya),2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,83.2,48.9,94.5,,delta,~38 weeks,,,
310,Penayo,Hayat vax,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,31.8,-41.2,67.1,,delta,~39 weeks,,,
310,Penayo,Covaxin,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,25.8,-37.1,59.9,,delta,~37 weeks,,,
310,Penayo,Pfizer,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,49.5,9.9,71.7,,omicron,~53 weeks,,,
310,Penayo,Pfizer,2,final,14-89,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,78,-97,97.5,,omicron,~11 weeks,,,
310,Penayo,Moderna,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,42.1,-105.4,83.7,,omicron,~52 weeks,,,
310,Penayo,AZD1222 (AstraZeneca),2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,10.1,-31,38.3,,omicron,~48 weeks,,,
310,Penayo,Sputnik V (Gamaleya),2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,25.7,-29.9,57.5,,omicron,~53 weeks,,,
310,Penayo,Sputnik V (Gamaleya),2,final,14-89,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,64.4,-44.6,92.2,,omicron,~11 weeks,,,
310,Penayo,Hayat vax,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,40.4,-5.1,66.2,,omicron,~54 weeks,,,
310,Penayo,Covaxin,2,final,14+,hospitalization with SARI,severe,Paraguay,≥18 years,general pop,13,-45.8,48,,omicron,~52 weeks,,,
311,Monge,Pfizer,2,final,14+,infection,infection,Spain,50-59 years,50-59 years,77,76,77,,delta,~21 weeks,,,
311,Monge,Pfizer,2,final,14+,symptomatic disease,symptomatic,Spain,50-59 years,50-59 years,77,76,78,,delta,~21 weeks,,,
311,Monge,Pfizer,2,final,14+,hospitalization,severe,Spain,50-59 years,50-59 years,97,97,98,,delta,~21 weeks,,,
311,Monge,Pfizer,2,final,14+,death,death,Spain,50-59 years,50-59 years,97,93,99,,delta,~21 weeks,,,
311,Monge,Moderna,2,final,14+,infection,infection,Spain,50-59 years,50-59 years,87,86,87,,delta,~21 weeks,,,
311,Monge,Moderna,2,final,14+,symptomatic disease,symptomatic,Spain,50-59 years,50-59 years,89,88,90,,delta,~21 weeks,,,
311,Monge,Moderna,2,final,14+,hospitalization,severe,Spain,50-59 years,50-59 years,98,97,99,,delta,~21 weeks,,,
311,Monge,Moderna,2,final,14+,death,death,Spain,50-59 years,50-59 years,94,75,99,,delta,~21 weeks,,,
311,Monge,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Spain,50-59 years,50-59 years,59,56,61,,delta,~21 weeks,,,
311,Monge,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Spain,50-59 years,50-59 years,59,55,62,,delta,~21 weeks,,,
311,Monge,AZD1222 (AstraZeneca),2,final,14+,hospitalization,severe,Spain,50-59 years,50-59 years,96,93,98,,delta,~21 weeks,,,
311,Monge,Janssen,1,final,14+,infection,infection,Spain,50-59 years,50-59 years,64,62,66,,delta,~21 weeks,,,
311,Monge,Janssen,1,final,14+,symptomatic disease,symptomatic,Spain,50-59 years,50-59 years,56,53,59,,delta,~21 weeks,,,
311,Monge,Janssen,1,final,14+,hospitalization,severe,Spain,50-59 years,50-59 years,86,83,89,,delta,~21 weeks,,,
311,Monge,Janssen,1,final,14+,death,death,Spain,50-59 years,50-59 years,89,64,97,,delta,~21 weeks,,,
311,Monge,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,infection,infection,Spain,50-59 years,50-59 years,88,85,91,,delta,~21 weeks,,,
311,Monge,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,symptomatic disease,symptomatic,Spain,50-59 years,50-59 years,82,75,87,,delta,~21 weeks,,,
311,Monge,AZD1222 (AstraZeneca) & any mRNA - heterologous,2,final,14+,hospitalization,severe,Spain,50-59 years,50-59 years,98,84,100,,delta,~21 weeks,,,
312,Huang,Ad5-nCOV (CanSino),2,final,14+,infection,infection,China,≥3 years,≥3 years,13.2,10.9,15.5,,omicron,~62 weeks,,,
312,Huang,Ad5-nCOV (CanSino),2,final,14+,severe/critical illness,severe,China,≥3 years,≥3 years,77.9,15.6,94.2,,omicron,~62 weeks,,,
313,Chico-Sanchez,Pfizer,2,final,12-120,infection,infection,Spain,HCW,HCW,91.6,89.6,93.2,,non-VOC & alpha,~22 weeks,,,
313,Chico-Sanchez,Pfizer,2,final,120+,infection,infection,Spain,HCW,HCW,71.5,67,75.5,,non-VOC & alpha,~22 weeks,,,
313,Chico-Sanchez,Moderna,2,final,12-120,infection,infection,Spain,HCW,HCW,95.2,88.3,98.1,,non-VOC & alpha,~22 weeks,,,
313,Chico-Sanchez,Moderna,2,final,120+,infection,infection,Spain,HCW,HCW,88.3,75.7,94.4,,non-VOC & alpha,~22 weeks,,,
313,Chico-Sanchez,Pfizer,2,final,12+,hospitalization,severe,Spain,HCW,HCW,96.8,76.1,99.6,,non-VOC & alpha,~22 weeks,,,
314,Mallah,Pfizer,2,final,7+,infection,infection,Spain,≥11 years,≥11 years,72,71,73,,alpha & delta,~42 weeks,,,
314,Mallah,Pfizer,2,final,7+,hospitalization,severe,Spain,≥11 years,≥11 years,74,70,77,,alpha & delta,~42 weeks,,,
315,Chatzilena,Pfizer,2,final,7+,hospitalization,severe,UK,≥18 years,general pop,82.5,76.2,87.2,,delta,~56 weeks,,,
315,Chatzilena,Pfizer,2,final,≤3 months,hospitalization,severe,UK,≥18 years,general pop,91.5,83.1,96.2,,delta,~56 weeks,,,
315,Chatzilena,Pfizer,2,final,>3 months,hospitalization,severe,UK,≥18 years,general pop,79.5,71.5,85.3,,delta,~56 weeks,,,
316,Collie,Pfizer,2,final,14-27,hospitalization,severe,South Africa,≥18 years,general pop,80.3,62.8,89.5,,omicron BA.1 or BA.2,~36 weeks,,,
316,Collie,Pfizer,2,final,7-8 months,hospitalization,severe,South Africa,≥18 years,general pop,38.4,16.9,54.4,,omicron BA.1 or BA.2,~36 weeks,,,
316,Collie,Pfizer,2,final,3-4 months,hospitalization,severe,South Africa,≥18 years,general pop,47.4,19.9,65.5,,omicron BA.4 or BA.5,~53 weeks,,,
316,Collie,Pfizer,2,final,9+ months,hospitalization,severe,South Africa,≥18 years,general pop,19.3,6.3,30.5,,omicron BA.4 or BA.5,~53 weeks,,,
317,Martin,Pfizer,2,final,14+,infection,infection,UK,patients with end-stage kidney disease undergoing hemodialysis,immunocompromised adults,62,18,82,,"non-VOC, alpha, & delta",~46 weeks,,,
317,Martin,AZD1222 (AstraZeneca),2,final,14+,infection,infection,UK,patients with end-stage kidney disease undergoing hemodialysis,immunocompromised adults,42,-22,70,,"non-VOC, alpha, & delta",~46 weeks,,,
318,Chung,Pfizer,2,final,7-59,infection,infection,Canada,≥16 years,general pop,89,88,90,,non-VOC & alpha,~6 weeks,,,
318,Chung,Pfizer,2,final,60-119,infection,infection,Canada,≥16 years,general pop,80,75,85,,non-VOC & alpha,~15 weeks,,,
318,Chung,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,≥16 years,general pop,94,91,96,,non-VOC & alpha,~6 weeks,,,
318,Chung,Pfizer,2,final,60-119,symptomatic disease,symptomatic,Canada,≥16 years,general pop,93,79,98,,non-VOC & alpha,~15 weeks,,,
318,Chung,Pfizer,2,final,7-59,severe disease,severe,Canada,≥16 years,general pop,95,90,97,,non-VOC & alpha,~6 weeks,,,
318,Chung,Pfizer,2,final,7-59,infection,infection,Canada,≥16 years,general pop,92,91,93,,alpha,~6 weeks,,,
318,Chung,Pfizer,2,final,120-179,infection,infection,Canada,≥16 years,general pop,82,79,85,,alpha,~24 weeks,,,
318,Chung,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,≥16 years,general pop,92,91,94,,alpha,~6 weeks,,,
318,Chung,Pfizer,2,final,120-179,symptomatic disease,symptomatic,Canada,≥16 years,general pop,86,78,91,,alpha,~24 weeks,,,
318,Chung,Pfizer,2,final,7-59,severe disease,severe,Canada,≥16 years,general pop,94,92,95,,alpha,~6 weeks,,,
318,Chung,Pfizer,2,final,120-179,severe disease,severe,Canada,≥16 years,general pop,97,95,98,,alpha,~24 weeks,,,
318,Chung,Pfizer,2,final,7-59,infection,infection,Canada,≥16 years,general pop,90,90,90,,delta,~6 weeks,,,
318,Chung,Pfizer,2,final,240+,infection,infection,Canada,≥16 years,general pop,78,76,80,,delta,~42 weeks,,,
318,Chung,Pfizer,2,final,7-59,symptomatic disease,symptomatic,Canada,≥16 years,general pop,94,94,95,,delta,~6 weeks,,,
318,Chung,Pfizer,2,final,240+,symptomatic disease,symptomatic,Canada,≥16 years,general pop,88,86,90,,delta,~42 weeks,,,
318,Chung,Pfizer,2,final,7-59,severe disease,severe,Canada,≥16 years,general pop,98,98,99,,delta,~6 weeks,,,
318,Chung,Pfizer,2,final,240+,severe disease,severe,Canada,≥16 years,general pop,98,95,99,,delta,~42 weeks,,,
319,Xu,Pfizer,2,final,28+,infection,infection,Sweden,≥65 years,≥65 years,85.8,83.8,88.2,,"non-VOC, alpha, delta, & omicron",~51 weeks,,,
319,Xu,Pfizer,2,final,350-371,infection,infection,Sweden,≥65 years,≥65 years,18.2,2.2,31.6,,"non-VOC, alpha, delta, & omicron",,,,
319,Xu,Pfizer,2,final,28+,hospitalization,severe,Sweden,≥65 years,≥65 years,87.2,83.6,90,,"non-VOC, alpha, delta, & omicron",~51 weeks,,,
319,Xu,Pfizer,2,final,350-371,hospitalization,severe,Sweden,≥65 years,≥65 years,68.5,45.5,81.8,,"non-VOC, alpha, delta, & omicron",,,,
319,Xu,Moderna,2,final,28+,infection,infection,Sweden,≥65 years,≥65 years,94.6,89.6,97.2,,"non-VOC, alpha, delta, & omicron",~51 weeks,,,
319,Xu,Moderna,2,final,350-371,infection,infection,Sweden,≥65 years,≥65 years,11.8,-55.5,50,,"non-VOC, alpha, delta, & omicron",,,,
319,Xu,Moderna,2,final,28+,hospitalization,severe,Sweden,≥65 years,≥65 years,96,89.5,98.5,,"non-VOC, alpha, delta, & omicron",~51 weeks,,,
319,Xu,Moderna,2,final,350-371,hospitalization,severe,Sweden,≥65 years,≥65 years,21.5,-89.2,67.4,,"non-VOC, alpha, delta, & omicron",,,,
319,Xu,AZD1222 (AstraZeneca),2,final,28+,infection,infection,Sweden,≥65 years,≥65 years,43.6,1.9,67.6,,"non-VOC, alpha, delta, & omicron",~39 weeks,,,
319,Xu,AZD1222 (AstraZeneca),2,final,266-287,infection,infection,Sweden,≥65 years,≥65 years,-2.3,-627.9,85.6,,"non-VOC, alpha, delta, & omicron",,,,
319,Xu,AZD1222 (AstraZeneca),2,final,28+,hospitalization,severe,Sweden,≥65 years,≥65 years,74.6,-5,93.9,,"non-VOC, alpha, delta, & omicron",~39 weeks,,,
319,Xu,AZD1222 (AstraZeneca),2,final,238-259,hospitalization,severe,Sweden,≥65 years,≥65 years,28.7,-37.6,63,,"non-VOC, alpha, delta, & omicron",,,,
320,Más-Bermejo,Abdala (CIBG),3,final,14+,severe disease,severe,Cuba,≥19 years,general pop,98.2,97.9,98.5,,delta,~20 weeks,,,
320,Más-Bermejo,Abdala (CIBG),3,final,14+,death,death,Cuba,≥19 years,general pop,98.7,98.3,99,,delta,~20 weeks,,,
321,Copur,CoronaVac (Sinovac),2,final,14+,infection,infection,Turkey,HCW,HCW,65,50,75,,alpha,~15 weeks,,,
322,Schrag,Pfizer,2,final,14+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,16,-22,42,,omicron,~55 weeks,,,
322,Schrag,Pfizer,2,final,14-149,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,3,-49,37,,omicron,,,,
322,Schrag,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,42,-16,72,,omicron,~55 weeks,,,
322,Schrag,Pfizer,2,final,14+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,77,28,93,,omicron,~55 weeks,,,
322,Schrag,Pfizer,2,final,14-149,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,86,41,97,,omicron,,,,
322,Schrag,Pfizer,2,final,150+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,64,-102,93,,omicron,~55 weeks,,,
322,Schrag,Pfizer,2,final,14+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,83,68,91,,delta,~55 weeks,,,
322,Schrag,Pfizer,2,final,14-149,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,84,69,92,,delta,,,,
322,Schrag,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,75,5,93,,delta,~55 weeks,,,
322,Schrag,Pfizer,2,final,14+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,98,96,99,,delta,,,,
322,Schrag,Pfizer,2,final,14-149,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,99,96,100,,delta,,,,
322,Schrag,Pfizer,2,final,150+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,96,86,99,,delta,~55 weeks,,,
323,Ferdinands,Pfizer,2,final,<2 months,ED or UC encounters,symptomatic,USA,≥18 years,general pop,63,57,68,,omicron,,,,
323,Ferdinands,Pfizer,2,final,300,ED or UC encounters,symptomatic,USA,≥18 years,general pop,22,5,36,,omicron,,,,
323,Ferdinands,Pfizer,2,final,<2 months,hospitalization,severe,USA,≥18 years,general pop,73,63,80,,omicron,,,,
323,Ferdinands,Pfizer,2,final,14+ months,hospitalization,severe,USA,≥18 years,general pop,19,6,30,,omicron,~67 weeks,,,
323,Ferdinands,Pfizer,2,final,<4 months,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,34,13,51,,omicron,,,,
323,Ferdinands,Pfizer,2,final,6+ months,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,20,1,36,,omicron,~67 weeks,,,
323,Ferdinands,Pfizer,2,final,<2 months,ED or UC encounters,symptomatic,USA,≥18 years,general pop,93,92,94,,delta,,,,
323,Ferdinands,Pfizer,2,final,150,ED or UC encounters,symptomatic,USA,≥18 years,general pop,66,60,72,,delta,,,,
323,Ferdinands,Pfizer,2,final,<2 months,hospitalization,severe,USA,≥18 years,general pop,96,95,97,,delta,,,,
323,Ferdinands,Pfizer,2,final,150,hospitalization,severe,USA,≥18 years,general pop,68,59,75,,delta,,,,
323,Ferdinands,Pfizer,2,final,<2 months,ED or UC encounters,symptomatic,USA,≥18 years,general pop,95,94,96,,alpha,~19 weeks,,,
323,Ferdinands,Pfizer,2,final,90,ED or UC encounters,symptomatic,USA,≥18 years,general pop,86,78,91,,alpha,~19 weeks,,,
323,Ferdinands,Pfizer,2,final,<2 months,hospitalization,severe,USA,≥18 years,general pop,94,93,95,,alpha,~19 weeks,,,
323,Ferdinands,Pfizer,2,final,90,hospitalization,severe,USA,≥18 years,general pop,87,77,93,,alpha,~19 weeks,,,
324,Link-Gelles,Pfizer,2,final,14-159,ED or UC encounters,symptomatic,USA,≥18 years,general pop,45,27,59,,omicron BA.4 or BA.5,,,,
324,Link-Gelles,Pfizer,2,final,150+,ED or UC encounters,symptomatic,USA,≥18 years,general pop,24,19,27,,omicron BA.4 or BA.5,~82 weeks,,,
324,Link-Gelles,Pfizer,2,final,150+,hospitalization,severe,USA,≥18 years,general pop,17,7,27,,omicron BA.4 or BA.5,~82 weeks,,,
324,Link-Gelles,Moderna,2,final,14-159,ED or UC encounters,symptomatic,USA,≥18 years,general pop,51,30,66,,omicron BA.4 or BA.5,,,,
324,Link-Gelles,Moderna,2,final,150+,ED or UC encounters,symptomatic,USA,≥18 years,general pop,30,25,34,,omicron BA.4 or BA.5,~82 weeks,,,
324,Link-Gelles,Moderna,2,final,150+,hospitalization,severe,USA,≥18 years,general pop,28,17,38,,omicron BA.4 or BA.5,~82 weeks,,,
324,Link-Gelles,Any mRNA - heterologous,2,final,14-159,ED or UC encounters,symptomatic,USA,≥18 years,general pop,70,52,81,,omicron BA.4 or BA.5,,,,
324,Link-Gelles,Any mRNA - heterologous,2,final,150+,ED or UC encounters,symptomatic,USA,≥18 years,general pop,38,29,46,,omicron BA.4 or BA.5,~82 weeks,,,
325,Grewal,Pfizer,2,final,0+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,3,-7,12,,omicron BA.1 or BA.2 or BA.4 or BA.5,~80 weeks,,,
325,Grewal,Pfizer,2,final,0+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,21,1,38,,omicron BA.1 or BA.2 or BA.4 or BA.5,~80 weeks,,,
325,Grewal,Pfizer,2,final,0+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,43,24,58,,omicron BA.1 or BA.2 or BA.4 or BA.5,~80 weeks,,,
326,Lin,Pfizer,2,final,~47 weeks,infection ,infection ,USA,≥5 years,≥5 years,37.5,36,39,,omicron,~47 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~60 weeks,infection ,infection ,USA,≥5 years,≥5 years,0.8,-1.5,3,,omicron,~60 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~47 weeks,hospitalization,severe,USA,≥5 years,≥5 years,58.8,49.3,66.5,,omicron,~47 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~60 weeks,hospitalization,severe,USA,≥5 years,≥5 years,29.4,50.4,76.9,,omicron,~60 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~47 weeks,death ,death ,USA,≥5 years,≥5 years,75.2,67.7,81,,omicron,~47 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~60 weeks,death ,death ,USA,≥5 years,≥5 years,59.1,27.2,77,,omicron,~60 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Moderna,2,final,~46 weeks,infection ,infection ,USA,≥5 years,≥5 years,47.2,45.8,48.5,,omicron,~46 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Moderna,2,final,~59 weeks,infection ,infection ,USA,≥5 years,≥5 years,30.3,28.9,32.9,,omicron,~59 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Moderna,2,final,~46 weeks,hospitalization,severe,USA,≥5 years,≥5 years,64.7,57.2,70.9,,omicron,~46 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Moderna,2,final,~59 weeks,hospitalization,severe,USA,≥5 years,≥5 years,61.5,49.6,70.6,,omicron,~59 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Moderna,2,final,~46 weeks,death ,death ,USA,≥5 years,≥5 years,69.6,62.3,75.5,,omicron,~46 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Moderna,2,final,~59 weeks,death ,death ,USA,≥5 years,≥5 years,48.3,22.6,65.4,,omicron,~59 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Janssen,2,final,~41 weeks,infection ,infection ,USA,≥5 years,≥5 years,48.8,47.2,50.4,,omicron,~41 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Janssen,2,final,~54 weeks,infection ,infection ,USA,≥5 years,≥5 years,49,46.4,51.4,,omicron,~54 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Janssen,2,final,~41 weeks,hospitalization,severe,USA,≥5 years,≥5 years,65.3,58.3,71.1,,omicron,~41 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Janssen,2,final,~54 weeks,hospitalization,severe,USA,≥5 years,≥5 years,53.3,26.7,70.2,,omicron,~54 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Janssen,2,final,~41 weeks,death ,death ,USA,≥5 years,≥5 years,76.1,69.2,81.4,,omicron,~41 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Janssen,2,final,~54 weeks,death ,death ,USA,≥5 years,≥5 years,77.5,19.6,93.7,,omicron,~54 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~25 weeks,infection ,infection ,USA,≥5 years,≥5 years,54.3,53.6,55,,delta,~25 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~38 weeks,infection ,infection ,USA,≥5 years,≥5 years,47.4,46.6,48.2,,delta,~38 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~25 weeks,hospitalization,severe,USA,≥5 years,≥5 years,85.8,83.4,87.8,,delta,~25 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~38 weeks,hospitalization,severe,USA,≥5 years,≥5 years,70.9,65.3,75.6,,delta,~38 weeks,,Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021,
326,Lin,Pfizer,2,final,~25 weeks,death ,death ,USA,≥5 years,≥5 years,89.6,87,91.6,,delta,~25 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~38 weeks,death ,death ,USA,≥5 years,≥5 years,77.4,70.6,82.6,,delta,~38 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~24 weeks,infection ,infection ,USA,≥5 years,≥5 years,69.2,68.5,69.9,,delta,~24 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~37 weeks,infection ,infection ,USA,≥5 years,≥5 years,48.4,47.5,49.3,,delta,~37 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~24 weeks,hospitalization,severe,USA,≥5 years,≥5 years,89.8,88.1,91.3,,delta,~24 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~37 weeks,hospitalization,severe,USA,≥5 years,≥5 years,72.7,67.8,77,,delta,~37 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~24 weeks,death ,death ,USA,≥5 years,≥5 years,93,91.1,94.5,,delta,~24 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~37 weeks,death ,death ,USA,≥5 years,≥5 years,85.1,80.1,88.8,,delta,~37 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~20 weeks,infection ,infection ,USA,≥5 years,≥5 years,59.2,57.7,60.7,,delta,~20 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~33 weeks,infection ,infection ,USA,≥5 years,≥5 years,60.5,58.9,62.1,,delta,~33 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~20 weeks,hospitalization,severe,USA,≥5 years,≥5 years,77.9,72.2,82.4,,delta,~20 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~33 weeks,hospitalization,severe,USA,≥5 years,≥5 years,70,64.8,74.5,,delta,~33 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~20 weeks,death ,death ,USA,≥5 years,≥5 years,83.8,76.1,89,,delta,~20 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~33 weeks,death ,death ,USA,≥5 years,≥5 years,79.2,73.1,84,,delta,~33 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~3 weeks,infection ,infection ,USA,≥5 years,≥5 years,67.6,66.9,68.3,,alpha,~3 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~21 weeks,infection ,infection ,USA,≥5 years,≥5 years,58.6,58,59.2,,alpha,~21 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~3 weeks,hospitalization,severe,USA,≥5 years,≥5 years,94.1,92.2,95.5,,alpha,~3 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~21 weeks,hospitalization,severe,USA,≥5 years,≥5 years,87.1,85,88.9,,alpha,~21 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~3 weeks,death ,death ,USA,≥5 years,≥5 years,97.1,94.7,98.4,,alpha,~3 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Pfizer,2,final,~21 weeks,death ,death ,USA,≥5 years,≥5 years,91.9,89.4,93.8,,alpha,~21 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~2 weeks,infection ,infection ,USA,≥5 years,≥5 years,90.1,89.6,90.7,,alpha,~2 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~20 weeks,infection ,infection ,USA,≥5 years,≥5 years,71.9,71.3,72.6,,alpha,~20 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~2 weeks,hospitalization,severe,USA,≥5 years,≥5 years,96.5,95.1,97.6,,alpha,~2 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~20 weeks,hospitalization,severe,USA,≥5 years,≥5 years,90.4,88.6,91.9,,alpha,~20 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~2 weeks,death ,death ,USA,≥5 years,≥5 years,97.2,95.1,98.4,,alpha,~2 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Moderna,2,final,~20 weeks,death ,death ,USA,≥5 years,≥5 years,92.8,90.3,94.6,,alpha,~20 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~2 weeks,infection ,infection ,USA,≥5 years,≥5 years,70.6,68.8,72.3,,alpha,~2 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~10 weeks,infection ,infection ,USA,≥5 years,≥5 years,63,60.8,65,,alpha,~10 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~2 weeks,hospitalization,severe,USA,≥5 years,≥5 years,67.9,56.5,76.3,,alpha,~2 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~10 weeks,hospitalization,severe,USA,≥5 years,≥5 years,79.3,71.7,84.8,,alpha,~10 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~2 weeks,death ,death ,USA,≥5 years,≥5 years,85.7,74.6,91.9,,alpha,~2 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
326,Lin,Janssen,2,final,~10 weeks,death ,death ,USA,≥5 years,≥5 years,80.5,75.7,84.4,,alpha,~10 weeks,,Note: this study includes additional VE estimates for individuals vaccinated during different time periods,
327,Rudan,Pfizer,2,final,14-35,symptomatic disease,symptomatic,UK (Scotland),12-15 years,12-15 years,81.2,77.7,84.2,omicron,omicron,,,,
327,Rudan,Pfizer,2,final,98+,symptomatic disease,symptomatic,UK (Scotland),12-15 years,12-15 years,48.7,22,66.3,omicron,omicron,~21 weeks,,,
327,Rudan,Pfizer,2,final,14-35,symptomatic disease,symptomatic,UK (Scotland),12-15 years,12-15 years,100,-∞,100,delta,delta,,,,
327,Rudan,Pfizer,2,final,42-63,symptomatic disease,symptomatic,UK (Scotland),12-15 years,12-15 years,92.9,42.5,99.1,delta,delta,~10 weeks,,,
327,Rudan,Pfizer,2,final,14-35,symptomatic disease,symptomatic,UK (Scotland),16-17 years,16-17 years,65.5,56,73,omicron,omicron,,,,
327,Rudan,Pfizer,2,final,98+,symptomatic disease,symptomatic,UK (Scotland),16-17 years,16-17 years,1.2,-49.3,34.6,omicron,omicron,~27 weeks,,,
327,Rudan,Pfizer,2,final,14-35,symptomatic disease,symptomatic,UK (Scotland),16-17 years,16-17 years,95.6,77,99.1,delta,delta,,,,
327,Rudan,Pfizer,2,final,42-63,symptomatic disease,symptomatic,UK (Scotland),16-17 years,16-17 years,96.7,51.3,99.8,delta,delta,~17 weeks,,,
328,Lewis,Pfizer,2,final,14+,infection,infection,USA,≥60 years,≥60 years,80,46.4,92.6,gamma,gamma,~14 weeks,,,
329,Buchan,Pfizer,2,final,7-59 ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,36,24,45,omicron,omicron,,,,
329,Buchan,Pfizer,2,final,240+ ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,2,-17,17,omicron,omicron,~49 weeks,,,
329,Buchan,Pfizer,2,final,120-179 ,severe disease,severe,Canada,≥18 years,general pop,75,51,87,omicron,omicron,,,,
329,Buchan,Pfizer,2,final,180-239 ,severe disease,severe,Canada,≥18 years,general pop,82,62,91,omicron,omicron,~32 weeks,,,
329,Buchan,Pfizer,2,final,7-59 ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,89,86,92,delta,delta,,,,
329,Buchan,Pfizer,2,final,240+ ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,80,74,84,delta,delta,~49 weeks,,,
329,Buchan,Pfizer,2,final,7-59 ,severe disease,severe,Canada,≥18 years,general pop,94,84,98,delta,delta,,,,
329,Buchan,Pfizer,2,final,240+,severe disease,severe,Canada,≥18 years,general pop,95,85,99,delta,delta,~49 weeks,,,
330,Risk,Pfizer,2,final,0-3 months,infection,infection,USA,12-17 years,12-17 years,54.5,17.8,76.9,omicron,omicron,,,This study does not adjust for calendar time,
330,Risk,Pfizer,2,final,≥6 months,infection,infection,USA,12-17 years,12-17 years,4.2,-20.2,23.6,omicron,omicron,~58 weeks,,This study does not adjust for calendar time,
330,Risk,Pfizer,2,final,0-3 months,infection,infection,USA,12-17 years,12-17 years,81.9,67.9,90.8,delta,delta,,,This study does not adjust for calendar time,
330,Risk,Pfizer,2,final,≥6 months,infection,infection,USA,12-17 years,12-17 years,65.3,34.6,83.8,delta,delta,~44 weeks,,This study does not adjust for calendar time,
331,Mimura,Pfizer,2,final,28,infection,infection,Japan,16-64 years,16-64 years,15.8,7.9,23.1,omicron,omicron,~43 weeks,,,
331,Mimura,Pfizer,2,final,28,symptomatic disease,symptomatic,Japan,16-64 years,16-64 years,21.2,11,30.3,omicron,omicron,~43 weeks,,,
331,Mimura,Pfizer,2,final,28,infection,infection,Japan,16-64 years,16-64 years,82.9,69.4,90.4,delta,delta,~31 weeks,,,
331,Mimura,Pfizer,2,final,28,symptomatic disease,symptomatic,Japan,16-64 years,16-64 years,95.7,82.5,98.9,delta,delta,~31 weeks,,,
332,Wan,Pfizer,2,final,14-180,infection,infection,"Hong Kong, SAR",60-79 years,60-79 years,17.3,15.2,19.3,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,hospitalization,severe,"Hong Kong, SAR",60-79 years,60-79 years,74.6,72.1,76.8,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,severe disease,severe,"Hong Kong, SAR",60-79 years,60-79 years,77.5,65.7,85.2,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,death,death,"Hong Kong, SAR",60-79 years,60-79 years,92.1,88.7,94.5,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,infection,infection,"Hong Kong, SAR",≥80 years,≥80 years,54.2,51.4,56.9,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,hospitalization,severe,"Hong Kong, SAR",≥80 years,≥80 years,81,78.2,83.5,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,severe disease,severe,"Hong Kong, SAR",≥80 years,≥80 years,82.7,62.7,92,,omicron BA.2,~24 weeks,,,
332,Wan,Pfizer,2,final,14-180,death,death,"Hong Kong, SAR",≥80 years,≥80 years,92.5,89.3,94.8,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,infection,infection,"Hong Kong, SAR",60-79 years,60-79 years,-23.1,-25.8,-20.5,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,hospitalization,severe,"Hong Kong, SAR",60-79 years,60-79 years,59.4,56.6,62,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,severe disease,severe,"Hong Kong, SAR",60-79 years,60-79 years,57.7,43.8,68.2,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,death,death,"Hong Kong, SAR",60-79 years,60-79 years,79.6,75,83.3,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,infection,infection,"Hong Kong, SAR",≥80 years,≥80 years,31.2,28.7,33.6,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,hospitalization,severe,"Hong Kong, SAR",≥80 years,≥80 years,58.4,55.8,60.9,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,severe disease,severe,"Hong Kong, SAR",≥80 years,≥80 years,55,38.6,67,,omicron BA.2,~24 weeks,,,
332,Wan,CoronaVac (Sinovac),2,final,14-180,death,death,"Hong Kong, SAR",≥80 years,≥80 years,69.4,65.6,72.8,,omicron BA.2,~24 weeks,,,
333,Chambers,Pfizer,2,final,7+,infection,infection,Canada,≥19 years,general pop,82,74,88,,alpha & delta,~44 weeks,,,
333,Chambers,Pfizer,2,final,7+,symptomatic disease,symptomatic,Canada,≥19 years,general pop,93,79,98,,alpha & delta,~44 weeks,,,
333,Chambers,Pfizer,2,final,7+,severe disease,severe,Canada,≥19 years,general pop,97,80,99,,alpha & delta,~44 weeks,,,
333,Chambers,AZD1222 (AstraZeneca),2,final,7+,infection,infection,Canada,≥19 years,general pop,77,34,92,,alpha & delta,~44 weeks,,,
333,Chambers,AZD1222 (AstraZeneca) + any mRNA - heterologous,2,final,7+,infection,infection,Canada,≥19 years,general pop,80,49,92,,alpha & delta,~44 weeks,,,
334,Consonni,Pfizer,2,final,7-119,infection,infection,Italy,HCW,HCW,70,54,80,,omicron,~67 weeks,,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",
334,Consonni,Pfizer,2,final,120+,infection,infection,Italy,HCW,HCW,16,0,43,,omicron,~67 weeks,,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",
334,Consonni,Pfizer,2,final,7-119,infection,infection,Italy,HCW,HCW,25,0,69,,omicron,~67 weeks,,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",
334,Consonni,Pfizer,2,final,120+,infection,infection,Italy,HCW,HCW,88,66,96,,omicron,~67 weeks,,"88.3% of cases were during the Omicron period; 8.2% and 3.5% of cases were during Alpha, and Delta periods, respectively",
335,Zerbo,Pfizer,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,26,-22,56,,omicron,~11 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,23,-6,44,,omicron,~13 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,19,-3,37,,omicron,~15 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,37,-21,67,,omicron,~8 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,5,-28,29,,omicron,~10 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,3,-19,21,,omicron,~12 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,-4,-84,41,,omicron,~5 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,12,-23,37,,omicron,~7 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,18,-4,36,,omicron,~9 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,61,-31,89,,delta,~11 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,48,-54,82,,delta,~13 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,49,-46,82,,delta,~15 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,91,63,98,,delta,~8 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,60,23,79,,delta,~10 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,65,33,81,,delta,~12 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,87,55,96,,delta,~5 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,70,43,84,,delta,~7 months,,,
335,Zerbo,Pfizer,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,54,27,71,,delta,~9 months,,,
336,Embi,Moderna,2,final,14-149,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompetent adults ≥18 years,general pop,90,89,91,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,150+,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompetent adults ≥18 years,general pop,84,83,85,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,14-149,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompetent adults ≥18 years,general pop,85,84,86,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,150+,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompetent adults ≥18 years,general pop,73,72,74,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,14-149,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥18 years,general pop,94,92,95,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,150+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥18 years,general pop,89,88,90,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,14-149,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥18 years,general pop,90,88,91,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,150+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥18 years,general pop,80,79,82,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,14-149,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompromised adults ≥18 years,immunocompromised adults,79,64,88,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,150+,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompromised adults ≥18 years,immunocompromised adults,64,54,72,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,14-149,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompromised adults ≥18 years,immunocompromised adults,62,45,73,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,150+,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompromised adults ≥18 years,immunocompromised adults,56,46,64,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,14-149,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,81,69,88,,delta,~46 weeks,,,
336,Embi,Moderna,2,final,150+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,73,68,77,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,14-149,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,68,58,75,,delta,~46 weeks,,,
336,Embi,Pfizer,2,final,150+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,64,58,69,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,14-149,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompetent adults ≥18 years,general pop,67,63,71,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,150+,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompetent adults ≥18 years,general pop,62,58,65,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,14-149,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥18 years,general pop,77,71,82,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,150+,hospitalization with COVID-like illness,severe,USA,immunocompetent adults ≥18 years,general pop,69,65,73,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,14-149,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompromised adults ≥18 years,immunocompromised adults,9,-66,50,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,150+,ED or UC visits with COVID-like illness,symptomatic,USA,immunocompromised adults ≥18 years,immunocompromised adults,-6,-49,25,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,14-149,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,35,-3,60,,delta,~46 weeks,,,
336,Embi,Janssen,1,final,150+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,43,23,58,,delta,~46 weeks,,,
337,Britton,Pfizer,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,40,34,46,,omicron BA.1,~56 weeks,,,
337,Britton,Pfizer,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,7,-16,25,,omicron BA.2/BA.2.12.1,~69 weeks,,,
337,Britton,Pfizer,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,38,23,50,,omicron BA.4/BA.5,~77 weeks,,,
337,Britton,Pfizer,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,22,10,33,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~77 weeks,,,
338,Surie,Pfizer,2,final,14-150,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,63,46,75,,omicron BA.1/BA.2,~74 weeks,,,
338,Surie,Pfizer,2,final,150+,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,34,20,46,,omicron BA.1/BA.2,~74 weeks,,,
338,Surie,Pfizer,2,final,14-150,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,83,35,96,,omicron BA.4/BA.5,~82 weeks,,,
338,Surie,Pfizer,2,final,150+,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,37,12,55,,omicron BA.4/BA.5,~82 weeks,,,
339,Collie,Janssen,1,final,14-20,infection,infection,South Africa,HCW ≥18 years with low physical activity,HCW with low physical activity,48,9.7,70.1,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,28+,infection,infection,South Africa,HCW ≥18 years with low physical activity,HCW with low physical activity,39.8,34,45.1,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,28+,hospitalization,severe,South Africa,HCW ≥18 years with low physical activity,HCW with low physical activity,60,39,73.8,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,14-20,infection,infection,South Africa,HCW ≥18 years with moderate physical activity,HCW years with moderate physical activity,39,-4.9,64.5,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,28+,infection,infection,South Africa,HCW ≥18 years with moderate physical activity,HCW years with moderate physical activity,36.3,31.3,41,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,28+,hospitalization,severe,South Africa,HCW ≥18 years with moderate physical activity,HCW years with moderate physical activity,72.1,55.2,82.6,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,14-20,infection,infection,South Africa,HCW ≥18 years with high physical activity,HCW years with high physical activity,51,16.8,71.1,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,28+,infection,infection,South Africa,HCW ≥18 years with high physical activity,HCW years with high physical activity,41.2,37.5,44.7,,beta & delta,~34 weeks,,,
339,Collie,Janssen,1,final,28+,hospitalization,severe,South Africa,HCW ≥18 years with high physical activity,HCW years with high physical activity,85.8,74.1,92.2,,beta & delta,~34 weeks,,,
340,Nordstrom,Pfizer,2,final,7+,infection,infection,Sweden,"adolescents vaccinated on or after January 1, 2022",adolescents,47,43,51,,omicron,~6 weeks,,,
340,Nordstrom,Pfizer,2,final,7+,infection,infection,Sweden,"adolescents vaccinated on or after September 1, 2021",adolescents,4,2,6,,omicron,~24 weeks,,,
340,Nordstrom,Pfizer,2,final,7+,hospitalization with COVID-19 as the main diagnosis,severe,Sweden,"adolescents vaccinated on or after November 15, 2021",adolescents,86,63,95,,omicron,~27 weeks,,,
340,Nordstrom,Pfizer,2,final,48+,hospitalization with COVID-19 as the main diagnosis,severe,Sweden,"adolescents vaccinated before November 15, 2021",adolescents,68,25,86,,omicron,~45 weeks,,,
341,Tartof,Pfizer,2,final,<6 months,ED visit for ARI,symptomatic,USA,≥18 years,general pop,30,-86,74,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
341,Tartof,Pfizer,2,final,≥6 months,ED visit for ARI,symptomatic,USA,≥18 years,general pop,44,20,61,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
341,Tartof,Pfizer,2,final,<6 months,UC visit for ARI,symptomatic,USA,≥18 years,general pop,50,10,72,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
341,Tartof,Pfizer,2,final,≥6 months,UC visit for ARI,symptomatic,USA,≥18 years,general pop,7,-11,22,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
341,Tartof,Pfizer,2,final,<6 months,outpatient care visit for ARI,symptomatic,USA,≥18 years,general pop,30,4,49,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
341,Tartof,Pfizer,2,final,≥6 months,outpatient care visit for ARI,symptomatic,USA,≥18 years,general pop,19,9,29,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
341,Tartof,Pfizer,2,final,≥6 months,hospitalization for ARI,severe,USA,≥18 years,general pop,-4,-118,50,omicron BA.4/BA.5,omicron BA.4/BA.5,~84 weeks,,,
342,Moghnieh,Sputnik V (Gamaleya),2,final,3-5 months,infection,infection,Lebanon,≥18 years,general pop,52.3,-27.4,78.7,delta,delta,~30 weeks,,,
342,Moghnieh,Sputnik V (Gamaleya),2,final,7-9 months,infection,infection,Lebanon,≥18 years,general pop,23.7,-84.7,62.8,delta,delta,~30 weeks,,,
342,Moghnieh,Sputnik V (Gamaleya),2,final,7-9 months,infection,infection,Lebanon,≥18 years,general pop,20.1,-94.7,61.6,delta,delta,~30 weeks,,,
342,Moghnieh,Pfizer,2,final,<3 months,infection,infection,Lebanon,≥18 years,general pop,95.1,78.4,99.3,delta,delta,~30 weeks,,,
342,Moghnieh,Pfizer,2,final,<7 months,infection,infection,Lebanon,≥18 years,general pop,67.5,12.8,87.2,delta,delta,~30 weeks,,,
342,Moghnieh,Pfizer,2,final,<7 months,infection,infection,Lebanon,≥18 years,general pop,71.8,22.3,89.1,delta,delta,~30 weeks,,,
342,Moghnieh,Sputnik V (Gamaleya),2,final,>6 months,infection,infection,Lebanon,≥18 years,general pop,-54.1,-151,0.84,omicron,omicron,~43 weeks,,,
342,Moghnieh,Sputnik V (Gamaleya),2,final,>6 months,infection,infection,Lebanon,≥18 years,general pop,-46,-149.7,10.1,omicron,omicron,~43 weeks,,,
342,Moghnieh,Pfizer,2,final,3-5 months,infection,infection,Lebanon,≥18 years,general pop,23.1,-28.7,52.1,omicron,omicron,~43 weeks,,,
342,Moghnieh,Pfizer,2,final,3-5 months,infection,infection,Lebanon,≥18 years,general pop,21.9,-38.9,54.1,omicron,omicron,~43 weeks,,,
343,Grewal,Pfizer,2,final,240-299,severe disease,severe,Canada,50-59 years,50-59 years,83,76,88,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,50-59 years,50-59 years,83,74,89,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,60-69 years,60-69 years,79,71,86,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,70-79 years,70-79 years,80,72,86,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,≥80 years,≥80 years,72,62,79,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Pfizer,2,final,240-299,severe disease,severe,Canada,50-59 years,50-59 years,87,43,97,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,50-59 years,50-59 years,56,30,72,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,60-69 years,60-69 years,43,16,61,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,70-79 years,70-79 years,48,25,64,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Pfizer,2,final,300+,severe disease,severe,Canada,≥80 years,≥80 years,40,18,56,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
344,Chemaitelly,Pfizer,2,final,91+ (90+ days post primary Omicron infection),reinfection,reinfection,Qatar,≥18 years with prior breakthrough Omicron infection,≥18 years with prior breakthrough Omicron infection,57,52,62,,omicron,~85 weeks,,,
345,Clemens,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Brazil,18-60 years,18-60 years,76,49.5,87.8,delta,delta,~12.5 weeks,,,
345,Clemens,AZD1222 (AstraZeneca),2,final,14+,severe disease,infection,Brazil,18-60 years,18-60 years,100,44.3,100,,delta,~12.5 weeks,,,
345,Clemens,,2,final,14+,infection,infection,Brazil,18-60 years,18-60 years,81.3,-298,97.9,gamma,gamma,~12.5 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants < 6 months,mothers of infants < 6 months,45,37,53,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants < 6 months of mothers receiving second dose in first trimester,infants < 6 months of mothers receiving second dose in first trimester,47,31,59,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants < 6 months of mothers receiving second dose in second trimester,infants < 6 months of mothers receiving second dose in second trimester,37,24,47,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants < 6 months of mothers receiving second dose in third trimester,infants < 6 months of mothers receiving second dose in third trimester,53,42,62,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants 0-8 weeks,infants 0-8 weeks,57,44,66,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants 9-16 weeks,infants 9-16 weeks,47,31,60,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants >16 weeks and < 6 months,infants >16 weeks and < 6 months,40,21,54,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,hospitalization,severe,Canada,infants < 6 months,infants < 6 months,58,44,69,,omicron,~66 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants < 6 months,infants < 6 months,95,88,98,,delta,~28 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,hospitalization,severe,Canada,infants < 6 months,infants < 6 months,94,74,100,,delta,~28 weeks,,,
346,Jorgensen,Pfizer,2,final,14+,infection,infection,Canada,infants < 6 months,infants < 6 months,44,38,54,,delta,~28 weeks,,,
347,Van Ewijk,Pfizer,2,final,14+,infection,infection,Netherlands,≥18 years,general pop,64,51,74,,delta,~41 weeks,,,
347,Van Ewijk,Pfizer,2,final,14+,symptomatic disease,symptomatic,Netherlands,≥18 years,general pop,64,49,75,,delta,~41 weeks,,,
347,Van Ewijk,Moderna,2,final,14+,infection,infection,Netherlands,≥18 years,general pop,76,62,85,,delta,~41 weeks,,,
347,Van Ewijk,Moderna,2,final,14+,symptomatic disease,symptomatic,Netherlands,≥18 years,general pop,75,58,85,,delta,~41 weeks,,,
347,Van Ewijk,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Netherlands,≥18 years,general pop,53,37,68,,delta,~41 weeks,,,
347,Van Ewijk,AZD1222 (AstraZeneca),2,final,14+,symptomatic disease,symptomatic,Netherlands,≥18 years,general pop,52,26,69,,delta,~41 weeks,,,
347,Van Ewijk,Janssen,1,final,28+,infection,infection,Netherlands,≥18 years,general pop,55,32,70,,delta,~36 weeks,,,
347,Van Ewijk,Janssen,1,final,28+,symptomatic disease,symptomatic,Netherlands,≥18 years,general pop,59,35,74,,delta,~36 weeks,,,
347,Van Ewijk,Pfizer,2,final,<120,infection,infection,Netherlands,≥18 years,general pop,74,63,81,,delta,,,,
347,Van Ewijk,Pfizer,2,final,>120,infection,infection,Netherlands,≥18 years,general pop,56,36,69,,delta,~41 weeks,,,
347,Van Ewijk,Pfizer,2,final,14+,infection,infection,Netherlands,≥18 years,general pop,59,25,70,,delta,~41 weeks,,,
347,Van Ewijk,Moderna,2,final,14+,infection,infection,Netherlands,≥18 years,general pop,73,59,83,,delta,~41 weeks,,,
347,Van Ewijk,AZD1222 (AstraZeneca),2,final,14+,infection,infection,Netherlands,≥18 years,general pop,48,25,64,,delta,~36 weeks,,,
347,Van Ewijk,Janssen,1,final,14+,infection,infection,Netherlands,≥18 years,general pop,50,24,66,,delta,~36 weeks,,,
348,Turbyfill,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompetent, ≥18 years",general pop,91,88,93,,alpha & delta,~30 weeks,,,
348,Turbyfill,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompetent, ≥18 years",general pop,84,80,88,,alpha & delta,~30 weeks,,,
348,Turbyfill,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,64,48,75,,alpha & delta,~30 weeks,,,
348,Turbyfill,Pfizer,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,53,22,72,,alpha & delta,~30 weeks,,,
349,Castelli,Pfizer,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,28.1,25.2,30.8,,omicron,~32.5 weeks,,,
349,Castelli,Moderna,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,17.9,14,21.5,,omicron,~32.5 weeks,,,
349,Castelli,Pfizer,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,40.6,29.4,50,,omicron,~32.5 weeks,,,
349,Castelli,Pfizer,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,31.5,26.3,36.4,,omicron,~32.5 weeks,,,
349,Castelli,Pfizer,2,final,15-30,infection,infection,Argentina,12-17 years,12-17 years,55.8,52.4,59,,omicron,~32.5 weeks,,,
349,Castelli,Pfizer,2,final,61+,infection,infection,Argentina,12-17 years,12-17 years,12.4,8.6,16.1,,omicron,~32.5 weeks,,,
349,Castelli,Pfizer,2,final,14+,death,death,Argentina,12-17 years,12-17 years,97.6,81,99.7,,omicron,~32.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,14+,infection,infection,Argentina,3-11 years,3-11 years,26,23.2,28.8,,omicron,~22.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,15-30,infection,infection,Argentina,3-11 years,3-11 years,37.6,34.2,40.8,,omicron,~22.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,61+,infection,infection,Argentina,3-11 years,3-11 years,2,1.8,5.6,,omicron,~22.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,Argentina,3-11 years,3-11 years,66.9,6.4,89.8,,omicron,~22.5 weeks,,,
349,Castelli,Pfizer,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,64.1,60.5,67.3,,delta,~15.5 weeks,,,
349,Castelli,Moderna,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,70.2,66.8,73.1,,delta,~15.5 weeks,,,
349,Castelli,Pfizer,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,88.9,66.1,96.4,,delta,~15.5 weeks,,,
349,Castelli,Pfizer,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,66.3,54,75.4,,delta,~15.5 weeks,,,
349,Castelli,Pfizer,2,final,15-30,infection,infection,Argentina,12-17 years,12-17 years,74.8,71.3,77.9,,delta,~15.5 weeks,,,
349,Castelli,Pfizer,2,final,61+,infection,infection,Argentina,12-17 years,12-17 years,56.3,50.2,61.7,,delta,~15.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,14+,infection,infection,Argentina,3-11 years,3-11 years,61.2,56.4,65.5,,delta,~5.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,15-30,infection,infection,Argentina,3-11 years,3-11 years,68.4,64.1,72.2,,delta,~5.5 weeks,,,
349,Castelli,BBIBP-CorV (Beijing CNBG),2,final,61+,infection,infection,Argentina,3-11 years,3-11 years,65.2,44,78.4,,delta,~5.5 weeks,,,
350,Fu,Pfizer,2,final,14+,infection,infection,USA,≥18 years,general pop,-122.3,-124.2,120.3,,omicron,~75.5 weeks,,,
350,Fu,Moderna,2,final,14+,infection,infection,USA,≥18 years,general pop,-163.5,-166.6,-160.5,,omicron,~73.5 weeks,,,
350,Fu,mRNA (heterologous),2,final,14+,infection,infection,USA,≥18 years,general pop,-19,-27.4,-11,,omicron,~75.5 weeks,,,
350,Fu,Janssen,1,final,14+,infection,infection,USA,≥18 years,general pop,-38.1,-44.2,32.2,,omicron,~69.5 weeks,,,
350,Fu,Pfizer,2,final,14+,infection,infection,USA,≥18 years,general pop,-25,-26.2,-23.8,,delta,~48.5 weeks,,,
350,Fu,Moderna,2,final,14+,infection,infection,USA,≥18 years,general pop,-11.3,-12.9,-9.8,,delta,~46.5 weeks,,,
350,Fu,mRNA (heterologous),2,final,14+,infection,infection,USA,≥18 years,general pop,-13.6,-22.7,-5.2,,delta,~48.5 weeks,,,
350,Fu,Janssen,1,final,14+,infection,infection,USA,≥18 years,general pop,33,29.2,36.5,,delta,~42.5 weeks,,,
350,Fu,Pfizer,2,final,14+,infection,infection,USA,≥18 years,general pop,77.9,77.2,78.5,,"pre-delta (non-VOC, alpha)",~23 weeks,,,
350,Fu,Moderna,2,final,14+,infection,infection,USA,≥18 years,general pop,85.9,85.1,86.5,,"pre-delta (non-VOC, alpha)",~21 weeks,,,
350,Fu,mRNA (heterologous),2,final,14+,infection,infection,USA,≥18 years,general pop,78.9,66.6,87.7,,"pre-delta (non-VOC, alpha)",~23 weeks,,,
350,Fu,Janssen,1,final,14+,infection,infection,USA,≥18 years,general pop,81.4,78.4,84.2,,"pre-delta (non-VOC, alpha)",~17 weeks,,,
350,Fu,Pfizer,2,final,1st month,infection,infection,USA,≥18 years,general pop,47.3,46,48.5,,pre-delta & delta & omicron,,,,
350,Fu,Pfizer,2,final,12th month,infection,infection,USA,≥18 years,general pop,-32.8,-37.4,-28.3,,pre-delta & delta & omicron,~50 weeks,,,
350,Fu,Moderna,2,final,1st month,infection,infection,USA,≥18 years,general pop,64.7,63.3,66,,pre-delta & delta & omicron,,,,
350,Fu,Moderna,2,final,12th month,infection,infection,USA,≥18 years,general pop,-36.4,-43.2,-29.8,,pre-delta & delta & omicron,~50 weeks,,,
350,Fu,mRNA (heterologous),2,final,1st month,infection,infection,USA,≥18 years,general pop,-35.5,-48.6,-23.6,,pre-delta & delta & omicron,,,,
350,Fu,mRNA (heterologous),2,final,8th month,infection,infection,USA,≥18 years,general pop,-1.4,-28.3,20,,pre-delta & delta & omicron,~34 weeks,,,
350,Fu,Janssen,1,final,1st month,infection,infection,USA,≥18 years,general pop,30.8,23.5,37.4,,pre-delta & delta & omicron,,,,
350,Fu,Janssen,1,final,12th month,infection,infection,USA,≥18 years,general pop,71.1,60.5,78.8,,pre-delta & delta & omicron,~50 weeks,,,
351,Cegolon,Pfizer,2,final,14+,infection,infection,Italy,HCW,HCW,41,-49,77,,"omicron BA.1, BA.2, BA.4/BA.5",~69 weeks,,,
351,Cegolon,Pfizer,2,final,14+,infection,infection,Italy,HCW,HCW,-4,-43,24,,"omicron BA.1, BA.2, BA.4/BA.5",~69 weeks,,,
352,Khanam,AZD1222 (AstraZeneca),2,final,<19 weeks,symptomatic disease,symptomatic,Bangladesh,≥18 years,general pop,3,-129,59,,delta,~36 weeks,,,
352,Khanam,AZD1222 (AstraZeneca),2,final,>19 weeks,symptomatic disease,symptomatic,Bangladesh,≥18 years,general pop,-35,-112,14,,delta,~36 weeks,,,
352,Khanam,AZD1222 (AstraZeneca),2,final,14+,death,death,Bangladesh,≥18 years,general pop,86,-23,98,,delta,~36 weeks,,,
352,Khanam,BBIBP-CorV (Beijing CNBG),2,final,<19 weeks,symptomatic disease,symptomatic,Bangladesh,≥18 years,general pop,34,-16,62,,delta,~36 weeks,,,
352,Khanam,BBIBP-CorV (Beijing CNBG),2,final,>19 weeks,symptomatic disease,symptomatic,Bangladesh,≥18 years,general pop,-36,-886,81,,delta,~36 weeks,,,
352,Khanam,BBIBP-CorV (Beijing CNBG),2,final,14+,death,death,Bangladesh,≥18 years,general pop,75,-124,97,,delta,~36 weeks,,,
352,Khanam,Moderna,2,final,14+,symptomatic disease,symptomatic,Bangladesh,≥18 years,general pop,64,10,86,,delta,~36 weeks,,,
353,Nittayasoot,BBIBP-CorV (Beijing CNBG),2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,65.8,39.4,80.7,,"delta & omicron BA.1, BA.2",~54 weeks,,,
353,Nittayasoot,AZD1222 (AstraZeneca),2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,58.4,39.9,71.2,,"delta & omicron BA.1, BA.3",~54 weeks,,,
353,Nittayasoot,Pfizer,2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,71.7,49.7,84.1,,"delta & omicron BA.1, BA.4",~54 weeks,,,
353,Nittayasoot,CoronaVac (Sinovac) & AZD1222 (AstraZeneca) - heterologous,2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,71.7,63.2,78.2,,"delta & omicron BA.1, BA.5",~54 weeks,,,
353,Nittayasoot,Pfizer,2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,79.7,7.3,95.6,,"delta & omicron BA.1, BA.6",~54 weeks,,,
353,Nittayasoot,Pfizer,2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,83.1,62.3,92.4,,"delta & omicron BA.1, BA.7",~54 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,78,75,80,,omicron BA.1,~60 weeks,,,
354,Carazo,Pfizer,2,final,7-90,hospitalization,severe,Canada,≥60 years,≥60 years,86,78,91,,omicron BA.1,~60 weeks,,,
354,Carazo,Pfizer,2,final,270-359,hospitalization,severe,Canada,≥60 years,≥60 years,68,37,84,,omicron BA.1,~60 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,60,50,67,,omicron BA.2,~73 weeks,,,
354,Carazo,Pfizer,2,final,7-90,hospitalization,severe,Canada,≥60 years,≥60 years,66,28,84,,omicron BA.2,~73 weeks,,,
354,Carazo,Pfizer,2,final,360-449,hospitalization,severe,Canada,≥60 years,≥60 years,73,-13,94,,omicron BA.2,~73 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,40,30,49,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Pfizer,2,final,7-90,hospitalization,severe,Canada,≥60 years,≥60 years,55,-95,89,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Pfizer,2,final,360-449,hospitalization,severe,Canada,≥60 years,≥60 years,47,35,57,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,97,96,99,,omicron BA.1,~60 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,92,86,96,,omicron BA.2,~73 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,99,94,100,,omicron BA.2,~73 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,92,80,97,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Pfizer,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,91,85,95,,omicron BA.4/BA.5,~94 weeks,,,
355,Anzalone,Pfizer,2,final,14+,hospitalization,severe,USA,≥18 years,general pop,42,38,45,,delta,~47 weeks,,,
356,Horne,Pfizer,2,final,21-48,infection,infection,UK,18-39 years,18-39 years,75,74,76,,"alpha, delta, & omicron",~45 weeks,,,
356,Horne,Pfizer,2,final,245-272,infection,infection,UK,18-39 years,18-39 years,-83,-294,15,,"alpha, delta, & omicron",~45 weeks,,,
356,Horne,Pfizer,2,final,21-48,hospitalization,severe,UK,18-39 years,18-39 years,96,93,97,,"alpha, delta, & omicron",~45 weeks,,,
356,Horne,Pfizer,2,final,245-272,hospitalization,severe,UK,18-39 years,18-39 years,-48,-217,31,,"alpha, delta, & omicron",~45 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,21-48,infection,infection,UK,40-64 years,40-64 years,22,19,25,,"alpha, delta, & omicron",~36 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,301-328,infection,infection,UK,40-64 years,40-64 years,41,-47,77,,"alpha, delta, & omicron",~36 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,21-48,hospitalization,severe,UK,40-64 years,40-64 years,95,93,96,,"alpha, delta, & omicron",~36 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,301-328,hospitalization,severe,UK,40-64 years,40-64 years,44,-41,78,,"alpha, delta, & omicron",~36 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,77-104,death,death,UK,40-64 years,40-64 years,99,96,100,,"alpha, delta, & omicron",~36 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,217-244,death,death,UK,40-64 years,40-64 years,74,36,89,,"alpha, delta, & omicron",~36 weeks,,,
356,Horne,Pfizer,2,final,21-48,infection,infection,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,78,73,82,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,329-356,infection,infection,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,28,-41,63,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,21-48,hospitalization,severe,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,97,92,99,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,329-356,hospitalization,severe,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,28,-38,62,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,105-132,death,death,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,96,92,98,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,245-272,death,death,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,37,-36,70,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,21-48,infection,infection,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,26,20,33,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,329-356,infection,infection,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,14,-42,48,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,21-48,hospitalization,severe,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,93,89,96,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,329-356,hospitalization,severe,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,21,-30,52,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,49-76,death,death,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,96,87,99,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,301-328,death,death,UK,18-64 years clinically vulnerable,18-64 years clinically vulnerable,50,-125,89,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,21-48,infection,infection,UK,≥65 years,≥65 years,77,67,84,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,329-356,infection,infection,UK,≥65 years,≥65 years,4,-30,29,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,21-48,hospitalization,severe,UK,≥65 years,≥65 years,92,86,95,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,329-356,hospitalization,severe,UK,≥65 years,≥65 years,2,-34,27,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,21-48,death,death,UK,≥65 years,≥65 years,97,92,99,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,Pfizer,2,final,329-356,death,death,UK,≥65 years,≥65 years,33,-49,70,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,21-48,infection,infection,UK,≥65 years,≥65 years,47,29,61,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,329-356,infection,infection,UK,≥65 years,≥65 years,-12,-54,18,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,21-48,hospitalization,severe,UK,≥65 years,≥65 years,86,75,92,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,329-356,hospitalization,severe,UK,≥65 years,≥65 years,-12,-53,18,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,49-76,death,death,UK,≥65 years,≥65 years,93,84,97,,"alpha, delta, & omicron",~48 weeks,,,
356,Horne,AZD1222 (AstraZeneca),2,final,329-356,death,death,UK,≥65 years,≥65 years,23,-82,68,,"alpha, delta, & omicron",~48 weeks,,,
357,Lewis,Pfizer,2,final,150+,hospitalization,severe,USA,≥18 years,general pop,46,30,58,,omicron BA.1/BA.2,~63 weeks,,,
357,Lewis,Janssen,1,final,60+,hospitalization,severe,USA,≥18 years,general pop,36,-4,60,,omicron BA.1/BA.2,~55 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",47,40,53,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",35,31,40,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",59,39,72,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",58,51,65,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",42,33,49,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",37,32,41,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",65,48,76,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",57,49,64,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",54,47,61,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",31,25,36,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",62,45,74,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",55,47,63,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",51,43,58,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",27,20,33,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",63,43,75,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",43,32,52,,omicron BA.1,~62 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",87,84,89,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",81,79,82,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",90,84,94,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",85,82,87,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",85,81,88,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",80,77,81,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",91,85,95,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",86,83,88,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",89,85,91,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",74,71,77,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",94,88,97,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",82,78,85,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",84,79,87,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",75,72,78,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",90,83,94,,delta,~48.5 weeks,,,
358,Dalton,Pfizer,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",84,80,87,,delta,~48.5 weeks,,,
359,Jang,Pfizer,2,final,15-30,infection,infection,South Korea,5-11 years,5-11 years,57.6,51.6,62.8,,omicron,~11 weeks,,,
359,Jang,Pfizer,2,final,31-60,infection,infection,South Korea,5-11 years,5-11 years,46.9,43.7,49.9,,omicron,~11 weeks,,,
359,Jang,Pfizer,2,final,61-90,infection,infection,South Korea,5-11 years,5-11 years,41.2,34.3,47.4,,omicron,~11 weeks,,,
359,Jang,Pfizer,2,final,15-30,ICU admission or death,severe,South Korea,5-11 years,5-11 years,100,100,100,,omicron,~11 weeks,,,
359,Jang,Pfizer,2,final,31-60,ICU admission or death,severe,South Korea,5-11 years,5-11 years,100,100,100,,omicron,~11 weeks,,,
359,Jang,Pfizer,2,final,61-90,ICU admission or death,severe,South Korea,5-11 years,5-11 years,100,100,100,,omicron,~11 weeks,,,
360,Peebles,Pfizer,2,final,14+,infection,infection,USA,LTCF staff <65 years,LTCF staff <65 years,80,67.6,87.7,,non-VOC & alpha,~17 weeks,,,
360,Peebles,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,LTCF staff <65 years,LTCF staff <65 years,87.5,69.4,94.9,,non-VOC & alpha,~17 weeks,,,
360,Peebles,Pfizer,2,final,14+,asymptomatic infection,asymptomatic,USA,LTCF staff <65 years,LTCF staff <65 years,68.9,36,84.9,,non-VOC & alpha,~17 weeks,,,
361,Tartof,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,-53,-205,23,,omicron,~64.5 weeks,,,
361,Tartof,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,45,-4,70,,omicron,~64.5 weeks,,,
361,Tartof,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,70,11,90,,delta,~46.5 weeks,,,
361,Tartof,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,23,-225,82,,delta,~46.5 weeks,,,
361,Tartof,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,17,-40,51,,omicron or delta,~64.5 weeks,,,
361,Tartof,Pfizer,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,42,-1,66,,omicron or delta,~64.5 weeks,,,
362,Villar,Pfizer,2,final,0+,infection,infection,Multiple,pregnant women,pregnant women,11,0,21,,omicron,~74.5 weeks,,,
362,Villar,Pfizer,2,final,0+,moderate disease,symptomatic,Multiple,pregnant women,pregnant women,41,22,55,,omicron,~74.5 weeks,,,
362,Villar,Pfizer,2,final,0+,severe disease or death,severe,Multiple,pregnant women,pregnant women,56,27,74,,omicron,~74.5 weeks,,,
363,Alkadi,Pfizer,2,final,14+,infection,infection,Qatar,≥18 years on chronic hemodialysis,≥18 years on chronic hemodialysis,94.3,89,97,,"non-VOC, alpha, & delta",~48 weeks,,,
363,Alkadi,Moderna,2,final,14+,infection,infection,Qatar,≥18 years on chronic hemodialysis,≥18 years on chronic hemodialysis,98.2,88.6,99.9,,"non-VOC, alpha, & delta",~40 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,31-60,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,97,75,99.5,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,91-120,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,93,69,99,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,31-60,hospitalization (severe),severe,Iran,≥5 years,≥5 years,87,80,92,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,151+,hospitalization (severe),severe,Iran,≥5 years,≥5 years,90,51,98,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,31-60,ICU admission,severe,Iran,≥5 years,≥5 years,57,-41,87,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,91-120,ICU admission,severe,Iran,≥5 years,≥5 years,12,-113,63,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,31-60,death,death,Iran,≥5 years,≥5 years,80,48,92,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,AZD1222 (AstraZeneca),2,final,121-150,death,death,Iran,≥5 years,≥5 years,92,48,99,,alpha & delta,~23 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,31-60,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,78,69,84,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,151+,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,95,67,99.4,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,31-60,hospitalization (severe),severe,Iran,≥5 years,≥5 years,71,68,75,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,151+,hospitalization (severe),severe,Iran,≥5 years,≥5 years,85,77,91,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,31-60,ICU admission,severe,Iran,≥5 years,≥5 years,25,-9,48,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,151+,ICU admission,severe,Iran,≥5 years,≥5 years,26,-77,69,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,31-60,death,death,Iran,≥5 years,≥5 years,41,23,55,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BBIBP-CorV (Beijing CNBG),2,final,151+,death,death,Iran,≥5 years,≥5 years,33,-40,69,,alpha & delta,~36 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,31-60,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,96,68,99.4,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,61-90,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,97,76,99.6,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,31-60,hospitalization (severe),severe,Iran,≥5 years,≥5 years,82,73,88,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,91-120,hospitalization (severe),severe,Iran,≥5 years,≥5 years,92,86,96,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,31-60,ICU admission,severe,Iran,≥5 years,≥5 years,61,-61,91,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,91-120,ICU admission,severe,Iran,≥5 years,≥5 years,35,-116,80,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,31-60,death,death,Iran,≥5 years,≥5 years,88,48,97,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,BIV1-CovIran,2,final,91-120,death,death,Iran,≥5 years,≥5 years,93,46,99,,alpha & delta,~21 weeks,,,
364,Heidarzadeh,Covaxin,2,final,61-90,hospitalization (severe),severe,Iran,≥5 years,≥5 years,55,-33,85,,alpha & delta,~35 weeks,,,
364,Heidarzadeh,Covaxin,2,final,151+,hospitalization (severe),severe,Iran,≥5 years,≥5 years,96,68,99.5,,alpha & delta,~35 weeks,,,
364,Heidarzadeh,Covaxin,2,final,91-120,death,death,Iran,≥5 years,≥5 years,4,-671,79,,alpha & delta,~35 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,31-60,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,74,-9,94,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,151+,hospitalization (moderate),severe,Iran,≥5 years,≥5 years,95,79,99,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,31-60,hospitalization (severe),severe,Iran,≥5 years,≥5 years,62,32,78,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,151+,hospitalization (severe),severe,Iran,≥5 years,≥5 years,93,88,96,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,91-120,ICU admission,severe,Iran,≥5 years,≥5 years,51,-258,94,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,151+,ICU admission,severe,Iran,≥5 years,≥5 years,18,-136,71,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,31-60,death,death,Iran,≥5 years,≥5 years,25,-149,78,,alpha & delta,~40 weeks,,,
364,Heidarzadeh,Sputnik V (Gamaleya),2,final,151+,death,death,Iran,≥5 years,≥5 years,93,47,99.1,,alpha & delta,~40 weeks,,,
365,Lin,Moderna,2,final,0 to ~4 weeks,infection,infection,USA,0-4 years,0-4 years,58,47.5,66.5,,omicron (all lineages),~23 weeks,,,
365,Lin,Moderna,2,final,~16-21 weeks,infection,infection,USA,0-4 years,0-4 years,47.6,27.7,62,,omicron (all lineages),~23 weeks,,,
365,Lin,Pfizer,2,final,0 to ~5 weeks,hospitalization or death,severe,USA,5-11 years,5-11 years,73.3,8.3,92.3,,omicron (all lineages),~57 weeks,,,
365,Lin,Pfizer,2,final,~20-25 weeks,hospitalization or death,severe,USA,5-11 years,5-11 years,2.9,-50.8,37.4,,omicron (all lineages),~57 weeks,,,
365,Lin,Pfizer,2,final,0 to ~5 weeks,infection,infection,USA,0-4 years,0-4 years,37.5,21.2,50.4,,omicron (all lineages),~24 weeks,,,
365,Lin,Pfizer,2,final,~16-21 weeks,infection,infection,USA,0-4 years,0-4 years,46.8,-0.3,71.8,,omicron (all lineages),~24 weeks,,,
365,Lin,Pfizer,2,final,0 to ~5 weeks,infection,infection,USA,5-11 years,5-11 years,65.3,58.1,71.2,,omicron (all lineages),~57 weeks,,,
365,Lin,Pfizer,2,final,~24-29 weeks,infection,infection,USA,5-11 years,5-11 years,4.6,-2.1,10.9,,omicron (all lineages),~57 weeks,,,
365,Lin,Pfizer,2,final,0 to ~5 weeks,infection,infection,USA,0-4 years,0-4 years,55.7,49.1,61.5,,omicron (all lineages),~24 weeks,,,
365,Lin,Pfizer,2,final,~16-21 weeks,infection,infection,USA,0-4 years,0-4 years,58.6,48.3,66.9,,omicron (all lineages),~24 weeks,,,
365,Lin,Pfizer,2,final,0 to ~5 weeks,infection,infection,USA,5-11 years,5-11 years,59.7,58.3,61,,omicron (all lineages),~57 weeks,,,
365,Lin,Pfizer,2,final,~36-41 weeks,infection,infection,USA,5-11 years,5-11 years,16,13.1,18.7,,omicron (all lineages),~57 weeks,,,
366,Battacharya,BBV152 (Bharat),2,final,7+,hospitalization with symptoms of pulmonary disease,severe,India,≥18 years,general pop,74,50.5,86,,delta,~22 weeks,,,
366,Battacharya,AZD1222 (Covishield),2,final,7+,hospitalization with symptoms of pulmonary disease,severe,India,≥18 years,general pop,79,53.1,81,,delta,~22 weeks,,,
367,Ellingson,Pfizer,2,final,14+,infection,infection,USA,frontline workers,general pop,43,35,57,,omicron,~63 weeks,,,
368,Niesen,Pfizer,2,final,14-73,symptomatic disease,symptomatic,USA,≥18 years,general pop,80.6,76.9,83.7,,delta,~54 weeks,,,
368,Niesen,Pfizer,2,final,314-355,symptomatic disease,symptomatic,USA,≥18 years,general pop,43.3,28.8,54.7,,delta,~54 weeks,,,
368,Niesen,Moderna,2,final,7-13,symptomatic disease,symptomatic,USA,≥18 years,general pop,94.8,88,97.8,,delta,~54 weeks,,,
368,Niesen,Moderna,2,final,254-313,symptomatic disease,symptomatic,USA,≥18 years,general pop,63.2,53.7,70.7,,delta,~54 weeks,,,
369,Toh,CoronaVac (Sinovac),2,final,15+,hospitalization,severe,Malaysia,≥18 years,general pop,76.5,45.6,89.8,,non-VOC & delta,~24 weeks,,,
370,Tartof,Pfizer,2,final,14-89,ED or UC encounters,symptomatic,USA,5-11 years,5-11 years,60,47,69,,"omicron BA.1, BA.2, BA.4/BA.5",~39 weeks,,,
370,Tartof,Pfizer,2,final,90+,ED or UC encounters,symptomatic,USA,5-11 years,5-11 years,28,8,43,,"omicron BA.1, BA.2, BA.4/BA.5",~39 weeks,,,
370,Tartof,Pfizer,2,final,90+,ED or UC encounters,symptomatic,USA,5-11 years,5-11 years,85,59,95,,delta,~5 weeks,,,
371,Sritipsukho,CoronaVac (Sinovac),2,final,<90 days,infection,infection,Thailand,≥18 years,general pop,47,7,70,,omicron BA.1/BA.2,~67 weeks,,,
371,Sritipsukho,CoronaVac (Sinovac),2,final,>90 days,infection,infection,Thailand,≥18 years,general pop,21,-15,47,,omicron BA.1/BA.2,~67 weeks,,,
371,Sritipsukho,CoronaVac (Sinovac),2,final,14+,moderate to critical disease,symptomatic,Thailand,≥18 years,general pop,-4,-50,45,,omicron BA.1/BA.2,~67 weeks,,,
371,Sritipsukho,AZD1222 (AstraZeneca),2,final,<90 days,infection,infection,Thailand,≥18 years,general pop,61,41,74,,omicron BA.1/BA.2,~67 weeks,,,
371,Sritipsukho,AZD1222 (AstraZeneca),2,final,>90 days,infection,infection,Thailand,≥18 years,general pop,30,0,51,,omicron BA.1/BA.2,~67 weeks,,,
371,Sritipsukho,AZD1222 (AstraZeneca),2,final,14+,moderate to critical disease,symptomatic,Thailand,≥18 years,general pop,56,25,74,,omicron BA.1/BA.2,~67 weeks,,,
372,Weng,Pfizer,2,final,14+,infection,infection,USA,≥12 years,≥12 years,94.6,83.4,98.3,,alpha,~48 weeks,,,
372,Weng,Moderna,2,final,14+,infection,infection,USA,≥12 years,≥12 years,97.5,82.5,99.7,,alpha,~48 weeks,,,
372,Weng,Pfizer,2,final,14+,infection,infection,USA,≥12 years,≥12 years,64.8,54.2,73,,delta,~48 weeks,,,
372,Weng,Moderna,2,final,14+,infection,infection,USA,≥12 years,≥12 years,65,52.9,74.1,,delta,~48 weeks,,,
372,Weng,Pfizer,2,final,14+,infection,infection,USA,≥12 years,≥12 years,31.6,19.6,42.5,,omicron BA.1,~48 weeks,,,
372,Weng,Moderna,2,final,14+,infection,infection,USA,≥12 years,≥12 years,25.6,10.7,39,,omicron BA.1,~48 weeks,,,
373,Huang,MVC-COV1901 (Medigen),2,final,14+,infection,infection,Taiwan,≥20 years,general pop,38.3,32.6,43.5,,"omicron BA.1, BA.2, BA.4/BA.5",~52 weeks,,,
373,Huang,MVC-COV1901 (Medigen),2,final,14+,moderate to severe disease,symptomatic,Taiwan,≥20 years,general pop,79.6,56.7,90.4,,"omicron BA.1, BA.2, BA.4/BA.5",~52 weeks,,,
6,Tande,Moderna,1+,1+,10,asymptomatic infection,asymptomatic,USA,pre-surgical hospital patients,pre-surgical hospital patients,79,63,88,,original,,,,
6,Tande,Moderna,2,final,>0,asymptomatic infection,asymptomatic,USA,pre-surgical hospital patients,pre-surgical hospital patients,80,56,91,,original,,,,
11,Thompson,Moderna,1,1,>14,infection ,infection,USA,HCW,HCW,80,59,90,,original,,,,
11,Thompson,Moderna,2,final,>14,infection ,infection,USA,HCW,HCW,90,68,97,,original,,,,
12,Bouton,Moderna,1+,1+,14,infection ,infection,USA,HCW,HCW,82,68,90,,original,,,,
14,Andrejko,Moderna,1,1,≥15,infection ,infection,USA,general pop,general pop,66.9,28.7,84.6,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Moderna,2,final,≥15,infection ,infection,USA,general pop,general pop,87.4,77.2,93.1,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Moderna,2,final,≥15,asymptomatic infection,asymptomatic,USA,general pop,general pop,68.3,27.9,85.7,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Moderna,2,final,≥15,symptomatic disease,symptomatic,USA,general pop,general pop,91.3,79.3,96.3,,B.1.427/ B.1.429 & alpha,,,,
14,Andrejko,Moderna,2,final,≥15,hospitalization,severe,USA,general pop,general pop,100,,,,B.1.427/ B.1.429 & alpha,,,,
22,Tenforde,Moderna,1+,1+,28,hospitalization,severe,USA,hospital patients ≥ 65 years,≥ 65 years,64,28,82,,original & alpha,,,,
22,Tenforde,Moderna,2,final,>14,hospitalization,severe,USA,hospital patients ≥ 65 years,≥ 65 years,94,49,99,,original & alpha,,,,
30,Pilishvili ,Moderna,1+,1+,21,symptomatic disease,symptomatic,USA,HCW,HCW,82,74,87,,unknown,,,,
30,Pilishvili ,Moderna,2,final,>7,symptomatic disease,symptomatic,USA,HCW,HCW,94,87,97,,unknown,,,,
34,Chung,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,61,56,66,alpha,alpha,,,,
34,Chung,Moderna,2,final,7+,symptomatic disease,symptomatic,Canada,general pop,general pop,90,85,94,alpha,alpha,15 weeks,,,
34,Chung,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,59,39,73,alpha,alpha,,,,
34,Chung,Moderna,2,final,0+,hospitalization or death,severe,Canada,general pop,general pop,94,59,99,alpha,alpha,15 weeks,,,
34,Chung,Moderna,1,1,14+,symptomatic disease,symptomatic,Canada,general pop,general pop,43,22,59,beta & gamma,beta & gamma,,,,
34,Chung,Moderna,2,final,7+,symptomatic disease,symptomatic,Canada,general pop,general pop,88,61,96,beta & gamma,beta & gamma,15 weeks,,,
34,Chung,Moderna,1,1,14+,hospitalization or death,severe,Canada,general pop,general pop,56,-9,82,   ,beta & gamma,,15 weeks,,
34,Chung,Moderna,2,final,7+,hospitalization or death,severe,Canada,general pop,general pop,100,,,   ,beta & gamma,beta & gamma,15 weeks,,
36,Khan,Moderna,1+,1+,21,infection ,infection,USA,hospital patients,general pop,-1,-50,32,,unknown,,,,
36,Khan,Moderna,2,final,7+,infection ,infection,USA,hospital patients,general pop,69,44,83,,unknown,14 weeks,,,
36,Khan,Moderna,1+,1+,21,hospitalization or death,severe,USA,hospital patients,general pop,9,-114,61,,unknown,,,,
36,Khan,Moderna,2,final,7+,hospitalization or death,severe,USA,hospital patients,general pop,49,-36,81,,unknown,14 weeks,,,
37,Salo,Moderna,1,1,4 weeks,infection ,infection,Finland,HCW,HCW,44.4,30.4,55.6,,alpha,,,,
37,Salo,Moderna,1+,1+,84,infection ,infection,Finland,HCW,HCW,63,56.3,68.7,,alpha,,,,
40,Skowornski,Moderna,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,67,57,75,alpha,alpha,,,,
40,Skowornski,Moderna,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,61,45,72,gamma,gamma,,,,
40,Skowornski,Moderna,1,1,21+,infection ,infection,Canada,> 70 years,> 70 years,72,58,81,non-VOC,non-VOC,,,,
45,Young-Xu,Moderna,1,1,7+,infection ,infection,USA,general pop,general pop,58,54,62,,original & alpha,,,,
45,Young-Xu,Moderna,2,final,7+,infection ,infection,USA,general pop,general pop,94,92,95,,original & alpha,~8 weeks,,,
45,Young-Xu,Moderna,1,1,7+,hospitalization,severe,USA,general pop,general pop,40,27,50,,original & alpha,,,,
45,Young-Xu,Moderna,2,final,7+,hospitalization,severe,USA,general pop,general pop,89,81,93,,original & alpha,~8 weeks,,,
45,Young-Xu,Moderna,1,1,7+,death,death,USA,general pop,general pop,55,21,74,,original & alpha,,,,
45,Young-Xu,Moderna,2,final,7+,death,death,USA,general pop,general pop,98.5,86.6,99.8,,original & alpha,~8 weeks,,,
45,Young-Xu,Moderna,1,1,7+,asymptomatic infection,asymptomatic,USA,general pop,general pop,58,41.7,69.7,,original & alpha,,,,
45,Young-Xu,Moderna,2,final,7+,asymptomatic infection,asymptomatic,USA,general pop,general pop,69.7,47.7,82.5,,original & alpha,~8 weeks,,,
45,Young-Xu,Moderna,1,1,7+,hospitalization,severe,USA,general pop,general pop,53,25.7,70.3,,original & alpha,,,,
45,Young-Xu,Moderna,2,final,7+,hospitalization,severe,USA,general pop,general pop,88.4,74.9,94.7,,original & alpha,~8 weeks,,,
45,Young-Xu,Moderna,1,1,7+,death,death,USA,general pop,general pop,55.6,26.6,73.2,,original & alpha,,,,
45,Young-Xu,Moderna,2,final,7+,death,death,USA,general pop,general pop,97,91.7,98.9,,original & alpha,~8 weeks,,,
48,Baum,Moderna,1,1,21+,infection ,infection,Finland,≥ 70 years,≥ 70 years,45,36,53,,original & alpha,,,,
48,Baum,Moderna,2,final,7+,infection ,infection,Finland,≥ 70 years,≥ 70 years,75,65,82,,original & alpha,16 weeks,,,
48,Baum,Moderna,1,1,21+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,63,49,74,,original & alpha,,,,
48,Baum,Moderna,2,final,7+,hospitalization,severe,Finland,≥ 70 years,≥ 70 years,93,70,98,,original & alpha,16 weeks,,,
48,Baum,Moderna,1,1,21+,infection ,infection,Finland,chronically ill,chronically ill,40,26,51,,original & alpha,,,,
48,Baum,Moderna,2,final,7+,infection ,infection,Finland,chronically ill,chronically ill,77,65,85,,original & alpha,16 weeks,,,
48,Baum,Moderna,1,1,21+,hospitalization,severe,Finland,chronically ill,chronically ill,82,56,93,,original & alpha,,,,
48,Baum,Moderna,2,final,7+,hospitalization,severe,Finland,chronically ill,chronically ill,90,29,99,,original & alpha,16 weeks,,,
51,Tenforde,Moderna,1+,1+,28,hospitalization,severe,USA,hospital patients,general pop,75.4,60.4,84.7,,original & alpha,,,,
51,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,hospital patients,general pop,86.6,79,91.4,,original & alpha,~2 weeks,,,
51,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,hospital patients,general pop,92.1,82.3,96.5,alpha,alpha,~2 weeks,,,
54,Bertollini,Moderna,2,final,14+,infection ,infection,Qatar,general pop,general pop,78,72,83,,"original, alpha & beta",~4 weeks,,,
55,John,Moderna,1+,1+,28,infection ,infection,USA,patients with cirrhosis,patients with cirrhosis,64.8,10.9,86.1,,original & alpha,,,,
55,John,Moderna,2,final,7+,infection ,infection,USA,patients with cirrhosis,patients with cirrhosis,78.6,25.5,93.8,,original & alpha,~10 weeks,,,
55,John,Moderna,1+,1+,28,hospitalization,severe,USA,patients with cirrhosis,patients with cirrhosis,100,99.3,100,,original & alpha,,,,
55,John,Moderna,2,final,7+,hospitalization,severe,USA,patients with cirrhosis,patients with cirrhosis,100,99,100,,original & alpha,~10 weeks,,,
55,John,Moderna,1+,1+,28,death,death,USA,patients with cirrhosis,patients with cirrhosis,100,99.3,100,,original & alpha,,,,
55,John,Moderna,2,final,7+,death,death,USA,patients with cirrhosis,patients with cirrhosis,100,99,100,,original & alpha,~10 weeks,,,
61,Butt,Moderna,1,1,0+,infection ,infection,USA,general pop,general pop,85,84.2,85.8,,original & alpha,,,,
61,Butt,Moderna,2,final,7+,infection ,infection,USA,general pop,general pop,97.1,96.6,97.5,,original & alpha,~6.5 weeks,,,
63,Kim,Moderna,1+,1+,28,symptomatic disease,symptomatic,USA,general pop,general pop,75,55,87,,non-VOC & alpha,,,,
63,Kim,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,general pop,general pop,91,83,95,,non-VOC & alpha,~18.5 weeks,,,
65,Carazo,Moderna,1,1,14+,hospitalization,severe,Canada,HCW,HCW,97.2,92.3,99,,non-VOC & alpha,,,,
65,Carazo,Moderna,1,1,14+,infection ,infection,Canada,HCW,HCW,60,53.6,65.5,alpha,alpha,,,,
65,Carazo,Moderna,2,final,7+,infection ,infection,Canada,HCW,HCW,92.6,87.1,95.8,alpha,alpha,~20 weeks,,,
65,Carazo,Moderna,1,1,14+,infection ,infection,Canada,HCW,HCW,77,72.6,80.7,non-VOC,non-VOC,,,,
65,Carazo,Moderna,2,final,7+,infection ,infection,Canada,HCW,HCW,86.5,56.8,95.8,non-VOC,non-VOC,~20 weeks,,,
73,Chemaitelly,Moderna,2,final,14+,infection ,infection,Qatar,transplant patients,transplant patients,46.6,0,73.7,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Moderna,2,final,42+,infection ,infection,Qatar,transplant patients,transplant patients,66,21.3,85.3,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Moderna,2,final,56+,infection ,infection,Qatar,transplant patients,transplant patients,73.9,33,89.9,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Moderna,2,final,14+,severe infection,severe,Qatar,transplant patients,transplant patients,72.3,0,90.9,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Moderna,2,final,42+,severe infection,severe,Qatar,transplant patients,transplant patients,85,35.7,96.5,,alpha & beta,~17 weeks,,,
73,Chemaitelly,Moderna,2,final,56+,severe infection,severe,Qatar,transplant patients,transplant patients,83.8,31.3,96.2,,alpha & beta,~17 weeks,,,
76,Chin,Moderna,1,1,14+,infection ,infection,USA,incarcerated persons,incarcerated persons,74,64,82,,non-VOC,,,,
76,Chin,Moderna,2,final,14+,infection ,infection,USA,incarcerated persons,incarcerated persons,97,88,99,,non-VOC,~5 weeks,,,
76,Chin,Moderna,1,1,14+,infection ,infection,USA,"incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",74,62,82,,non-VOC,,,,
76,Chin,Moderna,2,final,14+,infection ,infection,USA,"incarcerated persons, moderate/high risk for severe disease","incarcerated persons, moderate/high risk for severe disease",92,74,98,,non-VOC,~5 weeks,,,
77,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,immuncompetent,immuncompetent,90,87,91,,alpha & delta,~30 weeks,,,
77,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,immucompromised,"immunocompromised, ≥ 16 years",51,31,65,,alpha & delta,~30 weeks,,,
77,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,general pop,general pop,90,84,94,alpha,alpha,~30 weeks,,,
77,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,general pop,general pop,86,79,90,delta,delta,~30 weeks,,,
79,Prasad,Moderna,2,final,14+,post-operative infection,infection,USA,surgery patients,surgery patients,91,56,99,,non-VOC,~8 weeks,,,
83,Nunes,Moderna,1,1,28,hospitalization,severe,Portugal,65-79 years,65-79 years,78,61,87,,alpha & delta,,,,
83,Nunes,Moderna,2,final,14+,hospitalization,severe,Portugal,65-79 years,65-79 years,94,88,97,,alpha & delta,~14.5 weeks,,,
83,Nunes,Moderna,1,1,28,death,death,Portugal,65-79 years,65-79 years,77,56,88,,alpha & delta,,,,
83,Nunes,Moderna,2,final,14+,death,death,Portugal,65-79 years,65-79 years,96,92,98,,alpha & delta,~14.5 weeks,,,
83,Nunes,Moderna,1,1,28,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,55,36,69,,alpha & delta,,,,
83,Nunes,Moderna,2,final,14+,hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,82,72,89,,alpha & delta,~22.5 weeks,,,
83,Nunes,Moderna,1,1,28,death,death,Portugal,≥ 80 years,≥ 80 years,56,35,70,,alpha & delta,,,,
83,Nunes,Moderna,2,final,14+,death,death,Portugal,≥ 80 years,≥ 80 years,81,74,87,,alpha & delta,~22.5 weeks,,,
85,Giansante,Moderna,1,1,14+,infection,infection,Italy,HCW and staff,HCW and staff,85.5,75.9,91.3,,alpha & delta,,,,
85,Giansante,Moderna,2,final,14+,infection,infection,Italy,HCW and staff,HCW and staff,84.8,73.2,91.4,,alpha & delta,~16 weeks,,,
85,Giansante,Moderna,1,1,14+,symptomatic disease,symptomatic,Italy,HCW and staff,HCW and staff,81.7,62.7,91,,alpha & delta,,,,
85,Giansante,Moderna,2,final,14+,symptomatic disease,symptomatic,Italy,HCW and staff,HCW and staff,87.1,69.3,94.6,,alpha & delta,~16 weeks,,,
85,Giansante,Moderna,1,1,14+,infection,infection,Italy,HCW,HCW,87.8,76.5,93.7,,alpha & delta,,,,
85,Giansante,Moderna,2,final,14+,infection,infection,Italy,HCW,HCW,84.4,69.7,92,,alpha & delta,~16 weeks,,,
85,Giansante,Moderna,1,1,14+,symptomatic disease,symptomatic,Italy,HCW,HCW,83.1,60,92.9,,alpha & delta,,,,
85,Giansante,Moderna,2,final,14+,symptomatic disease,symptomatic,Italy,HCW,HCW,86.5,62.9,95.1,,alpha & delta,~16 weeks,,,
87,Barlow,Moderna,2,final,14+,infection,infection,USA,≥ 15 years,general pop,74,65,82,,delta,~4 weeks,,,
88,Tande,Moderna,1,1,20+,asymptomatic infection (January-March),asymptomatic,USA,surgery patients,surgery patients,44,-6,71,,non-VOC,,,,
88,Tande,Moderna,2,final,14+,asymptomatic infection (January-March),asymptomatic,USA,surgery patients,surgery patients,91,72,98,,non-VOC,~10 weeks,,,
88,Tande,Moderna,1,1,20+,asymptomatic infection (April-May),asymptomatic,USA,surgery patients,surgery patients,46,53,83,,alpha,,,,
88,Tande,Moderna,2,final,14+,asymptomatic infection (April-May),asymptomatic,USA,surgery patients,surgery patients,71,53,83,,alpha,~19 weeks,,,
88,Tande,Moderna,1,1,20+,asymptomatic infection (June-August),asymptomatic,USA,surgery patients,surgery patients,63,44,76,,delta,,,,
88,Tande,Moderna,2,final,14+,asymptomatic infection (June-August),asymptomatic,USA,surgery patients,surgery patients,63,44,76,,delta,~32 weeks,,,
89,Iliaki,Moderna,1,1,14+,infection,infection,USA,HCW,HCW,80.2,57.5,90.8,,alpha,,,,
89,Iliaki,Moderna,2,final,14+,infection,infection,USA,HCW,HCW,95.2,80,98.8,,alpha,~10 weeks,,,
90,Thompson,Moderna,1,1,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic respiratory condition,≥ 50 years with ≥ 1 chronic respiratory condition,56,47,64,,non-VOC & alpha,,,,
90,Thompson,Moderna,2,final,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic respiratory condition,≥ 50 years with ≥ 1 chronic respiratory condition,90,88,92,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Moderna,1,1,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic non-respiratory condition,≥ 50 years with ≥ 1 chronic non-respiratory condition,54,45,61,,non-VOC & alpha,,,,
90,Thompson,Moderna,2,final,14+,hospitalization,severe,USA,≥ 50 years with ≥ 1 chronic non-respiratory condition,≥ 50 years with ≥ 1 chronic non-respiratory condition,88,86,90,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Moderna,2,final,14-27,hospitalization,severe,USA,≥ 50 years,≥ 50 years,88,84,92,,non-VOC & alpha,~2 weeks,,,
90,Thompson,Moderna,2,final,112+,hospitalization,severe,USA,≥ 50 years,≥ 50 years,86,74,93,,non-VOC & alpha,~22 weeks,,,
90,Thompson,Moderna,2,final,14-27,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,92,88,95,,non-VOC & alpha,~2 weeks,,,
90,Thompson,Moderna,2,final,112+,ED or UC visits,symptomatic,USA,≥ 50 years,≥ 50 years,86,74,93,,non-VOC & alpha,~22 weeks,,,
91,Dagan,Moderna,1,1,21-27,infection,infection,Israel ,pregnant women,pregnant persons,71,33,94,,alpha,,,,
91,Dagan,Moderna,2,final,7-56,infection ,infection,Israel ,pregnant women,pregnant persons,96,89,100,,alpha,~11 weeks,,,
91,Dagan,Moderna,1,1,21-27,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,76,30,100,,alpha,,,,
91,Dagan,Moderna,2,final,7-56,symptomatic disease,symptomatic,Israel ,pregnant women,pregnant persons,97,91,100,,alpha,~11 weeks,,,
91,Dagan,Moderna,2,final,7-56,hospitalization,severe,Israel ,pregnant women,pregnant persons,89,43,100,,alpha,~11 weeks,,,
94,Bajema,Moderna,2,final,<104 days,hospitalization,severe,USA,hospitalized veterans,hospitalized veterans,86.1,76.5,91.8,,"alpha, delta, non-VOC",~13 weeks,,,
94,Bajema,Moderna,2,final,>104 days,hospitalization,severe,USA,hospitalized veterans,hospitalized veterans,87.2,78.2,92.5,,"alpha, delta, non-VOC",~28.5 weeks,,,
94,Bajema,Moderna,2,final,14+,hospitalization (February-June),severe,USA,hospitalized veterans,hospitalized veterans,84.1,74.1,90.2,,alpha,~23 weeks,,,
94,Bajema,Moderna,2,final,14+,hospitalization (July-August),severe,USA,hospitalized veterans,hospitalized veterans,89.3,80.1,94.3,,delta,~28.5 weeks,,,
98,Skowronski,Moderna,1,1,14-20,hospitalization,severe,Canada,50-69 years,50-69 years,74,60,83,,"alpha, gamma & delta",,,,
98,Skowronski,Moderna,1,1,98+,hospitalization,severe,Canada,50-69 years,50-69 years,65,47,77,,"alpha, gamma & delta",,,,
99,Pilishvili,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,HCW,HCW,88.9,84.7,92,,alpha,~14 weeks,,,
99,Pilishvili,Moderna,2,final,15-28,symptomatic disease,symptomatic,USA,HCW,HCW,96.3,92.5,98.2,,alpha,~14 weeks,,,
99,Pilishvili,Moderna,2,final,85-98,symptomatic disease,symptomatic,USA,HCW,HCW,80.7,61,90.4,,alpha,~14 weeks,,,
99,Pilishvili,Moderna,1,1,21,symptomatic disease,symptomatic,USA,immunocompromised HCW,immunocompromised HCW,39.1,-45,74.4,,alpha,,,,
99,Pilishvili,Moderna,1,1,21,symptomatic disease,symptomatic,USA,pregnant HCW,pregnant HCW,77.1,32.2,92.2,,alpha,,,,
105,Liu,Moderna,2,final,14+,infection,infection,USA,≥ 18 years,general pop,59,52,65,,alpha & delta,~35 weeks,,,
105,Liu,Moderna,2,final,14+,infection,infection,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,57,45,66,,alpha & delta,~35 weeks,,,
118,Embi,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,76,69,81,,non-VOC & alpha,~33 weeks,,,
118,Embi,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,91,90,93,,non-VOC & alpha,~33 weeks,,,
118,Embi,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥ 18 years",immunocompromised adults,79,74,83,,delta,~33 weeks,,,
118,Embi,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,90,89,91,,delta,~33 weeks,,,
121,Ng,Moderna,2,final,15+,Infection,infection,Singapore,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,61.6,37.5,80.4,delta,delta,~16.5 weeks,,,
121,Ng,Moderna,2,final,15+,symptomatic disease,symptomatic,Singapore,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,67.9,41.3,87.8,delta,delta,~16.5 weeks,,,
121,Ng,Moderna,2,final,15+,severe disease,severe,Singapore,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,100,,,delta,delta,~16.5 weeks,,,
127,Wu,Moderna,1,1,14+,Infection,infection,USA,cancer patients,immunocompromised adults,45,8,66,,non-VOC & alpha,,,,
127,Wu,Moderna,2,final,14+,Infection,infection,USA,cancer patients,immunocompromised adults,58,39,73,,non-VOC & alpha,15 weeks,,,
129,Yassi,Moderna,2,final,7+,Infection,infection,Canada,HCW,HCW,74.1,62.5,82.1,,"non-VOC, alpha, & delta",~40.5 weeks,,,
129,Yassi,Moderna,2,final,7+,Infection,infection,Canada,HCW,HCW,82.8,74,88.6,,"non-VOC, alpha, & delta",~40.5 weeks,,,
134,Machado,Moderna,2,final,14-41,symptomatic disease,symptomatic,Portugal,65-79 years,65-79 years,79,76,83,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,98+,symptomatic disease,symptomatic,Portugal,65-79 years,65-79 years,39,29,48,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,14-41,symptomatic disease,symptomatic,Portugal,≥ 80 years,≥ 80 years,72,61,79,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,124+,symptomatic disease,symptomatic,Portugal,≥ 80 years,≥ 80 years,34,29,48,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,14-41,Hospitalization,severe,Portugal,65-79 years,65-79 years,95,90,97,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,70+,Hospitalization,severe,Portugal,65-79 years,65-79 years,93,86,96,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,14-41,Hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,83,68,91,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,124+,Hospitalization,severe,Portugal,≥ 80 years,≥ 80 years,63,37,78,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,14-41,death,death,Portugal,65-79 years,65-79 years,95,88,98,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,70+,death,death,Portugal,65-79 years,65-79 years,93,87,96,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,14-41,death,death,Portugal,≥ 80 years,≥ 80 years,87,71,93,,alpha & delta,~29 weeks,,,
134,Machado,Moderna,2,final,124+,death,death,Portugal,≥ 80 years,≥ 80 years,75,64,82,,alpha & delta,~29 weeks,,,
136,Young-Xu,Moderna,2,final,14-43,Infection,infection,USA,males 65+,males 65+,94.5,90.7,96.7,,non-VOC & alpha,4 weeks,,,
136,Young-Xu,Moderna,2,final,74-103,Infection,infection,USA,males 65+,males 65+,87.9,85.9,89.5,,non-VOC & alpha,12 weeks,,,
136,Young-Xu,Moderna,2,final,14-43,Infection,infection,USA,males 65+,males 65+,92.1,87.2,95.1,,alpha & delta,4 weeks,,,
136,Young-Xu,Moderna,2,final,134-163,Infection,infection,USA,males 65+,males 65+,67.3,63.2,70.9,,alpha & delta,20 weeks,,,
136,Young-Xu,Moderna,2,final,14-43,Infection,infection,USA,males 65+,males 65+,62,45.6,73.5,,delta,4 weeks,,,
136,Young-Xu,Moderna,2,final,224-253,Infection,infection,USA,males 65+,males 65+,24.8,18.8,30.4,,delta,32 weeks,,,
142,Lewis,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,96,93,98,,alpha & delta,~30 weeks,,,
142,Lewis,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,93,89,95,,alpha & delta,~30 weeks,,,
142,Lewis,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,87,82,91,,alpha & delta,~30 weeks,,,
142,Lewis,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,83,72,88,,alpha & delta,~30 weeks,,,
143,Ioannou,Moderna,1,1,14+,infection (March 31 2021),infection,USA,≥ 18 years,general pop,31,26,35,,non-VOC & alpha,,,,
143,Ioannou,Moderna,2,final,7+,infection (March 31 2021),infection,USA,≥ 18 years,general pop,65,63,68,,non-VOC & alpha,~28 weeks,,,
143,Ioannou,Moderna,2,final,7+,infection (June 30 2021),infection,USA,≥ 18 years,general pop,69,67,70,,non-VOC & alpha,~28 weeks,,,
143,Ioannou,Moderna,1,1,14+,death (March 31 2021),death,USA,≥ 18 years,general pop,55,42,64,,non-VOC & alpha,,,,
143,Ioannou,Moderna,2,final,7+,death (March 31 2021),death,USA,≥ 18 years,general pop,89,84,92,,non-VOC & alpha,~28 weeks,,,
143,Ioannou,Moderna,2,final,7+,death (June 30 2021),death,USA,≥ 18 years,general pop,86,82,89,,non-VOC & alpha,~28 weeks,,,
154,Buchan,Moderna,2,final,7-59,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,36,24,45,omicron,omicron,~34 weeks,,,
154,Buchan,Moderna,2,final,240+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,2,-17,17,omicron,omicron,~34 weeks,,,
154,Buchan,Moderna,2,final,7-59,Infection,infection,Canada,≥ 18 years,general pop,5,-25,30,omicron,omicron,~34 weeks,,,
154,Buchan,Moderna,2,final,240+,Infection,infection,Canada,≥ 18 years,general pop,-18,-62,18,omicron,omicron,~34 weeks,,,
154,Buchan,Moderna,2,final,7-59,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,89,86,92,,delta,~34 weeks,,,
154,Buchan,Moderna,2,final,240+,symptomatic disease,symptomatic,Canada,≥ 18 years,general pop,80,74,84,,delta,~34 weeks,,,
154,Buchan,Moderna,2,final,7-59,Infection,infection,Canada,≥ 18 years,general pop,82,81,83,,delta,~34 weeks,,,
154,Buchan,Moderna,2,final,240+,Infection,infection,Canada,≥ 18 years,general pop,70,65,72,,delta,~34 weeks,,,
164,Young-Xu,Moderna,2,final,14+,infection,infection,USA,veterans 18+ years,veterans 18+ years,12,10,15,omicron,omicron,~48 weeks,,,
164,Young-Xu,Moderna,2,final,14+,hospitalization,severe,USA,veterans 18+ years,veterans 18+ years,63,58,67,omicron,omicron,~48 weeks,,,
164,Young-Xu,Moderna,2,final,14+,death,death,USA,veterans 18+ years,veterans 18+ years,77,67,83,omicron,omicron,~48 weeks,,,
164,Young-Xu,Moderna,2,final,14+,infection,infection,USA,veterans 18+ years,veterans 18+ years,54,50,57,delta,delta,~48 weeks,,,
164,Young-Xu,Moderna,2,final,14+,hospitalization,severe,USA,veterans 18+ years,veterans 18+ years,75,69,80,delta,delta,~48 weeks,,,
164,Young-Xu,Moderna,2,final,14+,death,death,USA,veterans 18+ years,veterans 18+ years,92,83,96,delta,delta,~48 weeks,,,
166,Amodio,Moderna,2,final,2 months,Infection,infection,Italy,≥ 18 years,general pop,81.3,80.3,82.3,,alpha & delta,~37 weeks,,,
166,Amodio,Moderna,2,final,8 months,infection,infection,Italy,≥ 18 years,general pop,57.8,55.4,60.2,,alpha & delta,~37 weeks,,,
166,Amodio,Moderna,2,final,2 months,severe disease,severe,Italy,≥ 18 years,general pop,96.1,94.5,97.7,,alpha & delta,~37 weeks,,,
166,Amodio,Moderna,2,final,8 months,severe disease,severe,Italy,≥ 18 years,general pop,90.3,86.2,94.4,,alpha & delta,~37 weeks,,,
166,Amodio,Moderna,2,final,2 months,death or intubation,severe,Italy,≥ 18 years,general pop,93.4,91.2,95.6,,alpha & delta,~37 weeks,,,
166,Amodio,Moderna,2,final,8 months,death or intubation,severe,Italy,≥ 18 years,general pop,83.7,75.1,92.3,,alpha & delta,~37 weeks,,,
167,Thompson,Moderna,2,final,14-179,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,52,46,58,,omicron,~32 weeks,,,
167,Thompson,Moderna,2,final,180+,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,38,32,43,,omicron,~32 weeks,,,
167,Thompson,Moderna,2,final,14-179,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,81,65,90,,omicron,~32 weeks,,,
167,Thompson,Moderna,2,final,180+,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,57,39,70,,omicron,~32 weeks,,,
167,Thompson,Moderna,2,final,14-179,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,86,85,87,,delta,~32 weeks,,,
167,Thompson,Moderna,2,final,180+,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,76,75,77,,delta,~32 weeks,,,
167,Thompson,Moderna,2,final,14-179,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,90,89,90,,delta,~32 weeks,,,
167,Thompson,Moderna,2,final,180+,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,81,80,82,,delta,~32 weeks,,,
169,Botton,Moderna,1,1,14+,hospitalization,severe,France,≥ 75 years,≥ 75 years,34,28,40,,non-VOC & alpha,,,,
169,Botton,Moderna,2,final,7+,hospitalization,severe,France,≥ 75 years,≥ 75 years,86,83,89,,non-VOC & alpha,~7 weeks,,,
173,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,hospital patients 18+ years,general pop,69,57,78,,delta,~47 weeks,,,
173,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,hospital patients 18+ years,general pop,82,77,86,,delta,~47 weeks,,,
178,Lauring,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,65,51,75,omicron,omicron,~3 weeks,,,
178,Lauring,Moderna,2,final,150+,hospitalization,severe,USA,≥ 18 years,general pop,85,83,87,delta,delta,~27 weeks,,,
178,Lauring,Moderna,2,final,>150,hospitalization,severe,USA,≥ 18 years,general pop,90,85,93,delta,delta,~27 weeks,,,
178,Lauring,Moderna,1,1,14+,hospitalization,severe,USA,≥ 18 years,general pop,77,71,81,,"alpha, delta, & omicron",,,,
185,Ferdinands,Moderna,2,final,<2 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,69,62,75,,omicron,~25 weeks,,,
185,Ferdinands,Moderna,2,final,≥5 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,37,34,40,,omicron,~25 weeks,,,
185,Ferdinands,Moderna,2,final,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,71,51,83,,omicron,~25 weeks,,,
185,Ferdinands,Moderna,2,final,≥5 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,54,48,59,,omicron,~25 weeks,,,
185,Ferdinands,Moderna,2,final,<2 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,92,91,94,,delta,~25 weeks,,,
185,Ferdinands,Moderna,2,final,≥5 months,ED or UC encounters,symptomatic,USA,ED encounters and hospital admissions,general pop,77,76,78,,delta,~25 weeks,,,
185,Ferdinands,Moderna,2,final,<2 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,94,92,96,,delta,~25 weeks,,,
185,Ferdinands,Moderna,2,final,≥5 months,hospitalization,severe,USA,ED encounters and hospital admissions,general pop,82,82,83,,delta,~25 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,52.0,33.0,65.0,,delta & omicron,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was in first 20 weeks,infants <6 months when timing of maternal vaccination was in first 20 weeks,38.0,3.0,60.0,,delta & omicron,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,69.0,50.0,80.0,,delta & omicron,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,38.0,8.0,58.0,,omicron,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was in first 20 weeks,infants <6 months when timing of maternal vaccination was in first 20 weeks,25.0,-26.0,56.0,,omicron,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,57.0,25.0,75.0,,omicron,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,infants <6 months when timing of maternal vaccination was anytime up to 14 days before delivery,80.0,60.0,90.0,,delta,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was in first 20 weeks,infants <6 months when timing of maternal vaccination was in first 20 weeks,68.0,19.0,87.0,,delta,~33 weeks,,,
187,Halasa,Moderna,2,final,14+,hospitalization,severe,USA,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,infants <6 months when timing of maternal vaccination was from 21 weeks' gestation up to 14 days before delivery,88.0,68.0,96.0,,delta,~33 weeks,,,
198,Oliver,Moderna,1,1,14+,infection,infection,Canada,hemodialysis patients,hemodialysis patients,41,24,54,,alpha,,,,
198,Oliver,Moderna,2,final,7+,infection,infection,Canada,hemodialysis patients,hemodialysis patients,69,58,78,,alpha,~22 weeks,,,
198,Oliver,Moderna,1,1,14+,severe disease,severe,Canada,hemodialysis patients,hemodialysis patients,46,23,63,,alpha,,,,
198,Oliver,Moderna,2,final,7+,severe disease,severe,Canada,hemodialysis patients,hemodialysis patients,83,70,90,,alpha,~22 weeks,,,
198,Oliver,Moderna,1,1,14+,hospitalization,severe,Canada,hemodialysis patients,hemodialysis patients,40,13,58,,alpha,,,,
198,Oliver,Moderna,2,final,7+,hospitalization,severe,Canada,hemodialysis patients,hemodialysis patients,82,69,90,,alpha,~22 weeks,,,
198,Oliver,Moderna,1,1,14+,death,death,Canada,hemodialysis patients,hemodialysis patients,71,40,86,,alpha,,,,
198,Oliver,Moderna,2,final,7+,death,death,Canada,hemodialysis patients,hemodialysis patients,85,59,95,,alpha,~22 weeks,,,
202,Shrotri,Moderna,1,1,28+,infection,infection,UK,LTCF residents,LTCF residents,31.7,-14.2,59.1,,alpha & delta,,,,
202,Shrotri,Moderna,2,final,14-83,Infection,infection,UK,LTCF residents,LTCF residents,25.5,-57.5,64.7,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,2,final,84+,Infection,infection,UK,LTCF residents,LTCF residents,26.3,-21.7,55.4,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,1,1,28+,hospitalization,severe,UK,LTCF residents,LTCF residents,40.8,-16,69.7,,alpha & delta,,,,
202,Shrotri,Moderna,2,final,14-83,hospitalization,severe,UK,LTCF residents,LTCF residents,88.8,16.8,98.5,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,2,final,84+,hospitalization,severe,UK,LTCF residents,LTCF residents,65.1,33.6,81.6,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,1,1,28+,death,death,UK,LTCF residents,LTCF residents,58.6,25.3,77,,alpha & delta,,,,
202,Shrotri,Moderna,2,final,14-83,death,death,UK,LTCF residents,LTCF residents,100,,,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,2,final,84+,death,death,UK,LTCF residents,LTCF residents,66.1,26,84.4,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,1,1,28+,Infection,infection,UK,LTCF staff,LTCF staff,27,4.4,44.3,,alpha & delta,,,,
202,Shrotri,Moderna,2,final,14-83,infection,infection,UK,LTCF staff,LTCF staff,60.7,44.2,72.4,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,2,final,84+,Infection,infection,UK,LTCF staff,LTCF staff,45.1,31.3,56.2,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,1,1,28+,hospitalization,severe,UK,LTCF staff,LTCF staff,100,,,,alpha & delta,,,,
202,Shrotri,Moderna,2,final,14-83,hospitalization,severe,UK,LTCF staff,LTCF staff,100,,,,alpha & delta,45 weeks,,,
202,Shrotri,Moderna,2,final,84+,hospitalization,severe,UK,LTCF staff,LTCF staff,92.1,69.3,97.9,,alpha & delta,45 weeks,,,
211,Tenforde,Moderna,2,final,14+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,79,66,87,,omicron,~45 weeks,,,
211,Tenforde,Moderna,2,final,14+,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,88,86,90,,delta,~45 weeks,,,
211,Tenforde,Moderna,2,final,14-150,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,92,90,94,,alpha,~45 weeks,,,
211,Tenforde,Moderna,2,final,>150,invasive mechanical ventilation or in-hospital death,severe,USA,hospitalized patients,general pop,84,80,87,,alpha,~45 weeks,,,
213,Wang,Moderna,2,final,14-179,infection,infection,USA,patients,general pop,26,22,30,,omicron,~23.5 weeks,,,
213,Wang,Moderna,2,final,180+,infection,infection,USA,patients,general pop,7,4,10,,omicron,54 weeks,,,
213,Wang,Moderna,2,final,14-179,infection,infection,USA,patients,general pop,70,68,72,,delta,~23.5 weeks,,,
213,Wang,Moderna,2,final,180+,infection,infection,USA,patients,general pop,53,52,55,,delta,54 weeks,,,
218,Starrfelt,Moderna,2,final,2-9 weeks,Infection,infection,Norway,≥ 18 years,general pop,84.1,83.2,85,,delta,~7 weeks,,,
218,Starrfelt,Moderna,2,final,18-25 weeks,Infection,infection,Norway,≥ 18 years,general pop,40.7,23.9,53.8,,delta,~23 weeks,,,
220,Nordstrom,Moderna,2,final,14+,Infection,infection,Sweden,≥ 18 years,general pop,68,63,72,,"non-VOC, alpha, & delta",~38 weeks,,,
223,Yoon,Moderna,2,final,14+,infection,infection,USA,HCW,HCW,46,25,61,omicron,omicron,~21 weeks,,,
223,Yoon,Moderna,2,final,14+,infection,infection,USA,HCW,HCW,65,49,76,delta,delta,~21 weeks,,,
224,Kwon,Moderna,2,final,14+,hospitalization,severe,USA,transplant recipients,transplant recipients,29,-19,58,,alpha & delta,~37 weeks,,,
224,Kwon,Moderna,2,final,14+,hospitalization,severe,USA,immunocompromised,immunocompromised adults,72,64,79,,alpha & delta,~37 weeks,,,
224,Kwon,Moderna,2,final,14+,hospitalization,severe,USA,immunocompetent adults,general pop,88,87,90,,alpha & delta,~37 weeks,,,
224,Kwon,Moderna,2,final,14+,supplemental oxygen/oxygen support,severe,USA,transplant recipients,transplant recipients,31,-27,63,,alpha & delta,~37 weeks,,,
224,Kwon,Moderna,2,final,14+,supplemental oxygen/oxygen support,severe,USA,immunocompromised,immunocompromised adults,73,64,80,,alpha & delta,~37 weeks,,,
224,Kwon,Moderna,2,final,14+,supplemental oxygen/oxygen support,severe,USA,immunocompetent adults,general pop,90,89,92,,alpha & delta,~37 weeks,,,
227,Kim,Moderna,2,final,14-149,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,45,14,66,omicron,omicron,~58 weeks,,,
227,Kim,Moderna,2,final,150+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,11,-21,35,omicron,omicron,~58 weeks,,,
227,Kim,Moderna,2,final,14-149,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,89,78,94,delta,delta,~48 weeks,,,
227,Kim,Moderna,2,final,150+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,58,44,68,delta,delta,~48 weeks,,,
230,Plumb,Moderna,1,1,14+,hospitalization,severe,USA,hospitalized adults,general pop,33,15,47.2,,omicron,,,,
230,Plumb,Moderna,1,1,14+,hospitalization,severe,USA,hospitalized adults,general pop,58.8,41.3,71.1,,delta,,,,
231,Dale,Moderna,2,final,14+,infection,infection,USA,≥ 18 years,general pop,51,-27,81,delta,delta,~25 weeks,,,
231,Dale,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥ 18 years,general pop,67,-7,90,delta,delta,~25 weeks,,,
231,Dale,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,61,-59,90,delta,delta,~25 weeks,,,
231,Dale,Moderna,2,final,14+,death,death,USA,≥ 18 years,general pop,80,-10,96,delta,delta,~25 weeks,,,
233,Nasreen,Moderna,2,final,7-55,hospitalization or death,severe,Canada,≥ 18 years,general pop,98,95,99,,"non-VOC, alpha, beta, gamma, & delta",~32 weeks,,,
233,Nasreen,Moderna,2,final,112+,hospitalization or death,severe,Canada,≥ 18 years,general pop,98,95,99,,"non-VOC, alpha, beta, gamma, & delta",~32 weeks,,,
236,Gram,Moderna,2,final,14-30,infection,infection,Denmark,12-59 years,12-59 years,39.8,38.4,41.2,,omicron,~56 weeks,,,
236,Gram,Moderna,2,final,120+,infection,infection,Denmark,12-59 years,12-59 years,13.2,12.5,13.9,,omicron,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,62.4,46.3,73.6,,omicron,~56 weeks,,,
236,Gram,Moderna,2,final,120+,hospitalization,severe,Denmark,12-59 years,12-59 years,65.9,62,69.4,,omicron,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,infection,infection,Denmark,12-59 years,12-59 years,92.2,91.8,92.6,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,120+,infection,infection,Denmark,12-59 years,12-59 years,64.9,64,65.8,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,hospitalization,severe,Denmark,12-59 years,12-59 years,99.1,98,99.6,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,120+,hospitalization,severe,Denmark,12-59 years,12-59 years,91.6,89.5,93.2,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,39.9,26.4,50.9,,omicron,~56 weeks,,,
236,Gram,Moderna,2,final,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,4.7,0.2,8.9,,omicron,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,82.2,75.3,87.1,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,49.8,46.5,52.8,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,31-60,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,97.7,95.2,98.9,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,120+,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,86.2,84.2,87.9,,delta,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,infection,infection,Denmark,≥ 60 years,≥ 60 years,91,88.5,92.9,,alpha,~56 weeks,,,
236,Gram,Moderna,2,final,120+,infection,infection,Denmark,≥ 60 years,≥ 60 years,71.5,54.7,82.1,,alpha,~56 weeks,,,
236,Gram,Moderna,2,final,14-30,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,96.4,92.6,98.3,,alpha,~56 weeks,,,
236,Gram,Moderna,2,final,120+,hospitalization,severe,Denmark,≥ 60 years,≥ 60 years,90.5,67,97.2,,alpha,~56 weeks,,,
237,Lind,Moderna,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,28.5,20,36.2,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,150+,infection,infection,USA,≥ 18 years,general pop,15.3,10.4,20,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,36.1,7.1,56.1,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,150+,infection,infection,USA,≥ 18 years,general pop,34,18.5,46.5,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,30.7,20.6,39.6,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,150+,infection,infection,USA,≥ 18 years,general pop,20,14,25.6,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,14-140,infection,infection,USA,≥ 18 years,general pop,14.3,-43.1,48.7,omicron,omicron,~40 weeks,,,
237,Lind,Moderna,2,final,150+,infection,infection,USA,≥ 18 years,general pop,18.8,-9,39.5,omicron,omicron,~40 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,83,80,86,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,severe disease,severe,Canada,individuals with rheumatoid arthritis,individuals with rheumatoid arthritis,92,88,95,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,89,83,93,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,severe disease,severe,Canada,individuals with ankylosing spondylitis,individuals with ankylosing spondylitis,97,83,99,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with psoriasis,individuals with psoriasis,84,81,86,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,severe disease,severe,Canada,individuals with psoriasis,individuals with psoriasis,92,86,95,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,infection,infection,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,79,74,82,,alpha & delta,~44 weeks,,,
239,Widdifield,Moderna,2,final,7+,severe disease,severe,Canada,individuals with inflammatory bowel disease,individuals with inflammatory bowel disease,94,88,97,,alpha & delta,~44 weeks,,,
241,Gonzalez,Moderna,2,final,14+,hospitalization,severe,Argentina,12-17 years,12-17 years,81,59.9,90.1,,delta & omicron,~17 weeks,,,
241,Gonzalez,Moderna,2,final,14+,hospitalization,severe,Argentina,12-17 years,12-17 years,78.2,42,90.3,,omicron,~25 weeks,,,
243,Castillo,Moderna,2,final,0-30,symptomatic disease,symptomatic,France,≥ 18 years,general pop,43,41,45,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,11,10,13,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,hospitalization,severe,France,≥ 18 years,general pop,59,49,70,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,hospitalization,severe,France,≥ 18 years,general pop,56,51,62,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,ICU admission,severe,France,≥ 18 years,general pop,70,40,97,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,ICU admission,severe,France,≥ 18 years,general pop,72,63,81,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,death,death,France,≥ 18 years,general pop,60,24,92,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,death,death,France,≥ 18 years,general pop,54,41,69,omicron,omicron,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,symptomatic disease,symptomatic,France,≥ 18 years,general pop,78,77,80,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,symptomatic disease,symptomatic,France,≥ 18 years,general pop,63,62,64,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,hospitalization,severe,France,≥ 18 years,general pop,91,87,95,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,hospitalization,severe,France,≥ 18 years,general pop,90,89,91,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,ICU admission,severe,France,≥ 18 years,general pop,93,86,99,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,ICU admission,severe,France,≥ 18 years,general pop,95,93,97,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,0-30,death,death,France,≥ 18 years,general pop,90,79,100,delta,delta,~48 weeks,,,
243,Castillo,Moderna,2,final,180+,death,death,France,≥ 18 years,general pop,87,83,91,delta,delta,~48 weeks,,,
248,Carazo,Moderna,2,final,7+,infection,infection,Canada,≥ 12 years,general pop,42,41,44,,omicron,~51 weeks,,,
248,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥ 12 years,general pop,76,74,78,,omicron,~51 weeks,,,
248,Carazo,Moderna,2,final,7+,infection,infection,Canada,≥ 12 years,general pop,23.2,21.2,27.4,,omicron,~51 weeks,,,
248,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥ 12 years,general pop,68.4,63.6,73.5,,omicron,~51 weeks,,,
252,Zahradka,Moderna,2,final,14+,infection,infection,Czech Republic,kidney transplant recipients,transplant recipients,45.6,12.4,67.6,,alpha,~12.5 weeks,,,
255,Lan,Moderna,2,final,14+,infection,infection,USA,HCW,HCW,82.3,75.1,87.4,,"non-VOC, alpha, & delta",~36 weeks,,,
255,Lan,Moderna,2,final,14+,infection,infection,USA,HCW,HCW,76.5,40.9,90.6,,"non-VOC, alpha, & delta",~36 weeks,,,
256,Tenforde,Moderna,2,final,14-179,hospitalization,severe,USA,immunocompetent adults,general pop,90,88,91,,alpha & delta,~23.5 weeks,,,
256,Tenforde,Moderna,2,final,180+,hospitalization,severe,USA,immunocompetent adults,general pop,82,79,85,,alpha & delta,~47 weeks,,,
256,Tenforde,Moderna,2,final,14+,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,63,55,69,,alpha & delta,~47 weeks,,,
256,Tenforde,Moderna,2,final,14-179,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,65,57,72,,alpha & delta,~23.5 weeks,,,
256,Tenforde,Moderna,2,final,180+,hospitalization,severe,USA,hospitalized immunocompromised adults,immunocompromised adults,53,38,65,,alpha & delta,~47 weeks,,,
256,Tenforde,Moderna,2,final,14-179,hospitalization,severe,USA,hospitalized adults,hospitalized adults,90,88,91,,delta,~23.5 weeks,,,
256,Tenforde,Moderna,2,final,180+,hospitalization,severe,USA,hospitalized adults,hospitalized adults,83,80,86,,delta,~47 weeks,,,
257,Fano,Moderna,2,final,40-44,infection,infection,Italy,≥ 12 years,general pop,70.9,69.3,72.4,,alpha & delta,~48 weeks,,,
257,Fano,Moderna,2,final,200+,infection,infection,Italy,≥ 12 years,general pop,22.7,18.5,26.8,,alpha & delta,~48 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison residents ≥ 18 years,prison residents,18.6,7.7,28.1,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison staff ≥ 18 years,prison staff,40.1,34,45.6,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison residents ≥ 18 years,prison residents,51.2,41.5,59.2,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison staff ≥ 18 years,prison staff,55.8,49.6,61.2,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison residents ≥ 18 years,prison residents,68.7,38.5,84.1,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison staff ≥ 18 years,prison staff,83.2,77.7,87.4,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,14.9,12.3,19.7,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,47.8,46.6,52.8,,omicron,~65 weeks,,,
261,Chin,Moderna,2,final,14+,infection,infection,USA,prison residents and staff ≥ 18 years,prison residents and staff,73.1,69.8,80.1,,omicron,~65 weeks,,,
262,Carlsen,Moderna,2,final,14+,infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester),infection during an infant's first 4 months of life,Norway,newborns,newborns,30,17,41,,omicron,~45 weeks,,,
262,Carlsen,Moderna,2,final,14+,infection during an infant's first 4 months of life (born to unvaccinated mothers and mothers vaccinated in 2nd or 3rd trimester),infection during an infant's first 4 months of life,Norway,newborns,newborns,71,56,81,,delta,~45 weeks,,,
263,Grewal,Moderna,2,final,0+,infection,infection,Canada,LTCF residents,LTCF residents,6,-5,15,omicron,omicron,~66 weeks,,,
263,Grewal,Moderna,2,final,0+,symptomatic disease,symptomatic,Canada,LTCF residents,LTCF residents,23,1,40,omicron,omicron,~66 weeks,,,
263,Grewal,Moderna,2,final,0+,hospitalization or death,severe,Canada,LTCF residents,LTCF residents,52,33,65,omicron,omicron,~66 weeks,,,
264,Spicer,Moderna,2,final,14+,infection,infection,USA,12-17 years,12-17 years,81,79.7,82.3,,delta,~36.5 weeks,,,
264,Spicer,Moderna,2,final,14+,infection,infection,USA,12-17 years,12-17 years,78.3,66.7,86.5,,delta,~36.5 weeks,,,
273,Magro,Moderna,2,final,14+,infection,infection,USA,SNF personnel 18+ years,SNF employees,1,55.9,81.8,,non-VOC & alpha,~10 weeks,,,
273,Magro,Moderna,2,final,14+,infection,infection,USA,SNF personnel 18+ years,SNF employees,32,1,54,,non-VOC & alpha,~10 weeks,,,
274,Moline,Moderna,2,final,14+,infection,infection,USA,SNF residents,SNF residents,65,25,84,,beta,~12 weeks,,,
275,Carazo,Moderna,2,final,14+,infection,infection,Canada,HCW,HCW,35,27,42,omicron BA.2,omicron BA.2,~70 weeks,,,
275,Carazo,Moderna,2,final,14+,symptomatic disease,symptomatic,Canada,HCW,HCW,61,52,69,omicron BA.2,omicron BA.2,~70 weeks,,,
282,Stephenson,Moderna,2,final,14+,hospitalization,severe,USA,≥ 18 years,general pop,85,81,89,,non-VOC & alpha,~18 weeks,,,
284,Link-Gelles,Moderna,2,final,14-140,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,47,44,50,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,150+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,39,37,41,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,14-140,hospitalization,severe,USA,≥ 18 years,general pop,68,63,73,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,150+,hospitalization,severe,USA,≥ 18 years,general pop,61,58,63,,omicron BA.1,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,14-140,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,59,40,71,,omicron BA.2,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,150+,ED or UC encounters,symptomatic,USA,≥ 18 years,general pop,18,10,26,,omicron BA.2,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,14-140,hospitalization,severe,USA,≥ 18 years,general pop,57,19,77,,omicron BA.2,~44 weeks,,,
284,Link-Gelles,Moderna,2,final,150+,hospitalization,severe,USA,≥ 18 years,general pop,24,12,35,,omicron BA.2,~44 weeks,,,
288,Mazagatos,Moderna,2,final,14+,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,92,78,97,,alpha & delta,~19 weeks,,,
288,Mazagatos,Moderna,2,final,<90,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,95,82,98,,alpha & delta,~19 weeks,,,
288,Mazagatos,Moderna,2,final,152+,hospitalization with SARI,severe,Spain,20-59 years,20-59 years,91,50,98,,alpha & delta,~19 weeks,,,
288,Mazagatos,Moderna,2,final,14+,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,97,86,99,,alpha & delta,~19 weeks,,,
288,Mazagatos,Moderna,2,final,<90,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,97,87,99,,alpha & delta,~19 weeks,,,
288,Mazagatos,Moderna,2,final,152+,hospitalization with SARI,severe,Spain,60-69 years,60-69 years,96,47,100,,alpha & delta,~19 weeks,,,
288,Mazagatos,Moderna,2,final,<90,hospitalization with SARI,severe,Spain,70-79 years,70-79 years,98,90,100,,alpha & delta,~23 weeks,,,
288,Mazagatos,Moderna,2,final,152+,hospitalization with SARI,severe,Spain,70-79 years,70-79 years,91,24,99,,alpha & delta,~23 weeks,,,
288,Mazagatos,Moderna,2,final,<90,hospitalization with SARI,severe,Spain,≥ 80 years,≥ 80 years,86,70,94,,alpha & delta,~33 weeks,,,
288,Mazagatos,Moderna,2,final,152+,hospitalization with SARI,severe,Spain,≥ 80 years,≥ 80 years,48,-51,82,,alpha & delta,~33 weeks,,,
292,Arashiro,Moderna,2,final,14-89,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,55,34,69,,omicron,~54 weeks,,,
292,Arashiro,Moderna,2,final,180+,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,52,37,63,,omicron,~54 weeks,,,
292,Arashiro,Moderna,2,final,14-89,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,88,80,92,,delta,~54 weeks,,,
292,Arashiro,Moderna,2,final,90-179,symptomatic disease,symptomatic,Japan,≥ 20 years,general pop,86,35,97,,delta,~54 weeks,,,
297,Lewis,Moderna,2,final,14+,infection,infection,USA,≥ 12 years,≥ 12 years,64,58,69,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Moderna,2,final,14+,infection,infection,USA,LTCF residents,LTCF residents,49,26,65,,"non-VOC, alpha, & delta",~46 weeks,,,
297,Lewis,Moderna,2,final,14+,infection,infection,USA,LTCF employees,LTCF employees,52,26,68,,"non-VOC, alpha, & delta",~46 weeks,,,
299,Risk,Moderna,2,final,14+,hospitalization,severe,USA,immunocompromised adults,immunocompromised adults,85,62,94,,omicron,~56 weeks,,,
299,Risk,Moderna,2,final,14+,hospitalization,severe,USA,immunocompetent adults,general pop,68,53,78,,omicron,~56 weeks,,,
299,Risk,Moderna,2,final,14+,ICU admission,severe,USA,≥ 18 years,general pop,92,66,98,,omicron,~56 weeks,,,
307,Lind,Moderna,2,final,14-89,infection,infection,USA,≥16 years,general pop,84.4,75.5,90,,alpha,~29 weeks,,,
307,Lind,Moderna,2,final,90-149,infection,infection,USA,≥16 years,general pop,96.5,75.1,99.5,,alpha,~29 weeks,,,
307,Lind,Moderna,2,final,14-89,symptomatic disease,symptomatic,USA,≥16 years,general pop,86.6,75.5,92.7,,alpha,~29 weeks,,,
307,Lind,Moderna,2,final,90-149,symptomatic disease,symptomatic,USA,≥16 years,general pop,93.8,55,99.1,,alpha,~29 weeks,,,
307,Lind,Moderna,2,final,14-89,hospitalization,severe,USA,≥16 years,general pop,85.5,65.5,93.9,,alpha,~29 weeks,,,
307,Lind,Moderna,2,final,90-149,hospitalization,severe,USA,≥16 years,general pop,82.2,-34.5,97.7,,alpha,~29 weeks,,,
307,Lind,Moderna,2,final,14-89,infection,infection,USA,≥16 years,general pop,68.9,58,77.1,,delta,~29 weeks,,,
307,Lind,Moderna,2,final,150+,infection,infection,USA,≥16 years,general pop,37.1,24,48.1,,delta,~29 weeks,,,
307,Lind,Moderna,2,final,14-89,symptomatic disease,symptomatic,USA,≥16 years,general pop,74.8,62.9,82.9,,delta,~29 weeks,,,
307,Lind,Moderna,2,final,150+,symptomatic disease,symptomatic,USA,≥16 years,general pop,48.4,32.8,60.4,,delta,~29 weeks,,,
307,Lind,Moderna,2,final,14-89,hospitalization,severe,USA,≥16 years,general pop,85.4,60.2,94.6,,delta,~29 weeks,,,
307,Lind,Moderna,2,final,150+,hospitalization,severe,USA,≥16 years,general pop,66.2,42.5,80.1,,delta,~29 weeks,,,
313,Chico-Sanchez,Moderna,2,final,12+,hospitalization,severe,Spain,HCW,HCW,96.8,76.1,99.6,,non-VOC & alpha,~22 weeks,,,
314,Mallah,Moderna,2,final,7+,infection,infection,Spain,≥11 years,≥11 years,72,71,73,,alpha & delta,~42 weeks,,,
314,Mallah,Moderna,2,final,7+,hospitalization,severe,Spain,≥11 years,≥11 years,74,70,77,,alpha & delta,~42 weeks,,,
318,Chung,Moderna,2,final,7-59,infection,infection,Canada,≥16 years,general pop,89,88,90,,non-VOC & alpha,~6 weeks,,,
318,Chung,Moderna,2,final,60-119,infection,infection,Canada,≥16 years,general pop,80,75,85,,non-VOC & alpha,~15 weeks,,,
318,Chung,Moderna,2,final,7-59,symptomatic disease,symptomatic,Canada,≥16 years,general pop,94,91,96,,non-VOC & alpha,~6 weeks,,,
318,Chung,Moderna,2,final,60-119,symptomatic disease,symptomatic,Canada,≥16 years,general pop,93,79,98,,non-VOC & alpha,~15 weeks,,,
318,Chung,Moderna,2,final,7-59,severe disease,severe,Canada,≥16 years,general pop,95,90,97,,non-VOC & alpha,~6 weeks,,,
318,Chung,Moderna,2,final,7-59,infection,infection,Canada,≥16 years,general pop,92,91,93,,alpha,~6 weeks,,,
318,Chung,Moderna,2,final,120-179,infection,infection,Canada,≥16 years,general pop,82,79,85,,alpha,~24 weeks,,,
318,Chung,Moderna,2,final,7-59,symptomatic disease,symptomatic,Canada,≥16 years,general pop,92,91,94,,alpha,~6 weeks,,,
318,Chung,Moderna,2,final,120-179,symptomatic disease,symptomatic,Canada,≥16 years,general pop,86,78,91,,alpha,~24 weeks,,,
318,Chung,Moderna,2,final,7-59,severe disease,severe,Canada,≥16 years,general pop,94,92,95,,alpha,~6 weeks,,,
318,Chung,Moderna,2,final,120-179,severe disease,severe,Canada,≥16 years,general pop,97,95,98,,alpha,~24 weeks,,,
318,Chung,Moderna,2,final,7-59,infection,infection,Canada,≥16 years,general pop,90,90,90,,delta,~6 weeks,,,
318,Chung,Moderna,2,final,240+,infection,infection,Canada,≥16 years,general pop,78,76,80,,delta,~42 weeks,,,
318,Chung,Moderna,2,final,7-59,symptomatic disease,symptomatic,Canada,≥16 years,general pop,94,94,95,,delta,~6 weeks,,,
318,Chung,Moderna,2,final,240+,symptomatic disease,symptomatic,Canada,≥16 years,general pop,88,86,90,,delta,~42 weeks,,,
318,Chung,Moderna,2,final,7-59,severe disease,severe,Canada,≥16 years,general pop,98,98,99,,delta,~6 weeks,,,
318,Chung,Moderna,2,final,240+,severe disease,severe,Canada,≥16 years,general pop,98,95,99,,delta,~42 weeks,,,
322,Schrag,Moderna,2,final,14+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,16,-22,42,,omicron,~55 weeks,,,
322,Schrag,Moderna,2,final,14-149,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,3,-49,37,,omicron,,,,
322,Schrag,Moderna,2,final,150+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,42,-16,72,,omicron,~55 weeks,,,
322,Schrag,Moderna,2,final,14+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,77,28,93,,omicron,~55 weeks,,,
322,Schrag,Moderna,2,final,14-149,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,86,41,97,,omicron,,,,
322,Schrag,Moderna,2,final,150+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,64,-102,93,,omicron,~55 weeks,,,
322,Schrag,Moderna,2,final,14+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,83,68,91,,delta,~55 weeks,,,
322,Schrag,Moderna,2,final,14-149,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,84,69,92,,delta,,,,
322,Schrag,Moderna,2,final,150+,ED or UC encounters,symptomatic,USA,pregnant persons 18-49 years,pregnant persons,75,5,93,,delta,~55 weeks,,,
322,Schrag,Moderna,2,final,14+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,98,96,99,,delta,,,,
322,Schrag,Moderna,2,final,14-149,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,99,96,100,,delta,,,,
322,Schrag,Moderna,2,final,150+,hospitalization,severe,USA,pregnant persons 18-49 years,pregnant persons,96,86,99,,delta,~55 weeks,,,
323,Ferdinands,Moderna,2,final,<2 months,ED or UC encounters,symptomatic,USA,≥18 years,general pop,63,57,68,,omicron,,,,
323,Ferdinands,Moderna,2,final,300,ED or UC encounters,symptomatic,USA,≥18 years,general pop,22,5,36,,omicron,,,,
323,Ferdinands,Moderna,2,final,<2 months,hospitalization,severe,USA,≥18 years,general pop,73,63,80,,omicron,,,,
323,Ferdinands,Moderna,2,final,14+ months,hospitalization,severe,USA,≥18 years,general pop,19,6,30,,omicron,~67 weeks,,,
323,Ferdinands,Moderna,2,final,<4 months,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,34,13,51,,omicron,,,,
323,Ferdinands,Moderna,2,final,6+ months,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,20,1,36,,omicron,~67 weeks,,,
323,Ferdinands,Moderna,2,final,<2 months,ED or UC encounters,symptomatic,USA,≥18 years,general pop,93,92,94,,delta,,,,
323,Ferdinands,Moderna,2,final,90,ED or UC encounters,symptomatic,USA,≥18 years,general pop,66,60,72,,delta,,,,
323,Ferdinands,Moderna,2,final,<2 months,hospitalization,severe,USA,≥18 years,general pop,96,95,97,,delta,,,,
323,Ferdinands,Moderna,2,final,90,hospitalization,severe,USA,≥18 years,general pop,68,59,75,,delta,,,,
323,Ferdinands,Moderna,2,final,<2 months,ED or UC encounters,symptomatic,USA,≥18 years,general pop,95,94,96,,alpha,~19 weeks,,,
323,Ferdinands,Moderna,2,final,90,ED or UC encounters,symptomatic,USA,≥18 years,general pop,86,78,91,,alpha,~19 weeks,,,
323,Ferdinands,Moderna,2,final,<2 months,hospitalization,severe,USA,≥18 years,general pop,94,93,95,,alpha,~19 weeks,,,
323,Ferdinands,Moderna,2,final,90,hospitalization,severe,USA,≥18 years,general pop,87,77,93,,alpha,~19 weeks,,,
325,Grewal,Moderna,2,final,0+,infection,infection,Canada,"LTCF residents, ≥60 years",LTCF residents,3,-7,12,,omicron BA.1 or BA.2 or BA.4 or BA.5,~80 weeks,,,
325,Grewal,Moderna,2,final,0+,symptomatic disease,symptomatic,Canada,"LTCF residents, ≥60 years",LTCF residents,21,1,38,,omicron BA.1 or BA.2 or BA.4 or BA.5,~80 weeks,,,
325,Grewal,Moderna,2,final,0+,severe disease,severe,Canada,"LTCF residents, ≥60 years",LTCF residents,43,24,58,,omicron BA.1 or BA.2 or BA.4 or BA.5,~80 weeks,,,
328,Lewis,Moderna,2,final,14+,infection,infection,USA,≥60 years,≥60 years,80,46.4,92.6,gamma,gamma,~14 weeks,,,
329,Buchan,Moderna,2,final,7-59 ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,36,24,45,omicron,omicron,,,,
329,Buchan,Moderna,2,final,240+ ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,2,-17,17,omicron,omicron,~49 weeks,,,
329,Buchan,Moderna,2,final,120-179 ,severe disease,severe,Canada,≥18 years,general pop,75,51,87,omicron,omicron,,,,
329,Buchan,Moderna,2,final,180-239 ,severe disease,severe,Canada,≥18 years,general pop,82,62,91,omicron,omicron,~32 weeks,,,
329,Buchan,Moderna,2,final,7-59 ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,89,86,92,delta,delta,,,,
329,Buchan,Moderna,2,final,240+ ,symptomatic disease,symptomatic,Canada,≥18 years,general pop,80,74,84,delta,delta,~49 weeks,,,
329,Buchan,Moderna,2,final,7-59 ,severe disease,severe,Canada,≥18 years,general pop,94,84,98,delta,delta,,,,
329,Buchan,Moderna,2,final,240+,severe disease,severe,Canada,≥18 years,general pop,95,85,99,delta,delta,~49 weeks,,,
331,Mimura,Moderna,2,final,28,infection,infection,Japan,16-64 years,16-64 years,15.8,7.9,23.1,omicron,omicron,~43 weeks,,,
331,Mimura,Moderna,2,final,28,symptomatic disease,symptomatic,Japan,16-64 years,16-64 years,21.2,11,30.3,omicron,omicron,~43 weeks,,,
331,Mimura,Moderna,2,final,28,infection,infection,Japan,16-64 years,16-64 years,82.9,69.4,90.4,delta,delta,~31 weeks,,,
331,Mimura,Moderna,2,final,28,symptomatic disease,symptomatic,Japan,16-64 years,16-64 years,95.7,82.5,98.9,delta,delta,~31 weeks,,,
333,Chambers,Moderna,2,final,7+,infection,infection,Canada,≥19 years,general pop,82,74,88,,alpha & delta,~44 weeks,,,
333,Chambers,Moderna,2,final,7+,symptomatic disease,symptomatic,Canada,≥19 years,general pop,93,79,98,,alpha & delta,~44 weeks,,,
333,Chambers,Moderna,2,final,7+,severe disease,severe,Canada,≥19 years,general pop,97,80,99,,alpha & delta,~44 weeks,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,26,-22,56,,omicron,~11 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,23,-6,44,,omicron,~13 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,19,-3,37,,omicron,~15 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,37,-21,67,,omicron,~8 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,5,-28,29,,omicron,~10 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,3,-19,21,,omicron,~12 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,-4,-84,41,,omicron,~5 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,12,-23,37,,omicron,~7 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,18,-4,36,,omicron,~9 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,61,-31,89,,delta,~11 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,48,-54,82,,delta,~13 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,49,-46,82,,delta,~15 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,91,63,98,,delta,~8 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,60,23,79,,delta,~10 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,65,33,81,,delta,~12 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 2 months of life,infection in the first 2 months of life,USA,infants born to mothers 16-50 years of age,infants,87,55,96,,delta,~5 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 4 months of life,infection in the first 4 months of life,USA,infants born to mothers 16-50 years of age,infants,70,43,84,,delta,~7 months,,,
335,Zerbo,Moderna,2,final,7+,infection in the first 6 months of life,infection in the first 6 months of life,USA,infants born to mothers 16-50 years of age,infants,54,27,71,,delta,~9 months,,,
337,Britton,Moderna,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,40,34,46,,omicron BA.1,~56 weeks,,,
337,Britton,Moderna,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,7,-16,25,,omicron BA.2/BA.2.12.1,~69 weeks,,,
337,Britton,Moderna,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,38,23,50,,omicron BA.4/BA.5,~77 weeks,,,
337,Britton,Moderna,2,final,14+,hospitalization with COVID-like illness,severe,USA,immunocompromised adults ≥18 years,immunocompromised adults,22,10,33,,omicron BA.2/BA.2.12.1/BA.4/BA.5,~77 weeks,,,
338,Surie,Moderna,2,final,14-150,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,63,46,75,,omicron BA.1/BA.2,~74 weeks,,,
338,Surie,Moderna,2,final,150+,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,34,20,46,,omicron BA.1/BA.2,~74 weeks,,,
338,Surie,Moderna,2,final,14-150,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,83,35,96,,omicron BA.4/BA.5,~82 weeks,,,
338,Surie,Moderna,2,final,150+,hospitalization with COVID-like illness,severe,USA,≥18 years,general pop,37,12,55,,omicron BA.4/BA.5,~82 weeks,,,
340,Nordstrom,Moderna,2,final,7+,infection,infection,Sweden,"adolescents vaccinated on or after January 1, 2022",adolescents,47,43,51,,omicron,~6 weeks,,,
340,Nordstrom,Moderna,2,final,7+,infection,infection,Sweden,"adolescents vaccinated on or after September 1, 2021",adolescents,4,2,6,,omicron,~24 weeks,,,
340,Nordstrom,Moderna,2,final,7+,hospitalization with COVID-19 as the main diagnosis,severe,Sweden,"adolescents vaccinated on or after November 15, 2021",adolescents,86,63,95,,omicron,~27 weeks,,,
340,Nordstrom,Moderna,2,final,48+,hospitalization with COVID-19 as the main diagnosis,severe,Sweden,"adolescents vaccinated before November 15, 2021",adolescents,68,25,86,,omicron,~45 weeks,,,
343,Grewal,Moderna,2,final,240-299,severe disease,severe,Canada,50-59 years,50-59 years,83,76,88,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,50-59 years,50-59 years,83,74,89,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,60-69 years,60-69 years,79,71,86,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,70-79 years,70-79 years,80,72,86,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,≥80 years,≥80 years,72,62,79,omicron BA.1/BA.2,omicron BA.1/BA.2,~74 weeks,,,
343,Grewal,Moderna,2,final,240-299,severe disease,severe,Canada,50-59 years,50-59 years,87,43,97,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,50-59 years,50-59 years,56,30,72,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,60-69 years,60-69 years,43,16,61,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,70-79 years,70-79 years,48,25,64,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
343,Grewal,Moderna,2,final,300+,severe disease,severe,Canada,≥80 years,≥80 years,40,18,56,omicron BA.4/BA.5,omicron BA.4/BA.5,~86 weeks,,,
344,Chemaitelly,Moderna,2,final,91+ (90+ days post primary Omicron infection),reinfection,reinfection,Qatar,≥18 years with prior breakthrough Omicron infection,≥18 years with prior breakthrough Omicron infection,57,52,62,,omicron,~85 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants < 6 months,mothers of infants < 6 months,45,37,53,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants < 6 months of mothers receiving second dose in first trimester,infants < 6 months of mothers receiving second dose in first trimester,47,31,59,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants < 6 months of mothers receiving second dose in second trimester,infants < 6 months of mothers receiving second dose in second trimester,37,24,47,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants < 6 months of mothers receiving second dose in third trimester,infants < 6 months of mothers receiving second dose in third trimester,53,42,62,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants 0-8 weeks,infants 0-8 weeks,57,44,66,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants 9-16 weeks,infants 9-16 weeks,47,31,60,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants >16 weeks and < 6 months,infants >16 weeks and < 6 months,40,21,54,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,hospitalization,severe,Canada,infants < 6 months,infants < 6 months,58,44,69,,omicron,~66 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants < 6 months,infants < 6 months,95,88,98,,delta,~28 weeks,,,
346,Jorgensen,Moderna,2,final,14+,hospitalization,severe,Canada,infants < 6 months,infants < 6 months,94,74,100,,delta,~28 weeks,,,
346,Jorgensen,Moderna,2,final,14+,infection,infection,Canada,infants < 6 months,infants < 6 months,44,38,54,,delta,~28 weeks,,,
347,Van Ewijk,Moderna,2,final,<120,infection,infection,Netherlands,≥18 years,general pop,74,63,81,,delta,,,,
347,Van Ewijk,Moderna,2,final,>120,infection,infection,Netherlands,≥18 years,general pop,56,36,69,,delta,~41 weeks,,,
348,Turbyfill,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompetent, ≥18 years",general pop,91,88,93,,alpha & delta,~30 weeks,,,
348,Turbyfill,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompetent, ≥18 years",general pop,84,80,88,,alpha & delta,~30 weeks,,,
348,Turbyfill,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,64,48,75,,alpha & delta,~30 weeks,,,
348,Turbyfill,Moderna,2,final,14+,hospitalization,severe,USA,"immunocompromised, ≥18 years",immunocompromised adults,53,22,72,,alpha & delta,~30 weeks,,,
349,Castelli,Moderna,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,40.6,29.4,50,,omicron,~32.5 weeks,,,
349,Castelli,Moderna,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,31.5,26.3,36.4,,omicron,~32.5 weeks,,,
349,Castelli,Moderna,2,final,15-30,infection,infection,Argentina,12-17 years,12-17 years,55.8,52.4,59,,omicron,~32.5 weeks,,,
349,Castelli,Moderna,2,final,61+,infection,infection,Argentina,12-17 years,12-17 years,12.4,8.6,16.1,,omicron,~32.5 weeks,,,
349,Castelli,Moderna,2,final,14+,death,death,Argentina,12-17 years,12-17 years,97.6,81,99.7,,omicron,~32.5 weeks,,,
349,Castelli,Moderna,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,88.9,66.1,96.4,,delta,~15.5 weeks,,,
349,Castelli,Moderna,2,final,14+,infection,infection,Argentina,12-17 years,12-17 years,66.3,54,75.4,,delta,~15.5 weeks,,,
349,Castelli,Moderna,2,final,15-30,infection,infection,Argentina,12-17 years,12-17 years,74.8,71.3,77.9,,delta,~15.5 weeks,,,
349,Castelli,Moderna,2,final,61+,infection,infection,Argentina,12-17 years,12-17 years,56.3,50.2,61.7,,delta,~15.5 weeks,,,
351,Cegolon,Moderna,2,final,14+,infection,infection,Italy,HCW,HCW,41,-49,77,,"omicron BA.1, BA.2, BA.4/BA.5",~69 weeks,,,
351,Cegolon,Moderna,2,final,14+,infection,infection,Italy,HCW,HCW,-4,-43,24,,"omicron BA.1, BA.2, BA.4/BA.5",~69 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,78,75,80,,omicron BA.1,~60 weeks,,,
354,Carazo,Moderna,2,final,7-90,hospitalization,severe,Canada,≥60 years,≥60 years,86,78,91,,omicron BA.1,~60 weeks,,,
354,Carazo,Moderna,2,final,270-359,hospitalization,severe,Canada,≥60 years,≥60 years,68,37,84,,omicron BA.1,~60 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,60,50,67,,omicron BA.2,~73 weeks,,,
354,Carazo,Moderna,2,final,7-90,hospitalization,severe,Canada,≥60 years,≥60 years,66,28,84,,omicron BA.2,~73 weeks,,,
354,Carazo,Moderna,2,final,360-449,hospitalization,severe,Canada,≥60 years,≥60 years,73,-13,94,,omicron BA.2,~73 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,40,30,49,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Moderna,2,final,7-90,hospitalization,severe,Canada,≥60 years,≥60 years,55,-95,89,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Moderna,2,final,360-449,hospitalization,severe,Canada,≥60 years,≥60 years,47,35,57,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,97,96,99,,omicron BA.1,~60 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,92,86,96,,omicron BA.2,~73 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,99,94,100,,omicron BA.2,~73 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,92,80,97,,omicron BA.4/BA.5,~94 weeks,,,
354,Carazo,Moderna,2,final,7+,hospitalization,severe,Canada,≥60 years,≥60 years,91,85,95,,omicron BA.4/BA.5,~94 weeks,,,
355,Anzalone,Moderna,2,final,14+,hospitalization,severe,USA,≥18 years,general pop,42,38,45,,delta,~47 weeks,,,
357,Lewis,Moderna,2,final,150+,hospitalization,severe,USA,≥18 years,general pop,46,30,58,,omicron BA.1/BA.2,~63 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",47,40,53,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",35,31,40,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",59,39,72,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",58,51,65,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",42,33,49,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",37,32,41,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",65,48,76,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",57,49,64,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",54,47,61,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",31,25,36,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",62,45,74,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",55,47,63,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",51,43,58,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",27,20,33,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",63,43,75,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",43,32,52,,omicron BA.1,~62 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",87,84,89,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",81,79,82,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",90,84,94,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 1","≥18 years, Social Vulnerability Index Quartile 1",85,82,87,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",85,81,88,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",80,77,81,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",91,85,95,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 2","≥18 years, Social Vulnerability Index Quartile 2",86,83,88,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",89,85,91,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",74,71,77,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",94,88,97,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 3","≥18 years, Social Vulnerability Index Quartile 3",82,78,85,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",84,79,87,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,ED/UC visit,symptomatic,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",75,72,78,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,14-149,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",90,83,94,,delta,~48.5 weeks,,,
358,Dalton,Moderna,2,final,150+,hospitalization,severe,USA,"≥18 years, Social Vulnerability Index Quartile 4","≥18 years, Social Vulnerability Index Quartile 4",84,80,87,,delta,~48.5 weeks,,,
361,Tartof,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,-53,-205,23,,omicron,~64.5 weeks,,,
361,Tartof,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,45,-4,70,,omicron,~64.5 weeks,,,
361,Tartof,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,70,11,90,,delta,~46.5 weeks,,,
361,Tartof,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,23,-225,82,,delta,~46.5 weeks,,,
361,Tartof,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,17,-40,51,,omicron or delta,~64.5 weeks,,,
361,Tartof,Moderna,2,final,14+,symptomatic disease,symptomatic,USA,≥18 years,general pop,42,-1,66,,omicron or delta,~64.5 weeks,,,
362,Villar,Moderna,2,final,0+,infection,infection,Multiple,pregnant women,pregnant women,11,0,21,,omicron,~74.5 weeks,,,
362,Villar,Moderna,2,final,0+,moderate disease,symptomatic,Multiple,pregnant women,pregnant women,41,22,55,,omicron,~74.5 weeks,,,
362,Villar,Moderna,2,final,0+,severe disease or death,severe,Multiple,pregnant women,pregnant women,56,27,74,,omicron,~74.5 weeks,,,
365,Lin,Moderna,2,final,0 to ~5 weeks,hospitalization or death,severe,USA,5-11 years,5-11 years,73.3,8.3,92.3,,omicron (all lineages),~57 weeks,,,
365,Lin,Moderna,2,final,~20-25 weeks,hospitalization or death,severe,USA,5-11 years,5-11 years,2.9,-50.8,37.4,,omicron (all lineages),~57 weeks,,,
365,Lin,Moderna,2,final,0 to ~5 weeks,infection,infection,USA,0-4 years,0-4 years,37.5,21.2,50.4,,omicron (all lineages),~24 weeks,,,
365,Lin,Moderna,2,final,~16-21 weeks,infection,infection,USA,0-4 years,0-4 years,46.8,-0.3,71.8,,omicron (all lineages),~24 weeks,,,
365,Lin,Moderna,2,final,0 to ~5 weeks,infection,infection,USA,5-11 years,5-11 years,65.3,58.1,71.2,,omicron (all lineages),~57 weeks,,,
365,Lin,Moderna,2,final,~24-29 weeks,infection,infection,USA,5-11 years,5-11 years,4.6,-2.1,10.9,,omicron (all lineages),~57 weeks,,,
365,Lin,Moderna,2,final,0 to ~5 weeks,infection,infection,USA,0-4 years,0-4 years,55.7,49.1,61.5,,omicron (all lineages),~24 weeks,,,
365,Lin,Moderna,2,final,~16-21 weeks,infection,infection,USA,0-4 years,0-4 years,58.6,48.3,66.9,,omicron (all lineages),~24 weeks,,,
365,Lin,Moderna,2,final,0 to ~5 weeks,infection,infection,USA,5-11 years,5-11 years,59.7,58.3,61,,omicron (all lineages),~57 weeks,,,
365,Lin,Moderna,2,final,~36-41 weeks,infection,infection,USA,5-11 years,5-11 years,16,13.1,18.7,,omicron (all lineages),~57 weeks,,,
367,Ellingson,Moderna,2,final,14+,infection,infection,USA,frontline workers,general pop,43,35,57,,omicron,~63 weeks,,,
103,Martinez-Baz,AstraZeneca,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,86,70,93,,"non-VOC, alpha, & delta",~21 weeks,,,
103,Martinez-Baz,AstraZeneca,2,final,<90,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,85,69,93,,"non-VOC, alpha, & delta",~11 weeks,,,
103,Martinez-Baz,AstraZeneca,2,final,14+,symptomatic disease,symptomatic,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,91,71,97,,"non-VOC, alpha, & delta",~21 weeks,,,
103,Martinez-Baz,AstraZeneca,2,final,14+,hospitalization,severe,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,95,79,99,,"non-VOC, alpha, & delta",~21 weeks,,,
103,Martinez-Baz,AstraZeneca,2,final,14+,infection,infection,Spain,contacts of SARS-CoV-2 index cases of all ages,contacts of index cases,86,45,97,delta,delta,~21 weeks,,,
308,Suphanchaimat,AstraZeneca,2,final,15-29,infection,infection,Thailand,≥18 years,general pop,79.9,74,84.5,,delta,~2 weeks,,,
308,Suphanchaimat,AstraZeneca,2,final,90+,infection,infection,Thailand,≥18 years,general pop,77.4,68.2,84,,delta,~19 weeks,,,
353,Nittayasoot,AstraZeneca,2,final,14+,pneumonia requiring invasive ventilation,severe,Thailand,≥18 years,general pop,83.1,62.3,92.4,,"delta & omicron BA.1, BA.7",~54 weeks,,,